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ABSTRACT
Background:	   20	   to	   30%	   of	   patients	   with	   GORD	   respond	   inadequately	   to	  conventional	   therapy.	   Most	   of	   these	   patients	   belong	   to	   the	   non-­‐erosive	   reClux	  disease	   group.	   Despite	   not	   having	   oesophagitis,	   in	   these	   patients	   oesophageal	  mucosal	  integrity	  appears	  to	  be	  impaired.
Aims:	  To	  study	  the	  dynamic	  in	  vitro	  and	  in	  vivo	  properties	  of	  oesophageal	  mucosal	  integrity	  in	  patients	  with	  non-­‐erosive	  reClux	  disease,	  and	  to	   test	  the	  feasibility	  of	  a	  topical	  mucosal	  protectant	  therapy.
Methods:	  In	   vitro	   studies	  of	  mucosal	   integrity	  were	  done	  on	  human	  oesophageal	  biopsies	   using	   Ussing	   chambers.	   Change	   in	   transepithelial	   electrical	   resistance	  (TER)	  on	  exposure	  to	  acidic	  solutions	  was	  measured.	  Integrity	  was	  assessed	  in	  vivo	  by	  measuring	  impedance	  change	  and	  subsequent	  recovery	  after	  oesophageal	  acid	  perfusion	   in	   symptomatic	   patients.	   Proximal	   and	   distal	   oesophageal	   mucosal	  integrity	  was	  assessed	  in	  vitro	  and	  in	   vivo.	   The	  effect	  of	  in	   vitro	  topical	  application	  of	   an	  alginate-­‐based	   solution	   on	   acid-­‐induced	   changes	   in	  mucosal	   integrity	  was	  tested.
Results:	  In	  vitro	  exposure	  of	  biopsies	  to	  acidic	  and	  weakly	  acidic	  solutions	  caused	  a	  greater	  impairment	  of	  integrity	   in	  symptomatic	  patients	  than	  in	  controls.	   In	  vivo	  oesophageal	   acid	   perfusion	   causes	   a	   profound	   drop	   in	   distal	   oesophageal	  impedance	  that	  is	  slow	  to	  recover.	  Recovery	  is	  slower	  in	  patients	  with	  non-­‐erosive	  reClux	   disease	   than	   in	   patients	   with	   functional	   heartburn,	   and	   a	   low	   baseline	  impedance	   is	   associated	   with	   painful	   perception	   of	   acid.	   Proximal	   oesophageal	  sensitivity	  appears	  unrelated	  to	  impaired	  mucosal	  integrity,	  but	  rather	  to	  a	  distinct	  sensory	   afferent	   nerve	   distribution.	   Topical	   pre-­‐treatment	   with	   an	   alginate	  solution	  is	  able	  to	  prevent	  acid-­‐induced	  changes	  in	  integrity	  in	  vitro.
Conclusion:	   Patients	   with	   non-­‐erosive	   reClux	   disease	   have	   a	   distinct	   mucosal	  vulnerability	   to	   acidic	   and	   weakly	   acidic	   solutions	   that	   may	   underlie	   persistent	  symptoms.	   A	   topical	   therapeutic	   approach	  may	   be	   a	   feasible	  add-­‐on	  strategy	   to	  treat	  GORD	  in	  the	  future.
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Gastro-­‐oesophageal	   reClux	   disease	   (GORD)	   is	   a	   common	   and	   sometimes	  debilitating	  disease.	  Recent	  years	  have	  produced	  insights	  into	  the	  pathophysiology	  of	  the	  disease,	  and	  particularly	  the	  concept	  has	  developed	  that	  there	  may	  be	  subtle	  oesophageal	  mucosal	   injury	   in	  reClux	  disease	  without	  macroscopic	   erosions.	   This	  chapter	   outlines	   the	  current	   understanding	  of	  GORD	  epidemiology,	   pathogenesis	  and	  treatment.	   It	  describes	  the	   concept	   of	  oesophageal	  mucosal	   integrity,	   and	  its	  potential	   role	   in	   disease	   pathogenesis.	   Finally,	   it	   will	   outline	   the	   remaining	  questions,	  and	  specify	  the	  aims	  of	  the	  thesis.
1.1 Introduction to gastro-oesophageal reflux disease
Gastro-­‐oesophageal	   reClux	   disease	   (GORD)	   has	   a	   global	   impact	   on	   health	   and	  quality	   of	   life,	   affecting	   much	   of	   the	   world’s	   population1.	   Whilst	   over	   recent	  decades	   there	   have	   undoubtedly	  been	   important	   and	  successful	   advances	   in	   the	  treatment	   of	   GORD,	   the	   prevalence	   of	   the	   disease	   appears	   to	   be	   increasing,	   not	  only	   in	   the	   traditionally	   affected	  Western	  populations,	   but	   also	   in	   areas	   such	  as	  Asia.	   Advances	   in	   technologies	   to	   detect	   GORD	   have	   allowed	   a	   more	   detailed	  classiCication	  than	  was	  present	  perhaps	  even	  20	  to	  30	  years	   ago,	  when	  the	  words	  “hiatus	  hernia”	  and	  “oesophagitis”	  were	  often	  used	  as	   empirical	  and	  undoubtedly	  sometimes	  incorrect	  terms	  for	  reClux	  disease2.	  These	  advances	  have	  also	  made	  the	  problem	  of	   treatment-­‐refractory	  GORD	  more	   apparent.	   This	   appears	   to	   be	  more	  common	  in	  certain	  subsets	  of	  GORD,	  including	  so-­‐called	  non-­‐erosive	  reClux	  disease	  (NERD)3.	   This	   increasingly	   encountered	   clinical	   problem,	   the	   association	   with	  
Chapter 1
22
Barrett’s	   oesophagus	   and	   oesophageal	   adenocarcinoma4,	   and	   perhaps	   an	  increasing	   awareness	   of	   the	   adverse	   effects	   of	   proton	   pump	   inhibitor	   (PPI)	  therapy5	  drive	  a	  continued	  need	  to	  understand	  the	  pathophysiology	  of	  the	  disease.
1.1.1	  Gastro-­‐oesophageal	  reMlux	  disease	  deMinition	  and	  classiMicationIn	  past	  years	  the	  deCinition	  of	  GORD	  has	  become	  more	  concrete,	  encompassing	  the	  clinico-­‐pathological	   consequences	  of	  material	   reCluxing	   from	  the	  stomach	  into	   the	  oesophagus.	   A	   group	   of	   experts	   convened	   in	  Montreal	   to	   produce	   a	   consensus	  deCinition	   and	   classiCication	   of	   GORD	   that	   has	   become	   widely	   accepted.	   The	  deCinition	   has	   become	   “a	   condition	  which	   develops	   when	   the	   reClux	   of	   stomach	  contents	   causes	   troublesome	   symptoms	   and/or	   complications”6.	   Similarly,	   a	  consensus	   report	   from	   a	   workshop	   in	   Genval	   concluded	   “The	   term	   gastro-­‐oesophageal	   reﬂux	  disease	   (GORD,	   reﬂux	   disease)	  should	  be	  used	   to	   include	   all	  individuals	   who	   are	   exposed	   to	   the	   risk	   of	   physical	   complications	   from	   gastro-­‐oesophageal	  reﬂux,	   or	  who	   experience	  clinically	   signiﬁcant	  impairment	   of	  health	  related	  well	  being	  (quality	  of	  life)	  due	  to	   reﬂux	  related	  symptoms,	   after	  adequate	  reassurance	  of	  the	  benign	  nature	  of	  their	  symptoms”7.	  Finally,	  another	  consensus	  meeting	  in	  Marrakech	  deCined	  GORD	  by	  “the	  presence	  of	  reClux	  oesophagitis	   (Los	  Angeles	  grades	  A–D)	  and/or	  when	  it	  causes	  reClux	  symptoms	  that	  are	  sufCicient	  to	  impair	   quality	   of	   life	   and/or	   when	   it	   is	   associated	   with	   a	   risk	   of	   long	   term	  complications”8.	  An	  important	  component	  to	  each	  of	  these	  deCinitions	  deCinitions	  is	  that	   reClux	  must	   cause	   symptoms	   and/or	   complications.	   This	   is	   because	   gastro-­‐oesophageal	  reClux	  is	  a	  daily	  occurrence	  in	  healthy	  individuals.	  Such	  physiological	  reClux	  can	  occur	  up	  to	  70	  times	  per	  day9.	  It	  also	  recognises	  that	  some	  patients	  may	  be	   completely	   asymptomatic	   from	   gastro-­‐oesophageal	   reClux,	   yet	   can	   develop	  complications	   such	   as	   silent	   oesophagitis	   and	  Barrett’s	   oesophagus.	   The	   clinical	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manifestations	   (whether	   symptoms	   or	   complications)	   can	   be	   divided	   into	  oesophageal	  syndromes,	  and	  extra-­‐oesophageal	  syndromes	  (Cigure	  1).
Figure	  1:	  The	  Montreal	  ClassiIication	  of	  GORD	  (from	  Vakil	  et	  al.	  2006)
1.1.2	  Symptomatic	  oesophageal	  syndromesIt	   can	   be	   seen	   that	   there	   are	   two	   symptomatic	   reClux	   oesophageal	   syndromes:	  typical	   reClux	   syndrome	   and	   reClux	   chest	   pain	   syndrome.	   The	  most	   established	  symptom	  associations	  with	  GORD	  are	  the	  so-­‐called	  “typical	  symptoms”:	  heartburn	  and	  regurgitation.	  Heartburn	  is	  a	  retrosternal	  burning	  sensation,	  and	  regurgitation	  is	   the	   perception	   of	   reCluxed	   gastric	   content	   into	   the	   mouth	   or	   hypopharynx.	  Although	   heartburn	   is	   not	   speciCic	   for	   GORD,	   results	   of	   studies	   using	   acid	  suppression	  therapies	  for	  treatment	  of	  heartburn	  provide	  strong	  indirect	  evidence	  that	   GORD	   is	   the	   most	   common	   cause	   of	   heartburn9-­‐11.	   When	   heartburn	   and	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regurgitation	  are	  present	  as	  the	  only	  symptoms,	  they	  are	  speciCic	  but	  not	  sensitive	  in	   the	   diagnosis	   of	   GORD12.	   However	   the	   Diamond	   study,	   published	   in	   2010,	  demonstrated	   that	   heartburn	   or	   regurgitation	   were	   the	   most	   troublesome	  symptoms	  in	  only	  49%	  of	  patients	  with	  GORD	  (with	  dyspepsia	  being	  the	  next	  most	  frequent	   primary	   symptom)13.	   Typical	   reClux	   symptoms	   are	   characteristically	  worsened	   after	   eating,	   on	   bending,	   and	   on	   lying	   down	   (especially	   on	   the	   right	  side).	  In	   chest	   pain	   reClux	   syndrome	   there	   are	   episodes	   of	   non-­‐heartburn	   chest	   pain	  caused	  by	  gastro-­‐oesophageal	  reClux.	  The	  pain	  can	  sometimes	  be	  indistinguishable	  from	  cardiac	  chest	  pain.	  Ambulatory	  oesophageal	  pH	  recordings	  have	  been	  used	  to	  document	  the	  direct	  association	  between	  reClux	  episodes	  and	  chest	  pain.	  
1.1.3	  Syndromes	  with	  oesophageal	  injuryReClux	   oesophagitis	   is	   deCined	   endoscopically	   by	   visible	   breaks	   in	   the	   distal	  oesophageal	  mucosa.	   Such	  oesophagitis	   is	  seen	   in	   less	   than	  50%	  of	  patients	  with	  GORD,	   and	  neither	   symptom	  pattern	  nor	   severity	   can	  predict	   its	  presence2,	   14,	   15.	  Oesophagitis	   is	   the	  most	   common	  macroscopic	   injury	  caused	  by	  GORD.	   In	  severe	  occasions	   it	   may	   result	   in	   an	   oesophageal	   stricture	   and	   thus	   cause	   dysphagia.	  Dysphagia	  can	  also	  occur	  in	  GORD	  in	  the	  absence	  of	  stricture16.	  This	  may	  be	  due	  to	  inClammatory	  damage	  to	   efferent	  (or	  perhaps	  afferent)	  neurones	   involved	   in	   the	  peristaltic	   process,	   leading	   to	   failure	   of	   bolus	   transit17.	   Chronic	   reClux	  may	   also	  cause	  metaplastic	  change	  of	  the	  squamous	   epithelium	  of	  the	  distal	   oesophagus	  to	  columnar	  epithelium:	  Barrett’s	  oesophagus.	  It	  is	  included	  in	  the	  oesophageal	  injury	  category	   since	   it	   is	   associated	   with	   a	   risk	   of	   developing	   oesophageal	  adenocarcinoma.
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1.1.4	  Extra-­‐oesophageal	  manifestations	  of	  GORD	  GORD	   has	   been	   implicated	   in	   extra-­‐oesophageal	   syndromes,	   notably	   chronic	  cough18,	  laryngitis19	   and	  asthma20.	  Whilst	  these	  syndromes	  are	  widely	  accepted	  to	  be	   inCluenced	   by	   GORD,	   accurately	   identifying	   these	   patients	   and	  understanding	  the	  underlying	  mechanisms	  has	  proved	  difCicult.
1.1.5	  Erosive	  oesophagitis,	  non-­‐erosive	  reMlux	  disease	  and	  functional	  heartburnIt	   is	   important	   to	   realise	  that	  typical	   heartburn	  symptoms	   in	  GORD	  may	  occur	   in	  the	  presence	  or	  absence	  of	  oesophageal	  erosions.	   Indeed,	  50-­‐70%	  of	  patients	  with	  GORD	   have	   a	   normal	   endoscopic	   appearance	   of	   the	   oesophageal	   mucosa21,	   22.	  Furthermore,	   using	   ambulatory	   oesophageal	   pH-­‐monitoring,	   researchers	   have	  been	  able	  to	  establish	  normal	  values	  of	  oesophageal	  acid	  exposure,	  and	  determine	  whether	  a	  symptomatic	  patient	  has	  pathological	  oesophageal	   acid	  exposure.	   This,	  along	   with	   clinical	   response	   to	   PPI	   treatment,	   allows	   further	   deCinition	   of	   the	  GORD	  phenotypes.	  The	  Rome	  III	  consensus	  criteria23	  thus	  subdivides	  patients	  into:	  1)	   erosive	   oesophagitis;	   2)	   non-­‐erosive	   reClux	   disease	   (NERD	   -­‐	   symptoms	   with	  normal	   endoscopic	   appearance	   and	   pathological	   oesophageal	   acid	   exposure	   +/-­‐	  positive	   symptom-­‐reClux	   association);	   3)	   hypersensitive	   oesophagus	   (symptoms	  with	  normal	  endoscopic	  appearance,	  physiological	  oesophageal	  acid	  exposure,	  but	  positive	  symptom-­‐reClux	  association);	   or	  4)	  functional	   heartburn	  (symptoms	  with	  normal	   endoscopic	   appearance,	   physiological	   oesophageal	   acid	  exposure,	   and	  no	  symptom-­‐reClux	  association).	  All	  but	  functional	  heartburn	  are	  deemed	  to	  Cit	  within	  the	  GORD	  umbrella:	  i.e.	  the	  symptoms	  are	  caused	  by	  reClux	  of	  gastric	  contents	  into	  the	  oesophagus.	  A	  diagnostic	  algorithm	  to	  explain	  this	  is	  demonstrated	  in	  Cigure	  2.
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  Figure	  2:	  A	  diagnostic	  algorithm	  for	  patients	  with	  reIlux	  symptoms
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1.2 Epidemiology and risk factors for gastro-oesophageal reflux disease
We	   understand	   that	   GORD	   is	   a	   very	   common	   condition,	   but	   truly	   accurate	  quantiCication	  of	  its	  prevalence	  may	  be	  difCicult	  since	  there	  is	  a	  relative	  scarcity	  of	  epidemiological	   data,	   and	  many	   people	   do	   not	   seek	   medical	   attention	   for	   their	  symptoms.	   When	   deCined	   as	   the	   presence	   of	   at	   least	   weekly	   heartburn	   or	  regurgitation,	   there	  is	  an	  estimated	  prevalence	  of	  10-­‐20%	  in	  Western	  Europe	  and	  North	  America24.	   From	  a	  primary	  care	  database,	   the	  incidence	  of	  GORD	  in	  the	  UK	  has	  been	  estimated	  at	  4.5-­‐5.4	  per	  1000	  person-­‐years25.Differences	   may	   exist	   between	   ethnic	   groups.	   In	   one	   study	   in	   the	   US,	   a	   higher	  prevalence	  of	  reClux	  symptoms	  was	  found	  in	  Hispanic	   subjects	  when	  compared	  to	  Caucasian	  subjects26.	  A	  systematic	  review	  of	  the	  prevalence	  of	  GORD	  in	  Asia	  found	  a	  range	  of	  2.5-­‐6.7%,	  but	  high	  quality	  data	  is	  limited27.
1.2.1	  Risk	  Factors	  for	  GORDThere	   is	   some	   evidence	   to	   support	   genetic,	   demographic	   and	   behavioural	  associations	  with	  the	  development	  of	  GORD.	  Patients	  with	  GORD	  more	  frequently	  have	   relatives	   with	   frequent	   GORD	   symptoms28.	   The	   strongest	   evidence	   for	   a	  genetic	   link	   comes	   from	   a	   twins	   study	   in	   the	   UK	   where	   a	   signiCicantly	   higher	  concordance	   of	   GORD	   prevalence	   was	   seen	   in	   monozygotic	   versus	   dizygotic	  twins29.	   A	   second	   twin	   study	   found	   that	   there	   was	   a	   stronger	   within-­‐pair	  association	  of	  GORD	  (and	  IBS)	  within	  monozygotic	   compared	  to	  dizygotic	   twins.	  However,	  when	  these	  differences	  were	  controlled	  for	  the	  presence	   of	  depression	  and	  anxiety	  they	  lost	  signiCicance30.	   A	   further	  study	  found	  a	  signiCicant	  association	  of	   GORD	   symptoms	   between	   immediate	   relatives	   that	  was	   not	   seen	   in	   spouses,	  again	   suggesting	   a	   genetic	   inCluence	   that	   was	   separate	   from	   environmental	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inCluences31.	   Clustering	   of	   hiatus	   hernia	   (a	   risk	   factor	   for	   GORD)	   has	   been	  described	   in	   5	  generations	   of	   a	   family32.	   The	   collagen	   type	   3	   alpha	   1	   (COL3A1)	  gene	  has	  been	  found	  to	  be	  a	  disease-­‐associated	  gene	  in	  paediatric	  and	  adult	  GORD,	  and	   with	   the	   presence	   of	   hiatus	   hernia	   in	   males33.	   This	   gene	   encodes	   type	   3	  collagen,	  which	  has	  an	  important	  role	  in	  tissue	  strength	  and	  Clexibility,	  and	  in	  the	  early	   phases	   of	   wound	   healing.	   More	   recently	   the	   4-­‐Amino-­‐butyrate	  Aminotransferase	  (ABAT)	  gene	  has	  been	  found	  to	  be	  associated	  with	  the	  presence	  of	  GORD	  in	  children,	  and	  inhibition	  of	  ABAT	  in	  dogs	  causes	   inhibition	  of	  transient	  lower	  oesophageal	   sphincter	  relaxations	  and	  a	   reduction	   in	  the	  number	  of	  reClux	  episodes34.There	  has	  been	  much	  investigation	  into	   genetic	   inCluences	  on	  the	  development	  of	  Barrett’s	   oesophagus	   and	   oesophageal	   adenocarcinoma.	   The	   relative	   risks	   of	  Barrett’s	   oesophagus	   and	   oesophageal	   adenocarcinoma	   are	   increased	   by	  approximately	  2-­‐	  to	  4-­‐fold	  when	  one	   Cirst	  degree	  relative	  is	  affected35.	   A	   complex	  segregation	   analysis	   of	   patients	   with	   Barrett’s	   oesophagus	   and	   oesophageal	  adenocarcinoma	   has	   suggested	   an	   incomplete	   dominant	   inheritance	   with	   a	  polygenic	   component36.	   Finally,	   a	  recent	   genome-­‐wide	  association	   study	  of	   1852	  patients	  with	  Barrett’s	  oesophagus	  identiCied	  two	  genetic	  variants	  associated	  with	  increased	  risk37.Studies	   have	   repeatedly	   shown	   that	   there	   is	   no	   sex	   preponderance	   in	   GORD	  (excluding	  during	  pregnancy	  in	  females)29,	  31,	  38-­‐40.	  	  There	  appears	  to	  be	  a	  very	  small	   increase	  in	  GORD	  symptom	  prevalence	  seen	  with	  increasing	   age29,	   39.	   The	   UK	  GP	   database	   study	   found	   that	   prevalence	   increased	  until	  the	  age	  of	  69,	  then	  decreased	  thereafter25.	   In	  a	  US	  study,	   this	  trend	  was	  also	  seen,	  but	  the	  reversal	  in	  prevalence	  occurred	  earlier,	  at	  5540.	  It	  is	  important	  to	  note	  that	  these	  studies	  are	  based	  on	  symptoms	  alone,	   and	  so	   cannot	   take	  into	  account	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the	   prevalence	   of	   complications	   such	   as	   oesophagitis	   and	  Barrett’s	   oesophagus,	  nor	  do	  they	  consider	  extra-­‐oesophageal	  manifestations.Several	   studies	   have	   demonstrated	   an	   increasing	   prevalence	   of	   GORD	   with	   an	  excess	  body	  mass/higher	  body	  mass	  index	  (BMI).	  In	  the	  Olmsted	  County	  studies	  a	  high	  BMI	  was	   associated	  with	  an	  OR	  of	  2.8	  (95%	  CI	  1.7-­‐4.5)	  for	   the	   presence	  of	  GORD31,	   39,	   41.	   In	  the	  UK	  GP	  database	  study	  a	  BMI	  >25	  was	   signiCicantly	  associated	  with	  GORD	   (OR	   1.3,	   95%CI	   1.2-­‐1.5)25,	   and	   a	  Georgia	  Medicaid	  study	   reported	  a	  positive	  relationship	  between	  obesity	  and	  GORD	  (OR	  2.8,	  95%	  CI	  2.1-­‐3.6)40.	   	  It	  has	  even	  been	  shown	  that	  modest	  weight	  gain,	  even	  in	  subjects	  with	  normal	  BMI,	  may	  cause	  or	  exacerbate	  GORD	  symptoms42.	  	  Some	   behaviours	   are	   frequently	   considered	   to	   be	   related	   to	   GORD,	   the	   most	  commonly	   discussed	  being	   cigarette	   smoking,	   alcohol	   consumption	   and	   caffeine	  consumption.	   	   Indeed,	   several	   cross-­‐sectional	   studies	  have	   reported	  a	  signiCicant	  positive	   association	   between	  GORD	  symptoms	   and	  smoking,	  with	   odds	   ratios	   of	  between	  1.1	  and	  2.629,	   31,	   39.	  The	  evidence	  for	  alcohol	  and	  caffeine	  consumption	  is	  less	  clear.	  A	  US	  study	  has	  reported	  a	  positive	  association	  between	  GORD	  diagnosis	  and	  alcohol	  consumption40.	   In	  contrast,	  two	  UK	  studies	  were	  able	  to	   Cind	  no	   such	  association25,	   29.	   Although	   often	   anecdotally	   reported	   as	   a	   precipitant	   factor	   for	  reClux	   symptoms,	   three	   cross-­‐sectional	   studies	   were	   unable	   to	   Cind	   a	   positive	  association	  between	  caffeine	   consumption	  and	  GORD31,	   43,	   44.	   The	  UK	  GP	  database	  found	   signiCicant	   associations	   with	   a	   number	   of	   drug	   treatments	   (including	  nitrates,	   oral	   steroids	  and	  NSAIDs,	  but	  not	  aspirin)25.	   The	  Olmsted	  County	  survey	  found	  no	  such	  association	  with	  NSAIDs40.	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1.2.2	  Comorbid	  factors	  in	  GORDFurther	  information	   from	   the	  UK	  GP	  database	   found	   that	  a	  diagnosis	   of	   irritable	  bowel	  syndrome	  or	  peptic	  ulcer	  disease	  is	  associated	  with	  an	  increased	  likelihood	  of	   GORD	   diagnosis25.	   There	   is	   also	   a	   signiCicant	   overlap	   between	   GORD	   (both	  erosive	  and	  non-­‐erosive)	  and	  dyspeptic	  symptoms,	  higher	  than	  would	  be	  expected	  due	   to	   chance	   alone38.	   This	   overlap	  may	   be	   driven	  particularly	   by	   patients	  with	  functional	   heartburn	   who	   have	   not	   been	   distinguished	   from	   non-­‐erosive	   reClux	  disease	   in	   symptom-­‐based	   studies45.	   Obstructive	   respiratory	   diseases	   may	   alter	  abdomino-­‐thoracic	   pressure	  gradients,	  and	  indeed	  cough,	   COPD	  and	  asthma	  have	  been	  found	  to	  have	  a	  positive	  association	  with	  the	  presence	  of	  GORD	  symptoms25,	  
40.	   Furthermore,	   as	   mentioned	  above,	   there	   is	   likely	   to	   be	   a	  proportion	  of	   these	  respiratory	  diseases	  that	  are	  in	  fact	  caused	  by	  GORD.	  Finally,	   there	  is	  an	  association	  of	  GORD	  with	  psychiatric	  disease.	   In	  China,	   anxiety	  and	  depression	  were	  both	  found	  to	  be	  more	  common	  in	  patients	  with	  GORD46.	  Two	  Western	   studies	   also	   reported	   a	   signiCicant	   association	   of	   GORD	   with	   a	  psychosomatic	   checklist	   score31,	   44.	   Within	   the	   spectrum	   of	   GORD,	   patients	  with	  NERD	   and	   functional	   heartburn	   are	   more	   likely	   to	   be	   affected	   by	   stress.	  Furthermore,	   patients	   with	   co-­‐morbid	   psychological	   distress	   have	   an	   increased	  symptom	  burden,	  and	  poorer	  response	  to	  PPI47.
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1.3 The balance of aggressive and defensive factors in GORD
The	  human	  upper	   gastrointestinal	   tract	  manifests	   several	   properties	  that	   defend	  against	   the	   occurrence	   of	   gastro-­‐oesophageal	   reClux.	   Since	   gastro-­‐oesophageal	  reClux	   is	   a	   physiological	   phenomenon	   (indeed,	   in	   healthy	   individuals	   the	  oesophageal	  mucosa	  can	  be	  acidiCied	  for	  up	  to	  4%	  of	  the	  day48)	  it	  follows	  that	  these	  properties	   do	   not	   completely	   inhibit	   reClux	   occurring.	   It	   also	   follows	   that	   the	  oesophagus	   itself	   must	   have	   properties	   that	   prevent	   damage	   occurring	   when	  reClux	   occurs,	   as	   in	   the	   vast	   majority	   this	   physiological	   reClux	   is	   asymptomatic.	  Thus,	  with	  gastro-­‐oesophageal	  reClux	  there	  is	  a	  balance	  between	  the	  rigorousness	  of	   the	   defensive	   properties,	   and	   the	   aggressiveness	   of	   the	   reClux	   (in	   terms	   of	  amount	   and	   composition)	   that	   determines	   whether	   gastro-­‐oesophageal	   reClux	  becomes	   pathological.	   Some	   understanding	   of	   these	   defensive	   and	   aggressive	  factors	   in	   GORD	   has	   led	   to	   the	   development	   of	   many	   therapies	   (both	  pharmacological	   and	   surgical).	   Greater	   understanding	   of	   the	   details	   of	   this	  relationship	  may	  allow	  future	  therapies	  to	  be	  developed.
1.3.1	  Aggressive	  factors	  in	  GORDThe	   central	   aggressor	   in	   gastroesophageal	   reClux	   disease	   is	   the	   reCluxate:	   the	  material	   that	  moves	  in	  a	  retrograde	  fashion	  from	  the	  stomach	  to	   the	  oesophagus	  during	  reClux	  episodes.	  The	  reCluxate	  may	   contain	  varying	  concentrations	  of	  acid,	  pepsin,	   gas,	   or	   contents	   of	   duodenal	   reClux	   (such	   as	   bile	   acid	   and	   pancreatic	  enzymes).	  On	  one	  hand,	   the	  reCluxate	  is	   deCined	  and	  characterised	  by	  a	  multitude	  of	   pathophysiological	   variables.	   On	   the	   other	   hand,	   the	   contents	   and	  characteristics	  of	   the	  reCluxate	  are	  essential	   for	   the	  pathological	   consequences	  of	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GORD.	   Gastroesophageal	   reClux	   disease	  may	  manifest	   in	  different	  ways;	   in	   some	  the	   reClux	   episodes	   are	   only	  minimally	   (if	   at	   all)	   symptomatic	   and	   in	  others	   the	  symptoms	   are	   debilitating.	   Likewise,	   in	   many	   there	   is	   no	   macroscopic	   mucosal	  injury	  (NERD),	   and	  in	  others	  there	   is	   severe	  oesophagitis	  or	  even	  metaplasia	  and	  neoplasia.	  Amongst	  GORD	  sufferers	  there	  will	  be	  people	  who	  are	  mostly	  sensitive	  to	   acidic	   reClux	  and	  can	  be	  effectively	   treated	  with	  proton	  pump	   inhibitor	   (PPI)	  therapy.	   In	   others	   there	   is	   an	   apparent	   hypersensitivity	   of	   the	   oesophagus,	   and	  symptoms	   are	   perceived	   in	   response	   to	   weakly	   acidic	   or	   non-­‐acid	   reClux.	   These	  observations	  serve	  to	  illustrate	  the	  heterogeneity	  of	  GORD,	  and	  as	  such	  there	  must	  be	  variables	   at	   play	   that	   determine	  whether	   the	   line	   between	   physiological	   and	  pathological	   reClux	  is	   crossed,	   whether	   by	  mucosal	   damage,	   by	   symptoms,	   or	   by	  both.	   The	   reCluxate	   is	   one	   of	   these	   variables,	   and	   a	   vitally	   important	   one.	   This	  section	   will	   Cirst	   discuss	   the	   aggressive	   components	   of	   the	   reCluxate,	   and	   then	  outline	  the	  defensive	  factors	  that	  protect	  the	  healthy	  individual	  from	  symptomatic	  perception	  of	  reClux.
1.3.1.1	  Acid	  reMluxThe	  usual	  pH	   of	  the	  stomach	  is	  highly	   acidic	  at	  approximately	  1.5–3.5.	  When	  this	  gastric	   juice	  reCluxes	   into	   the	  oesophagus,	   the	  oesophageal	  mucosa	  is	   exposed	  to	  acid.	   In	  some	  situations	  the	  reCluxate	  will	  be	  less	  acidic	  due	  to	  a	  higher	  gastric	  pH:	  most	  commonly	  after	  a	  meal,	   and	  in	  patients	  treated	  with	  proton	  pump	  inhibitors	  (PPIs).	  These	  powerfully	  block	  gastric	  acid	  secretion,	  and	  by	  doing	  so	  usually	  raise	  the	  gastric	  pH	  to	  above	  449.	  In	  the	  post-­‐prandial	  state	  ingested	  food	  acts	  as	  a	  buffer	  to	  the	  gastric	  acid,	  and	  as	  such	  the	  majority	  of	  stomach	  contents	  during	  this	  period	  has	   a	  pH	  a	  little	  greater	   than	  4.	   It	  has	  been	  noted	  that	  gastric	   fullness	  encourages	  post-­‐prandial	   reClux,	   and	  one	  would	  therefore	  expect	  this	  reClux	  to	  be	  of	  a	  higher	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pH	  than	  in	  the	  fasting	  state.	  However,	  during	  the	  post-­‐prandial	   state	  conventional	  intragastric	   pH	   monitoring	   5	   cm	   below	   the	   lower	   oesophageal	   sphincter	   (LOS)	  often	   reveals	   discrepancies	   between	   gastric	   pH	   and	   that	   of	   the	   reCluxate	   in	   the	  oesophagus,	  with	  a	  lower	  pH	  in	  the	  oesophagus	  than	  in	  the	  stomach	  during	  reClux	  episodes.	  These	  observations	  can	  be	  explained	  by	  the	  presence	  of	  an	  “acid	  pocket”	  in	   the	   proximal	   stomach	   in	   the	   90	   minutes	   post-­‐prandially50.	   This	   area,	   that	  develops	  on	  top	  of	  ingested	  food	  after	  a	  meal,	  is	  a	  rich	  source	  of	  acid	  for	  reClux	  into	  the	  distal	  oesophagus	  during	  this	  period.	   The	  acid	  pocket	  is	  not	  something	  that	  is	  present	  during	  the	   fasting	  state,	   but	  can	  be	  detected	  in	  the	  proximal	  stomach	  (by	  pH	  pull-­‐through	  techniques)	  for	  up	  to	  90	  minutes	  after	  a	  meal51.	  Although	  the	  acid	  pocket	   can	   be	   found	   in	   healthy	   volunteers,	   by	   comparison	   the	   acid	   pocket	   in	  patients	  with	  GORD	  has	   a	  greater	  distal	   extent,	   and	  extends	  proximally	   closer	   to	  the	   lower	   oesophageal	   sphincter.	   The	   size	   of	   the	   pocket	   is	   increased	   by	   the	  presence	  of	  a	  hiatus	  hernia50.	  Scintigraphy	  studies	  have	  indicated	  that	  acid	  reClux	  is	  more	   likely	   to	   occur	  when	  the	  acid	  pocket	   is	   located	  at	   or	  above	   the	   level	   of	  the	  diaphragm52.
Acid	  reMlux:	  role	  in	  symptom	  perceptionDespite	   the	  increasing	  complexities	   that	   have	  been	  discovered,	   it	   holds	   true	   that	  acid	  exposure	  in	  the	  oesophagus	   is	  very	  important	  in	  symptoms	  genesis	  in	  GORD.	  In	  experimental	  conditions	  the	  infusion	  of	  hydrochloric	  acid	  solution	  into	  the	  mid-­‐oesophagus	   is	   able	   to	   reproduce	  heartburn	  symptoms,	   and	  with	   increasing	   acid	  concentrations	  the	  duration	  of	  exposure	  required	  to	  cause	  symptoms	  decreases53.	  The	  generation	  of	  symptoms	  in	  these	  experiments	  is	  most	  consistent	  at	  pH	  1–2,	   i.e.	  the	  pH	  of	  normal	  gastric	  juices.Using	   oesophageal	   24-­‐hour	   pH	   recordings	   in	   GORD	   patients	   with	   erosive	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oesophagitis	   a	   temporal	   relationship	   between	   pH	   falls	   and	   symptoms	   has	   been	  demonstrated54,	   and	  using	  pH-­‐MII	  monitoring	   symptomatic	   GORD	  patients	   have	  been	  seen	  to	  have	  more	  acid	  reClux	  events	  than	  normal	  subjects55.
Weakly	  acid	  reMlux:	  role	  in	  symptom	  perceptionThe	  studies	  outlined	  above	  have	  illustrated	  the	  ability	  of	  acid	  to	  cause	  symptoms	  in	  GORD.	  However,	   in	   vivo,	   heartburn	  is	  not	  speciCic	   to	   strong	  acid	  stimulus.	   During	  reClux	   in	   the	   “on”	   PPI	   condition,	   the	   oesophageal	   mucosa	   is	   exposed	   to	   gastric	  contents	  in	  the	  range	  pH	  4-­‐6.556.	  The	  phrase	  “weakly	  acidic	  reClux”	  has	  been	  coined	  to	  describe	  acid	  reClux	  of	  pH	  >4.	  Prolonged	   pH	   monitoring	   studies	   reveal	   a	   poor	   correlation	   between	   acid	   reClux	  events	   and	   heartburn	   sensation,	   and	   so	   it	   is	   possible	   that	   weakly	   acidic	   reClux	  events	   also	   have	   a	   role	   in	   symptoms	   perception.	   Even	   though	   the	   early	   acid	  perfusion	  experiments	  by	  Smith	  et	  al.	  led	  to	  a	  belief	  that	  heartburn	  was	  as	  a	  result	  of	  strongly	  acidic	   reClux,	   on	  closer	  examination	  they	  also	   demonstrate	  that	  higher	  pH	   solutions	   can	  cause	  heartburn53.	   Although	  symptoms	   took	   longer	   to	   develop,	  even	  with	  pH	   6–7	  perfusions	   symptoms	  occurred	  in	  50%	   of	  subjects.	   Combined	  oesophageal	   pH	   and	   impedance	   measurement	   techniques	   have	   enabled	   further	  investigation	  in	  more	  physiological	  settings.	  This	  is	  because	  impedance	  techniques	  allow	   the	  detection	  of	  reClux	  events	   irrespective	  of	  the	  pH.	   By	  combining	  pH	   and	  impedance	   data	   from	   the	   same	   catheter	  one	   can	   ascertain	  the	   pH	   of	   reClux	   even	  when	  not	  acidic.	  Data	  from	  GORD	  patients	  has	  shown	  that	  up	  to	  30%	  of	  symptoms	  may	  be	  associated	  with	  reClux	  episodes	  with	  a	  pH	   of	  4–755,	   56.	   Emerenziani	  et	  al.	  showed	   that	   although	   most	   symptoms	   were	   related	   to	   acid,	   NERD	   patients	   in	  particular	   were	   sensitive	   to	   weakly	   acidic	   reClux	   events	   (accounting	   for	   24%	   of	  their	   symptoms)57.	   Such	  observations	  may	  be	   important	   in	   explaining	  persistent	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symptoms	   “on	   PPI”,	   and	   the	  mechanisms	   of	  mucosal	   sensitivity	   to	   reCluxates	   of	  weakly	  acidic	  pH	  should	  be	  explored	  in	  order	  to	  develop	  more	  effective	  therapies	  for	  PPI-­‐refractory	  patients.
Acid	  reMlux:	  role	  in	  mucosal	  injuryIf	  acid	  and	  weak	  acid	  can	  be	  a	  cause	  of	  symptoms	   in	  GORD,	  what	  of	   their	  role	   in	  mucosal	   damage?	   For	   strongly	   acidic	   reCluxate,	   the	   evidence	   is	   compelling.	   In	  animal	   studies,	   exposure	   to	   the	   oesophageal	   mucosa	   with	   acid	   alone	   (or	   in	  combination	  with	  pepsin)	  can	  induce	  oesophagitis58.	   Ambulatory	  oesophageal	  pH	  studies	   show	   that	   increasing	   levels	   of	   oesophageal	   acid	   exposure	  are	   associated	  with	  increasing	   severity	  of	  oesophageal	   lesions	   in	  human	  patients59,	   60.	   Using	  24-­‐hour	  pH-­‐impedance	  monitoring	  Savarino	  et	  al.	  demonstrated	  a	  higher	  acid	  (pH	  <4)	  exposure	  time,	  a	  higher	  total	  number	  of	  acid	  reClux	  events,	  and	  a	  higher	  mean	  acid	  clearance	  time	  for	  patients	  with	  erosive	  oesophagitis	  when	  compared	   to	  patients	  with	  NERD61.	  Taken	  together	  these	  studies	  would	  suggest	  that	  an	  increase	  in	  acid	  (pH	   <4)	  exposure	  is	   important	   for	   the	  development	  of	  mucosal	   damage	  in	  reClux	  disease.	   Perhaps	   most	   persuasive	   argument	   is	   the	   dramatic	   (>70%)	   rate	   of	  endoscopic	  healing	  when	  patients	  are	  treated	  for	  8	  weeks	  with	  PPIs9.Although	   weak	   acid	   is	   important	   for	   the	   generation	   of	   symptoms	   in	   GORD,	   it	  appears	  less	  able	  to	  cause	  macroscopic	  mucosal	  damage	  since	  there	  are	  no	  studies	  reporting	   an	   association	   between	   the	   amount	   of	   weakly	   acid	   reClux	   and	  oesophageal	  erosion	  formation.
1.3.1.2	  Duodeno-­‐gastro-­‐oesophageal	  reMluxThe	  aforementioned	  pH-­‐impedance	  studies	  of	  reClux	  in	  GORD	  have	  illustrated	  that	  acid	  is	  undoubtedly	  important	  for	  symptoms	  and	  mucosal	  injury.	  However,	   not	  all	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patients	  with	  acid	  reClux	  get	  symptoms	  or	  oesophagitis:	  do	  other	  properties	  of	  the	  reCluxate	   also	   play	   a	   role?	   The	   reCluxate	   consists	   of	   not	   just	   acid,	   but	   other	  components	   of	   gastric	   juice	   including	   pepsin,	   and	   elements	   of	   duodeno-­‐gastro-­‐oesophageal	  reClux	  (DGOR)	  such	  as	  bile	  acids.It	   has	   long	   been	   known	   that	   DGOR	   occurs,	   but	   its	   accurate	   quantiCication	   has	  proven	   difCicult,	   largely	   for	   technical	   reasons.	   Early	   studies	   of	   DGOR	   used	   pH	  monitoring	   for	   its	   detection,	   working	   on	   the	   assumption	   that	   reClux	   containing	  duodenal	   juice	   will	   have	   an	   alkaline	   pH.	   More	   recently	   an	   ambulatory	   bilirubin	  monitoring	  system	  has	  been	  used,	  and	  has	  offered	  clariCication	  of	  this	  assumption.	  Ambulatory	   bilirubin	   monitoring	   enables	   spectrophotometric	   measurement	   of	  oesophageal	   luminal	   bilirubin	   concentrations,	   which	   closely	   correlates	   with	  DGOR62.	   Whereas	   previously	   the	   presence	   of	   alkaline	   or	   non-­‐acid	   oesophageal	  reClux	  was	  considered	  to	  be	  a	  marker	  of	  DGOR,	   this	  is	  not	  the	  case:	  simultaneous	  measurement	   of	   oesophageal	   bilirubin	   spectrophotometry	   and	   pH-­‐impedance	  have	  shown	   that	   biliary	   reClux	   and	   non-­‐acid	   (pH	   >	   4)	   reClux	   are	   not	   equivalent.	  Furthermore,	  most	  DGOR	  occurs	  in	  an	  acidic	  environment63.ReClux	  of	  duodenal	   contents	   into	   the	  oesophagus	   has	  been	  hypothesised	  to	   cause	  damage	   due	  to	   the	   toxic	   effects	   of	  components	  such	  as	  bile	   acids	   and	  pancreatic	  enzymes.	   Gastric	   bile	   acid	   concentrations	   may	   be	   between	   0.3	   mmol/l	   and	   2	  mmol/l64-­‐66.	  Whereas	  conjugated	  bile	  acids	  are	  most	  commonly	  found	  in	  DGOR,	   in	  the	  “on”	  PPI	  condition	  there	  may	  also	  be	  signiCicant	  presence	  of	  unconjugated	  bile	  acids	  due	  to	  gastric	  bacterial	  overgrowth	  and	  subsequent	  bacterial	  deconjugation	  in	  the	  stomach67.	  
DGOR:	  role	  in	  symptom	  perceptionA	   few	   studies	  have	   looked	  at	   the	   relevance	   of	  DGOR	   in	  symptoms	   perception	   in	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GORD	  patients.	   Marshall	   et	   al.	   studied	  59	  patients	   with	   typical	   reClux	   symptoms	  and	  found	   that	   only	   6%	  of	   symptomatic	   events	  were	   related	   to	   DGOR68.	   Similar	  ambulatory	  monitoring	   studies	   by	   Koek	   et	   al.	   in	   patients	   with	  GORD	   “off”	  acid-­‐suppressive	  therapy	  again	  demonstrated	  that	  reClux	  symptoms	  are	  mainly	  related	  to	   acid	  reClux,	   or	   to	  mixed	  acid/bile–acid	  reClux	  events;	   fewer	   than	  10%	  of	  reClux	  episodes	   are	   related	   to	   bile	   reClux	   alone69.	   Perhaps	   a	   more	   interesting	   group	   to	  consider	   is	   those	  patients	  with	   persistent	   symptoms	   “on”	  PPI,	   for	   in	   this	   group	  acidic	   reClux	   is	   unlikely	   to	   play	   such	  a	  prominent	   role.	   The	   role	  of	   DGOR	   in	   the	  generation	  of	  persistent	  symptoms	  in	  this	  group	  remains	  uncertain.	  Initial	   studies	  by	  a	  group	  in	  Leuven	  suggested	  a	  signiCicant	  role	  for	  DGOR	  in	  PPI-­‐refractory	  GORD.	  Tack	   et	   al.	   found	  DGOR	   alone	   to	   be	   rather	   important,	   being	   related	   to	   18%	   of	  symptomatic	   episodes	   vs.	   7%	   for	   acid	   and	   10%	   for	   mixed	   reClux70.	   Conversely,	  other	   studies	   have	   suggested	   a	   less	   important	   role	   for	   DGOR	   in	   PPI-­‐refractory	  GORD.	  Karamanolis	   et	  al.	   found	  DGOR	   alone	  to	  be	  related	   to	   4%	  of	   symptomatic	  episodes	   vs.	   10%	   for	   acid	   reClux	   and	   17%	   for	   mixed	   reClux71.	   More	   recently,	  Gasiorowska	  et	  al.	  studied	  a	  similar	  group	  of	  patients,	  and	  again	  found	  DGOR	  alone	  to	   be	  of	   a	   relatively	   lesser	  relevance,	   being	  related	   to	   9%	  of	   symptom	   events	   vs.	  32%	  for	  acid,	  and	  32%	  for	  mixed	  reClux72.	   In	  this	  study,	  treatment	  failure	  after	  PPI	  was	  found	  to	  be	  more	  associated	  with	  persistent	  acid	  reClux	  than	  with	  DGOR.It	  can	  be	  concluded	  that	  DGOR	  alone	  may	  be	  responsible	  for	  a	  signiCicant	  minority	  of	  symptoms	  in	  GORD	  patients	  “on”	  or	  “off”	  PPI	  treatment,	  although	  its	  importance	  is	  less	  than	  that	  of	  acid.
DGOR:	  role	  in	  oesophagitisAs	  with	  acid,	   it	  is	  of	  clinical	   importance	  not	  only	   to	   consider	  the	   role	  of	  DGOR	  in	  symptom	  perception	  in	  GORD,	  but	  also	  its	  role	  in	  producing	  mucosal	  injury.	  Animal	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experiments	   have	   suggested	   a	   likely	   role.	   For	  example,	   canine	   bile	   is	   capable	  of	  producing	  oesophagitis	  in	  a	  dog	  model	  with	  biliary	  diversion	  and	  a	  jejunal	  conduit	  anastomosing	  directly	   to	   the	  oesophagus73.	   Harmon	   et	   al.	   examined	  the	   effect	  of	  pH	  on	  oesophageal	  injury	  in	  rabbit	  mucosa74.	  Using	  hydrogen	  ion	  permeability	  as	  a	  marker	  of	  mucosal	   injury,	   they	  found	  that	   the	   addition	  of	  bile	  acids	  to	  acidic	  and	  weakly	   acidic	   solutions	   greatly	   increased	   mucosal	   injury	   proportional	   to	   their	  concentration	   (0	   to	   5	   mM).	   Furthermore,	   they	   demonstrated	   that	   taurine	  conjugated	   bile	   acids	   (taurocholic	   acid	   and	   taurodeoxycholic	   acid)	   signiCicantly	  increased	  injury	  at	  pH	  2,	   but	   the	  unconjugated	  bile	  acids	   increased	  injury	  at	  pH	  7	  (owing	  to	  the	  different	  pKa	  of	  conjugated	  and	  unconjugated	  bile	  acids).Clinical	  studies	  of	  the	   importance	  of	  bile	  acids	   in	  human	  oesophageal	   injury	  have	  been	   contradictory.	   Two	   different	   intra-­‐oesophageal	   aspiration	   studies	   have	  demonstrated	  conClicting	  results	   regarding	  the	  association	  between	  the	  degree	  of	  oesophageal	  injury	  and	  bile	  acid	  concentrations	  in	  GORD	  patients75,	  76.	  In	  summary,	  it	   seems	   likely	  that	   DGOR	  plays	   a	   role	   in	   the	  development	  of	  mucosal	  erosion	   in	  GORD,	  but	  as	  with	  symptoms	  its	  inCluence	  appears	  less	  than	  that	  of	  acidity.	  
Role	  of	  bile	  acids	  in	  Barrett’s	  oesophagus	  and	  oesophageal	  adenocarcinomaThe	  increasing	  prevalence	  of	  oesophageal	  adenocarcinoma	  despite	  widespread	  use	  of	  proton	  pump	  inhibitors	  has	  led	  to	   speculation	  that	   other	  reClux	  factors	  such	  as	  bile	   acids	   may	   have	   an	   important	   role	   in	   Barrett’s	   oesophagus	   and	   associated	  tumours.	   Barrett’s-­‐like	   intestinal	   metaplasia	   of	   the	  oesophagus	   and	  oesophageal	  adenocarcinoma	   occur	   in	   rat	   models	   of	   bile	   reClux	   (via	   surgical	  oesophagojejunostomy).	  This	  occurs	  with	  or	  without	  total	  gastrectomy	  suggesting	  it	   is	   the	   bile	   reClux	   causing	   the	   effect77-­‐79.	   In	   addition,	   patients	   with	   Barrett’s	  oesophagus	   appear	   to	   have	   greater	  oesophageal	   concentration	  of	  bile	   acids	   than	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patients	  with	  GORD	  but	  without	   Barrett’s80.	   Mechanistic	  support	   is	  added	  by	   the	  observations	   that	   bile	   acids	   are	   able	   to	   cause	   in	   vitro	   and	   in	   vivo	   damage	   to	  epithelial	  DNA	  in	  Barrett’s	  cell	  lines	  and	  in	  Barrett’s	  biopsies81.	  
1.3.1.3	  PepsinPepsin	  is	  an	  enzyme	  whose	  precursor,	  pepsinogen,	  is	  released	  by	  chief	  cells	  in	  the	  stomach.	   Its	  proteolytic	  activity	  has	   long	  established	  it	  as	  a	  possible	  candidate	   in	  mucosal	  injury	  in	  GORD,	  particularly	  in	  association	  with	  acid	  reClux	  (pepsin	  causes	  the	  most	  damage	  at	  its	  optimal	  pH	  activity	  range	  of	  pH	  2–3).	  Some	  evidence	  exists	  for	   its	   role.	   Ex	   vivo	   studies	   in	   rabbits	   showed	   that	   acid	   infusion	   only	   caused	  oesophageal	   mucosal	   injury	   when	   combined	   with	   pepsin82,	   and	   feline	   studies	  showed	   that	  mucosal	   damage	   could	  occur	   at	   higher	   pH	   if	   pepsin	  was	   present58.	  Finally,	   Nagahama	  et	   al.	   found	   that	   experimentally-­‐induced	  oesophagitis	   (caused	  by	   pyloric	   ligation)	   could	   be	   prevented	   by	   the	   intra-­‐gastric	   administration	   of	  pepstatin,	  a	  pepsin	  inhibitor83.It	   is	   likely	   that	   pepsin	   plays	   a	   synergistic	   role	  with	   acid	   in	   the	   development	   of	  mucosal	  injury	  in	  GORD.
1.3.2	  Defensive	  factors	  in	  GORDThe	   human	   body	   has	   a	   variety	   of	   defence	   mechanisms	   against	   the	   noxious	  aggressors	   of	   gastro-­‐oesophageal	   reCluxate.	   These	   range	   from	   gross	   anatomical	  features	  to	  microscopic	  and	  molecular	  physiological	  properties	  that	  guard	  against	  injury	   from	   the	   noxious	   aggressors	   of	   the	   reCluxate.	   The	   following	   summary	  discusses	   these	   anatomical	   and	   macro-­‐physiological	   features	   (Cigure	   3)	   at	   the	  stomach,	  gastro-­‐oesophageal	  junction,	  and	  oesophageal	  levels.
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Figure	  3:	  Defence	  mechanisms	  against	  GORD
1.3.2.1	  StomachIt	   is	   believed	   that	   effective	   gastric	   emptying	   is	   important	   in	   reducing	   gastro-­‐oesophageal	   reClux,	   since	  most	   reClux	  occurs	   in	   the	  post-­‐prandial	   situation	  when	  the	   stomach	   is	   full	   of	   material	   and	   gastro-­‐oesophageal	   pressure	   gradients	   are	  greatest.	   Indeed,	   several	   studies	   (although	   not	   all)	   have	   shown	   that	   gastric	  emptying	  is	  delayed	  in	  a	  variable	  proportion	  of	  patients	  with	  GORD84-­‐87.	  However,	  a	   problem	   with	   these	   studies	   may	   be	   the	   prevalence	   of	   “abnormal”	   gastric	  emptying	   studies	   in	   healthy	   volunteers.	   For	   example,	   one	   study	   found	   delayed	  gastric	   emptying	   (by	   scintigraphy)	   in	   37%	   of	   GORD	   patients	   and	   in	   44%	   of	  controls87.More	  recent	  studies	  have	  focused	  on	  the	  proximal	  stomach	  particularly,	   since	  this	  distinct	  area	   of	  the	   stomach	  may	   be	  more	   relevant	   to	   reClux	  events.	  Two	  studies	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have	  indeed	  shown	  that	  delayed	  recovery	  of	  proximal	   gastric	  tone	  after	  a	  meal	   is	  delayed	   in	   GORD	   patients	   compared	   to	   controls88,	   89.	   In	   agreement	   with	   this,	  Stacher	  et	   al.	   found	  a	  correlation	  between	  slow	  proximal,	   but	   not	   slow	   distal	   or	  total	   gastric	   emptying,	   with	  24-­‐hour	  oesophageal	   acid	  exposure	   in	  patients	  with	  symptoms	  of	  GORD	  and	  delayed	  gastric	  emptying86.	  The	  proximal	  stomach	  motility	  also	   appears	   to	   be	   vitally	   important	   in	   modulating	   formation	   of	   the	   proximal	  stomach	   acid	   pocket	   after	   a	   meal.	   Treatment	   with	   the	   prokinetic	   azithromycin	  reduces	  number	  of	  acid	  reClux	  events,	  seemingly	  by	  causing	  the	  acid	  pocket	  to	  form	  in	  a	  more	  distal	  position52.From	   the	   above	   observations,	   it	   appears	   likely	   that	   normal	   gastric	   motility	   and	  emptying	  can	  play	  a	  role	  in	  guarding	  against	  pathological	  gastroesophageal	  reClux.
1.3.2.2	  The	  antireMlux	  barrierThe	  gastro-­‐oesophageal	   junction	  (GOJ)	  is	   a	  specialised	  anatomical	  complex	  that	  is	  designed	   to	   allow	   passage	   of	   swallowed	   boluses	   from	   the	   oesophagus	   into	   the	  stomach,	   while	  at	   the	   same	   time	   control	   reClux	  of	   gastric	   contents	  back	   into	   the	  oesophagus.	   It	  consists	  of	   two	   structures:	   the	  lower	   oesophageal	   sphincter	  (LOS)	  and	  the	  crural	  diaphragm.The	  GOJ	  is	  situated	  at	   the	  interface	  between	  the	  thoracic	  and	  abdominal	   cavities,	  across	   which	   there	   is	   a	   pressure	   gradient	   that	   varies	   throughout	   respiration.	  During	   inspiration	  there	   is	   a	   decrease	   in	   intra-­‐thoracic	   pressure	  and	  increase	   in	  intra-­‐abdominal	   pressure,	   a	   situation	   that	   favours	   the	   occurrence	   of	   gastro-­‐oesophageal	   reClux.	   The	  GOJ	   forms	   a	  high-­‐pressure	   zone	   between	   these	   cavities	  that,	  under	  normal	  conditions,	  prevents	  reClux	  of	  contents.	  The	   LOS	   is	   a	   specialised	   part	   of	   the	   oesophageal	   smooth	   muscle	   and	   is	  approximately	   4	   cm	   long.	   In	   healthy	   individuals	   it	   exerts	   a	   tonic	   (but	   variable)	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pressure	   of	   15-­‐30	  mmHg	  above	   the	   intragastric	   pressure90,	   91.	   This	   accounts	   for	  approximately	   90%	   of	   the	   basal	   pressure	   of	   the	   GOJ.	   The	   remaining	   10%	   is	  provided	  by	  the	  crural	  diaphragm,	  which	  overlaps	  the	  LOS	  for	  approximately	  2	  cm	  (unless	   there	  is	  a	  hiatal	  hernia,	  where	  there	  are	  two	  distinct	  pressure	  zones,	  with	  the	  LOS	   found	   in	   the	  thorax	  above	   the	   level	   of	  the	  diaphragm).	   This	   provides	   an	  essential	   compensatory	   mechanism	   that	   maintains	   pressure,	   particularly	   during	  inspiration	   and	   straining	   (when	   it	   contracts).	   This	   compensation	   can	   prevent	  reClux	   even	   in	   times	   of	   absent	   LOS	   pressure92,	   93.	   Thus	   the	   LOS	   and	   crural	  diaphragm	   act	   in	   a	   coordinated,	   supplementary	   fashion	   to	   prevent	   gastro-­‐oesophageal	  reClux	  occurring.	   	  The	  presence	  of	  a	  hiatus	  hernia	  means	  that	  the	  two	  mechanisms	   are	   not	   working	   effectively	   in	   tandem,	   and	   the	   basal	   gastro-­‐oesophageal	   junction	  pressure	  is	   lower,	   leading	  to	   increased	  risk	   of	  reClux94.	   The	  hernia	  sac	  can	  also	   serve	  as	  a	  reservoir	  of	  acid	  contents	   that	  are	  readily	  available	  for	  reClux	  during	  LOS	  relaxations.	  This	  mechanism	  may	  prolong	  oesophageal	  acid	  exposure,	   and	   indeed	   most	   patients	   with	   severe	   oesophagitis	   have	   a	   hiatus	  hernia95.	  Transient	   lower	   oesophageal	   sphincter	   relaxations	   (TLOSRs)	  are	  a	   physiological	  mechanism	  whereby	  the	  LOS	  and	  crural	  (but	  not	   costal)	  diaphragm	  involuntarily	  relax	   to	   vent	   excess	   gastric	   gas	   (belching).	   They	   can	   be	   deCined	   as	   an	   abrupt	  decrease	  in	  LOS	  and	  crural	   pressure	  to	  the	   level	   of	  intragastric	   pressure	  that	   are	  not	  triggered	  by	  a	  swallow96.	   	  Most	  reClux	  events,	  whether	  in	  healthy	  controls	  or	  in	  patients,	   occur	   during	   a	   TLOSR97,	   98.	   In	   healthy	   volunteers,	   70-­‐100%	   of	   reClux	  episodes	  occur	  during	  TLOSRs98,	  99.	   In	  patients,	  63-­‐74%	  of	  reClux	  events	  are	  due	  to	  TLOSRs99,	  100.	  The	  lower	  percentage	  in	  patients	  is	  because	  swallow-­‐induced	  reClux,	  extremely	   low	  basal	   LOS	   tone	   and	  straining	   are	   likely	   to	   play	  a	   slightly	  stronger	  role.	   TLOSRs	   are	   triggered	  by	  distension	  of	  the	  proximal	  stomach,	   and	  serve	  as	  a	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prolonged	  (typically	  10-­‐45	  seconds)	  weakness	  in	  the	  anti-­‐reClux	  capabilities	  of	  the	  GOJ.	   Meals	   are	  associated	  with	   an	   increase	   in	  post-­‐prandial	   TLOSR	   frequency101,	  and	   an	   increase	   in	   frequency	   of	   TLOSRs	   is	   associated	   with	   reClux	   events	   in	  patients91,	   101,	   102.	   In	   humans,	   TLOSRs	   only	   occur	   during	   the	   awake	   state.	   The	  current	   belief	   on	   the	   neural	   activation	   of	   TLOSRs	   is	   that	   they	   are	   a	   vagally-­‐mediated	  event	  predominantly	  stimulated	  by	  activation	  of	  proximal	  gastric	  stretch	  receptors.	   Obliteration	   of	   the	   vagus	   in	   dogs	   ceases	   TLOSRs103,	   and	   absence	   of	  TLOSRs	   in	   achalasia	   suggests	   a	   similar	   neural	   mechanism	   of	  TLOSRs	   to	   that	   of	  swallow-­‐induced	  relaxations	  (which	  are	  vagally-­‐mediated)104.
1.3.2.3	  Oesophageal	  clearance	  mechanismsOesophageal	   body	  motility	   is	   a	  key	   factor	   in	  maintaining	   defence	   against	   gastro-­‐oesophageal	   reClux.	   Peristalsis	   is	   important	   both	   for	   clearance	   of	   the	   reCluxed	  material	   back	   into	   the	  stomach,	   and	   for	   the	   delivery	   of	   buffering	  bicarbonate	   in	  saliva	  to	  the	  distal	  oesophagus.	  Peristalsis	   in	   response	   to	   a	  reClux	  event	   can	  either	   be	  swallow-­‐induced	  (primary	  peristalsis)	   or	   due	   to	   a	   distension-­‐induced	   reClex	   not	   related	   to	   a	   swallow	  (secondary	   peristalsis).	   Primary	   peristalsis	   is	   the	   most	   frequent	   response	   to	   a	  gastro-­‐oesophageal	   reClux	   event	   in	   both	   healthy	   subjects	   and	   patients	   with	  GORD105.	   However,	   primary	   peristalsis	   may	   be	   more	   often	   impaired	   in	   GORD	  patients	   compared	   to	   healthy	   volunteers.	   A	   study	   by	   Dodds	   et	   al.	   showed	  incomplete	   peristalsis	   in	   27%	   of	   GORD	   patients	   versus	   7%	   of	   controls,	   and	  oesophageal	   acid	   clearance	  was	   inversely	   related	   to	   the	   rate	   of	   intact	   swallow-­‐induced	   peristalsis106.	   A	   more	   recent	   study	   has	   shown	   that	   severe	   ineffective	  oesophageal	  motility	  carried	  an	   independent	   risk	   of	  prolonged	  oesophageal	   acid	  clearance	   (OR	   2.9)107.	   Indeed,	   peristaltic	   function	   appears	   to	   worsen	   as	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oesophagitis	   severity	   increases108,	   and	   impaired	   oesophageal	   motility	   is	   more	  prevalent	  in	  erosive	  oesophagitis	  patients	  than	  in	  patients	  with	  NERD107.	  Secondary	   peristalsis	   is	   a	   reClex	   mechanism	   triggered	   by	   oesophageal	   body	  distension,	   usually	   either	   due	   to	   a	   retained	   swallowed	   bolus	   or	   a	   gastro-­‐oesophageal	   reClux	  event.	   DeCicient	   secondary	   peristalsis	   has	   been	   implicated	   in	  GORD.	  It	  has	  been	  demonstrated	  that	  the	  frequency	  of	  secondary	  peristalsis	  events	  is	   lower	   in	   patients	   with	   GORD	   than	   in	   healthy	   individuals106.	   Triggering	   of	  secondary	  peristalsis	  requires	  intact	  afferent	  signalling.	  There	  is	  evidence	  that	  this	  may	   be	   defective	   in	   oesophagitis,	   where	   the	   time	   to	   triggering	   of	   secondary	  peristalsis	  is	  delayed	  compared	  to	  healthy	  controls106,	  109.Of	  course,	   it	   is	   not	   yet	   entirely	   clear	   whether	   ineffective	  oesophageal	  motility	   in	  GORD	  is	  a	  primary	  event	  promoting	  oesophageal	  acid	  exposure,	  or	  a	  phenomenon	  that	  is	  secondary	  to	  the	  reClux	  disease	  itself.	  Studies	  in	  cats	  where	  oesophagitis	  was	  experimentally	   produced	   and	   then	   healed	   suggest	   that,	   at	   least	   in	   the	   case	   of	  severe	  oesophagitis,	  impaired	  oesophageal	  motility	  can	  be	  a	  reversible	  response	  to	  oesophageal	  inClammation17.	   In	  contrast,	   a	  number	  of	  human	  studies	  have	  shown	  that	   treatment	   of	   oesophagitis	   with	   anti-­‐secretory	   drugs	   does	   not	   improve	  effectiveness	  of	  primary	  or	  secondary	  peristalsis110,	  111.Mechanical	  clearance	  by	  way	  of	  peristalsis	  is	  the	  major	  mechanism	  for	  clearance	  of	  reCluxed	  acid,	   but	  an	  important	  secondary	  role	  is	   played	  by	  the	  chemical	  effect	  of	  saliva	  that	  is	  delivered	  to	  the	  distal	  oesophagus	  during	  swallowing.	  Overall	  it	  takes	  7	  to	  10	  swallows	  to	  restore	  normal	  pH	  to	  the	  distal	   oesophagus	  after	  acidiCication	  with	  a	  15	  ml	  bolus	  of	  acid,	  and	  stimulation	  of	  saliva	  secretion	  reduces	  the	  time	  to	  acid	   clearance112.	   Saliva	   production	   is	   increased	   on	   acidic	   stimulation	   of	   the	  oesophagus	   (causing	   symptoms	   of	   waterbrash).	   It	   has	   been	   shown	   that	   acid	  perfusion	  of	   the	   healthy	   oesophagus	   induces	   parotid	  salivary	   secretion	   in	   a	  pH-­‐
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dependent	  manner113.	  This	  salivary	  response	  is	  more	  profound	  when	  the	  proximal	  rather	  than	  distal	  oesophagus	  is	  exposed	  to	  acid114.
1.3.3	  Epithelial	  defensive	  mechanismsThe	  aforementioned	  macroscopic	   features	   are	   undoubtedly	   important	   in	  defence	  against	  GORD.	   	   However,	   perhaps	   the	  most	   important	   reason	  why	   physiological	  acid	   reClux	   does	   not	   cause	   mucosal	   inClammation	   and	   erosion	   in	   healthy	  individuals	   is	   the	   fact	   that	   the	   human	   oesophageal	   epithelium	   has	   an	   array	   of	  protective	  mechanisms	  and	  characteristics	  to	  prevent	  damage	  occurring.	  As	   a	   generalisation,	   the	   epithelial	   defence	   mechanisms	   can	   be	   split	   into	   three	  separate	   (but	   not	  necessarily	   mutually	   exclusive)	  parts:	  pre-­‐epithelial,	   epithelial,	  and	  post-­‐epithelial	  defence	  (Cigure	  4).
Figure	  4:	  Epithelial	  mechanisms	  of	  defence	  against	  GORD
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1.3.3.1	  Pre-­‐epithelial	  defencePre-­‐epithelial	  defences	  are	  those	  that	  act	  as	  a	  barrier	  to	  limit	  contact	  of	  the	  gastro-­‐oesophageal	  reCluxate	  with	  the	  oesophageal	  epithelium.	  These	  include	  the	  mucous	  layer,	  and	  bicarbonate	  ions.	  Oesophageal	  submucosal	  glands	  lie	  within	  the	  oesophageal	  submucosa.	  Each	  gland	  culminates	  in	  a	  single	  duct	  that	  collects	  acinar	  secretions	  and	  delivers	   them	  to	  the	  oesophageal	  lumen.	   The	  predominant	  cell	   type	  in	  the	  submucosal	   gland	  acinus	   is	  the	   chief	   cell,	   which	   secretes	   mucous.	   In	   contrast	   to	   the	   mucous	   layer	   of	   the	  stomach	   (which	   contains	   the	   mucoproteins	   MUC5AC	   and	  MUC6115),	   the	   mucous	  layer	  of	  the	  oesophagus	   is	   relatively	  ineffective	  as	  a	  barrier.	  The	  mucous	  secreted	  by	   the	   oesophageal	   submucous	   glands	   contains	   a	   water-­‐soluble	   mucoprotein	  (MUC5B)	   that	   serves	   well	   as	   a	   lubricant,	   but	   not	   well	   as	   a	   protectant116.	   The	  mucous	   layer	   does	   not	   block	   diffusion	  of	   hydrogen	   ions.	   As	   such,	   the	   pH	   at	   the	  oesophageal	  epithelium	   falls	   rapidly	   to	   2-­‐3	  when	  the	   luminal	  pH	  is	   2.0	   (a	  typical	  pH	  of	   the	  gastroesophageal	   reCluxate)117.	   In	  the	   submucous	   gland	  acini	   there	   are	  also	   subsidiary	   cells	   that	   produce	   a	   watery,	   bicarbonate-­‐rich	   secretion118.	   This	  bicarbonate	   secretion	   can	   be	   stimulated,	   in	   humans,	   by	   vagal	   excitation	   and	  oesophageal	   acid	   perfusion119,	   120.	   In	   the	   supine	   position	   whilst	   sleeping	  (eliminating	  the	  effects	  of	  gravity	  and	  swallowing)	  this	  bicarbonate	  secretion	  into	  the	   lumen	   appears	   to	   be	   able	   to	   raise	   the	   oesophageal	   pH	   at	   a	   rate	   of	  approximately	   1	   pH	   unit	   per	   10	   minutes97,	   and	   thus	   may	   be	   very	   important	  particularly	  in	  nocturnal	  reClux	  when	  primary	  peristalsis	  occurs	  infrequently.
1.3.3.2	  Epithelial	  defenceOesophageal	   epithelial	   defence	   is	   required	  when	   pre-­‐epithelial	   mechanisms	   are	  not	   sufCicient	   to	   prevent	   the	   noxious	   components	   of	   the	   reCluxate	   coming	   into	  
Chapter 1
47
contact	  with	  the	   epithelium.	   The	  oesophageal	   epithelium	   is	   a	  multilayered,	   non-­‐keratinised	   stratiCied	   squamous	   epithelium.	   It	   consists	   of	   the	   stratum	   corneum,	  stratum	  spinosum	  and	  the	  stratum	  germinativum.	  The	  stratum	  corneum	  is	  closest	  to	   the	   lumen	   and	   consists	   of	   multiple	   layers	   of	   Clat	   cells	   in	   various	   stages	   of	  desquamation.	   It	  acts	   as	   a	  barrier	   to	   the	  passage	   of	   ions	   and	  aqueous	  molecules	  from	  lumen	  to	  deeper	  epithelium.	  This	  permeability	  barrier	  is	  formed	  by	  apical	  cell	  membranes	  and	  apical	  junctional	  complexes	  that	  prevent	  the	  diffusion	  of	  luminal	  acid	   into	   the	  cells	  or	   intercellular	   spaces.	   The	  apical	  cell	  membranes	  prevent	  this	  diffusion	   by	   their	   hydrophobic	   nature,	   and	   due	   to	   the	   fact	   that	   their	   cation	  channels	   are	   inhibited	   by	   luminal	   acidity.	   The	   apical	   junctional	   complexes	   are	  essential	  for	  maintenance	  of	  mucosal	  integrity.	  They	  are	  formed	  by	  tight	  junctions,	  adherens	   junctions	   and	   desmosomes.	   These	   structures	   greatly	   limit	   the	   rate	   of	  paracellular	   ion	   diffusion121,	   122,	   which	   is	   very	   important	   since	   transcellular	   ion	  diffusion	  from	  lumen	   to	   basolateral	   aspect	   of	  the	   cell	   is	   extremely	   limited	   in	   the	  oesophagus.	   Each	  of	   these	  components	  has	  an	  extracellular,	   transmembrane	  and	  intracellular	   domain	   responsible	   for	   cell	   signalling	   and	   barrier	   function.	   Their	  barrier	   function	   is	   provided	   by	   component	   proteins	   bridging	   the	   intercellular	  space.	  The	  tight	  junction	  is	  positioned	  at	  the	  boundary	  of	  the	  apical	  and	  basolateral	  plasma	  membrane	   domains.	   The	  gate	   function	   of	   the	   tight	   junction	   controls	   the	  paracellular	  pathway	  for	  ion	  movement	  in	  between	  cells	  in	  an	  epithelial	  layer.	   For	  tight	   junctions	   the	   major	   proteins	   are	   members	   of	   the	   claudin	   and	   occludin	  families.	   At	   least	   19	   claudins	   have	   been	   found	   in	   the	   oesophageal	   mucosa,	   but	  claudin	   1	   and	   4	   are	   the	   most	   prominent.	   The	   structure	   of	   claudin-­‐based	   tight	  junctions	  is	  yet	  to	  be	  fully	  resolved,	  but	  the	  primary	  role	  of	  claudins	  appears	  to	  be	  related	   to	   the	   regulation	   of	   paracellular	   selectivity	   to	   small	   ions123.	   The	  heterologous	  expression	  in	  monolayers	  of	  the	  majority	  of	  claudin	  isoforms	  leads	  to	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an	   experimental	   increase	   of	   the	   transepithelial	   electrical	   resistance	   (see	   later),	  predominantly	   due	   to	   a	   selective	   decrease	   in	   cation	   permeability124-­‐128.	   In	   a	   rat	  model	   it	   was	   shown	   that	   rats	   with	   reClux	   oesophagitis	   have	   an	   increased	  expression	   of	   claudin	   1,	   a	   decreased	   expression	   of	   claudin	   3,	   and	   an	   altered	  localisation	  of	  claudin	  4	  compared	  to	  control	  rats129.	  Occludin	   is	   becoming	   increasingly	   recognised	   as	   an	   important	   transmembrane	  protein	  localising	  at	  the	  tight	  junction.	   It	  comprises	  four	  transmembrane	  domains,	  a	  long	  carboxyl-­‐terminal	  cytoplasmic	  domain,	   a	  short	  amino-­‐terminal	  cytoplasmic	  domain,	   two	   extracellular	   loops,	   and	   one	   intracellular	   turn130.	   It	   is	   directly	  associated	  with	   the	   cytoplasmic,	   tight	   junction	   constitutive	   protein	  ZO-­‐1131.	   The	  barrier	  role	  of	  occludin	  is	  not	  yet	  fully	  understood,	  but	  it	  may	  perform	  a	  regulatory	  role	  for	  claudins.	  ZO-­‐1	  binds	  to	  occludin	  (and	  other	  tight	  junction	  proteins	  such	  as	  claudin-­‐1)	  and	  is	  essential	   for	   the	  integrity	  of	  the	  tight	  junction132.	   ZO-­‐1	  has	  been	  proposed	   to	   be	   a	   scaffolding	   protein	   between	   transmembrane	   and	   cytoplasmic	  proteins,	  and	  possibly	  to	  form	  a	  link	  between	  the	  adherens	  and	  tight	  junctions.Along	  with	  the	  more	  apically	   located	  tight	  junction,	  an	  intact	  adherens	  junction	  is	  also	   required	   for	   integrity	   of	   the	   epithelial	   barrier133.	   The	   adherens	   junction	  performs	   important	   roles	   in	   cell-­‐cell	   adhesion	   and	   regulation	   of	   the	   actin	  cytoskeleton.	   Cadherins,	   especially	  E-­‐cadherin,	  are	  the	  major	  protein	  components	  of	   the	  adherens	   junction.	  They	   initiate	   cellular	  contacts	   through	  pairing	  between	  cadherins	  on	  opposing	  cells.	  They	  can	  also	  bind	  to	  cytoplasmic	  proteins	  (catenins)	  which	   locally	   regulate	   actin	   cytoskeleton	   organisation,	   cadherin	   stability	   and	  intracellular	   signalling	  pathways	   that	   control	   gene	   transcription134.	   Formation	  of	  the	   adherens	   junction	   leads	   to	   tight	   junction	   formation,	   but	   after	   assembly	   E-­‐cadherin	  is	  not	  required	  to	  maintain	  tight	  junction	  organisation135.
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Unlike	   adherens	   and	   tight	   junctions,	   desmosomes	   do	   not	   fully	   encircle	   the	   cell.	  They	   do,	   however,	   contribute	   to	   cell-­‐cell	   apposition	   by	   acting	   as	   spot	   weld-­‐like	  adhesions	  arranged	  around	  the	   cell	   plasma	  membranes.	   They	  act	   as	   anchors	   for	  intermediate	  Cilaments	  that	  project	  into	  the	  cell	  cytoplasm.	  Desmosomes	  appear	  to	  be	  more	  important	  in	  structural	  rather	  than	  ionic	  integrity	  of	  cells,	  and	  they	  act	  to	  resist	  against	  shearing	  forces.
The	  barrier	  formed	  by	  tight	  junctions,	  adherens	  junctions	  and	  desmosomes	  is	  not	  perfect,	   and	   sometimes	   acid	   is	   able	   to	   penetrate.	   Consequently	   there	   must	   be	  further	   epithelial	   defences	   in	   place	   to	   protect	   the	   tissue.	   Intracellular	   proteins,	  phosphates	  and	  bicarbonate	  are	  able	  to	  buffer	  the	  pH	  when	  hydrogen	  ions	  diffuse	  into	  the	  oesophageal	  epithelial	  cells.	  Bicarbonate	  can	  readily	  diffuse	  from	  the	  blood	  into	   the	   intracellular	   space,	   and	   can	   also	  be	  produced	  de	   novo	   in	   the	  cytosol	   via	  carbonic	  anhydrase136.Excess	  acid	  can	  also	  be	  transported	  actively	  out	  of	  the	  epithelial	  cells.	  This	  is	  done	  on	   the	   basolateral	   membrane	   by	   sodium-­‐dependent	   chloride-­‐bicarbonate	  exchangers,	  and	  by	  sodium-­‐hydrogen	  anion	  exchangers137,	  138.
1.3.3.3	  Post-­‐epithelial	  defenceThe	  blood	  supply	  to	   the	  epithelium	  forms	  the	  basis	  of	  most	  post-­‐epithelial	  defence	  against	   reClux.	   Tissue	   acid-­‐base	   balance	   is	   preserved	   by	   delivery	   of	   bicarbonate	  from	  the	  blood	  to	  the	  epithelium	  to	  neutralise	  acid	  pH	  shifts.	  In	  cases	  of	  increased	  tissue	  acid	  load	  the	  blood	  Clow	  is	  able	  to	  increase	  to	  deliver	  more	  bicarbonate	  (and	  remove	  more	  carbon	  dioxide).	  The	  blood	  is,	  of	  course,	  also	  a	  source	  of	  nutrients	  to	  aid	  repair	  of	  damaged	  epithelium.
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1.4 Oesophageal mucosal integrity
The	   integrity	   of	   the	   epithelial	   defences	   already	   described	   are	   likely	   to	   be	   of	  paramount	   importance	   in	   protection	   against	   gastro-­‐oesophageal	   reClux	   induced	  symptoms	   and	   complications.	   Impairment	   of	   these	   epithelial	   defences	   are	  increasingly	   being	   realised	   in	   GORD,	   and	   are	   an	   exciting	   area	   for	   research	   into	  pathogenesis	  and,	  potentially,	  new	  therapeutic	  interventions.The	  morphological	  and	  functional	  barrier	  effectiveness	  of	  the	  oesophageal	  mucosal	  epithelium	  may	  otherwise	  be	  termed	  as	  the	  oesophageal	  mucosal	  integrity.	  Clearly	  in	   erosive	  oesophagitis	   there	  is	   a	   breakdown	   in	  the	   epithelial	   integrity	   that	  may	  allow	   penetration	  of	  noxious	   reCluxate	   deep	   into	   the	  mucosa.	   However,	   in	  non-­‐erosive	  reClux	  disease	  the	  integrity	  of	  the	  mucosa	  is	   less	  easy	  to	  assess.	   A	  number	  of	   methods	   have	   now	   been	   devised	   to	   enable	   expression	   of	   epithelial	   defence	  properties	  in	  non-­‐erosive	  reClux	  disease.	  Thus,	   the	  integrity	  of	  the	  mucosa	  can	  be	  expressed	  in	  terms	  of:
1) Functional	  integrity• The	  integrity	  of	  barrier	  function	  as	  demonstrated	  by	  permeability	   (e.g.	  to	  ions	  or	  small	  molecules).
1) Morphological	  integrity• Macroscopic	  (oesophageal	  erosions,	  as	  in	  erosive	  oesophagitis).• Microscopic	  (epithelial	  changes	  on	  light	  or	  electron	  microscopy).
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1.4.1	  Functional	  measurements	  of	  oesophageal	  mucosal	  integrity
1.4.1.1	  In	  vitro	  studiesFunctional	  demonstration	  of	  mucosal	  integrity	  and	  its	  impairment	  in	  GORD	  is	  not	  a	  new	  concept.	  Electrical	  potential	  differences	  across	  the	  wall	  of	  the	  gastrointestinal	  tract	   were	   Cirst	   described	   in	  1834139.	   Over	   60	   years	   ago	   it	  was	   realised	   that,	   on	  measuring	  the	  transmural	  potential	  difference,	  the	  charge	  of	  the	  luminal	  surface	  of	  the	  stomach	  was	  negative	  in	  relation	  to	   the	  serosal	  surface140,	   141.	  Subsequently	  it	  was	   demonstrated	   that	   there	   is	   a	   positive	   change	   in	   the	   transmural	   potential	  difference	  on	  transition	  from	  the	  gastric	   columnar	  epithelium	  to	  the	  oesophageal	  squamous	  epithelium142.It	   was	   found	   in	   1964	   that,	   in	   the	   stomach,	   areas	   of	   mucosal	   damage	   were	  associated	  with	   reduced	   transmucosal	   potential	   difference143.	   In	  1969	  Beck	   and	  Hernandez	  used	  a	  “through	  the	  oesophagoscope”	  electrode	  to	  measure	  variations	  in	  potential	  difference	  over	  lesions	  where	  the	  mucosal	  integrity	  of	  the	  oesophagus	  was	   destroyed	   by	   erosions.	   They	   found	   that	   there	   was	   a	   profound	   drop	   (less	  negative)	  in	   potential	   difference	  measured	   over	   the	   ulcerated	   area	   compared	   to	  the	   surrounding	   oesophageal	   mucosa144.	   As	   such,	   it	   was	   proposed	   that	  measurements	   of	   potential	   difference	   could	   be	   a	   surrogate	   of	   the	   oesophageal	  mucosal	  integrity.	  Khamis	  et	  al.	  proposed	  potential	  difference	  as	  a	  possible	  tool	  in	  diagnosis	  of	  GORD	  in	   1978145.	   They	   studied	   19	   patients	   with	   upper	   gastrointestinal	   symptoms	  (dysphagia,	   restrosternal	   discomfort,	   heartburn,	   and	   epigastric	   pain)	   by	  gastroscopy	   and	   biopsy.	   They	   used	   a	   “through	   the	   endoscope”	   electrode,	  referenced	   to	   the	   skin,	   to	   measure	   transmural	   potential	   difference	   during	   the	  procedure.	   Potential	   difference	   was	   measured	   at	   the	   distal	   oesophagus,	   and	   a	  mucosal	   biopsy	   taken	  from	  the	  same	   area	   for	  histological	   analysis.	   Nine	  patients	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fulCilled	  the	   authors’	  histological	   criteria	  (basal	   cell	  hyperplasia	   and	  extension	  of	  the	  papillae)	  for	  gastro-­‐oesophageal	   reClux	  disease,	   and	   ten	  patients	   had	  normal	  biopsies.	   The	  mean	   value	   of	   the	   oesophageal	   potential	   difference	   in	   those	  with	  normal	   biopsies	  was	   −14.4mV,	  whereas	   in	  those	  with	  “reClux”	  changes	   the	   value	  was	   +9.4mV.	   Consequently	   the	   authors	   suggested	   that	   the	   potential	   difference	  might	   aid	   in	   diagnosis	   of	   GORD.	   It	   should	   be	   realised	   that	   such	   a	   histological	  method	  is	  a	  non-­‐speciCic	  approach	  (probably	  with	  low	   sensitivity)	  to	  diagnosis	  of	  GORD,	  and	  this	  will	  have	  had	  an	  impact	  on	  the	  validity	  of	  the	  Cindings.The	  possibility	  of	  measuring	  oesophageal	   potential	  difference	  as	  a	  diagnostic	   tool	  was	  revisited	  by	  Orlando	  et	  al.	  in	  1982146.	  They	  measured	  potential	  difference	  and	  took	   mucosal	   biopsies	   from	   the	   oesophagus	   of	   103	   patients	   with	   symptoms	   of	  heartburn,	   chest	   pain	  or	   dysphagia.	   The	  potential	   difference	  was	   measured	   in	  a	  station	  pull-­‐through	  manner	  from	  distal	  to	  proximal	  oesophagus.	  They	  again	  found	  that	  a	  low	  (less	  negative)	  potential	  difference	  is	   found	  in	  areas	  of	  macroscopically	  inClamed	  mucosa.	   It	  was	  postulated	  that	  the	  oesophageal	  potential	  difference	  may	  become	   lower	   due	   to	   a	   decrease	   in	   tissue	   resistance.	   However,	   the	   potential	  difference	  was	   less	   sensitive	   at	   detecting	   less	   severe,	  microscopic,	   inClammation.	  This	   is	   important	   since	   the	  diagnostic	   challenge	   is	   the	  distinction	   of	  non-­‐erosive	  reClux	  disease	  from	  functional	  heartburn,	  which	  could	  not	  be	  met	  by	  this	  approach.The	   same	   group	   investigated	   the	   pathophysiological	   sequence	   further	   using	   an	  animal	  model	   in	  which	  potential	  difference	  was	  measured147.	   	  They	  developed	  a	  model	  of	  progressive	  acid	  damage	   in	  the	  oesophageal	  mucosa	  of	  rabbits	  by	   intra-­‐oesophageal	   catheter	   perfusion	   of	   acid	   and	   pepsin.	   The	   in	   vivo	   oesophageal	  potential	   difference	   was	   measured	   before,	   during	   and	   after	   the	   perfusion.	   At	  speciCic	   periods	   related	   to	   changes	   in	   potential	   difference,	   the	   rabbits	   were	  sacriCiced,	  the	  oesophagus	  removed,	  and	  the	  mucosa	  placed	  in	  Ussing	  chambers	  for	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studies	   of	   sodium	   and	   chloride	   transport.	   They	   found	   that	   medium	   to	   high	  concentrations	   of	   acid	   perfusion	   caused	   a	   reduction	   in	   transmural	   potential	  difference	  in	  vivo.	  The	  studies	  identiCied	  the	  mechanism	  for	  acid	  movement	  across	  the	   epithelium.	   This	   can	   potentially	   be	   paracellular,	   transcellular,	   or	   both.	   The	  Ussing	   chamber	   experiments	   show	   a	  reduced	  electrical	   resistance	  and	   increased	  bidirectional	   chloride	   transport	   on	   acid	   exposure,	   suggesting	   paracellular	  movement	  is	  predominantly	  occurring.Tobey	  et	  al.	   investigated	  the	  implications	  of	  this	  possibility	  on	  permeability	   in	  the	  rabbit	   oesophagus	  when	  exposed	  to	   acid	  in	  vitro148.	   	  They	  placed	  strips	  of	  rabbit	  mucosa	   in	  Ussing	   chambers	   and	  exposed	  them	   to	   acid	  and	  acid-­‐pepsin	  solutions,	  conducting	  circuit	  analysis	  and	  permeability	  studies.	  The	  circuit	  analysis	  was	  done	  to	   calculate	  the	  RT	  (transepithelial	   resistance),	   Ra	   (apical	  membrane	  resistance),	  Rb	  (basolateral	  membrane	  resistance),	   and	  RS	  (shunt,	   or	  paracellular	  resistance).	  The	   RT	   can	   be	   calculated	   according	   to	   Ohm’s	   law	   (V=IR).	   The	   resistance	   is	  calculated	  from	  knowing	  the	  open	  circuit	  transepithelial	  voltage	  potential,	   and	  the	  current	   required	   to	   clamp	  the	  potential	   to	   a	   constant	   (e.g.	   zero).	   The	  calculated	  resistance	  multiplied	  by	   the	  surface	  area	  of	  the	  preparation	  is	  the	  RT	   (equivalent	  to	   transepithelial	  electrical	   resistance,	   TER).	   It	  has	   previously	  been	  demonstrated	  that	  RT	  =	  (Ra	  +	  Rb).RS	  /	  (Ra	  +	  Rb	  +	  RS)149.	  The	  investigators	  used	  nystatin	  in	  the	  basal	   chamber	   to	   effectively	   eliminate	   the	   Rb	   component	   of	   RT	   (nystatin	  permeabilises	   the	   basolateral	   membrane	   of	   the	   cell	   epithelium),	   and	   allow	  approximation	  of	  the	  RT	  to	  Ra	  +	  RS.	  After	   treatment	  with	  nystatin	  both	  chamber	  solutions	  were	  Cilled	  with	  a	  sodium-­‐	  and	  potassium-­‐free	  solution	  to	  abolish	  sodium	  and	   potassium	   diffusion	   across	   the	   apical	   membrane	   through	   sodium	   channels	  (eliminating	  Ra).	   	   RT	  was	   recorded	  again	  as	   an	  approximation	  of	  RS.	  They	  were	  able	  to	  demonstrate	  that	  in	  a	  physiological	  solution,	  RT	  very	  closely	  approximates	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RS:	  i.e.	  almost	  all	  ion	  transit	  occurs	  via	  the	  paracellular	  route.	   	  This	  is	  why,	   in	  more	  recent	   studies,	   the	   RT	   (TER)	   has	   been	   used	   in	   preference	   to	   the	   potential	  difference	   in	  measurement	   of	   oesophageal	   mucosal	   integrity:	   it	   offers	   a	   better	  reClection	  of	  the	  paracellular	  barrier,	  and	  it	  also	  offers	  a	  correction	  according	  to	  the	  surface	  area	  of	  the	  epithelium	  being	  studied.During	  30	  minutes	   exposure	   of	   the	  oesophageal	   tissue	   to	   acid	   (pH	   1)	  and	  acid-­‐pepsin	  (pH	  2	  +	  1	  mg/ml	  pepsin)	  solutions	  in	  the	  “basal”	  Ussing	  chamber,	   the	  RT	  of	  the	  mucosa	  fell	  by	  approximately	  50%.	  They	  were	  further	  able	  to	  demonstrate	  that	  the	  decline	  in	  RT	  is	  almost	  completely	  caused	  by	  a	  decline	  in	  RS,	  i.e.	  is	  caused	  by	  an	  increase	   in	   paracellular	   tissue	   permeability.	   Having	   established	   increased	   shunt	  permeability	   on	   exposure	   of	   oesophageal	   epithelium	   to	   acid,	   the	   authors	  investigated	  the	  size	  of	  this	   shunt	   leak	   by	  measuring	  the	   permeability	   to	   various	  sized	   dextran	   molecules.	   They	   found	   little	   or	   no	   dextran	   permeability	   (and	   no	  reduction	  in	  RT)	  on	  exposure	  of	  the	  epithelium	  to	   a	  control	   (pH	  7.4)	  solution,	  but	  acid	   and	  acid-­‐pepsin	  exposure	  resulted	   in	   signiCicantly	   increased	  permeability	   to	  dextrans	   up	   to	   20	   kD	   in	   size.	   Furthermore,	   they	   found	   an	   inverse	   and	   linear	  relationship	  between	  RT	  and	  dextran	  permeability.	  Thus	   far	  it	  had	  been	  established	  that,	   in	  rabbits,	   strong	  acids	  at	  pH	  1	  or	  pH	  2	  are	  able	   to	   cause	   an	   increased	   paracellular	   permeability	   of	   the	   oesophageal	  epithelium.	  However,	  there	  had	  also	  been	  clinical	  observations	  that	  patients	  taking	  proton	  pump	  inhibitors	  can	  also	   perceive	  weakly	  acidic	   (pH	  4-­‐6)	  reClux	  events	  as	  symptomatic56,	   150.	   In	   addition,	   as	   previously	   mentioned,	   there	   has	   long	   been	  consideration	   that	   components	   of	   DGOR	   (especially	   bile	   acids)	   are	   involved	   in	  GORD	  pathogenesis70,	   151,	   152.	   Farré	   et	   al.	   investigated	  the	   in	   vitro	   effects	  of	   acidic	  and	   weakly	   acidic	   solutions	   containing	   pepsin	   and	   bile	   acids	   on	   RT	   and	  permeability	   to	   Cluorescein	   molecules153.	   Again	   they	   used	   rabbit	   oesophageal	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mucosal	   in	   an	   Ussing	   chamber	   model.	   Again,	   they	   found	   that	   exposure	   of	   the	  mucosa	  to	  a	  neutral	  (pH	  7.4)	  solution	  had	  no	  effect	  on	  epithelial	  RT.	  However	  they	  found	   that	   exposure	   of	   rabbit	   oesophageal	   mucosa	   to	   acidic	   and	  weakly	   acidic	  solutions	  containing	  low	  (0.5	  to	  5	  mM)	  concentrations	  of	  bile	  acids	  and	  pepsin	  (1	  mg/ml)	  caused	  a	  fall	   in	  the	  RT	  and	  an	  increase	  in	  the	  permeability	  to	   Cluorescein.	  The	  most	   striking	   effect	  was	   seen	  in	  the	   case	  of	   strongly	   acidic	   (pH	   2)	  solutions	  containing	   bile	  acid	  and	  pepsin.	  Weakly	  acidic	   solutions	  containing	  bile	   acid	  and	  pepsin	   caused	   a	   smaller,	   yet	   signiCicant,	   fall	   in	   RT	   and	   increase	   in	   Cluorescein	  permeability.	   Bile	   acids	   in	   neutral	   (pH	   7.4)	   solutions	   with	   pepsin	   caused	   no	  increase	  in	  permeability	  to	  Cluorescein.	  In	  this	  study	  there	  was	  a	  strong	  correlation	  (r=0.83)	  between	   the	  TER	   values	  and	  and	  permeability	  to	   Cluorescein,	   suggesting	  that	  the	  TER	  is	  a	  good	  reClection	  of	  the	  tissue	  permeability.Data	  on	  functional	   integrity	   in	  human	  subjects	   is	  much	  more	  sparse.	   Tobey	  et	  al.	  have	  published	  data	  of	  baseline	  electrical	   properties	  of	  squamous	  epithelium	  and	  Barrett’s	   columnar	   epithelium	   from	   biopsies	   taken	   at	   upper	   gastrointestinal	  endoscopy122.	   They	   found	  that	   the	  transepithelial	   potential	  difference	  is	   lower	   in	  squamous	   epithelium	   than	   in	   Barrett’s	   columnar	   epithelium.	   Using	   electrical	  parameter	  measurements	  at	  baseline	  and	  after	  bathing	  solution	  ionic	  replacement,	  they	  again	   found	   that	   the	  potential	   difference	   in	   squamous	   epithelium	   reClects	  a	  low	   level	   of	   active	   ion	   transport	   combined	   with	   a	   high	   level	   of	   tissue	   shunt	  resistance.	   In	  Barrett’s	  columnar	  epithelium	  they	  demonstrated	  that	  the	  potential	  difference	  reClects	  a	  high	  level	  of	  active	  transport	  and	  a	  low	  level	  of	  resistance.	  This	  was	  interpreted	  as	  showing	  that	  the	  Barrett’s	  epithelium	  has	  a	  greater	  capacity	  for	  cation	  (including	  hydrogen)	  and	  bicarbonate	  secretion	  than	  squamous	  epithelium,	  a	  potential	  protective	  mechanism.	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Finally,	  also	  in	  human	  subjects,	  Jovov	  et	  al.	  investigated	  oesophageal	  biopsies	  of	  20	  patients	  with	  GORD,	  and	  23	  healthy	  controls.	   In	  Ussing	  chambers	  they	  bathed	  the	  biopsies	   in	   neutral	   solutions,	   but	   did	   not	  perform	  exposures	   to	   acidic	   solutions.	  They	   found	   that	   the	   baseline	   RT	   was	   signiCicantly	   lower	   at	   baseline	   in	   GORD	  patients	   than	   in	   controls,	   and	   that	   Cluorescein	   Clux	   across	   the	   epithelium	   was	  signiCicantly	  greater	  over	  2	  hours	  in	  GORD	  patients	  than	  in	  controls133.	  The	  above,	  in	   vitro,	  studies	  suggest	  that	  the	  contact	  of	  acid	  and	  perhaps	  weak	  acid	  (plus	   or	  minus	  bile	   acid	  and	   pepsin)	  with	  animal	   oesophageal	  mucosa	   is	   able	   to	  produce	  an	   impairment	   of	  mucosal	   functional	   integrity	   in	   terms	  of	  failure	  of	  the	  barrier	  mechanism	  against	  paracellular	  passage	  of	  ions	  and	  small	  molecules.	  What	  is	   unknown	   is	   how	   the	   functional	   integrity	   (in	   terms	   of	   RT,	   or	   TER)	  of	  human	  oesophageal	   mucosa	   dynamically	   responds	   to	   acid	   and	   bile	   acid	   exposure,	   or,	  importantly,	   whether	   the	   mucosa	   of	   patients	   with	   reClux	   symptoms	   is	   more	  vulnerable	  to	  the	  exposure	  than	  other	  subjects.
1.4.1.2	  In	  vivo	  studiesEfforts	  have	   recently	  been	  made	  to	   test	  oesophageal	  mucosal	   integrity	   in	   vivo,	   in	  humans.	  Multichannel	  oesophageal	  intraluminal	  impedance	  is	  a	  technique	  that	  has	  been	   developed	   to	   complement	   measurements	   of	   pH	   in	   reClux	   studies154.	   It	   has	  recently	  been	  highlighted	  as	  an	  interesting	  surrogate	  tool	  for	  in	  vivo	  assessment	  of	  oesophageal	  mucosal	  integrity.	  The	  technique	  allows	  detection	  of	  the	  movement	  of	  a	  bolus	  through	  the	  oesophagus.	   It	  does	   this	  by	  measuring	   the	  change	  of	  current	  Clow	  between	  a	  pair	  of	  electrodes.	  The	  current	  is	  not	  able	  to	  pass	  directly	  along	  the	  catheter,	   so	   it	  must	  pass	   through	  a	  material	   external	   to	   the	  catheter	   that	   bridges	  the	   gap	   between	   the	   electrode	   pair.	   Liquids	   (containing	   ions,	   such	   as	   gastro-­‐oesophageal	   reCluxate)	   are	   excellent	   electrical	   conductors	   and	   cause	   a	   fall	   in	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impedance	   as	   it	   bridges	   the	   electrode	   pair.	   In	   the	   empty	   oesophagus	   it	   is	   the	  oesophageal	  mucosa	   that	  bridges	   the	   space	   between	   impedance	   electrode	   pairs,	  and	  thus	  it	  is	  the	  mucosa	  that	  offers	  the	  resistance	  to	  direct	  current	  Clow	  (Cigure	  5).	  If	  the	  mucosa	  is	  more	  permeable	  to	  ionic	  Clow	  the	  baseline	  impedance	  will	  be	  seen	  to	   be	   lower.	   	   As	   such,	   the	   baseline	   impedance	  may	  offer	   insight	   into	   the	   barrier	  integrity	   of	   the	   oesophageal	   mucosa.	   Indeed,	   a	   study	   of	   baseline	   impedance	   in	  patients	  GORD	   found	  that	   baseline	  impedance	  was	  signiCicantly	  lower	   in	  subjects	  with	  Barrett’s	  oesophagus	  and	  erosive	  oesophagitis	  than	  in	  those	  with	  non-­‐erosive	  reClux	  disease155.
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Figure	   5:	   In	   the	   top	  diagram	   there	   is	   a	   liquid	   reIlux	   event,	   and	  the	   impedance	   to	   current	   Ilow	  between	  electrodes	   in	  an	  impedance	  segment	   is	   produced	  by	   the	   reIluxate.	  On	  the	  bottom,	   in	  the	  empty,	  collapsed	  oesophagus	  it	  is	  the	  mucosa	  that	  offers	  impedance	  to	  current	  Ilow	  
Further	   evidence	   for	   the	   use	   of	   oesophageal	   impedance	   as	   a	   technique	   to	  investigate	  mucosal	   integrity	   came	   from	  a	   study	   by	   Kessing	   et	   al.156.	   This	   group	  studied	  baseline	  oesophageal	  impedance	  in	  24	  GORD	  patients	  with,	  and	  24	  GORD	  patients	   without	   pathological	   acid	   exposure	   on	   24-­‐hour	   ambulatory	   reClux	  monitoring	  (those	  without	   pathological	  exposure	  were	  deCined	  as	   GORD	  due	  to	  a	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positive	   reClux-­‐symptom	   association,	   i.e.	   acid	   hypersensitive	   oesophagus).	   The	  patients	  were	  compared	  to	  10	  healthy	  volunteers.	  Baseline	  impedance	  was	  highest	  in	   the	   control	   group,	   lower	   in	   the	   GORD	   patients	   without	   pathological	   acid	  exposure,	   and	  lowest	   in	  those	  with	  pathological	  acid	  exposure	  (2827Ω	  vs.	   2090Ω	  vs.	   781Ω	  respectively).	   There	  was	   a	  signiCicant	   negative	   correlation	   between	  24-­‐hour	   oesophageal	   acid	   exposure	   time	   and	   baseline	   impedance.	   A	   further	   20	  patients	  with	  refractory	  GORD	  were	  tested	  twice,	   once	  “on”	  PPI	  and	  once	  “off”	  PPI	  therapy.	   Median	  distal	   baseline	   impedance	   “off”	  PPI	  was	   signiCicantly	   lower	  than	  “on”	  PPI	  (886	  Ω	  vs.	  1372	  Ω).	  Thus,	   the	   baseline	   impedance	   appears	   to	   be	   able	   to	   give	   an	   insight	   into	   the	  integrity	   of	   the	  oesophageal	   mucosa.	   To	   test	   this	   hypothesis	   further,	   Farré	  et	  al.	  performed	   in	   vivo	   perfusions	   of	   pH	   1	   and	   pH	   1.5	   solutions	   in	   rabbits	   whilst	  simultaneously	   measuring	   oesophageal	   impedance157.	   After	   completion	   of	   a	   30-­‐minute	   perfusion,	   impedance	   measurements	   were	   continued	   for	   a	   further	   30	  minutes,	   following	   which	   the	   animals	   were	   sacriCiced.	   The	   oesophageal	   mucosa	  was	   then	  mounted	   in	   Ussing	   chambers	   to	   measure	   the	   transepithelial	   electrical	  resistance.	   A	   positive	   correlation	  was	   found	  between	   the	   post-­‐infusion	   baseline	  impedance	  and	  the	  subsequent	  transepithelial	  electrical	   resistance	  (TER)	  (r=0.72,	  p=0.002),	   suggesting	   that	   the	   impedance	   does	   indeed	   reClect	   the	   paracellular	  permeability	  of	  the	  mucosal	  epithelium.	  A	  recent	  study	  from	  a	  group	  in	  Peking	  has	  added	  further	  weight	  to	  the	  association	  between	  impedance	  and	  mucosal	  integrity	  by	  Cinding	  a	   signiCicant	  negative	  correlation	  between	  the	  baseline	  impedance	  and	  intercellular	   space	   diameter	   (see	   later)(r=-­‐0.64,	   p<0.001)158.	   	   In	   the	  aforementioned	  study	  by	  Farré	  et	  al.	  an	  interesting	  phenomenon	  was	  shown	  from	  intra-­‐oesophageal	   perfusions	   of	   neutral,	   and	   acidic	   solutions	   in	  healthy	   humans.	  There	  was	  no	  fall	  in	  oesophageal	  impedance	  that	  occurred	  after	  perfusion	  with	  the	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neutral	  solution.	  However,	  after	  perfusion	  with	  acidic	  (pH	  1)	  solution	  a	  signiCicant	  reduction	  in	  impedance	  from	  baseline	  could	  be	  seen	  (a	  53%	  decrease	  on	  average)	  that	  outlasted	  the	  duration	  of	  the	  acid	  exposure	  (Cigure	  6).
Figure	   6:	   Impedance	   baselines	   recovered	   almost	   immediately	   after	   cessation	   of	   the	   saline	  perfusion,	  but	  remained	  low	  after	  cessation	  of	  the	  acid	  perfusion	  in	  the	  study	  by	  Farré	  et	  al.	  2011
Furthermore,	  this	  impedance	  had	  not	  recovered	  to	  baseline	  2	  hours	  after	  cessation	  of	   the	   perfusion	   (remaining	   at	   a	   mean	   48%	   reduction).	   This	   suggests	   that	   the	  mucosal	  integrity	  changes	  effected	  by	  acid	  do	  not	  rapidly	  reverse.	  This	   recovery	   of	   impedance	   has	   only	   been	   tested	   in	   healthy	   subjects	   without	  symptoms,	  not	  in	  patients.	  Even	  in	  the	  healthy	  subjects	  there	  was	  some	  important	  inter-­‐individual	  variability	  in	  the	  recovery	  of	  the	  impedance	  after	  acid	  perfusion	  in	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subjects.	  It	  is	  possible	  that	  variability	  in	  mucosal	  recovery	  could	  have	  an	  impact	  on	  susceptibility	   to	   GORD.	   It	   is	   thus	   far	   unknown	  whether	   the	   recovery	   capacity	   of	  mucosal	  integrity	  after	  acid	  damage	  is	  variable	  amongst	  patient	  phenotypes.
1.4.2	  Morphological	  measurements	  of	  oesophageal	  mucosal	  integrityIt	  had	  been	  noted	  during	  some	  of	  the	  earlier	  functional	  studies	  that	  are	  mentioned	  above	   that,	   as	   the	   epithelial	   electrical	   resistance	  decreased	  in	  rabbit	   oesophagus	  on	   exposure	   to	   acid,	   a	   change	   in	   morphological	   appearances	   of	   the	   mucosa	  appeared.	   When	  Orlando	   et	   al.	   perfused	   the	   rabbit	   oesophagus	   with	   acid,	   they	  found	  that	  at	  a	  time	  of	  early	  acid	  damage	  (where	  potential	  difference	  had	  fallen	  by	  40-­‐50%),	   dilated	   intercellular	   spaces	   (DIS)	   could	   be	   seen	   under	   electron	  microscopy,	   but	  not	  light	  microscopy	  (Cigure	  7).	  As	  acid	  perfusion	  continued,	   light	  and	   electron	   microscopy	   revealed	   intraepithelial	   cellular	   necrosis,	   oedema	   and	  vesicle	  formation,	   predominantly	  in	  the	  mid-­‐zone	  of	  the	  stratum	   spinatum.	  All	  of	  these	   changes	   occurred	   in	   the	   absence	   of	  macroscopic	   erosion	   or	   exudate159.	   In	  addition,	   the	   presence	   of	   DIS	   in	   these	   experimental	   models	   correlated	   with	   a	  decrease	  in	  TER	  and	  an	  increase	  in	  transepithelial	  mannitol	   Clux.	  This	  observation	  was	   subsequently	   reproduced	   in	   other	   animal	   studies	   of	   oesophageal	   acid	  exposure147,	  160.	  Similarly,	   in	  the	  Ussing	  chamber	  studies	  of	  Farré	  et	  al.	  mentioned	  in	   the	   previous	   section,	   the	   fall	   in	   TER	   and	   increase	   in	   Cluorescein	  permeability	  seen	   on	   exposure	   of	   rabbit	   oesophageal	   mucosa	   to	   weakly	   acidic	   solution	  containing	  bile	  acids	  was	  accompanied	  by	  the	  development	  of	  DIS153.
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Figure	   7:	   Above,	   an	   electron	   photograph	   of	   normal	   oesophageal	   epithelium.	   Below,	   abnormal	  epithelium	  displaying	  dilated	  intercellular	  spaces.	  
The	   formation	  of	  DIS	   appears	   to	   be	   an	   reCluxate-­‐induced	   phenomenon	  since	   the	  same	   group	  were	  able	   to	   demonstrate	   that	   acid	  and	  weak	   acid	  perfusion	  of	   the	  healthy	   human	   oesophagus	   in	   vivo	   is	   able	   to	   cause	   formation	   of	   DIS161.	  Oesophageal	   biopsies	   were	   taken	   from	   healthy	   volunteers	   before	   and	   after	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perfusion	  with	  a	  neutral	  (pH	  7.2),	  weakly	  acidic	  (pH	  5.5),	  or	  acidic	   (pH	  2)	  solution	  containing	   pepsin	   and	   glycocholic	   acid.	   Intercellular	   spaces	   were	   normal	   at	  baseline,	  and	  remained	  normal	  after	  exposure	  to	  the	  neutral	  solution.	  It	  was	  found	  that	  perfusion	  of	  weakly	  acidic	  or	  acidic	  solution	  for	  30	  minutes	  was	  able	  to	  induce	  DIS	  in	  these	  subjects.As	   a	  result	  of	  these	  Cindings,	   interest	  was	  generated	  in	   the	  relevance	  of	  DIS	  as	   an	  early	  marker	  of	  reClux	  disease.	  Furthermore,	   it	  seemed	  possible	  that	  the	  presence	  of	  DIS	  was	  a	  morphological	  marker	  of	  an	  impaired	  oesophageal	  mucosal	  integrity:	  that	   the	   presence	   of	  DIS	  was	   the	   defect	   that	   allowed	   passage	   of	   ions	   (including	  hydrogen)	  and	  molecules	  across	  the	  acid-­‐damaged	  epithelium,	  and	  as	  such	  may	  be	  responsible	  for	  symptoms	  in	  NERD162.	  Tobey	   et	   al.	   were	   the	   Cirst	   to	   investigate	   whether	   DIS	   was	   present	   in	   human	  subjects	  with	  reClux	  symptoms.	   They	   took	  oesophageal	  biopsies	   from	  11	  patients	  with,	  and	  13	  patients	  without	  recurrent	  heartburn	  symptoms163.	   	  Six	  symptomatic	  patients	  had	  erosive	  oesophagitis,	   and	  5	  had	  no	  endoscopic	   erosions.	   They	   found	  that	   the	   intercellular	   space	   diameter	   on	   electron	   microscopy	   was	   signiCicantly	  greater	   in	   patients	   with	   reClux	   than	   in	   asymptomatic	   subjects.	   This	   was	   true	  regardless	  of	  whether	  the	  patient	  had	  erosive	  or	  non-­‐erosive	  reClux	  disease	  (mean±SEM;	   controls	   0.46	  ±	  0.06	  μm,	   erosive	  reClux	  0.80	  ±	  0.12	  μm,	   non-­‐erosive	  reClux	  1.00	  ±	  0.15	  μm).Caviglia	   et	   al.	   followed	  this	   up	   by	   taking	   oesophageal	   biopsies	   from	  33	  patients	  with	  NERD,	   6	  patients	  with	  erosive	  oesophagitis,	   and	  12	   asymptomatic	   controls.	  They	  again	  found	  that	   intercellular	  space	  was	   increased	  in	  patients	   compared	  to	  controls	  (by	  a	  factor	  of	  3	  times),	  irrespective	  of	  whether	  the	  patients	  had	  NERD	  or	  erosive	  oesophagitis164.	   The	  same	  group	  also	  demonstrated	  that	  DIS	  was	  present	  in	  patients	  with	  heartburn	  symptoms	  but	  normal	  oesophageal	  acid	  exposure.	   It	  is	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unclear	   whether	   these	   patients	   had	   functional	   heartburn	   or	   hypersensitive	  oesophagus	  since	  reClux-­‐symptom	  association	  data	  was	  not	  given165.	  Weight	  was	  added	  to	  the	  association	  between	  DIS	  and	  symptoms	  in	  reClux	  disease	  by	  the	  study	  by	  Calabrese	  et	  al.166.	   They	  took	  oesophageal	  biopsies	  of	  38	  patients	  with	  GORD	   (22	   NERD,	   16	   erosive	   reClux	   disease)	   at	   baseline,	   and	  after	   3	   and	  6	  months	  of	  40	  mg	  omeprazole	  daily.	  At	  baseline,	   all	  patients	  were	  deemed	  to	  have	  DIS	  (>74	  μm,	  as	  determined	  by	  the	  95th	  percentile	  value	  of	  normal	  subjects).	  After	  3	  and	  6	  months	   of	  treatment,	   92.1%	  and	  97.4%	  of	  cases	   displayed	  resolution	  of	  normal	   intercellular	   spaces	   respectively.	   Recovery	   of	   DIS	   was	   accompanied	   by	  regression	  of	  heartburn	  in	  all	  cases.	  The	  three	  patients	  with	  persistent	  symptoms	  after	   3	  months	   of	  PPI	   therapy,	   and	   the	   single	   patient	  with	  persistent	   symptoms	  after	   6	   months	   of	   therapy,	   showed	   incomplete	   healing	   of	   DIS.	   This	   perhaps	  suggests	  a	  strong	   association	  with	  DIS	  and	  reClux	  symptoms,	   if	  not	  a	  causal	   role.	  This	   concept	   was	   strengthened	   by	   a	   study	   speciCically	   looking	   at	   patients	   with	  reClux	  symptoms	   refractory	   to	   PPI	  therapy167.	   In	   this	  study,	   oesophageal	   biopsies	  were	  taken	  from	  15	  patients	  with	  GORD	  not	  responding	  to,	  but	  taking,	  PPI	  therapy,	  and	  also	   from	  11	  patients	  with	  functional	  heartburn,	  and	  from	  11	  healthy	  control	  subjects.	   The	   mean	   intercellular	   space	   in	   epithelium	   viewed	   under	   electron	  microscopy	   was	   signiCicantly	   greater	   in	   those	   with	   refractory	   GORD	   than	   in	  patients	   with	   functional	   heartburn	   or	   controls	   (0.87	   vs.	   0.42	   vs.	   0.32	   μm	  respectively,	  Cigure	  8).
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Figure	  8:	  Persistence	  of	  DIS	  in	  patients	  with	  refractory	  gastro-­‐oesophageal	  reIlux	  disease,	  but	  not	  in	  controls	  or	  patients	  with	  functional	  heartburn.	  From	  Vela	  et	  al.	  2011	  
There	  are	   some	   limitations	   of	  measuring	   DIS	   in	   patients	   with	   reClux	  symptoms.	  First,	   it	   is	   not	   speciCic	   to	   GORD	   and	   is	   also	   found	   in	   other	  oesophageal	  mucosal	  inClammatory	   diseases.	   Second,	   it	   is	   a	   difCicult	   to	   perform	   a	   truly	   random	  measurement	   of	   DIS.	   In	   any	   one	   electron	   microscopy	   image	   there	   are	   wide	  variations	  of	   intercellular	   space	   diameter,	   and	   how	   the	  measurement	   points	   are	  chosen	   has	   not	   been	   clearly	   deCined	   in	   the	   studies.	   Finally,	   DIS	   serves	   as	   a	  “snapshot”	  of	  one	  point	  in	  time.	  It	  tells	  us	  little	  about	  how	  the	  mucosa	  responds	  to	  acid	  challenges	  in	  a	  dynamic	  situation.In	   summary,	   the	   integrity	   of	   the	   oesophageal	   mucosa	   can	   be	   studied	   by	  morphological	   or	   functional	   means.	   The	  dynamic	   functional	   changes	   in	   integrity	  (e.g.	   during	   an	   acid	   challenge)	   have	   not	   been	   studied	   in	   patients.	   Further	  investigation	  of	  the	   integrity	  behaviour	  of	  mucosa	   in	  different	  human	  phenotypes	  (e.g.	   healthy	   controls	   and	   heartburn	   phenotypes)	   may	   allow	   insight	   into	   the	  mucosal	   pathophysiology	   of	   GORD,	   and	   lead	   towards	   development	   of	   novel	  therapies.
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1.5 Sensory mechanism in heartburn perception
The	   mechanisms	   of	   symptom	   perception	   in	   oesophageal	   disease	   are	   not	   fully	  elucidated,	   but	   are	   clearly	  relevant	   to	  GORD	  pathogenesis.	   Symptom	  phenomena	  are	  formed	  by	  a	  complex	  interaction	  of	  noxious	  oesophageal	   stimuli,	   oesophageal	  nociceptor	  activation,	  afferent	  nociceptive	  nerve	  Cibres,	  and	  central	  processing.It	  is	  known	  that	  experimental	  perfusion	  of	  acid	  into	   the	  human	  mid-­‐oesophagus	  is	  able	  to	   reproduce	  heartburn	   symptoms,	   and	  with	  increasing	  acid	   concentrations	  the	  duration	  of	  exposure	   required	   to	   cause	  symptoms	   decreases53.	   Furthermore,	  reClux	   studies	   using	   transnasal	   catheters	   have	   shown	   distal	   oesophageal	   acid	  exposure	  to	  be	  higher	  in	  patients	  with	  heartburn48,	   168	  and	  have	  been	  able	  to	  show	  a	   temporal	   relationship	   between	   acid	   reClux	   episodes	   and	   heartburn	  perception169-­‐171.	   Finally,	   gastric	   acid	   suppression	   therapy	   is	   often	   an	   effective	  treatment	  for	  heartburn10.	  As	  such,	  it	  can	  be	  implied	  that,	  at	  least	  in	  a	  proportion	  of	  patients,	   gastric	  acid	   reClux	   into	   the	   oesophagus	   is	   a	   cause	  of	  heartburn.	   	   During	  such	  an	  acidic	  reClux	  event	  stimulation	  of	  acid-­‐sensitive	  receptors	  on	  nerves	  in	  the	  oesophageal	  wall	  is	  likely	  to	  be	  important	  event	  in	  perception.
1.5.1	  Nociceptive	  sensory	  Mibres	  and	  receptors	  in	  the	  oesophagusUnlike	   somatic	   nociception,	   visceral	   nociception	   from	   the	   gut	   is	   enacted	  by	   two	  extrinsic	  innervations	  as	  well	  as	  an	  intrinsic	  innervation.	  The	  extrinsic	  innervation	  is	   formed	  of	  vagal	   and	   spinal	   visceral	   afferent	   nerve	   Cibres,	   and	  both	  types	   have	  nerve	  endings	  in	  all	   layers	  of	  the	  gut	  wall.	  Most	  afferent	  axons	  are	  unmyelinated	  C-­‐Cibres,	  with	  a	  minority	  being	  myelinated	  Aδ-­‐Cibres172.	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Vagal	  afferent	   Cibres	  project	  to	   the	  vagus	  nerve	  via	  the	  superior	  laryngeal	  nerves,	  recurrent	   laryngeal	   nerves,	   and	   vagal	   branches	   within	   the	   oesophageal	   plexus.	  Vagal	  afferent	  cell	  bodies	  are	  located	  in	  the	  jugular	  and	  nodose	  ganglia	  with	  central	  projections	  to	   the	  nucleus	  of	   the	  tractus	   solitarius.	   Spinal	   afferent	  cell	   bodies	   are	  located	  in	  the	  cervical	  and	  thoracic	  dorsal	  root	  ganglia.	  The	  spinal	  levels	  of	  visceral	  preganglionic	   afferents	   are	   signiCicantly	   fewer	   than	   somatic	   afferents,	   and	   are	  spread	  out	  across	   a	   range	   of	  dorsal	   root	   ganglia,	   and	   this	   probably	   explains	   the	  relative	   poor	   localisation	   of	   visceral	   pain173.	   First-­‐order	   neurones	   synapse	  with	  second-­‐order	  neurones	  in	  the	  dorsal	  horn	  of	  the	  spinal	  cord,	  which	  ascend	  via	  the	  spinoreticular	   and	  spinothalamic	   tracts	  to	   the	  reticular	  nuclei	   and	  thalamus.	   The	  latter	   tract	   transmits	   conscious	   sensation,	   whereas	   the	   former	  mostly	   activates	  unconscious	  responses	  to	  visceral	  sensory	  input.Spinal	   visceral	   afferents	   represent	   10-­‐20%	   of	   nerve	   Cibres	   in	   the	   splanchnic	  nerves174.	   It	   is	   suggested	   that	   spinal	   Cibres	   are	   the	   most	   important	   afferent	  innervation	  in	  visceral	  nociception172.	  However,	  it	  has	  also	  been	  demonstrated	  that	  (at	   least	   in	  guinea	  pigs)	  vagal	  nerves	   supply	   the	  oesophagus	  with	  nociceptors	  as	  well	  as	  tension	  mechanoceptors175,	  176.Afferent	  Cibres	  projecting	  to	  the	  oesophagus	  can	  be	  excited	  by	  the	  presence	  of	  acid,	  most	   probably	   due	   to	   a	   direct	   action	   on	   the	   neurones177,	   178.	   Indeed,	   vagal	   and	  spinal	   afferent	   nerves	   have	   been	   shown	   to	   express	   cation	   channels	   that	   act	   as	  molecular	  acid	  sensors.	  There	  is	  no	  single	  acid-­‐sensitive	  receptor	  that	  modulates	  acid	  sensitivity,	   and	  so	   far	   several	   candidate	   channels	   have	  been	  identiCied.	  Acid-­‐sensitive	   ion	   channels	   (ASICs)	   belong	   to	   the	   voltage-­‐insensitive,	   amiloride-­‐sensitive	  family	  of	  epithelial	  cation	  channels179.	  ASIC1,	   ASIC2	  and	  ASIC3	  are	  acid-­‐gated	  and	  as	  such	  may	  be	  involved	  in	  nociception	  during	  an	  acid	  reClux	  event.	  They	  are	   also	   likely	   to	   have	   a	   role	   in	   mechanosensitivity180.	   Their	   role	   in	   GORD	   is	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unknown,	   but	   in	   a	  mouse	  model	   deletion	  of	   ASIC3	   caused	   reduced	   response	   of	  acid-­‐sensitive	  nociceptors181.Transient	   receptor	   potential	   vanilloid	   receptors	   (TRPV	   receptors)	   are	   also	  important	   candidate	   receptors	   for	   acid-­‐induced	   oesophageal	   nociception.	   As	   a	  group	   of	   over	   30	   proteins,	   TRPV	   channels	   serve	   a	   diverse	   array	   of	   sensory	  functions	   including	  hearing,	   touch,	   osmolality	  and	   pain182.	   TRPV1	  and	  TRPV4,	   in	  particular,	   are	   able	   to	   respond	   to	   acidosis.	   At	   a	   pH	   of	   less	   than	   6,	   these	   cation	  channels	   are	   activated	   forming	   a	   sustained	   channel	   current179,	   183.	   Besides	   acid,	  heat	   and	   vanilloids	   such	   as	   capsaicin	   can	   also	   gate	   TRPV1	   channels.	   TRPV1	   is	  expressed	   in	  the	  mucosa,	  musculature	  and	  enteric	   nerve	  plexuses	   in	   the	  rat	  gut,	  and	  by	  vagal	   and	  spinal	  afferents	   throughout	  the	  gastrointestinal	   tract184,	   185.	   The	  transduction	   threshold	   of	   TRPV1	   is	   reduced	   by	   phosphorylation	   via	   protein	  kinases	   A	   and	  C.	   These	   protein	  kinases	   are	   activated	   in	   response	   to	   injury	   in	  a	  cAMP-­‐dependent	   manner	   and	   are	   modulated	   by	   signals	   from	   other	   G-­‐protein-­‐coupled	   receptors	   including	   those	   to	   5-­‐HT	   and	   proteases	   (especially	   protease-­‐activated	   receptor	   2,	   PAR2,	   which	   may	   be	   important	   since	   reClux	   events	   often	  contain	  pepsin)186,	  187.P2X	   purinoceptors	   are	   ligand-­‐gated	  membrane	   cation	   channels	   that	   open	  when	  extracellular	   ATP	   is	   bound188.	   P2X2-­‐containing	   purinoceptors	   are	   sensitised	   by	  acid	   in	   the	   presence	   of	   ATP	   (which	   is	   liberated	   from	   the	   cells	   in	   response	   to	  various	   physiological	   and	  pathological	   stimuli).	   ATP	  has	   been	  shown	  to	   sensitise	  vagal	   afferents	   to	  mechanical	   stimuli	   in	  the	   ferret	  oesophagus189.	   Although	  these	  Cindings	  make	  purinoceptors	   attractive	  candidates	   in	  reClux-­‐induced	  nociception,	  their	  role	  in	  gastrointestinal	  nociception	  is	  thus	  far	  unclear.
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1.5.2	  Oesophageal	  sensitisationHeightened	   visceral	   sensitivity	   (visceral	   hypersensitivity)	   is	   a	   hallmark	   of	  functional	   gastrointestinal	   disorders.	   This	   hypersensitivity	   may	   be	   due	   to	  excessive	   sensory	   transmission	   from	   the	   viscera	   to	   the	   brain	   (peripheral	  sensitisation),	  aberrant	  central	  processing	  (central	  sensitisation),	  or	  a	  combination	  of	  both.In	   peripheral	   sensitisation	   there	   is	   a	   decreased	   threshold	   and	   exaggerated	  magnitude	  of	  sensory	  response	  to	  a	  given	  stimulus.	  This	  is	  usually	  affected	  by	  local	  injury	  and	  inClammation.	  An	  easily	  relatable	  example	  is	  the	  increased	  sensitivity	  of	  skin	  in	  the	  area	  surrounding	  a	  burn.	  Sensitising	  mediators	  are	  potentially	  numerous,	  and	  chemical	  mediators	  are	  likely	  to	   include	   various	   amines,	   protanoids,	   purines,	   proteases	   and	   cytokines.	   These	  may	  act	  by	  direct	  activation	  of	  receptors	  coupled	  to	  the	  opening	  of	  ion	  channels	  on	  afferent	  nerve	  terminals,	  causing	  depolarisation	  and	  Ciring.	  Alternatively	  they	  may	  act	  indirectly	  by	  sensitisation	  in	  the	  absence	  of	  direct	  activation,	   for	  example	  by	  G-­‐protein-­‐coupled	   alterations	   in	   second	   messenger	   systems	   that	   in	   turn	   lead	   to	  phosphorylation	  of	  membrane	  receptors	  and	  ion	  channels	  that	  control	  excitability	  of	  afferent	  endings.	  Finally	  they	  may	  cause	  changes	  in	  the	  genetic	  phenotype	  of	  the	  mediators,	   channels	   and	   receptors	   expressed	   by	   the	   afferent	   terminals190.	  Peripheral	  sensitisation	  can	  be	  rapid	  and	  short-­‐lasting,	  but	  in	  the	  case	  of	  prolonged	  or	   repetitive	   injury	   or	   inClammation	   it	   is	   the	   changes	   in	   genetic	   expression	   that	  lead	  to	  prolonged	  peripheral	  sensitisation.	  Repetitive	   Ciring	   of	   nociceptive	   signals	   from	   the	   periphery	   is	   able	   to	   alter	   the	  amount	   and	   pattern	   of	   neurotransmitters	   released	   from	   the	   sensory	   nerve	  terminals	  in	  the	  spinal	  cord	  and	  brain,	  and	  thus	  can	  alter	  the	  central	  processing	  of	  visceral	   sensory	   information191.	   Such	   central	   sensitisation	   may	   contribute	   to	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visceral	   hypersensitivity	   in	   the	   oesophagus,	   particularly	   in	   functional	   disorders	  such	   as	   functional	   heartburn.	   It	   is	   also	   the	   mechanism	   believed	   to	   underlie	  secondary	   hyperalgesia:	   a	   phenomenon	   whereby	   there	   is	   increased	  responsiveness	   to	   stimuli	   distant	   to	   the	   site	   of	   injury	   or	   inClammation.	   Altered	  synaptic	  transmission	  in	  the	  spinal	  cord	  leads	  to	  a	  decrease	  in	  threshold,	  increased	  responsiveness,	   and	  widening	  of	  spinal	   nociceptive	   neuronal	   Cields192.	   Indeed,	   it	  has	  been	  shown	  that	  patients	  with	  NERD	  have	  not	  only	  increased	  sensitivity	  of	  the	  oesophagus88,	   193,	   but	   also	   increased	  somatic	  sensitivity	  of	  the	  chest	  wall194.	   This	  suggests	   that	   central	   sensitisation	   is	   likely	   to	   play	   at	   least	   a	   part	   in	   acid	   and	  mechanosensitivity	   in	   NERD.	   The	   secondary	   hyperalgesia	   can	   be	   attenuated	   by	  prostaglandin	  E2	   receptor-­‐1	  antagonism	   and	   by	   the	  NMDA	   receptor	   antagonist,	  ketamine195,	  196.A	   Cinal	   probable	   component	   to	   oesophageal	   pain	   is	   psychoneuroimmune	  modulation.	   Many	   patients	   with	   heartburn	   report	   that	   psychological	   stress	  worsens	   their	   symptoms197.	   Acute	   experimental	   stress	   is	   known	   to	   reduce	   pain	  thresholds	  to	  oesophageal	  acid	  perfusion198.	   Whilst	   this	   is	   likely	  to	  be,	  at	   least	   in	  part,	   a	  central	   phenomenon,	   it	   is	   noteworthy	   that	   acute	   stress	   is	   able	   to	   induce	  oesophageal	   mucosal	   changes	   of	   dilated	   intercellular	   spaces	   in	   rats199.	   It	   is	  tempting	  to	  wonder	  if	  this	  phenomenon	  is	  due	  to	  release	  of	  mast	  cell	  inClammatory	  mediators	   in	   response	   to	   stress,	   since	   we	   know	   that	   mast	   cells	   express	  corticotrophin-­‐releasing	   hormone	   (CRH)	  receptors,	   and	  we	   also	   know	   that	   CRH	  receptors	  can	  be	  located	  in	  the	  rat	  oesophageal	  mucosa200.
1.5.3	  Link	  between	  mucosal	  integrity	  and	  oesophageal	  sensitisationBy	  allowing	  increased	  access	  of	  noxious	  components	  through	  the	  epithelial	  barrier	  to	   areas	   of	   dense	   nociceptor	   presence,	   the	   reClux-­‐induced	   impairment	   of	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oesophageal	   mucosal	   integrity	   will,	   in	   effect,	   produce	   a	   state	   of	   peripheral	  oesophageal	  sensitisation.	   If	   this	  nociceptor	  activity	   is	   allowed	  to	   continue	  it	   can	  lead	   to	   an	   additional	   state	   of	   central	   sensitisation	   by	  mechanisms	   documented	  above.	   As	   such,	   protection	   of	   oesophageal	   mucosal	   integrity	   is	   an	   important	  therapeutic	  consideration	  in	  treatment	  of	  reClux	  disease.
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1.6 Differences between the distal and proximal oesophagus in GORD
The	  average	  human	  oesophagus	  is	  approximately	  20-­‐22	  cm	  in	  length	  (with	  a	  range	  of	   approximately	   17-­‐30	   cm),	   from	   upper	   to	   lower	   oesophageal	   sphincters.	  Physiologically	   and	   anatomically	   the	   proximal	   and	   distal	   oesophagus	   are	   quite	  distinct.	   The	   upper	   5%	   of	   the	   oesophagus,	   including	   the	   upper	   oesophageal	  sphincter,	   is	   composed	   of	   striated	   muscle.	   The	   distal	   50-­‐60%	   is	   composed	   of	  smooth	  muscle.	   Between	  these	   two	   distinct	   zones	   is	   a	  transition	   zone	  where	   the	  change	  from	  striated	  to	  smooth	  muscle	  progressively	  occurs.There	   is	   a	   myenteric	   plexus	   of	   ganglion	   cells	   found	   in	   both	   upper	   and	   lower	  oesophagus,	   but	   it	   appears	   to	   be	  more	  dense	   in	  the	   smooth	  muscle	  portion.	   The	  submucosal	  plexus	  is	  sparse201.	  Knowledge	   of	   the	   mucosal	   innervation	   of	   the	   human	   oesophageal	   mucosa	   is	  limited,	   and	  most	   research	   has	   focused	   on	   the	   animal	   oesophagus.	   In	   animals,	  vagal	  mucosal	  afferent	  innervation	  appears	  to	  be	  unevenly	  distributed	  through	  the	  oesophagus.	  Vagal	   sensitivity	  and	  innervation	  appears	  to	  be	  concentrated	  mostly	  in	  the	  upper	  third	  of	  the	  oesophagus	  in	  the	  rat,	   cat	  and	  monkey	  oesophagus202-­‐204.	  In	   cats	   at	   least,	   this	   appears	   to	   be	   associated	   with	   a	   functional	   differentiation,	  whereby	  the	  proximal	  oesophagus	  appears	  to	  be	  more	  sensitive	  to	  mechanical	  and	  chemical	  stimulation	  than	  the	  distal	  oesophagus205.Historically,	   most	   investigation	   of	   gastro-­‐oesophageal	   reClux	   disease	   has	   been	  focused	  on	   the	  distal	   oesophagus.	   Of	   course,	   this	   is	   perhaps	  not	   surprising	   since	  most	  exposure	  to	  the	  reCluxate	  occurs	  at	  the	  distal	  oesophagus.	  Consequently	  it	  is	  at	   the	  distal,	   not	   the	  proximal,	   oesophagus	  where	  erosive	   oesophagitis,	   Barrett’s	  oesophagus	  and	  oesophageal	  adenocarcinoma	  occur.	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Whilst	   it	  does	  not	  appear	  to	  be	  frequently	  affected	  by	  mucosal	  damage	   in	  GORD,	  there	  is	  increasing	  realisation	  of	  the	  importance	  of	  the	  proximal	  oesophagus	  in	  the	  perception	  of	  oesophageal	  symptoms	  in	  humans.	  There	  is	  now	  data	  to	  suggest	  that,	  in	   some	   cases,	   the	   proximal	   oesophagus	   may	   be	   even	   more	   important	   to	  perception	   than	  the	   distal	   oesophagus.	   It	   has	   been	   suggested	  that	   this	  may	   be	  a	  protective	  mechanism,	  whereby	  the	  presence	  of	  reClux	  in	  the	  upper	  oesophagus	  is	  a	   threat	   to	   the	   respiratory	   system	   and	   its	   recognition	   is	   essential.	   There	   is	  experimental	  data	  to	  suggest	  a	  difference	  in	  perception	  at	  the	  distal	  and	  proximal	  oesophagus	   in	   humans.	   Patel	   and	   Rao	   investigated	   sensitivity	   to	   oesophageal	  distension	  at	  different	  levels	  of	  the	  oesophagus	  in	  a	  group	  of	  healthy	  volunteers206.	  Intensity	   of	   oesophageal	   sensation	   to	   intra-­‐oesophageal	   balloon	   distension	  was	  measured	   at	   1)	   the	   lower	   oesophageal	   sphincter;	   2)	   5	   cm	   above	   the	   lower	  oesophageal	  sphincter;	  3)	  10	  cm	  above	   the	  lower	  oesophageal	   sphincter;	  4)	  5	  cm	  below	  the	  upper	  oesophageal	  sphincter.	   	  At	  the	  lower	  oesophageal	  sphincter	  level	  all	   subjects	   perceived	   the	   distension,	   but	   not	   as	   pain	   or	   discomfort.	   At	   all	   other	  levels	   a	  painful	   stimulus	  was	   felt	  with	  increasing	  distension.	   They	   found	  that	   the	  proximal	   oesophagus	   was	   the	   most	   sensitive	   region	   to	   distension,	   and	   the	  sensitivity	  decreased	  the	  more	  distal	  it	  was	  tested.These	   Cindings	   were	   reproduced	  more	   recently	   by	  Krarup	   et	   al.	   They	   compared	  sensitivity	   to	  balloon	  distension	  at	  4	  cm	  and	  14	  cm	  above	  the	  lower	  oesophageal	  sphincter	   in	  healthy	   volunteers	   and	   patients	   with	   Barrett’s	   oesophagus.	   In	   both	  groups	  sensory	  and	  pain	  thresholds	  were	  lower	  in	  the	  proximal	  oesophagus	  than	  in	   the	   distal	   oesophagus207.	   Interestingly,	   in	   the	   same	   study	   no	   difference	   was	  found	  in	  thermal	  sensitivity	  between	  the	  distal	  and	  proximal	  oesophagus.	  There	  is	  some	  data	  to	  suggest	  that,	  in	  patients	  with	  non-­‐erosive	  reClux	  disease	  (but	  possibly	  not	   controls),	   the	   proximal	   oesophagus	   is	   more	   sensitive	   to	   experimental	   acid	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perfusion	  than	  the	  distal	  oesophagus208.	  It	  is,	  of	  course,	  very	  difCicult	  to	  perfuse	  the	  proximal	  oesophagus	  without	  simultaneously	  perfusing	  the	  distal	  oesophagus,	  and	  a	  robust	  model	  to	  test	  acidiCication	  of	  the	  proximal	  oesophagus	  in	  isolation	  has	  not	  been	  described.The	   potential	   clinical	   relevance	   of	   a	   difference	   in	   sensitivity	   of	   the	   distal	   and	  proximal	  oesophagus	  has	  been	  highlighted	  in	  gastro-­‐oesophageal	  reClux	  disease	  by	  a	  number	  of	  reClux	  physiology	  studies.	  We	  know	  from	  both	  oesophageal	  pH209	  and	  impedance210	   studies	   that	   patients	   with	   gastro-­‐oesophageal	   reClux	   have	   more	  reClux	   events	   reaching	   the	   proximal	   oesophagus	   than	   healthy	   subjects.	   More	  interestingly,	   it	  has	  also	  become	  apparent	  that	  patients	  are	  more	  likely	  to	  perceive	  a	  reClux	  event	  if	  it	  reaches	  the	  proximal	  oesophagus	  (usually	  determined	  as	  15	  cm	  above	   the	   lower	   oesophageal	   sphincter).	   Cicala	   et	   al.,	   using	   oesophageal	  impedance,	   discovered	  that	  a	  reClux	  event	  of	  a	  given	  duration	  is	  more	   likely	  to	  be	  perceived	  if	  it	   reaches	   the	  proximal	   oesophagus	   than	  if	  it	   reaches	   only	   the	  distal	  oesophagus211.	  The	   characteristics	   of	   perceived	   reClux	   events	   have	   also	   been	   investigated	   in	  patients	   taking	  proton	  pump	   inhibitors.	   This	   is	   of	   clinical	   relevance	   since	   up	   to	  40%	  of	  patients	  with	  non-­‐erosive	  reClux	  disease	   have	  a	   sub-­‐optimal	   response	   to	  therapy,	   representing	   the	   main	   unmet	   need	   in	   GORD	   therapy.	   Two	   impedance	  studies	  in	  patients	  “on”	  PPI	  found	  that	  a	  reClux	  event	  is	  more	  likely	  to	  be	  perceived	  if	   it	   reaches	   the	  proximal	   oesophagus.	   In	  one	   of	  these,	   proximal	   extent	   of	  reClux	  was	   one	   of	   only	   two	   factors	   associated	   with	   an	   increased	   odds	   ratio	   of	  perception212.	   In	   the	   other	   study	   proximal	   extent	   of	   reClux	   was	   the	   only	   factor	  associated	  with	  an	  increased	  chance	   of	   reClux	   perception213.	   It	   is	   notable	   that	   in	  both	  of	  these	  studies	  factors	  such	  as	  residual	  acid	  reClux	  and	  patient	  age	  or	  sex	  did	  not	   inCluence	   perception	   “on”	   PPI.	   Supporting	   the	   concept	   of	   proximal	   reClux	  
Chapter 1
75
events	   being	  perceived	   in	   the	   “on”	  PPI	   condition,	   a	   further	   impedance	   study	   by	  Emerenziani	  et	  al.	   showed	  that	  not	  only	  acid,	  but	  also	  weakly	  acidic	  reClux	  events	  are	  more	  likely	  to	  be	  perceived	  in	  the	  proximal	  oesophagus214.
Although	   the	   clinical	   signiCicance	   of	   the	   proximal	   oesophagus	   appears	   clear,	   the	  mechanisms	   underlying	   its	   apparent	   relative	   sensitivity	   compared	   to	   the	   distal	  oesophagus	  are	  not.	  There	  is	  no	  data	  published	  on	  the	  distribution	  of	  oesophageal	  mucosal	  afferent	  nerves	  in	  humans.	  There	  is	  also	  no	  data	  on	  the	  mucosal	  integrity	  of	  the	  proximal	  oesophagus	  in	  health	  and	  disease.
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1.7 Treatment of GORD
A	   relatively	   small	   proportion	   of	   patients	  with	   gastro-­‐oesophageal	   reClux	  disease	  develop	   complications,	   in	   the	   form	   of	   strictures,	   Barrett’s	   oesophagus,	   and	  oesophageal	   adenocarcinoma.	   In	   treating	   the	   disease,	   it	   is	   sensible	   to	   aim	   for	  mucosal	   healing	   in	  patients	  with	  erosive	  oesophagitis	   (especially	   if	   severe)	  since	  chronic	   macroscopic	   inClammation	   is	   likely	   to	   predispose	   to	   complication.	   High	  acid	   exposure215,	   216	   over	   a	   prolonged	  period	   of	   time217	   appear	   to	   predispose	   to	  Barrett’s	   oesophagus	   and	   adenocarcinoma.	   However,	   other	   factors	   such	   as	   bile	  acids	   also	   appear	   to	   be	   important81,	   215,	   218,	   219,	   and	   at	   present	   it	   is	   unknown	  whether	   pharmacological	   or	   surgical	   intervention	   modiCies	   the	   risk.	   As	   such,	  presently,	   apart	   from	   in	   a	   minority	   (perhaps	   less	   than	   25%),	   the	   treatment	   of	  gastro-­‐oesophageal	  reClux	  disease	  is	  symptomatic	  and	  can	  take	  the	  form	  of	  lifestyle	  modiCication,	  medical	  therapy,	  or	  surgery.
1.7.1	  Lifestyle	  modiMicationsMany	   patients	   with	  gastro-­‐oesophageal	   reClux	   symptoms	   begin	   to	   address	   their	  symptoms	   by	   making	   lifestyle	   modiCications.	   Some	   changes	   are	   based	   on	   good	  outcome	  evidence,	  more	  are	  based	  on	  hypothetical	  beneCit,	  and	  other	  interventions	  are	   sometimes	   dubious	   in	   their	   efCicacy.	   Most	   informed	   changes	   are	   based	   on	  physiological	   data	   that	   certain	   foods,	   drugs	   and	   body	   properties	   (such	   as	   body	  mass	   index	   and	   body	   position)	  may	   inCluence	   reClux,	   either	   by	   modifying	   reClux	  content	  or	  amount,	  or	  modifying	  transient	  lower	  oesophageal	  sphincter	  relaxation	  frequency.
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Several	  foods	  can	  reduce	  lower	  oesophageal	  sphincter	  pressure	  (such	  as	  chocolate,	  coffee	  and	  onions)220,	  221.	  Chocolate	  and	  caffeinated	  coffee	  can	  also	  augment	  gastric	  acid	  production222,	   223	  and	  therefore	  avoidance	   is	  often	  suggested.	   A	   high-­‐fat	  meal	  increases	  reClux	  frequency	  in	  patients	  with	  GORD224,	  but	   it	  is	  unclear	  whether	  this	  is	  a	  a	  fat-­‐speciCic	  effect	  (perhaps	  due	  to	  delay	  of	  gastric	  emptying),	  or	  whether	  it	  is	  due	   to	  meal	   size	   (since	  a	   large	  meal	  will	   lead	  to	   fundic	   distension	  and	   transient	  lower	  oesophageal	  sphincter	  relaxation).	  Symptomatic	   reClux	   does	   appear	   to	   have	   a	   relationship	   with	   body	   mass	   index	  (BMI).	   A	   meta-­‐analysis	   found	   odds	   ratios	   of	   1.43	   and	   1.94	   for	   risk	   of	   GORD	  symptoms	  in	  overweight	  and	  obese	  patients	  respectively225.	  A	  BMI	  of	  greater	  than	  30	  kg/m2	  is	  associated	  with	  a	  greater	  risk	  of	  failure	  of	  anti-­‐reClux	  surgery226.	  ReClux	  events	  appear	  to	  reach	  a	  more	  proximal	  oesophageal	  extent	  in	  GORD	  patients	  with	  a	   larger	   waist	   circumference227.	   It	   is	   also	   clear	   that	   increasing	  BMI	   is	   a	   risk	   for	  development	   of	   adenocarcinoma	   in	   patients	   with	   Barrett’s	   oesophagus228.	  Although	  outcome	  data	  suggesting	  improvement	  of	  symptoms	  with	  weight	  loss	   in	  GORD	  is	   lacking,	   it	   is	   of	  course	   likely	   to	   be	  beneCicial	   to	   overall	   health,	   and	  may	  reduce	  reClux	  symptoms	  in	  obese	  patients.Alcohol	   can	   reduce	   lower	   oesophageal	   sphincter	   pressure	   by	   acting	  as	   a	   muscle	  relaxant.	  White	  wine	  may	  have	  a	  more	  profound	  effect	  than	  red	  wine	  on	  sphincter	  pressure,	   and	  beer	  may	   be	  worse	   than	  both	  types	   of	  wine229.	  Avoiding	  beer	  may,	  therefore,	   be	   beneCicial	   for	   reClux	   symptoms.	   Perhaps	   tempering	   the	   need	   for	  advice	   against	   drinking	  wine	   is	   some	  epidemiological	   evidence	  associating	   wine	  (but	  not	  beer)	  with	  a	  reduced	  risk	  of	  oesophageal	  adenocarcinoma230-­‐232.	  Probably	  the	  most	  logical	  dietary	  advice	  to	  reduce	  reClux	  is	  to	  avoid	  eating	  in	  the	  2	  hours	  before	  sleep.	  Most	  reClux	  occurs	  in	  the	  Cirst	  4	  hours	   after	  going	  to	   bed,	  and	  proximal	   acid	   reClux	   is	  most	   common	   during	   sleep.	   Patients	   eating	   in	   the	   1	   to	   2	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hours	   before	   sleep	   are	   more	   likely	   to	   experience	   excess	   nocturnal	   gastro-­‐oesophageal	   reClux233.	  Many	  people	  advocate	   elevation	  of	   the	  head	   of	  the	   bed	  at	  night	   to	   reduce	   nocturnal	   reClux.	   This	   does	   appear	   to	   speed	   up	   oesophageal	  clearance234,	   and	   there	   is	   some	   evidence	   to	   suggest	   it	   can	   improve	   reClux	  symptoms235.	  Perhaps	  of	  greater	  beneCit	  may	  be	  left	  lateral	  posture	  whilst	  sleeping.	  Acid	  exposure	  time	  and	  number	  of	  reClux	  episodes	  has	  been	  found	  to	  be	  reduced	  in	  this	  position	  when	  compared	  to	  the	  right	  lateral,	  supine	  and	  prone	  positions236,	  237.	  This	  observation	  may	  be	  partly	  due	  to	  a	  reduction	  in	  transient	  lower	  oesophageal	  sphincter	  relaxations	  in	  the	  left	  lateral	  position238.Several	   cross-­‐sectional	   studies	   have	   found	  a	   positive	   association	  between	  GORD	  symptoms	   and	  smoking29,	   31,	   39,	   and	  so	   smoking	  cessation	  would	  seem	  sensible.	   A	  recent	   abstract	   presentation	   indicated	   that	   reduction	   of	   smoking	   improves	  symptoms	  in	  patients	  with	  severe	  symptoms	  taking	  anti-­‐secretory	  medication239.
1.7.2	  Pharmacological	  therapyPharmacological	   treatment	   of	   gastro-­‐oesophageal	   reClux	   disease	   has	   been	  dominated	  by	   anti-­‐secretory	  drugs	   (i.e.	   drugs	   that	   reduce	   gastric	  acid	  secretion),	  and	  with	  good	  reason	  for	   in	  many	  patients	   they	  have	  excellent	  efCicacy	  and	  good	  tolerability.	   There	   are,	   however,	   other	   pharmacological	   therapies	   (some	   older,	  some	  newer)	  that	  are	  used	  or	  have	  been	  trialled.	  The	  need	  for	  alternative	  therapies	  reClects	  the	  failure	  of	  anti-­‐secretory	  drugs	  in	  some	  cases,	   and	  increasing	  concerns	  about	  long-­‐term	  safety	  of	  standard	  therapies.
1.7.2.1	  Anti-­‐secretory	  drugs	  (H2-­‐receptor	  antagonists	  and	  proton	  pump	  inhibitors)Two	   drug	   classes	   are	   available	   to	   reduce	   gastric	   acid	   production	   in	   GORD:	   H2-­‐receptor	  antagonists	  (H2RAs),	  and	  proton-­‐pump	  inhibitors	  (PPIs).
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Approximately	   two	   litres	   of	   gastric	   acid	   is	   produced	  by	   the	   parietal	   cells	   of	   the	  human	   stomach	  each	  day.	   Three	  main	   stimuli	   are	   able	   to	   act	   on	  the	   basolateral	  aspect	  of	  the	  parietal	  cell	  to	  promote	  acid	  production.	  Gastrin	  is	  secreted	  by	  G	  cells	  in	  the	  gastric	  antrum	  in	  response	  to	  food	  in	  the	  stomach,	  and	  reaches	  the	  parietal	  cells	  by	  blood.	  Acetylcholine	   is	  released	  by	   the	  vagus	  nerve,	  probably	  in	  response	  to	  the	  sight,	  smell	  and	  taste	  of	  food.	  Gastrin	  and	  acetylcholine	  are	  able	  to	  stimulate	  enterochromafCin-­‐like	   cells	   to	   release	   histamine,	   which	   is	   then	   able	   to	   bind	   to	  histamine	   receptors	   on	   parietal	   cells.	   Histamine	   binding	   effects	   a	   second	  messenger	   pathway	   (predominantly	   via	   cAMP)	  which	   activates	   the	   parietal	   cell	  proton	  pump.	  Activation	  of	  the	  proton	  pump	  causes	  exchange	  of	  a	  H+	  for	  a	  K+	  at	  the	  secretory	   canaliculus,	   driven	   by	   a	   H+/K+-­‐ATPase.	   It	   follows	   that	   inhibition	   of	  gastrin,	   acetylcholine	   or	   histamine	   would	   lead	   to	   a	   reduction	   in	   gastric	   acid	  production.	  Only	  histamine	  antagonists	  are	  approved	  for	  use	  in	  GORD,	  and	  H2RAs	  are	  indeed	  able	  to	  cause	  a	  rise	  in	  gastric	  pH	  and	  be	  used	  in	  the	  treatment	  of	  GORD.	  It	  also	   follows	  that	  blocking	  the	  proton	  pump	  itself	  blocks	  the	   Cinal	   component	  of	  the	  acid	  secretion	  pathway	  and	  will	   lead	  to	  a	  greater	  degree	  of	  acid	  suppression,	  and	   this	   is	   indeed	   seen	   in	   proton-­‐pump	   inhibitors.	   For	   healing	   of	   erosive	  oesophagitis,	  it	  can	  be	  seen	  that	  the	  degree	  of	  healing	  is	  related	  to	  the	  time	  gastric	  acid	  is	  above	  a	  pH	  of	  4240.	  Below	  this	  pH	  direct	  acid	  exposure	  appears	  able	  to	  cause	  oesophagitis,	   and	   pepsinogen	   is	   activated	   to	   pepsin,	   which	   is	   likely	   to	   further	  contribute	  to	  oesophageal	  injury.	  As	  this	  thesis	  repeatedly	  emphasises,	  symptoms	  in	  GORD	  are	  more	  complicated	  than	  the	  presence	  or	  absence	  of	  erosions,	  and	  there	  is	  no	  conclusive	  data	  correlating	  duration	  of	  intragastric	  pH	  control	  and	  symptoms	  relief.	  However,	  clinical	  data	  on	  efCicacy	  is	  available	  and	  will	  be	  discussed	  below.Before	   the	   advent	   of	   PPIs,	   H2RAs	   (histamine	   receptor-­‐2	   antagonists)	   were	   the	  mainstay	   of	  GORD	   therapy.	   At	  peak	   action	  they	   block	   gastric	   acid	  production	   by	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60-­‐70%241.	   Endoscopic	   healing	   oesophagitis	   was	   found	   in	  a	  meta-­‐analysis	   to	   be	  31-­‐82%	   (27-­‐45%	  where	   there	   is	   only	   grade	   1	   or	   2	   oesophagitis)242.	   Report	   of	  symptoms	   resolution	   has	   been	   similarly	   varied,	   with	   Cigures	   between	   31%	   and	  88%	  quoted243.	   Overall	  H2RAs	  are	  very	  well	   tolerated.	   Some	  patients	  complain	  of	  nausea,	   abdominal	   pain	   and	   nausea.	   Some	   H2RA	   drugs	   can	   interact	   with	   the	  cytochrome	  P450	  system,	   and	  so	  can	  cause	  clinically	   signiCicant	   interactions	  with	  drugs	   such	   as	   warfarin,	   phenytoin	   and	   theophylline.	   Cimetidine	   can	   also	   cause	  gynaecomastia	  in	  men.	  Another	  important	  problem	  with	  H2RAs	  is	  tachyphylaxis.	  A	  study	   showed	   that	   addition	   of	   nighttime	   ranitidine	   (an	   H2RA)	   to	   PPI	   therapy	  caused	   an	   initial	   improvement	   in	   nocturnal	   pH	   control,	   but	   this	   effect	   is	  signiCicantly	  decreased	  after	  1	  week	  of	  regular	  dosing.	  After	  1	  month	  there	  was	  no	  beneCit	  at	  all	  seen	  by	  the	  addition	  of	  ranitidine244.	  It	  would	  seem	  that	  intermittent,	  as	  required	  dosing	  of	  H2RAs	  is	  likely	  to	  be	  more	  beneCicial	  than	  continuous	  dosing.PPIs	  are	  currently	   the	  most	   efCicacious	  medical	   therapy	   for	   GORD,	   and	  suppress	  gastric	   acid	  secretion	  to	  a	  signiCicantly	  greater	   extent	   than	  H2RAs245.	   Examples	  of	  PPIs	  are	  omeprazole,	  lansoprazole,	   rabeprazole,	  prantoprazole,	  esomeprazole	  and	  dexlansoprazole.	  All	  PPIs	  are	  weak	  bases	  that	  highly	  selectively	  accumulate	  in	  the	  secretory	  canaliculi	  at	  pH	  less	  than	  4.	  Here	  the	  inactive	  benzimidazole	  of	  the	  PPI	  is	  converted	   to	   a	   cationic	   sulphonamide	   which	   binds	   to	   and	   blocks	   the	   proton	  pump246.	   Since	   PPIs	   bind	   to	   actively	   secreting	  pumps,	   they	   are	  most	   efCicacious	  when	  given	  before	  a	  meal	  (ideally	  the	  Cirst	  meal	  of	  the	  day).	  Dexlansoprazole	  may	  be	  an	  exception	  to	  this	  rule,	  since	  it	  has	  a	  two-­‐phase	  absorption	  at	  90	  minutes	  and	  4	   to	   5	   hours	   after	   ingestion,	   meaning	   that	   accuracy	   of	   meal	   timing	   may	   be	  somewhat	   less	   important.	   All	   PPIs	   bind	  to	   proton	  pumps	   irreversibly,	   and	   so	   to	  regain	  secretory	  activity	  after	  PPI	  administration	  new	  pumps	  must	  be	  synthesised.	  Complete	   acid	  suppression	  is	   not	  achieved	  since	   not	  all	   pumps	   are	   active	  at	   the	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same	   time,	   and	   there	   is	   continuous	   re-­‐synthesis	   of	  pumps	   resulting	   in	  a	   steady-­‐state	   situation.	   Nevertheless	   PPIs	   usually	   suppress	   70-­‐80%	   of	   gastric	   acid	  secretion247,	  248.	  PPIs	  are	  metabolised	  by	  enzymes	  in	  the	  cytochrome	  P450	  system.	  In	  terms	  of	  gastric	  pH	  control,	  a	  once-­‐daily	  morning	  dose	  of	  PPI	  gives	  a	  between	  11	  and	  15	  hours	  of	  gastric	  pH	  >4	  during	  a	  24	  hour	  period.	  Esomeprazole	  at	  a	  40	  mg	  once	  daily	  dose	  gives	   approximately	  an	  additional	  2	  hours	  of	  pH	  >4	  per	  24	  hours	  (15.3	   hours)	   than	  omeprazole	  20	  mg	  once	   daily249.	   It	   has	   been	  claimed	   that	   the	  newer	   PPI	   preparation,	   dexlansoprazole,	   may	   allow	   16	  hours	   gastric	   pH	   >4	   per	  day250.Along	  with	  their	  excellent	  gastric	  acid	  suppression,	  PPIs	  also	  have	  proven	  beneCits	  over	   H2RAs	   for	   healing	   of	   oesophagitis.	   A	   double-­‐blind	   study	   comparing	  omeprazole	  40	  mg	  daily	  with	  ranitidine	  150	  mg	  twice	  daily	   found	  omeprazole	  to	  heal	   oesophagitis	   faster,	   and	   achieve	   mucosal	   healing	   more	   frequently	   than	  ranitidine	  (oesophagitis	  healing	  rates	  at	  12	  weeks	  were	  91%	  for	  omeprazole	  and	  54%	   for	   ranitidine	   in	   subjects	   with	   grade	   2	   or	   3	   oesophagitis)251.	   In	   various	  studies,	   all	   available	   PPIs	   are	   very	   effective	   at	   healing	   reClux	   oesophagitis,	   and	  there	   is	   likely	   to	   be	   little	   real-­‐life	   difference	   between	   them	   in	   their	   relative	  efCicacy252-­‐257.Outcome	  studies	  of	  symptom	  improvement	  with	  PPI	   treatment	  will	   inevitably	  be	  more	  subjective	  than	  those	  addressing	  oesophagitis	  healing.	  Nevertheless,	  they	  are	  important	   since	   healing	   of	   oesophagitis	   does	   not	   necessarily	   correlate	   with	  symptom	   relief,	   a	   fact	   that	   is	   reinforced	   by	   the	   presence	   of	   symptoms	   in	   non-­‐erosive	   reClux	   disease.	   There	   are	   a	   number	   of	   studies	   that	   have	   looked	   at	   the	  efCicacy	  of	  PPIs	   in	  treating	   heartburn	  in	  patients	  with	  suspected	  GORD,	  and	  each	  PPI	   provides	   a	   Cigure	   of	   approximately	   70-­‐80%	   heartburn-­‐free	   days252-­‐256.	  Dexlansoprazole	  60	  mg	  once	  daily	  has	  achieved	  a	  diary	  report	  of	  96%	  heartburn-­‐
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free	  days	  after	  6	  months	  of	  treatment	  in	  patients	  with	  erosive	  oesophagitis,	  which	  was	   signiCicantly	   higher	   than	   placebo	   (29%,	   p<0.0025)258,	   but	   head-­‐to-­‐head	  studies	  with	  other	  PPIs	  are	  not	  yet	  published.	  
1.7.2.2	  AntacidsOver	  the	  counter	  antacid	  preparations	  are	  often	  used	  in	  cases	   of	  mild	  heartburn,	  and	  as	  an	  early	  course	  of	  action	  by	  symptomatic	  subjects	  usually	  before	  consulting	  a	  doctor.	  Antacids	  neutralise	  gastric	  juice	  acidity	  and	  increase	  the	  pH.	  Examples	  of	  “true”	  antacids	  are	  sodium	  bicarbonate,	  magnesium	  hydroxide,	  calcium	  carbonate,	  and	  aluminium	   hydroxide.	   Although	  very	  commonly	  used,	   study	  data	  on	  antacid	  efCicacy	  is	  relatively	  sparse.	  Studies	  have	  offered	  conClicting	  results	  as	  to	  whether	  antacids	   demonstrate	   a	   beneCit	   of	   antacid	   over	   placebo	   in	   terms	   of	   heartburn	  improvement259-­‐261.	  There	  is	  no	  evidence	  that	  antacids	  are	  beneCicial	  in	  healing	  of	  oesophagitis.	  The	  most	  common	  regime	  of	  antacid	  use	  is	  on	  an	  as	   required	  basis	  for	   symptomatic	   improvement	   only.	   More	   frequent	   use	   may	   be	   harmful	   since	  magnesium-­‐containing	   antacids	   can	   cause	   diarrhoea,	   and	   aluminium-­‐containing	  antacids	   may	   cause	   constipation,	   and	   both	   can	   accumulate	   to	   toxic	   levels,	  particularly	   in	  the	  presence	  of	   renal	   failure.	   Excess	  calcium	  ingestion	  can	   lead	  to	  hypercalcaemia,	  and	  milk-­‐alkali	  syndrome.
1.7.2.3	  Sucralfate	  and	  alginatesSince	   damage	   to	   the	   epithelium	  may	   occur	   in	   non-­‐erosive	   reClux,	   there	  may	   be	  potential	  for	  development	  of	  topical	  therapies	  that	  protect	  the	  mucosa	  locally	  from	  the	  noxious	  reCluxate	  (such	  as	  in	  the	  way	  topical	  sun	  cream	  protects	  the	  skin	  from	  ultraviolet	   light).	   The	   two	   main	   topical	   agents	   with	   this	   property	   are	  sucralfate,	  and	  alginate-­‐containing	  therapies.
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Sucralfate,	   is	   a	   sucrose	  sulphate-­‐aluminium	  complex.	   It	  is	  believed	  to	   bind	   to	   the	  oesophageal	   mucosa,	   particularly	   in	   ulcerated	   areas	   (by	   adhering	   to	   positively	  charged	  proteins	  at	  the	  ulcer	  base),	  perhaps	  protecting	  against	  further	  diffusion	  of	  acid,	   pepsin	   and	   bile	   acids262.	   It	   has	   been	   found	   to	   have	   equivalent	   heartburn	  resolution	  and	  oesophagitis	  healing	  to	  H2RAs	  in	  two	  studies263,	  264.	  Alginate	  preparations	  have	  been	  added	  to	   antacids	   in	  products	  such	  as	  Gaviscon	  and	  Gaviscon	   Advance,	   and	   this	   addition	  appears	   to	   act	   in	   a	   manner	   unique	   to	  simple	   antacid	   formulations,	   via	   physical	   rather	   than	   chemical	   properties.	  Alginates	   are	   natural	   polysaccharide	   polymers	   isolated	   from	   brown	   seaweed.	  Chemically	   they	   are	   copolymers	   of	   α-­‐L-­‐guluronic	   and	   β-­‐D-­‐mannuronic	   acid	  residues	   connected	   by	   1:4	   glycosidic	   linkages.	   In	   an	   acidic	   environment	   alginic	  salts	  and	  alginic	  acids	  precipitate	  within	  minutes	   to	   form	  a	  viscous	  gel.	   This	  gel	  is	  then	  able	  to	   form	  a	  physical	  raft	  on	  top	  of	  the	  gastric	   juice.	  This	  Cloating	  capability	  is	  often	  enhanced	  by	  the	  inclusion	  of	  bicarbonate,	  which	  facilitates	  the	  production	  of	  CO2	   in	  the	  acid	  stomach	  environment,	  which	  is	  proposed	  to	   turn	  the	  raft	   into	  a	  foam	   that	   aids	   buoyancy265.	   It	   has	   also	   been	   proposed	   that	   the	   alginate	   may	  promote	   adherence	   to	   the	  oesophageal	   mucosa,	   where	  it	  may	   be	   able	   to	   protect	  against	   reClux	   locally.	   As	   yet,	   this	   potential	   is	   untested.	   Several	   studies	   have	  investigated	   the	   efCicacy	   of	  alginate-­‐antacids	   in	   treatment	   of	   gastro-­‐oesophageal	  reClux	   symptoms.	   Randomised	  double-­‐blind	   trials	   of	  Gaviscon	   (tablets	   or	   liquid)	  have	  found	  these	  alginates	  to	  be	  superior	  to	  placebo	  for	  heartburn	  control266,	  267.	  In	  comparison	  with	  omeprazole,	  alginate-­‐antacids	  are	  predictably	  inferior	  to	  PPI	  in	  symptomatic	  relief	  in	  patients	  with	  heartburn268.	  Similarly,	  Gaviscon	  tablets	  were	  found	  to	  be	  inferior	  to	  the	  H2RA	  famotidine	  in	  preventing	  post-­‐prandial	  heartburn	  when	  given	  before	  a	  meal269.	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1.7.2.4	  Prokinetic	  therapiesProkinetic	   agents	   are	   often	   considered	   in	   patients	   not	   responding	   to	   standard	  medical	   therapy.	   Theoretically	   this	   is	   attractive,	   given	  their	  potential	   to	   increase	  the	   lower	   oesophageal	   sphincter	   pressure,	   to	   speed	   gastric	   emptying,	   and	   to	  enhance	   oesophageal	   acid	   clearance.	   In	   the	   UK	   the	  most	   commonly	   prescribed	  agents	   are	   domperidone	   and	  metoclopramide	  (both	  dopamine	   antagonists).	   The	  antibiotic	  erythromycin	  acts	  as	  a	  motilin	  agonist	   and	   increases	   gastric	   emptying.	  Metoclopramide	   is	   a	   potent	   dopamine	   antagonist	   with	   peripheral	   and	   central	  effects,	   stimulating	   gastrointestinal	   smooth	   muscle	   and	   acting	   as	   a	   powerful	  centrally	  acting	  anti-­‐emetic.	  It	  has	  been	  found	  to	  be	  equally	  effective	  as	  cimetidine	  and	  better	  than	  placebo	  in	  treatment	  of	  reClux	  symptoms270,	   271,	  but	  not	   in	  healing	  erosive	  oesophagitis.	   Its	  use	  is	  limited	  by	  central	  side-­‐effect	  such	  as	  anxiety,	  motor	  restlessness,	   hallucinations	   and	   drowsiness.	   Domperidone	   is	   another	   dopamine	  antagonist	   that	   stimulates	   oesophageal	   peristalsis,	   increases	   lower	   oesophageal	  sphincter	  pressure,	   and	   speeds	  gastric	   emptying272.	   It	   has	   also	   been	  found	  to	   be	  superior	  to	  placebo	  and	  equivalent	  to	  H2RAs	  in	  symptom	  reduction	  in	  GORD273,	  274.	  Since	   there	   is	   little	   central	   activity	  of	   domperidone	   it	   is	   generally	  well	   tolerated	  with	   a	   good	   side-­‐effect	   proCile.	   Perhaps	   the	   most	   problematic	   side-­‐effect	   is	  hyperprolactinaemia.
1.7.2.5	  SurgerySurgical	   intervention	   for	   GORD	   was	   often	   inadequate	   until	   Nissen	   discovered	  (serendipitously)	  that	   creating	  a	  wrap	  of	  the	  proximal	  stomach	  around	  the	  lower	  oesophageal	  sphincter	  resulted	  in	  a	  functioning	  anti-­‐reClux	  barrier,	  and	  a	  potential	  cure	  for	  the	  disease275.	  Over	  the	  years	  since	  there	  has	  been	  a	  waxing	  and	  waning	  of	  the	  popularity	  of	  anti-­‐reClux	  surgery.	   	  Although	  they	  were	  far	  superior	  to	  available	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treatments	   (even	   with	   the	   arrival	   of	   H2RAs,	   surgery	   offered	   superior	   symptom	  control276),	  surgical	  procedures	  were	  general	  reserved	  for	  severe	  and	  complicated	  GORD	   since	   a	   laparotomy	   was	   required.	   When	   highly	   effective	   PPI	   therapy	  was	  introduced	  in	  1989,	  the	  result	  was	  a	  sharp	  decline	  in	  anti-­‐reClux	  procedures.	  Then,	  throughout	   the	   1990s	   the	   increasing	   use	   of	   laparoscopic	   techniques	   caused	   a	  resurgence	  in	  surgery	  again.	  However,	  since	  2000	  surgical	  therapy	  has	  been	  on	  the	  decline	   again.	   Partly	   this	   has	   been	   because	   the	   costs	   of	  PPIs	   decreased	   as	   they	  became	  generically	  available,	  but	  also	  because	  there	  has	  been	  some	  doubt	  as	  to	  the	  long-­‐term	   efCicacy	   of	   anti-­‐reClux	   surgery.	   A	   follow-­‐up	   to	   the	   initial	   study	   by	  Spechler	  that	   compared	  H2RAs	   and	  anti-­‐reClux	  surgery	   showed	  that,	   at	  10	  years,	  62%	   of	   patients	   in	   the	   surgery	   group	   were	   using	   anti-­‐reClux	   medications	  regularly277.	   It	  appears	  likely	  that	  both	  centre	  expertise278	  and	  patient	  selection	  is	  of	  paramount	  importance.	   There	  is	  still	   likely	   to	  be	  a	  place	  for	  surgery,	   especially	  when	  one	  considers	   that,	   on	  survey,	  30%	  of	  GORD	  patients	  are	  either	  marginally	  satisCied	   or	   totally	   dissatisCied	   by	   their	   PPI	   therapy279,	   280.	   PPI	   therapy	   is	   often	  needed	   lifelong,	   and	   as	   such	   patient	   concordance	   with	   therapy	   can	   inCluence	  effectiveness	   of	   therapy.	   There	   are	  also	   recent	   concerns	   about	   the	   safety	   of	   PPI	  therapy5	   that	  may	  be	   inCluencing	  patients’	  satisfaction	  with	  the	  drugs.	  One	  of	  the	  most	  common	  reasons	  for	  referral	  for	  surgery	  is	  refractoriness	  to	  PPI	  therapy,	  but	  it	   is	   known	   that,	   along	  with	  the	  presence	  of	   typical	   reClux	   symptoms	   (heartburn	  and	  regurgitation)	   and	   abnormal	   pH	   exposure	   on	   reClux	   testing,	   good	   symptom	  response	   to	   PPI	   is	   an	   associated	   with	   a	   positive	   outcome	   from	   anti-­‐reClux	  surgery281,	   282.	   At	   least	  in	  part	   this	   is	  because	   these	  factors	  often	  distinguish	  true	  reClux	  symptoms	  from	  non-­‐reClux	  heartburn	  (functional	  heartburn)	  and	  alternative	  problems	   such	   as	   dyspepsia.	   Hence	   perhaps	   the	   ideal	   patient	   for	   anti-­‐reClux	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Although	   the	   advent	   of	   proton	   pump	   inhibitors	   (PPIs)	   has	   revolutionised	   the	  treatment	   of	   gastro-­‐oesophageal	   reClux	   disease	   in	   recent	   decades,	   it	   has	   been	  estimated	   that	  10	  to	   40%	  of	   patients	  with	  GORD	  symptoms	   have	   an	   incomplete	  response	   to	   treatment22,	   283,	   a	   signiCicant	   clinical	   problem	   given	   the	   high	  prevalence	  of	  the	  disease.	  The	   treatment	   response	   in	   non-­‐erosive	   reClux	   disease	   (NERD)	   is	   controversial,	  having	  historically	  been	  considered	  inferior	  to	   response	  in	  erosive	  disease,	   in	  the	  region	  of	  40%22,	  284.	  A	  recent	  study	  has	  reported	  that	  patients	  with	  NERD	  are	  more	  likely	  to	  only	  partially	  respond	  to	  PPI	  therapy283.	  However,	  a	  recent	  meta-­‐analysis	  has	   questioned	   this	   inferior	   response,	   suggesting	   that	   in	   well-­‐deCined	   (with	  symptom,	   endoscopic	   and	   objective	   reClux	   analysis)	   patients	   with	   NERD,	   the	  treatment	   response	  may	  be	  as	  high	  as	  70%284.	   	  Nevertheless	   it	  is	  clear	  that	  there	  are	  a	  signiCicant	  number	  of	  patients	  with	  GORD	  who	  are	  inadequately	  treated	  with	  PPI	  (in	  fact	  a	  recent	  systematic	  review	  of	  subjective	  opinions	  of	  patients	  revealed	  that	  only	  34%	  were	  extremely	  satisCied	  with	  their	  PPI	  therapy283).	  As	  such	  there	  is	  an	  unmet	  need	  to	  develop	  new	  therapies	  for	  PPI	  non-­‐responders.	  Recent	  attempts	  to	   treat	   refractory	   GORD	   by	   inhibiting	   transient	   lower	   oesophageal	   sphincter	  relaxations	   have	   been	   met	   with	   disappointing	   clinical	   response285,	   286.	   An	  alternative	  approach	  to	  such	  patients	  may	  be	  required.	  This	  chapter	  has	  illustrated	  the	   potential	   role	   of	   impaired	   oesophageal	   mucosal	   integrity	   in	   disease	  pathogenesis.	  It	  may	  be	  that	  a	  topical	  treatment	  that	  can	  “protect”	  the	  mucosa	  from	  damage	   to	   its	   barrier	   integrity	   could	   be	   an	   interesting	   future	   strategy	   for	  refractory	  patients.	  It	  is	  possible	  that,	  due	  to	  their	  bioadhesive	  properties,	  alginate	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compounds	   could	   form	   a	   basis	   of	   such	   a	   therapy.	   Such	   a	   possibility	   requires	  further	  experimental	  evaluation.
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1.9 Remaining questions and aims of thesis
After	   reviewing	   the	   current	   literature,	   it	   can	   be	   proposed	   that	   a	   better	  understanding	   of	   human	   oesophageal	   mucosa	   physiology	   and	   pathophysiology	  may	   contribute	   to	   a)	   better	   understanding	   of	   refractory	   GORD,	   and	   b)	   new	  treatment	  strategies.	  
To	   move	   forward	   in	   these	   Cields	   the	   following	   remaining	   questions	   have	   been	  identiCied:
1) How	   does	   human	   oesophageal	   mucosa	   compare	   with	   animal	   oesophageal	  mucosa	  previously	  described	  in	  experimental	  work?2) How	   does	   the	   normal	   human	   oesophageal	   mucosa	   respond	   when	   it	   is	  exposed	  to	  reClux	  (experimentally	  and	  in	  vivo)?3) Is	  the	  oesophageal	  mucosa	  different	  or	  more	  vulnerable	  to	  reClux	  in	  different	  disease	  phenotypes?4) Is	  the	  regional	  difference	  in	  oesophageal	  sensitivity	  observed	  in	  humans	  due	  to	  distinct	  oesophageal	  mucosal	  characteristics?5) What	  is	   the	  relationship	  between	  human	  oesophageal	  sensitivity	   to	  acid	  and	  oesophageal	  mucosal	  status	  and	  functional	  behaviour?6) Can	   the	   human	   oesophageal	   mucosa	   integrity	   be	   protected	   with	   a	   topical	  agent?
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To	  answer	  these	  questions	  the	  aim	  of	  this	  PhD	  research	  project	  was	  to:
1) Assess	   the	   in	   vitro	   functional	   behaviour	   of	   human	   oesophageal	   mucosa	   in	  biopsies	  from	  asymptomatic	  controls	  and	  patients	  with	  reClux	  symptoms.
2) Evaluate,	   in	  vivo,	  the	  integrity	  of	  oesophageal	  mucosa	  in	  basal	  conditions	  and	  during	  exposure	  to	  acid	  using	  oesophageal	  impedance	  monitoring.	  
3) Compare	   the	   aforementioned	   oesophageal	   mucosa	   functional	   behaviour	   in	  
vivo	   between	   patients	   with	   functional	   heartburn	   and	   non-­‐erosive	   reClux	  disease.
4) Characterise,	   in	   vitro	   and	   in	   vivo,	   the	   differences	   in	   basal	   and	   functional	  behaviour	  of	  distal	  and	  proximal	  human	  oesophageal	  mucosa.





CHAPTER 2: METHODS AND MATERIALS
The	  methods	  and	  materials	  used	  in	  the	  studies	  presented	  in	  this	  thesis	  will	  brieCly	  be	  described	  here,	   and	  speciCic	  methods	  will	  be	  presented	  in	  greater	  detail	   in	  the	  relevant	  chapter.
2.1 In vitro studiesThe	  in	  vitro	  general	  methods	  are	  applicable	  to	  the	  studies	  presented	  in	  Chapter	  3:	  
In	   vitro	   assessment	   of	  oesophageal	   mucosal	   integrity	   in	  patients	   with	  heartburn	  without	   oesophagitis;	   Chapter	   5:	   in	   vivo	   and	   in	   vitro	   assessment	   of	   mucosal	  integrity	   in	   the	   distal	   and	   proximal	   oesophagus,	   and;	   Chapter	   6:	   protection	   of	  human	  oesophageal	  mucosal	  integrity.	  
2.1.1	  Endoscopy	  and	  oesophageal	  mucosal	  biopsyAll	   endoscopic	   biopsies	   were	   taken	   at	   the	   endoscopy	   unit	   of	   the	   Royal	   London	  Hospital.	  Endoscopy	  was	  performed	  per-­‐orally	  using	  Olympus	  video	  gastroscopes	  with	  a	  2.8	  mm	  working	  channel.	  The	  gastro-­‐oesophageal	  junction	  was	  identiCied	  as	  the	  location	  of	   the	  proximal	   extent	  of	   the	  gastric	   folds.	   The	  presence	  of	  Barrett’s	  oesophagus	   was	   excluded	   by	   ensuring	   that	   the	   squamo-­‐columnar	   junction	  corresponded	  to	   the	   this	   level.	   The	   level	   of	  the	   gastro-­‐oesophageal	   junction	  was	  measured	   relative	   to	   the	   external	   aspect	   of	   the	   mouth	   guard	   using	   the	   ‘on	   the	  endoscope’	  measurements.	  Distal	  oesophageal	  biopsies	  were	  taken	  at	  5	  cm	  above,	  and	  proximal	   biopsies	   at	   20	   cm	   above	   the	   gastro-­‐oesophageal	   junction.	   Boston	  ScientiCic	   Radial	   Jaw	   3	   biopsy	   forceps	   (with	   2.2	  mm	   jaws)	  without	   needle	   were	  used	   to	   take	   biopsies.	   Biopsies	   were	   removed	   one	   “bite”	   at	   a	   time,	   and	   as	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tangentially	  as	  possible	  with	  use	  of	  suction	  and	  angulation.	   Biopsies	  were	  placed	  immediately	   (with	   a	   blunt	   needle)	   into	   pre-­‐oxygenated	   Krebs-­‐Henseleit	  physiological	   buffer	   at	   pH	   7.4	   (for	   Ussing	   chamber	   studies)	   or	   4%	  paraformaldehyde	  in	  1mM	  phosphate	  buffer	  (for	  immunohistochemistry	  studies).
2.1.2	   Ussing	  chamber	  technique:	  measurements	  of	  mucosal	  transepithelial	  electrical	  
resistanceThe	   technique	   involves	   placing	   an	   epithelial	   tissue	   across	   an	   aperture	   that	  separates	   two	  halves	  of	  a	  chamber.	   	   In	   the	  cases	  of	  the	   studies	  presented	  in	  this	  thesis,	   the	   epithelial	   tissue	   was	   a	   human	  oesophageal	   mucosal	   biopsy.	   The	   two	  halves	   of	   the	   chamber	   can	   be	   Cilled	   with	   (usually	   physiological)	   solutions,	   and	  electrodes	  are	  placed	  in	  each	  chamber	  that	  are	  able	  to	  measure	  and	  induce	  current	  and	  voltage	  across	  the	  tissue.	  By	  placing	  the	  tissue	  across	  two	  separated	  halves	  of	  the	   chamber	   and	   Cilling	   each	   half	   with	   an	   identical	   volume	   of	   an	   identical	  electrolyte	   solution,	   osmotic	   and	   hydrostatic	   gradients	   for	   ion	   movement	   are	  eliminated.	   	  Voltage	  electrodes	  are	  placed	  close	  to	  the	  mucosa	  on	  both	  sides	  of	  the	  chamber	   to	   allow	   measurement	   of	   the	   transepithelial	   voltage.	   	   Current-­‐passing	  electrodes	  are	  placed	  laterally	  to	  the	  voltage	  electrodes,	   forming	  a	  circuit	  that	  can	  pass	   current	   across	   the	   epithelium	   for	   the	   purpose	   of	   voltage	   clamping.	   	   The	  current	   required	   for	   voltage	   clamping	   is	   calculated	   from	   the	   inherent	  transepithelial	  voltage	  and	  the	  resistance	  of	  the	  mucosa	  and	  circuit	  (I	  =	  V/R).In	   using	   the	   Ussing	   chamber	   for	   physiological	   studies,	   the	   orientation	   of	   the	  epithelium	  placed	  across	  it	  is	  important.	   	  The	  tissue	  is	  placed	  so	   that	  the	  mucosal	  membrane	  and	  “basal”	  membrane	  each	  face	  one	  half	  of	  the	  chamber,	  so	  producing	  a	   “luminal”	   and	   “basal”	   chamber	   that	   are	   Cilled	   independently	   with	   solutions.	  Typically	  (and	  in	  the	  case	  of	  the	  experiments	  in	  Chapters	  3,	  5	  and	  6)	  the	  chambers	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are	  Cilled	  with	  a	  physiological	  Krebs	  bicarbonate	  Ringer	  solution.	   	  The	  composition	  of	   the	   Krebs’	   solution	   was	   (mM):	   NaCl	   (118.1),	   KCl	   (4.69),	   MgSO4.7H2O	   (1.18),	  KH2PO4	  (1.18),	  D-­‐glucose	  (11.1),	  NaHCO3	  (25.0)	  and	  CaCl2.6H2O	  (2.5).This	  solution	  was	  continuously	  perfused	  by	  carbogen	  gas	  (95%	  O2,	  5%	  CO2).	   	  This	  mixture	  provides	  a	  high	  partial	  pressure	  of	  oxygen	  to	  the	  tissue,	  which	  is	  required	  to	  overcome	  the	  lack	  of	  haemoglobin	  delivery.	   	  The	  pCO2	  provided	  is	  similar	  to	  that	  of	  venous	  blood	  and	  helps	  maintain	  the	  buffer	  at	  a	  physiological	  pH.	   	  The	  system	  is	  heated	  by	  a	  water	  bath	  system	  to	  body	  temperature.Before	   starting	   electrical	   measurements	   across	   the	   epithelium,	   the	   system	   was	  calibrated.	   	   The	  solution	  was	  placed	  in	  the	  chambers	  without	   the	  tissue	  in	  place,	  and	   electrical	   bias	   eliminated	   by	   zeroing	   the	   voltage	   difference	   between	   the	  voltage	   electrodes	   and	   the	   inherent	   resistance	   of	   the	   solution.	   This,	   and	  subsequent	   measurement	   was	   done	   using	   the	   proprietary	   software,	   VCC	   Clamp	  (Mussler	  ScientiCic	  Instruments,	  Aachen,	  Germany).The	   voltage	   clamp	   can	   be	   used	   to	   calculate	   the	   transepithelial	   resistance	   (the	  reciprocal	  of	  the	  conductance).	   	  This	  is	  done	  by	  pulsing	  a	  small	   command	  voltage	  and	  measuring	  the	  resulting	  change	  in	  current	  (conductance	  =	  Δcurrent	  /	  pulsed	  voltage).	  	  More	  than	  90%	  of	  intestinal	  conductance	  occurs	  through	  the	  paracellular	  pathway,	   which	  is	   regulated	  by	   tight	   junctions	  and	  the	   apposition	   of	  basolateral	  membranes	   of	   adjacent	   epithelial	   cells.	   	   Therefore	   changes	   in	   conductance	   (or	  resistance)	  can	  indicate	  changes	  in	  the	  mucosal	  integrity.The	  solution	  in	  the	  “basal”	  chamber	  was	  replaced	  with	  a	  solution	  that	  represented	  reCluxate-­‐like	  material	  (acid	  +	  pepsin	  +	  bile	  acid).	  The	  test	  exposure	  solutions	  used	  in	  the	  experiments	  of	  this	  thesis	  (acid	  pH	  2,	  and	  weakly	  acidic	  pH	  5)	  were	  prepared	  by	   adjusting	   the	   pH	   of	   the	   Kreb’s	   physiological	   solution	   using	   HCl	   and	   NaOH.	  Porcine	  pepsin	  was	  added	  at	   a	  concentration	  of	  1	  mg/ml.	  Deoxycholic	  acid	  1	  mM	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was	   added	   to	   the	   weakly	   acidic	   solution	   (it	   is	   not	   soluble	   at	   pH	   2)	   and	  taurodeoxycholic	   acid	   1	   mM	   was	   added	   to	   the	   acidic	   solution.	   The	   change	   in	  transepithelial	  electrical	  resistance	  (TER)	  that	  occurs	  during	  a	  30	  minute	  “luminal”	  exposure	  was	  calculated.
2.1.3	  Immunohistochemical	  studies:	  assessment	  of	  mucosal	  afferent	  nerve	  MibresProximal	   and	  distal	   oesophageal	  biopsies	   were	  Cixed	   in	   4%	  paraformaldehyde	   in	  0.1	  M	   phosphate	   buffer	   overnight.	   This	  was	   followed	   by	   cryoprotection	   in	  30%	  sucrose	  in	  phosphate-­‐buffered	  saline	  (PBS)	  for	  24-­‐hours	  at	   40C,	   followed	  by	  30%	  sucrose	  PBS:OCT	   embedding	  compound	  (1:1)	  at	  40C.	   Sections	  were	  embedded	   in	  OCT	  at	  -­‐250C	  and	  10	  μm	  sections	  were	  cut	  on	  a	  cryostat	  and	  mounted	  on	  positively	  charged	  glass	  slides.	   Sections	  were	   then	  air-­‐dried	   for	   1	  hour.	   400	  µl	   per	   slide	  of	  10%	  horse	  serum	  in	  PBS	  (blocking	  agent	  to	   prevent	  non-­‐speciCic	  binding)	  +	  0.3%	  Triton-­‐X100	   (detergent	   to	   destroy	   cell	   membranes	   and	   increase	   antigen	  penetration)	  was	  applied	  and	  left	  at	  room	  temperature	  for	  1	  hour.	   	  Sections	  were	  then	  incubated	  with	  a	  primary	  antibody	  to	  calcitonin	  gene-­‐related	  peptide	  (CGRP)	  (1:500	  Monoclonal	   mouse	   anti-­‐human,	   Pierce	   Antibodies	  ABS	   026-­‐05-­‐02)	  at	  40C	  overnight.	   The	  primary	   antibody	  was	  made	  up	   in	   10%	  horse	   serum	   in	  PBS	   and	  0.3%	  Triton-­‐X100.	  Sections	  were	  then	  washed	  three	  times	  for	  10	  minutes	  in	  PBS	  +	  Triton-­‐X100,	   followed	   by	   incubation	  with	   the	   secondary	   antibody	   (donkey	   anti-­‐mouse	   Invitrogen,	   labeled	   with	   green-­‐Cluorescent	   Alexa	   Fluor	   488	   dye)	   and	  incubated	   for	  4	  hours	   in	  darkness.	   Sections	  were	  then	  washed	  again	   three	  times	  for	  10	  minutes,	  and	  mounted	  with	  Vectashield	  HardSetTM.	  Fluorescence	  was	  visualised	  using	  an	  epiCluorescent	  microscope	  (Olympus	  BX61).	  All	   images	   were	   obtained	   with	   a	   40x	   oil	   immersion	   lens	   under	   the	   488	   nm	  excitation	  setting.	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2.2 In vivo studies
2.2.1	  Oesophageal	  high	  resolution	  manometryStudies	  were	  performed	  at	  the	  upper	  gastrointestinal	  physiology	  unit	  of	  the	  Royal	  London	   Hospital.	   Before	   impedance	   measurements,	   the	   lower	   oesophageal	  sphincter	  location	  was	   determined	  using	  oesophageal	  manometry.	  After	  pressure	  calibration,	   a	   4.2	   mm	   diameter,	   solid-­‐state	   high	   resolution	   oesophageal	  manometry	   catheter	   (ManoScanTM	   catheter,	   Given	   Imaging,	   USA)	   with	   36	  circumferential	   pressure	   channels	   was	   placed	   transnasally.	   Manometry	   images	  were	  observed	  real-­‐time	  using	  proprietary	  software	  (ManoviewTM,	   Given	  Imaging,	  USA).	  Correct	  placement	  was	  deemed	  when	  the	  catheter	  had	  traversed	  the	  crural	  diaphragm,	   and	  an	   image	  was	   obtained	   that	   included	  pressure	   recordings	   from	  pharynx,	   oesophagus	   and	   proximal	   stomach	   simultaneously.	   The	   lower	  oesophageal	   sphincter	   (LOS)	  was	   identiCied	  as	   a	   high	  pressure	  area	   at	   the	   distal	  margin	   of	   the	   oesophageal	   body	   (see	   Cigure	   9).	   Recording	   the	   catheter	  measurement	  at	   the	  nares	  enabled	  calculation	  of	  the	  LOS	  position	  relative	  to	  this	  point.	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Figure	  9:	  Demonstration	  of	  the	  LOS	  on	  a	  normal	  high	  resolution	  manometry	  plot
2.2.2	  ReMlux	  monitoring	  and	  impedance	  baseline	  measurementsAfter	  oesophageal	  manometry	   testing,	   the	  manometry	  catheter	  was	   removed,	  and	  impedance	   monitoring	   was	   performed.	   To	   this	   end	   a	   combined	   oesophageal	  impedance-­‐pH	  catheter	  (Comfortec®Z/pH	  ZAI-­‐BG	  -­‐44,	  Sandhill	  ScientiCic,	  USA)	  was	  used.	  This	  is	  a	  2.13	  mm	  diameter	  catheter	  containing	  6	  impedance	  segments	  and	  2	  pH	   channels.	   When	   correctly	   placed	   with	   reference	   to	   the	   manometrically-­‐determined	  LOS	  position,	   the	  impedance	  channels	  are	  located	  at	  3,	  5,	  7,	   9,	  15	  and	  17	  cm	  above	  the	  LOS,	   and	  the	  pH	  sensors	  5	  cm	  above	  and	  10	  cm	  below	  the	  LOS.	  This	  catheter	  also	  has	  an	  integrated	  sphincter	  locator	  port	  at	  11	  cm	  above	  the	  LOS.	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This	   can	   be	  water	   perfused	   to	   allow	   pressure	  measurement	   and	   location	   of	   the	  sphincter	  by	  manometry,	   but	   it	   can	  also	   be	  used	  to	   perfuse	  the	  oesophagus	  with	  liquids.	  Prior	  to	  insertion	  into	  the	  nasal	  cavity,	  the	  pH	  probes	  (which	  are	  internally	  referenced)	  are	  calibrated	  in	  pH	  7	  and	  pH	  4	  solutions.After	   insertion,	   the	  patient	  was	  asked	  to	  remain	  in	  a	   seated	  position	  for	   baseline	  and	  perfusion	  studies.	  Perfusions	  were	  by	  way	  of	  a	  peristaltic	  pump	  attached	  to	  a	  3-­‐way	  tap,	  which	  in	  turn	  was	   connected	  to	  neutral	   (normal	   saline	  buffered	  to	  pH	  6.7	  with	  phosphate	  buffer)	  and	  acid	  (HCl	  at	  pH	  1).	  Rate	  of	  perfusion	  was	  checked	  
ex	  vivo	  before	  each	  perfusion	  experiment.Any	  symptoms	  during	  perfusions	  were	  measured	  on	  a	  0-­‐10	  visual	   analogue	  scale,	  where	  0	  is	  no	  pain	  and	  10	  is	  the	  worst	  pain	  imaginable.24-­‐hour	  pH-­‐impedance	  studies	  were	  analysed	  according	  to	  a	  consensus	   report	  of	  detection	  and	  deCinitions	  of	  reClux	  studies287.
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CHAPTER 3: IN VITRO ASSESSMENT OF OESOPHAGEAL MUCOSAL 
INTEGRITY IN PATIENTS WITH HEARTBURN WITHOUT OESOPHAGITIS
3.1 Introduction 
In	  erosive	  gastro-­‐oesophageal	  reClux	  disease	  it	  is	  relatively	  easy	  to	  understand	  how	  exposure	  of	  the	  defective,	   inClamed	  oesophageal	  mucosa	  to	  noxious	  components	  of	  the	  reClux	  can	  lead	  to	  unpleasant	  sensation	  and	  hence	  reClux	  symptoms.	  However,	  the	  mechanism	  of	  heartburn	  perception	  in	  patients	  without	  oesophageal	  erosions	  is	   much	   less	  well	   understood.	   The	  majority	   of	   patients	   with	  gastro-­‐oesophageal	  reClux	  disease	  have	  normal	  macroscopic	  oesophageal	   Cindings	  on	  endoscopy22.	   In	  patients	  with	  such	  non-­‐erosive	   reClux	  disease	  symptoms	  are	  still	  being	   caused	  by	  the	  exposure	  of	  the	  “normal”	  mucosa	  to	  components	  of	  gastro-­‐oesophageal	  reClux;	  whether	   associated	  with	  excessive	   gastro-­‐oesophageal	   reCluxate	  exposure,	   or	   by	  hypersensitivity	  of	  the	  oesophagus	  to	  normal	  amounts	  of	  reClux.	  Of	  likely	  relevance	  to	   the	   pathophysiology	   of	   non-­‐erosive	   reClux	   disease	   is	   that,	   although	  macroscopically	  normal,	  the	  mucosa	  may	  still	  have	  microscopic	  and/or	  functional	  abnormalities163,	  165,	   167.	  The	  oesophageal	  mucosal	   integrity	   is	  a	  critical	   protective	  mechanism	   against	   gastroesophageal	   reClux.	   Impairment	   of	   oesophageal	  mucosa	  integrity	  may	  lead	  either	  to	  signiCicant	  inClammation	  and	  erosive	  reClux	  disease288,	  or	  permeation	  of	  noxious	   components	  of	  the	  reCluxate	  (e.g.	  H+,	   bile	  acids,	  pepsin)	  that	   stimulate	   release	   of	   epithelial	   cell	   mediators289	   or	   directly	   activate	  nociceptors162,	   producing	   typical	   reClux	   symptoms	   without	   signiCicant	  inClammation.	  Impairment	  of	  oesophageal	  mucosal	  integrity	  in	  macroscopically	  normal	  tissue	  can	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be	  demonstrated	  as	  ultrastructural	  microscopic	   changes	   (i.e.	   dilated	  intercellular	  spaces,	  DIS)	  and/or	  in	   functional	   terms.	   In	   vitro	  Ussing	  chamber	  experiments	   can	  demonstrate	   decreased	   transepithelial	   electrical	   resistance	   (TER)	   and	   increased	  permeability	  of	  the	  mucosa	  to	  passage	  of	  small	  molecules122,	  153,	  290.	  The	   relationship	   between	   the	   ultrastructural	   and	   functional	   changes	   in	  oesophageal	  mucosa	   integrity	   is	   probably	  complex.	  DIS	  has	   been	  suggested	  to	   be	  caused	  by	   an	   initial	   increased	  permeability	   to	   ionic	   Clow	  through	   the	  epithelium.	  Movement	  of	  chloride	  ions	  is	  then	  followed	  osmotically	  by	  water	  which	  enters	  the	  intercellular	  spaces	  and	  causes	  dilation291.	  It	  is	  therefore	  probable	  that	  changes	   in	  TER	   would	  be	   seen	   before	   the	   development	   of	  DIS,	   since	   the	  movement	   of	   ions	  (detected	  by	  TER)	  would	  occur	  before	  the	  water	  enters	  the	  intercellular	  spaces.	  TER	   appears	   to	   be	  a	  good	  marker	  of	  mucosal	   permeability.	   In	  experiments	  using	  humans	  and	  animals,	  TER	  has	  been	  shown	  to	  correlate	  well	  with	  other	  measures	  of	  permeability,	   and	   is	   decreased	   when	   DIS	   is	   present153,	   157.	   Thus	   far,	   human	  oesophageal	  mucosal	  integrity	  has	  been	  measured	  in	  static	  conditions:	  i.e.	  in	  terms	  of	   DIS	   or	   baseline	   TER.	   In	   fact,	   it	   is	   possible	   to	   evaluate	   oesophageal	   mucosal	  integrity	   in	  human	  biopsies	   both	  in	   static	  conditions,	   and	  in	  response	   to	   a	  stress	  stimulus	   (i.e.	   acid	  exposure).	   The	  use	  of	   continuous	  measurement	   of	  TER	   allows	  evaluation	   of	  dynamic	   changes	   in	   oesophageal	  mucosal	   integrity	   on	  exposure	   to	  noxious	  solutions.	  Unlike	  determination	  of	  DIS	  (an	  “all	   or	  nothing”	  phenomenon),	  continuous	   measurement	   of	   TER	   allows	   a	   quantiCication	   of	   relative	   changes	   in	  mucosal	   integrity	   over	   time.	   This	   dynamic	   response	   of	  oesophageal	  mucosa	  has	  not	   yet	   been	   tested	   in	   human	  tissue,	   but	   may	   allow	   evaluation	   of	   the	  degree	   of	  integrity	  change	  that	  occurs	  in	  different	  populations	  of	  human	  patients.	  As	  such	  it	  allows	  assessment	  of	  integrity	  response	  to	  a	  “stress	  test”	  of	  noxious	  exposures.The	   most	   common	   phenotype	   of	   GORD	   patients	   currently	   evaluated	   by	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gastroenterologists	   is	   the	   patient	   referred	   with	   reClux	   symptoms	   and	   negative	  endoscopy292.	   It	   is	   known	  that	   patients	   with	   non-­‐erosive	  reClux	   disease	   “off	  PPI”	  and	  with	  refractory	  non-­‐erosive	  reClux	  disease	  “on	  PPI”	  have	  persistent	  DIS167.	  It	  is	  also	   known	  that	  successful	  PPI	  treatment	  reduces	   intercellular	  space	  diameter166.	  These	  Cindings	  suggest	   that	  an	  impaired	  oesophageal	  mucosal	   integrity	  may	  have	  an	   important	   role	   in	   the	   pathogenesis	   of	   ongoing	   symptoms.	   It	   is	   of	   interest	   to	  know	   how	   the	   oesophageal	   mucosal	   integrity	   of	   these	   patients	   responds	   to	   a	  “stress	   test”	  of	  acidic	   solutions,	   and	  whether	   it	  displays	  an	  abnormal	  handling	  of	  acid	  that	  may	  be	  important	  in	  disease	  pathogenesis.
The	   hypothesis	   of	   this	   study	   is	   that	   in	   patients	   with	   heartburn	   and	   a	  macroscopically	   normal	   oesophageal	   mucosa	   there	   is	   persistent	   underlying	  mucosal	   vulnerability	   that	  can	  predispose	  to	  ongoing	  symptoms,	   hypersensitivity	  to	  normal	  or	  low	  amount	  of	  acid	  or	  weakly	  acidic	  exposure,	  or	  early	  relapse	  after	  PPI	   treatment	   withdrawal.	   Such	   vulnerability	   might	   be	   expressed	   as	   a	   subtle	  impairment	  of	  mucosal	  handling	  of	  acid	  that	  might	  be	  detected	  during	  continuous	  TER	  measurements	  in	  human	  biopsies.	  




3.2.1	  Study	  design	  and	  populationThe	  study	  was	  a	  prospective	  comparison	  of	  dynamic	  mucosal	   integrity	   in	  patients	  with	  typical	  reClux	  symptoms	  and	  asymptomatic	  controls.All	  subjects	  were	  recruited	  for	  the	  study	  at	  the	  gastrointestinal	  endoscopy	  unit	  of	  the	  Royal	  London	  Hospital.	  	  Oesophageal	   biopsies	   were	   taken	   from	   patients	   having	   upper	   gastrointestinal	  endoscopy	  for	  heartburn	  (troublesome,	  daily	  retrosternal	  ascending	  burning).	   For	  comparison,	   biopsies	   were	   also	   taken	   from	   control	   subjects	   with	   no	   upper	  gastrointestinal	   symptoms	   (having	   endoscopy	   for	   iron	   deCiciency	   anaemia	   or	  diarrhoea).	  Subjects	  with	  oesophageal	   erosions	   or	  Barrett’s	  oesophagus	   were	  excluded	   from	  the	  study.	  Overall	   78	  subjects	  were	   recruited	   for	   the	   study.	   From	  9	  subjects	  biopsies	   were	  used	  for	   reproducibility	  validation,	   from	  5	  subjects	  biopsies	  were	  used	   to	   assess	  orientation,	   from	   11	   subjects	   biopsies	   were	   used	   to	   compare	   functional	   and	  morphological	  Cindings,	  and	  biopsies	  from	  the	  remaining	  53	  subjects	  were	  used	  for	  the	  main	  study.
3.2.2	  EndoscopyEndoscopic	   procedures	   were	   performed	   under	   midazolam	   sedation	   or	   with	  pharyngeal	   local	   anaesthetic	   spray.	   	   Three	   oesophageal	   mucosal	   biopsies	   were	  taken	  (Radial	  Jaw	  3	  forceps,	  Boston	  ScientiCic,	  USA)	  from	  3	  cm	  above	  the	  squamo-­‐columnar	   junction,	   and	   immediately	   placed	   in	   a	   pre-­‐oxygenated	   Krebs-­‐Henseleit	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buffer	  solution	  at	  pH	  7.4.	  The	  biopsies	  were	  rapidly	   transported	  to	  the	  laboratory	  for	  Ussing	  Chamber	  study.	  All	  biopsies	  for	  the	  following	  studies	  were	  taken	  by	  the	  same	  endoscopist	  (Dr	  Woodland)	  using	  the	  same	  technique.	  
3.2.3	  Orientation	  of	  biopsiesOesophageal	  biopsies	  were	  Cirst	  orientated	  under	  stereo-­‐microscopy	  to	  determine	  the	  luminal	  and	  basal	  sides.	  Accurate	   orientation	   is	   essential	   for	   the	   conduct	   of	   this	   study.	   Alongside	   a	  consultant	   gastrointestinal	   pathologist	   (Dr	   J	   Chin-­‐Aleong),	   the	   criteria	   for	  determining	  orientation	  was	  Cirst	  established.	  
The	  following	  indicators	  of	  biopsy	  orientation	  were	  used:1) Macroscopically,	  the	  biopsies	  form	  a	  curved	  shape	  due	  to	  the	  pinching	  action	  of	   the	  biopsy	   forceps.	   The	   convex	   surface	   of	   the	   curve	   is	   thus	   usually	   the	  luminal	  aspect	  of	  the	  biopsy	  (Cigure	  10).
2) Microscopically	   (under	   high	   powered	   stereomicroscope,	   Cigure	   11),	   the	  following	  features	  are	  able	  to	  indicate	  the	  orientation:	  • The	   papillae	   are	   visible	   as	   pale	   dots	   on	   the	   luminal	   aspect	   of	   the	  biopsy.• A	  very	  thin,	   Clat	   layer	  of	  tissue	  (superCicial	   Clat	  squamous	   layer)	  can	  often	  be	  seen	  originating	  at	  the	  edges	  of	  the	  luminal	  aspect.• The	   basal	   aspect	   of	   the	   biopsy	   can	   be	   identiCied	   by	   an	   irregular	  appearance	  of	  connective	  tissue.
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Figure	  10:	  Illustration	  of	  mucosal	  biopsy	  technique	  resulting	  in	  biopsy	  shape
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Figure	  11:	  Stereo-­‐microscopy	  image	  of	  oesophageal	  biopsy	  highlighting	  features	  of	  the	  luminal	  and	  basal	  surfaces
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3.2.3.1	  Validation	  of	  biopsy	  orientation	  techniqueThe	  validity	  of	  this	  orientation	  process	  was	  tested	  in	  10	  biopsies	  from	  5	  patients.	  Biopsies	  were	  mounted	  within	  the	  adaptors	   (see	  below)	  with	  the	  surface	  deemed	  the	  basal	   aspect	  facing	  upwards.	  A	  small	  volume	  of	  toludine	  blue	  dye	  was	  applied	  to	   this	  surface,	   thus	  selectively	   staining	  the	  expected	  “basal”	  aspect	  of	  the	  biopsy.	  The	   stained	   biopsy	   was	   then	   Cixed	   immediately	   in	   formalin	   and	   stained	   with	  haematoxylin	  and	  eosin.	   Sections	  were	  embedded,	   cut,	   and	   light	  microscopy	  was	  used	  to	  conCirm	  whether	  the	  correct	  orientation	  had	  been	  identiCied.
3.2.4	  Ussing	  chamber	  experimentsThe	  biopsies	  were	  placed	  into	  the	  Ussing	  chamber	  (Mussler	  ScientiCic	  Instruments,	  Aachen,	   Germany)	  using	   specially	  made	  adaptors	   (Cigure	   12).	   The	   adaptors	  were	  cut	  from	  radiographic	  Cilm,	  with	  a	  central	  aperture	  of	  1.5	  mm	  diameter	  (0.017	  cm2	  area).	   The	  adaptors	  were	  scored	  on	  the	  side	  in	  contact	  with	  the	  biopsy	  to	  reduce	  the	   chance	   of	   biopsy	   slipping	   from	   covering	   the	   aperture.	   Biopsies	   were	   only	  studied	  further	  if	  they	  were	  clearly	  seen	  to	  be	  covering	  the	  aperture	  (overlapping	  all	  edges)	  under	  stereo-­‐microscopy.
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The	   two	   halves	   of	   the	   Ussing	   chamber	   are	  seen	  with	  the	  biopsy	  adaptors.
The	   biopsy	  adaptor	  Iits	   over	  the	   half	   of	   the	  Ussing	  chamber,	   and	   the	  biopsy	  is	  placed	   to	  cover	   the	   aperture.	   The	   second	   adaptor	   is	  placed	   over	   the	   biopsy,	   and	   Iinally	   the	   two	  halves	   of	   the	   chamber	   are	   joined	   and	  fastened	  with	  metal	  “O”	  rings.
The	   chamber	   and	   biopsies	   are	   seen	   placed	  together.	   In	   this	   orientation	   the	   luminal	  aspect	   of	   the	   biopsy	  will	  be	   facing	   the	   right	  half	  of	  the	  chamber	  as	  viewed	  in	  the	  picture.
Figure	  12:	  Description	  of	  biopsy	  placement	  in	  Ussing	  chamber
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Immediately	  on	  mounting	  the	  biopsies	  they	  were	  bathed	  on	  both	  luminal	  and	  basal	  sides	   with	   Krebs-­‐Henseleit	   buffer	   at	   pH	   7.4,	   37oC,	   and	   the	   solution	   was	  continuously	   bubbled	  with	  carbogen	  gas.	   After	  making	  a	  correction	   for	   Cluid	  and	  circuit	   resistance,	   transmucosal	   potential	   difference	  was	  continuously	  monitored	  with	  Ag/AgCl	  electrodes.	  The	  basal	  transepithelial	  resistance	  (TER)	  was	  calculated	  according	   to	   Ohm’s	   law	   from	   the	   voltage	   deClections	   induced	  by	   bipolar	   current	  pulses	  of	  50	  μA,	  duration	  200	  ms	  every	  6	  seconds	  applied	  through	  platinum	  wires.	  All	   experiments	   were	   conducted	   in	   open-­‐circuit	   conditions.	   The	   system	   was	  equilibrated	   at	   370C	   until	   a	   stable	   TER	   baseline	   was	   established	   (typically	   20	  minutes).	   Biopsies	  with	  a	  baseline	  TER	  of	  less	  than	  50	  Ω.cm2	  were	  excluded	  from	  further	  analysis	   since	  these	  were	  deemed	  to	  be	  unsatisfactory.	  Biopsies	  were	  also	  excluded	   if	   they	  did	   not	   demonstrate	   the	   characteristic	   curve	   to	   plateau	  of	   TER	  increase	  during	  the	  equilibration	  (pilot	  studies	  had	  indicated	  to	  us	  that	  if	  there	  was	  a	   leak,	   i.e.	   a	   hole	   due	   to	   incomplete	   covering	   of	   the	   chamber	   aperture	   by	   the	  biopsy,	   the	  TER	   pattern	  over	  the	  initial	  equilibration	  period	  was	  a	  Clat	   line	  rather	  than	  the	  usual	  gradual	  increase	  to	  a	  plateau	  over	  15	  to	  20	  minutes).	  After	   a	   stable	   baseline	   was	   achieved	   the	   solution	   in	   the	   "luminal"	   bath	   of	   the	  chambers	  was	  replaced	  with	  the	  “test	  solution”,	  either:
1) Neutral	  solution:	  Krebs-­‐Henseleit	  at	  pH	  7.4,	  or	  2) Weakly	  acidic	  solution:	  Krebs-­‐Henseleit	  at	  pH	  5	  +	  1	  mg/ml	  porcine	  pepsin	  +	  1	  mM	  deoxycholic	  acid,	  or	  3) Acidic	   solution:	   Krebs-­‐Henseleit	  at	  pH	   2	  +	  1	  mg/ml	  porcine	  pepsin	  +	  1	  mM	  taurodeoxycholic	  acid	  (Cigure	  13A).
Each	  subject	  had	  one	  biopsy	   exposed	   to	   one	   of	  the	   test	   solutions	   (i.e.	   with	   each	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subject	  having	  three	  biopsies,	  each	  test	  solution	  could	  be	  studied	  for	  each	  subject).	  The	  biopsies	  were	  exposed	  to	  the	  test	  solution	  for	  30	  minutes.
Figure	  13:	  Study	  scheme	  A 	  demonstrating	  placement	  of	  test	   solutions	   in	  Ussing	  chamber,	  and,	  B 	  a	  representative	  TER	  recording
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The	  TER	  was	  measured	  continuously	  throughout	  the	  exposure.	   The	  baseline	  TER	  was	   determined	   as	   the	   TER	   after	   equilibration,	   immediately	   before	   the	   “test	  solution”	  was	  placed	  in	  the	  luminal	  bath.	  The	   change	   in	   TER	   caused	   by	   the	   test	   solution	  was	   expressed	   as	   a	   percentage	  change	  at	  the	  end	  of	  30	  minutes	  exposure,	   relative	  to	  the	  TER	  at	  the	  beginning	  of	  exposure	  (Cigure	  13B).After	  the	  exposure,	  1	  mg/ml	  Cluorescein	  (375	  Da)	  was	  placed	  in	  the	  basal	  chamber	  to	  exclude	  obvious	  leak	  across	  the	  biopsy	  into	  the	  opposite	  chamber	  (which	  would	  require	  results	  to	  be	  discarded).
3.2.5	  Reproducibility	  studyIt	  is	  important	  to	   assess	   the	  reproducibility	  of	  the	  methods	  used	  in	  this	   study,	   i.e.	  do	  two	  biopsies	  taken	  from	  the	  same	  patient	  respond	  to	  an	  acidic	  exposure	  in	  the	  same	  way?	  To	  investigate	  this	  9	  subjects	  were	  studied	  to	  assess	  repeatability	  of	  the	  Ussing	   chamber	   results.	   Biopsies	   were	   taken	   from	   subjects	   attending	   the	   Royal	  London	   Hospital	   endoscopy	   department	   for	   various	   upper	   gastrointestinal	  complaints,	  but	  without	  oesophagitis	  or	  Barrett’s	   oesophagus.	  Two	  biopsies	   from	  the	   same	   subject	   were	   taken	   from	   3	  cm	   above	   the	   gastro-­‐oesophageal	   junction,	  were	  immediately	  placed	  into	  Krebs-­‐Henseleit	  solution	  at	  pH	  7.4,	   then	  placed	  into	  two	   separate	   Ussing	   chambers.	   After	   equilibration,	   the	   “luminal”	   bath	   of	   each	  chamber	  was	   replaced	  with	  Krebs-­‐Henseleit	   at	  pH	  5	  +	  1mg/ml	   porcine	  pepsin	   +	  1mM	  deoxycholic	  acid.	  Each	  biopsy	  was	  exposed	  to	   the	  weakly	  acidic	  solution	  for	  30	   minutes	   and	   percentage	   change	   in	   TER	   after	   30	   minutes	   was	   calculated.	  Consistency	   between	   the	   two	   biopsies’	   results	   was	   assessed	   by	   calculating	  Cronbach’s	  alpha.	  Weakly	  acidic	  solution	  was	  chosen	  to	   test	  reproducibility	  since	  these	  solutions	  do	  not	  cause	  a	  fall	  in	  TER	  in	  all	  subjects,	  so	  consistency	  of	  response	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within	  patients	  on	  exposure	  to	  this	  solution	  was	  deemed	  of	  particular	  importance.
3.2.6	   Assessment	  of	  biopsy	  thickness	  and	  relationship	  with	   basal	  TER	  and	  change	   in	  
TER	  on	  acid	  exposureIt	  is	  possible	  that	   the	  thickness	  of	  an	  oesophageal	  biopsy	  may	   inCluence	   the	  basal	  TER,	  and	  the	  percentage	  change	  on	  exposure	  to	  acid.	  To	  quantify	  biopsy	  thickness,	  Cixation	   for	   histological	   analysis	   is	   needed.	   Unfortunately,	   if	  a	  biopsy	   is	   Cixed	   for	  histology	  purposes,	   it	  cannot	  subsequently	  be	  studied	  physiologically	  in	  the	  Ussing	  chamber.	   Similarly,	   a	   biopsy	   Cixed	   for	   histology	   after	   Ussing	   chamber	   study	   is	  unlikely	  to	  be	  representative	  of	  the	  biopsy	  pre-­‐exposure.	  	  To	   attempt	   to	   address	   this	   issue	   to	   an	   acceptable	   extent,	   a	   further	   study	   of	   11	  patients	  with	  typical	  reClux	  symptoms	  was	  conducted.	  The	  aim	  of	  this	  study	  was	  to:1)	  Assess	   the	   consistency	   of	   the	   biopsy	   thickness	   (expressed	   as	   the	   number	   of	  epithelial	  layers)	  in	  biopsies	  taken	  by	  the	  study	  endoscopist	  (Dr	  Woodland).2)	  Assess,	  in	  pairs	  of	  biopsies	  taken	  in	  parallel	  (i.e.	   2	  per	  subject	  from	  3	  cm	  above	  the	   gastro-­‐oesophageal	   junction)	   the	   relationship	   between	   biopsy	   thickness,	  baseline	  TER,	  and	  drop	  in	  TER	  when	  exposed	  to	  the	  acidic	  solution.From	  each	   subject	   one	  biopsy	  was	   Cixed	   immediately	   in	   formalin,	   and	   the	  other	  biopsy	   was	   placed	   in	   Krebs-­‐Henseleit	   solution	   at	   pH	   7.4.	   The	   biopsy	   placed	   in	  Krebs-­‐Henseleit	   was	   transferred	   to	   an	   Ussing	   chamber,	   and	   the	   basal	   TER	   and	  change	   in	   TER	   from	   baseline	   after	   30	   minutes	   exposure	   to	   an	   acidic	   solution	  (Krebs-­‐Henseleit	  at	  pH	  2	  +	  1mg/ml	  porcine	  pepsin	  +	  1mM	  taurodeoxycholic	  acid)	  was	  calculated	  as	  described	  above.The	  biopsy	  in	  formalin	  was	  placed	  in	  a	  frozen	  block	  and	  cut	  into	   frozen	  sections	  of	  10	  µm	   thickness	   using	  a	   cryostat.	   Biopsies	   were	   stained	  with	   haematoxylin	   and	  eosin,	   and	   sections	   from	   the	   centre	   of	   the	   biopsy	   were	   assessed	   by	   light	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microscopy.	   The	   number	   of	  epithelial	   layers	   from	  basal	   to	   luminal	   aspect	   of	   the	  biopsy	  were	  counted.	  The	  number	  of	  epithelial	  layers	  was	  correlated	  with	  the	  basal	  TER	  and	  percentage	  change	  in	  TER	  from	  baseline	  in	  the	  corresponding	  paired	  biopsy.




3.3.1	  SubjectsOf	   the	   53	   subjects	   from	   the	   main	   Ussing	   chamber	   study,	   28	   were	   from	  symptomatic	   patients,	   25	   were	   asymptomatic	   controls.	   6	   symptomatic	   and	   3	  control	   subjects	   were	   excluded	   due	   2	   or	   more	   biopsies	   being	   considered	  inadequate	  (by	   inadequate	  chamber	  aperture	  coverage	  or	  basal	  TER	   less	  than	  50	  Ω.cm2).	   15	   of	   the	   remaining	   22	   control	   subjects,	   and	   17	   of	   the	   remaining	   22	  patients	   had	   3	   biopsies	   able	   to	   be	   studied	   with	   each	   of	   the	   test	   solutions.	   The	  remaining	  7	  controls	  and	  5	  patients	  had	  2	  adequate	  biopsies	  and	  were	  tested	  only	  with	   the	   neutral	   and	   weakly	   acidic	   test	   solutions.	   None	   of	   the	   studied	   biopsies	  displayed	   evidence	   of	   Cluorescein	   leakage	   when	   tested	   at	   the	   end	   of	   the	  experiment.	  As	  such,	   22	  symptomatic	  (mean	  age	  49,	   range	  20-­‐76)	  and	  22	  control	  subjects	   (mean	  age	   47,	   range	   18-­‐78)	  were	   studied	   in	   Cinal	   analysis.	   All	   patients	  except	  for	  one	  were	  taking	  PPI	  at	  the	  time	  of	  endoscopy.	  No	  control	  subjects	  were	  on	  PPI.	   The	   further	  demographic	   and	  medical	   data	  of	   each	  group	  is	   displayed	   in	  table	  1	  below.
Age Sex Comorbidity PPI	  therapy Other	  therapy Smoker
PATIENTS
1 49 M Nil Omeprazole	  20mg1 Gaviscon	  Advance Y
2 35 M Asthma Lansoprazole	  30mg1 Salbutamol	   N
3 45 M Chronic	  pancreatitis Omeprazole	  20mg1 Loperamide,	  creon Y
4 58 M Diabetes	  mellitus,	  asthma Lansoprazole	  30mg
2 Gliclazide,	  metformin,	  simvastatin,	  salbutamol N
5 53 M Diabetes	  mellitus	   Omeprazole	  20mg1 Simvastatin,	  metforminN
6 51 F Nil Lansoprazole	  30mg1 Nil N
7 66 F Hypothyroidism,	  hypertension Lansoprazole	  30mg
2 Thyroxine,	  amlodipine Ex
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8 46 M Nil Lansoprazole	  30mg2 Nil Y
9 76 F Polymyalgia	  rheumatica Omeprazole	  20mg1 Prednisolone,	  adcal N
10 40 F Nil Esomeprazole	  20mg2 Ranitidine N
11 28 M Asthma Omeprazole	  20mg1 Salbutamol,	  becotide Y
12 54 M Nil Omeprazole	  20mg2 Nil Y
13 38 M Hypothyroidism Omeprazole	  20mg1 Thyroxine Ex
14 48 M Nil Omeprazole	  20mg2 Nil N
15 63 F Nil Lansoprazole	  30mg1 Nil Ex
16 20 F Nil Lansoprazole	  30mg1 Nil N
17 68 F Epilepsy,	  hypertension Omeprazole	  20mg1 Epilim	  chrono,	  bendroIluazide N
18 52 M Hypercholesterolaemia Nil Simvastatin N
19 68 M Benign	  prostatic	  hypertrophy Lansoprazole	  30mg
1 Tamsulosin N
20 68 M GIST Omeprazole	  20mg1 Nil Ex
21 32 F Nil Lansoprazole	  30mg1 Ranitidine N
22 48 M Ischaemic	  heart	  disease Omeprazole	  20mg2 Aspirin,	  atorvastatin,	  lisinopril,	  GTN Ex
CONTROLS
1 78 M Hypertension,	  ischaemic	  heart	  disease Nil Aspirin,	  simvastatin,	  amlodipine,	  isosorbide	  mononitrate Ex
2 32 F Nil Nil Nil Y
3 42 F Hypertension Nil Ramipril Ex
4 65 F Diabetes	  mellitus,	  asthma Nil Gliclazide,	  ramipril N
5 58 F Migraine Nil Sumatriptan N
6 40 F Hypertension Nil Ramipril N
7 43 F Nil Nil Nil N
8 25 F Nil Nil Nil N
9 54 F Nil Nil HRT N
10 20 F Nil Nil Nil N
11 39 M Hay	  fever Nil Cetirizine Y
12 18 M Nil Nil Loperamide N
13 72 M Diabetes	  mellitus Nil Metformin Ex
14 21 F Nil Nil Nil N
15 39 F Nil Nil Nil N
16 78 M COPD Nil Seretide Ex
17 52 M Nil Nil Nil Ex
18 59 M Nil Nil Nil Y
19 53 M Diabetes	  mellitus,	  hypertension Nil Gliclazide,	  metformin,	  simvastatin,	  ramipril Y
20 69 F Hypercholesterolaemia Nil Atorvastatin,	  loratidineN
21 41 M Nil Nil Nil Y
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22 59 F COPD Nil Seretide ExTable	   1:	   Study	   patient	   characteristics.	  M=male;	   F=female;	   COPD=chronic	   obstructive	   pulmonary	  disease;	  GIST=gastrointestinal	  stromal	  tumour;	  1=once	  daily;	  2=twice	  daily;	  GTN=glyceryl	  trinitrate
In	  summary	   the	  mean	  age	  in	  the	  symptomatic	   patient	   group	  was	  50	  (range	  20	  −	  76),	  and	  in	  the	  control	  group	  was	  48	  (range	  18	  −	  78).	  There	  were	  8	  females	  in	  the	  patient	  group	  and	  13	  females	  in	  the	  control	  group.	  All	  symptomatic	  patients	  except	  one	  were	   taking	   current	   PPI.	   The	   one	  who	   had	   stopped	  had	  been	   off	   PPI	   for	   3	  months	  due	  to	  perceived	  lack	  of	  response.
3.3.2	  Validation	  of	  biopsy	  orientation	  technique10	  biopsies	  were	  assessed	  for	  accuracy	  of	  orientation	  using	  the	  criteria	  mentioned.	  On	  haematoxylin	  and	  eosin	   staining,	   all	   biopsies	   were	   conCirmed	   to	   be	  correctly	  orientated.	  An	  example	  of	  a	  correctly	  stained	  specimen	  is	  seen	  in	  Cigure	  14.
Figure	  14:	  A	  haematoxylin	  and	  eosin	  stained	  oesophageal	  mucosal	  biopsy	  demonstrating	  additional	  toludine	  blue	  staining	  at	  the	  basal	  surface
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3.3.3	  Ussing	  chamber	  studies
3.3.3.1	  Baseline	  transepithelial	  electrical	  resistanceOesophageal	  biopsies	  in	  symptomatic	  patients	  had	  a	  mean	  TER	  baseline	  of	   	  115	  ±	  30.1	  Ω.cm2.	  In	  controls	  the	  mean	  TER	  baseline	  was	  107	  ±	  49.8	  Ω.cm2.	  There	  was	  no	  signiCicant	  difference	  between	  these	  values	  (p=0.15,	  Cigure	  15).
Figure	   15:	   Baseline	   TER	   in	   control	   subjects	   with	   no	   upper	   gastrointestinal	   symptoms,	   and	   in	  patients	  with	  symptomatic	  heartburn
3.3.3.2	  TER	  response	  to	  test	  solution	  exposureAfter	  30	  minutes	  exposure	  to	  the	  neutral	  test	  solution	  the	  mean	  percentage	  change	  from	   baseline	  was	   3.0	   ±	   7.3%	   in	   symptomatic	   patients,	   and	   was	   7.0	   ±	   7.3%	   in	  controls.	   There	  was	  no	   signiCicant	   difference	  in	  TER	   change	  on	  neutral	   exposure	  between	  the	  two	  groups	  (p=0.14).When	  all	  subjects	  are	  taken	  into	  account	  (symptomatic	  patients	  and	  controls),	  30-­‐
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minute	  exposure	  to	  the	  weakly	  acidic	  test	  solution	  caused	  a	  very	  small	  decrease	  in	  TER	   from	   baseline	   (-­‐1.6	   ±	   10.1%,	   n=41).	   Exposure	   to	   the	   acidic	   test	   solution	  caused	  a	   larger	  decrease	   in	  TER	  (-­‐14.4	  ±	  15.3%,	   n=32)	  than	  seen	  for	  neutral	  and	  weakly	  acidic	  solutions	  (p<0.0001	  for	  both	  comparisons).	  Figure	  16	  demonstrates	  this.
Figure	   16:	   Percentage	   change	   in	   TER	   from	   baseline	   in	   all	   subjects	   (symptomatic	   patients	   and	  controls)	  on	  biopsy	  exposure	  to	  neutral,	  weakly	  acidic	  and	  acidic	  solutions	  
When	  comparing	   the	   change	   in	   TER	   that	   occurs	   in	  response	   to	   test	   solutions	   in	  symptomatic	  patients	  and	  control	  subjects,	  one	  can	  see	  a	  differential	  effect.	  Thirty	  minutes	  exposure	  to	  the	  weakly	  acidic	  test	  solution	  caused	  a	  greater	  fall	   in	  TER	   in	  symptomatic	   patients	   than	   in	   controls	   (-­‐7.2	   ±	   5.5%,	   n=19	   vs.	   3.2	  ±	   7.3%,	   n=22	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p<0.05).	  Likewise	  30	  minutes	  exposure	  to	   the	  acidic	  test	  solution	  caused	  a	  greater	  fall	  in	  TER	  in	  symptomatic	  patients	  than	  in	  controls	  (-­‐22.8	  ±	  11.9%,	  n=15	  vs.	  -­‐9.4	  ±	  15.1%,	  n=17,	  p<0.01,	  Cigure	  17).
Figure	  17:	  Differential	  TER	  response	  on	  exposure	  to	  weakly	  acidic	  solution	  (left)	  and	  acidic	  solution	  (right)	  in	  control	  subjects	  and	  symptomatic	  patients	  
3.3.4	  Reproducibility	  studyThe	   calculated	   Cronbach’s	   alpha	   for	   the	   biopsy	   pairs	   in	   this	   study	   was	   0.81,	  representing	   good	   test-­‐retest	   reliability	   with	   this	   methodology	   (table	   2).	   It	   is	  acknowledged	   that	   the	  patient	  phenotype	   studied	  was	  more	   heterogeneous	   than	  for	   the	   other	   studies,	   but	   it	   is	   expected	   that	   re-­‐test	   consistency	   should	   not	   be	  affected	  by	  this.
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Percentage	  change	  in	  TER	  after	  30	  mins	  exposure	  to	  weakly	  acidic	  
solution
Subject Biopsy	  1 Biopsy	  21 -­‐20.6 -­‐8.12 -­‐2.3 -­‐5.43 2.3 7.44 0.0 1.25 -­‐6.2 -­‐7.16 6.7 9.07 -­‐6.4 -­‐11.28 0.2 -­‐1.59 -­‐2.4 -­‐11.1
Table	  2:	  Results	  of	  reproducibility	  study
3.3.5	   Assessment	  of	  biopsy	  thickness	  and	  relationship	  with	   basal	  TER	  and	  change	   in	  







Change	  in	  TER	  from	  baseline	  on	  exposure	  to	  acidic	  
solution	  (%)1 27 95 -­‐1.22 29 280 -­‐52.73 29 81 -­‐22.94 30 68 -­‐63.25 31 70 -­‐12.96 31 119 -­‐2.77 35 155 -­‐22.78 36 119 -­‐23.59 37 285 -­‐7.510 41 167 -­‐20.411 46 233 -­‐23
Table	  3:	  Assessment	  of	  relationship	  between	  biopsy	  thickness	  and	  TER
Thus	   the	   median	   number	   of	   epithelial	   layers	   in	   the	   biopsies	   was	   31,	   with	   a	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standard	  deviation	  of	  4.8.
There	  was	   no	   signiCicant	  correlation	  between	  the	  number	  of	  epithelial	   cell	   layers	  and	  the	  baseline	  TER	  in	  the	  corresponding	  paired	  biopsy	  (r=0.4,	  p=0.28,	  Cigure	  18).In	  addition,	   there	  was	  no	   signiCicant	  correlation	  between	  the	  number	  of	  epithelial	  cell	   layers	   and	   the	   change	   in	   TER	   on	   exposure	   to	   the	   acidic	   solution	   in	   the	  corresponding	  paired	  biopsy	  (r=0.57,	  p=0.11,	  Cigure	  19).	  
Figure	  18:	  Correlation	  of	  number	  of	  epithelial	  layers	  on	  histological	  specimen	  with	  the	  baseline	  TER	  of	  the	  corresponding	  biopsy.
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The	  hypothesis	  of	  this	  study	  was	   that	  patients	  with	  heartburn	  without	  endoscopic	  mucosal	   erosions	   have	   a	   persistent	   mucosal	   vulnerability	   to	   acid	   that	   can	   be	  detected	  during	  continuous	  TER	  measurements	  in	  their	  biopsies.	  
The	  study	  results	  were	  the	  following:	  1) Exposure	   of	   human	   oesophageal	   mucosal	   biopsies	   to	   acidic	   solutions	  (containing	   pepsin	   and	   bile	   acids)	   provokes	   a	   decrease	   in	   transepithelial	  electrical	  resistance	  (TER).	  2) The	   fall	   in	   TER	   observed	   in	   biopsies	   from	   patients	   with	   symptoms	   is	  signiCicantly	   more	   pronounced	   than	   that	   observed	   in	   biopsies	   from	  asymptomatic	  controls.3. In	  symptomatic	   patients	   (but	   not	   controls),	   even	   exposure	  to	  weakly	  acidic	  solutions	  provokes	  a	  signiCicant	  drop	  in	  TER.	  
In	   healthy	   subjects,	   a	   degree	   of	   gastro-­‐oesophageal	   reClux	   is	   physiological	   and	  asymptomatic.	   In	   contrast,	   in	   patients	   with	   gastro-­‐oesophageal	   reClux	   disease,	  contact	  with	  the	  oesophageal	  mucosa	  by	  gastric	  contents	  results	  in	  symptoms	  such	  as	  heartburn.	   The	   reason	  for	   a	   symptomatic	  perception	  of	  a	  reClux	  event	  may	   be	  due	   to	   a	   variety	  of	   factors	   including	   the	  chemical	   and	  physical	   properties	  of	   the	  reCluxate,	   the	   sensitivity	   of	   nociceptors	   and	   afferent	   nerve	   Cibres,	   and	   central	  sensitivity.	   However	   a	  signiCicant	   contributor	  may	   be	   the	  barrier	  integrity	  of	  the	  oesophageal	   mucosa.	   The	   human	   stratiCied	   squamous	   epithelium	   forms	   a	   tight	  protective	  barrier	  against	  the	  noxious	  components	  of	  gastroesophageal	   reCluxate.	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Both	  injurious	  factors	  (e.g.	  duration	  of	  acid	  exposure60,	  and	  presence	  of	  pepsin	  and	  bile	  acids80,	  82)	  and	  defensive	  factors	  (e.g.	   acid	  buffering,	   acid	  transport	  and	  tissue	  repair293)	   determine	   mucosal	   integrity.	   The	   oesophageal	   epithelial	   apical	   cell	  membranes	   and	  apical	   junctional	   complexes	   provide	   a	  permeability	   barrier	   that	  prevents	   the	   permeation	   of	   noxious	   substances	   into	   the	   cells	   and	   intercellular	  spaces121.	  The	  apical	  junctional	  complexes	  are	  formed	  by	  tight	  junctions,	  adherens	  junctions	   and	   desmosomes,	   and	   act	   as	   an	   effective	   barrier	   to	   paracellular	   ion	  movement293.The	  oesophageal	  mucosa	  of	  symptomatic	  patients	  may	  not	  be	  completely	  normal,	  and	  often	  demonstrates	  dilated	  intercellular	  spaces	  (DIS).	  DIS	  usually	   resolves	   in	  parallel	   with	   symptom	   resolution	   on	   treatment	   with	   PPIs166.	   A	   proportion	   of	  patients	  with	  remaining	  symptoms	   in	  spite	  of	  PPI	   treatment	  show	  persistence	  of	  DIS	  in	  oesophageal	  biopsies167.	  It	  is	  possible	  that	  patients	  with	  symptomatic	  reClux	  disease	  have	  an	  excess	  vulnerability	   to	  acid	  or	  weak	  acid	  that	  means	  their	  barrier	  integrity	   is	   further	   impaired	   on	   exposure	   compared	   to	   control	   subjects.	  Furthermore,	  a	  signiCicant	  group	  of	  patients	  not	  responding	  well	  to	  PPI,	   including	  NERD	  (40%)	  and	   functional	   heartburn	   (80%)	  have	  no	   DIS167.	   It	   is	   possible	   that	  these	   symptomatic	   patients	   without	   DIS	   still	   have	   a	   functional	   mucosal	  impairment	   that	  might	   potentially	   underlie	   their	   symptoms.	   That	   is	  why	   in	   this	  study	  a	  method	  was	   used	  that	   allows	   detection	  of	   subtle	   differences	   in	  dynamic	  mucosal	  behaviour	  when	  exposed	  to	  a	  noxious	  solution	  regardless	  of	  the	  mucosal	  basal	   status.	   Indeed,	   the	   results	   showed	   that	   patients	   and	   controls	   had	   similar	  basal	  mucosal	  electrical	  resistance,	  but	  they	  differed	  in	  their	  response	  to	  a	  “stress”	  test	  i.e.	  exposure	  to	  acid	  and	  weak	  acid	  solutions	  containing	  pepsin	  and	  bile	  acids.	  	  	  The	  use	  of	  TER	  as	  a	  functional	  marker	  of	  mucosal	  integrity	  might	  have	  advantages	  over	   the	  “static”	  measurement	  of	  DIS.	   It	   allows	  dynamic	  measurement	  of	  changes	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in	   integrity	   e.g.	   during	   an	   exposure	   to	   acid	   and	   assessment	   of	   pharmacological	  intervention	   over	   time.	   Previous	   studies	   of	   dynamic	   properties	   of	   oesophageal	  resistance	  in	  response	  to	  acid	  challenge	  have	  been	  limited	  mostly	  to	  animals148,	  153.The	   results	   of	   this	   study	   enable	   us	   to	   make	   a	   comparison	   between	   TER	  measurements	   in	   human	  oesophageal	   tissue,	   and	   that	   found	   in	  previous	   animal	  studies.	   	  An	  immediately	  noticeable	  Cinding	  is	  that	  the	  baseline	  TER	  in	  the	  human	  mucosa	  is	  much	  lower	  than	  that	  seen	  in	  other	  animals.	   In	  Ussing	  chamber	  studies	  of	  rabbit	  oesophageal	  mucosa,	  Farré	  et	  al.	   found	  baseline	  TER	  values	   in	  the	  range	  of	  approximately	   1500	  to	  2500	  Ω.cm2	   153.	   The	   separate	  group	  of	  Tobey	  et	  al.	   also	  measured	   baseline	   rabbit	   oesophageal	   mucosal	   TER	   to	   be	   approximately	   2000	  Ω.cm2	   148.	   However,	   our	   human	  data	  appears	   in	  keeping	  with	  other	   groups	  who	  have	  looked	  at	  baseline	  TER	  of	  biopsies	  in	  Ussing	  chamber	  models.	   Jovov	  et	  al.	   in	  the	  USA	  have	  measured	  baseline	  human	  oesophageal	  mucosal	  TER	  to	  be	  between	  approximately	  70	  to	   300	  Ω.cm2	  133,	   and	  Weijenborg	  et	  al.	   in	  the	  Netherlands	  have	  found	  values	  between	  approximately	  70	  to	  125	  Ω.cm2	  294.	  Our	  human	  oesophageal	  baseline	  TER	   values	  were	   between	  68	  and	  285	  Ω.cm2,	   concurring	  with	  the	  other	  groups’	   Cindings.	   A	   part	   of	   the	   reason	   for	   this	   discrepancy	   between	   rabbit	   and	  human	   baseline	   TER	   may	   be	   due	   to	   size	   of	   the	   tissue	   sample.	   In	   the	  aforementioned	   studies	   rabbit	   oesophagus	   was	   cut	   in	   sections	   and	  mounted	   in	  chambers	  with	  an	  aperture	  of	  0.3	  to	  1.2	  cm2.	   In	  the	  human	  studies	  an	  aperture	  of	  0.017	  cm2	  was	  used.	  There	   is	  considerably	  more	  “edge	  effect”	  at	  smaller	  aperture	  sizes:	  i.e.	  there	  is	  inevitably	  damage	  at	  the	  edge	  of	  the	  biopsy	  due	  to	  pressure	  from	  the	  apposing	  halves	  of	  the	  chamber,	  and	  for	  a	  smaller	  aperture	  the	  circumference	  where	   this	   damage	   occurs	   is	   a	   higher	   overall	   proportion	   of	   the	   tissue	   being	  studied.	   This	  effect	   should	  be	   a	   constant	   for	   all	   of	  the	  experiments.	   However,	   we	  have	  conducted	   comparative	  studies	  using	  human	  oesophageal	  mucosal	   sections	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taken	  from	  surgical	  resections	  and	  mounted	  in	  chambers	  with	  a	  0.5	  cm2	  aperture.	  These	  still	  had	  a	  much	  lower	  baseline	  TER	  than	  seen	  in	  rabbits	  (approximately	  300	  to	   400	   Ω.cm2).	   This	   suggests	   an	   inherent	   difference	   in	   the	   baseline	   integrity	  characteristics	  of	  rabbit	  and	  human	  oesophageal	  mucosa.	  Since	  the	  TER	  is	  formed	  almost	  entirely	   from	   characteristics	   of	  paracellular	   ion	  diffusion,	   it	   suggests	   that	  this	  pathway	  is	  more	  ionically	  permeable	  in	  humans	  than	  in	  rabbits.	  Differences	  in	  resistance	  in	  this	  pathway	  are	  likely	  to	  be	  due	  to	  differences	   in	  the	  tight	  junction-­‐apical	  membrane	  morphology	  and/or	   function	  between	  species,	  but	   this	   is	   as	  yet	  untested.Another	  noticeable	  feature	  of	  the	  baseline	  TER	  in	  our	  study,	  and	  in	  that	  of	  others,	  is	   that	  there	  is	  a	  large	   (almost	  5-­‐fold)	  variability	   in	  values	  from	  the	  lowest	   to	   the	  highest,	   even	   in	   healthy	   subjects.	   This	   appears	   to	   be	   a	   wide	   variability	   for	   a	  physiological	  measurement	  and	  is	  thus	  far	  unexplained.	  It	  is	  possible	  that	  it	  in	  part	  is	   reClective	  of	  variations	   that	   are	   inherent	   to	   the	   technique	   (e.g.	   size	  of	  biopsy,	   ,	  trauma	  during	  biopsy	  process,	   degree	  of	  edge	  effect),	  and	  as	  such	  is	   illustrative	  of	  limitations	  of	  thus	  method	  of	  study.	  We	  also	  know	  that	  variations	  in	  tight	  junction	  expression	  can	  result	  in	  wide	  variations	  in	  TER	  in	  cell	  culture	  lines124,	  125.	  It	  would	  be	  very	  interesting	  to	  examine	  tight	  junction	  expression	  in	  the	  context	  of	  this	  TER	  variability.	  The	  focus	  of	  the	  measurements	  in	  this	  study	   is	  on	  dynamic	  changes	   in	  TER	   on	   exposure	   to	   acid,	   and	   the	   use	   of	   percentage	   changes	   is	   an	   attempt	   to	  control	  for	  the	  variability	  in	  baseline	  TER.	  As	  such	  we	  hope	  that	  some	  of	  the	  effect	  of	  the	  variability	  is	  mitigated	  by	  the	  use	  of	  these	  measurements.The	  dynamic	   changes	   in	  TER	   that	   occur	  on	  acid	  challenge	   in	  this	   study	  reveal	   an	  apparent	   distinct	   vulnerability	   of	   the	   mucosa	   in	   patients	   with	   typical	   reClux	  symptoms.	  The	  reason	  for	  this	  increased	  vulnerability	  is	  unclear.	  It	  is	  possible	  that	  the	  chronic	   effects	  of	   acid	  exposure	  causes	  a	   fragility	   to	   the	  normal	  oesophageal	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barrier	  mechanisms	  (e.g.	  tight	  junctions)	  against	  the	  reCluxate,	  or	  it	  is	  possible	  that	  the	   vulnerability	   is	   the	   initial	   (perhaps	   genetic)	   pathology	   that	   favours	  symptomatic	  perception	  of	  reClux	  events.	  The	  reason	  for	  heartburn	  in	  the	  absence	  of	   mucosal	   erosions	   is	   incompletely	   understood.	   It	   is	   highly	   probable	   that	   the	  mucosal	   barrier	   integrity	   is	   only	   part	   of	   a	   complex	   interaction	   between	   the	  reCluxate,	   epithelial	   cells	   secretion,	   the	   activity	   of	   oesophageal	   nociceptors,	   and	  sensitivity	   of	   afferent	   nerves295-­‐297.	   Thus,	   whilst	   the	   small	   difference	   in	  mucosal	  integrity	   seen	   between	   patients	   and	   controls	   in	   this	   study	   appears	   clear,	   this	  difference	  may	   only	   explain	   a	   proportion	   of	   the	   symptom	   pathogenesis	   in	  non-­‐erosive	  gastro-­‐oesophageal	  reClux	  disease.	  The	  barrier	  dysfunction	  observed	  might	  be	   an	   initial	   event	   that	   can	   be	   further	   ampliCied	   by	   the	   other	  mechanisms	   and,	  therefore,	   the	   initial	   weakening	   of	   the	   mucosal	   barrier	   may	   be	   an	   essential	  pathophysiological	  event.	  	  This	   study	   assessed	   the	   in	   vitro	   oesophageal	   mucosal	   handling	   of	   solutions	  simulating	   both	   the	   “off”	   and	   “on”	   PPI	   condition.	   During	   reClux	   in	   “on”	   PPI	  conditions,	  the	  oesophageal	  mucosa	  is	  exposed	  to	  gastric	  contents	  in	  the	  range	  pH	  4-­‐6.556.	  Gastric	  bile	  acid	  concentrations	  can	  be	  between	  0.3	  and	  2	  mM64-­‐66.	  We	  used	  different	   bile	   acids	   for	   our	   weakly	   acidic	   and	   acidic	   solutions.	   Whereas	  taurodeoxycholic	   acid	   is	   present	   in	   oesophageal	   aspirates	   in	  gastro-­‐oesophageal	  reClux	   patients	   not	   taking	  PPIs,	   unconjugated	  bile	  acids	   such	   as	   deoxycholic	   acid	  are	  seen	  in	  higher	  concentrations	  in	  patients	  “on”	  PPI.	  This	  is	  likely	  to	  be	  a	  result	  of	  gastric	   bacterial	   overgrowth	  and	   subsequent	   bacterial	  bile	   acid	  deconjugation	   in	  the	   less	   noxious	   gastric	   pH	   environment	   that	  occurs	   “on”	  PPI67.	   Previous	   animal	  experiments	   have	   assessed	   the	   effect	   of	   different	   bile	   acids	   on	   oesophageal	  mucosal	   integrity161.	   These	   studied	   taurodeoxycholic	   acid,	   deoxycholic	   acid,	   and	  glycocholic	  acid	  in	  acidic	  (pH	  2)	  and	  weakly	  acidic	  (pH	  5)	  solutions	  using	  an	  Ussing	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chamber	  model.	  They	  found	  that	  there	  was	  a	  dose-­‐dependent	  reduction	  in	  TER	  (at	  0.5,	   2	  and	  5	  mM	  concentrations),	   however	  most	   profound	  reductions	  were	   seen	  with	   taurodeoxycholic	   acid	   and	   glycocholic	   acid	   in	   acidic	   conditions,	   and	  taurodeoxycholic	  acid	  and	  deoxycholic	  acid	  in	  weakly	  acidic	  conditions.	  As	   expected,	   in	  the	  present	   study	  the	  effect	  of	  acid	  solutions	  on	  mucosa	  integrity	  was	  signiCicantly	  stronger	  than	  that	  of	  weakly	  acidic	  solutions.	  However,	  the	  latter	  also	   showed	  a	  differential	  mucosal	   behaviour	  between	  symptomatic	  patients	  and	  controls.	   It	   caused	   a	   fall	   in	   mucosal	   TER	   in	   symptomatic	   patients,	   but	   not	   in	  controls.	   This	  suggests	  that,	   in	  patients,	  mucosal	  vulnerability	   is	  such	  that	  weakly	  acidic	   reCluxates	  may	  produce	  changes	  underlying	  clinical	  observations	  of	  weakly	  acidic	   reClux-­‐symptom	   association	   in	   some	   patients	   with	   refractory	   gastro-­‐oesophageal	  reClux	  disease298.	  	  	  It	   is	   noteworthy	   that,	   at	   baseline,	   there	   were	   no	   differences	   in	   integrity	   seen	  between	   patients	   and	  controls.	   This	   is	   in	  keeping	  with	   recent	   studies	   that	   have	  demonstrated	  no	  difference	  between	  baseline	  TER	   in	  patients	   and	  controls294,	   or	  between	  PPI-­‐refractory	   and	  PPI-­‐responsive	  reClux	  patients299.	   In	  contrast,	   studies	  using	   in	   vivo	   impedance	   have	   demonstrated	   lower	   impedance	   in	   gastro-­‐oesophageal	   reClux	   disease	   patients	   than	   in	   patients	   with	   functional	   heartburn	  (Chapter	   4	   of	   this	   thesis)	   or	   controls156.	   There	   are	   a	   number	   of	   possible	  explanations	   for	  this.	  First,	   the	  size	  of	  the	  tissue	  studied	   in	  an	  Ussing	  chamber	  is	  much	  smaller	  than	  studied	  using	  impedance.	   Second,	   there	  are	  other	   factors	   that	  may	  affect	  resistance	  (e.g.	  saliva,	  blood	  Clow,	  bicarbonate	  secretion)	  in	  vivo	  that	  are	  not	  seen	  in	  vitro.	  Finally,	   it	   is	  likely	  that	   there	  are	  inherent	  inconsistencies	  in	  the	  biopsy	   technique	   that	   are	   not	   present	   in	   impedance.	   This	   study	   has	   found	   that	  there	   is	   a	   variation	   of	   biopsy	   thickness	   that	   occurs,	   even	   when	   the	   same	  endoscopist	  takes	  the	  biopsies	  (range	  27	  to	  41	  epithelial	  cell	   layers).	  Although	  we	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found	   that	   there	  was	   no	   signiCicant	   correlation	  between	   epithelial	   thickness	   and	  baseline	  TER,	   it	  is	  appreciated	  that	  the	  lack	  of	  statistical	   signiCicance	  does	  not	  rule	  out	   an	   association,	   particularly	   since	   the	   sample	  size	   is	   fairly	   small.	   In	   addition,	  impedance	   measures	   a	   circumferential	   area	   of	   mucosa,	   but	   a	   biopsy	   is	   only	   a	  sample	  of	  a	  few	  millimetres	  of	  a	  mucosal	  region.	  We	  know	  that	  acid	  exposure	  can	  vary	  circumferentially	  at	  the	  distal	  oesophagus	  (e.g.	  more	  exposure	  in	  the	  furrows	  of	  the	  folds),	   and	  this	  cannot	  be	  easily	   controlled	  for	   in	  the	  biopsy	  technique.	   It	  is	  possible	  that	  these	  variable	  in	  baseline	  TER	  add	  greater	  weight	  to	   the	  importance	  of	   the	   tissue	   response	  to	   acid	  challenge	  that	   is	   seen	   in	  the	   current	   study,	   rather	  than	  relying	  on	  static	  baseline	  measurements.Within	   the	   group	  of	   patients	   with	   heartburn	  without	   oesophagitis	   in	   this	   study,	  there	   were	   probably	   patients	   with	   erosive	   disease	   healed	   by	   previous	   PPI	  treatment,	   “real”	   non-­‐erosive	   reClux	   disease	   patients,	   and	   functional	   heartburn	  patients.	   Those	   with	   erosive	   disease	   healed	  by	   PPI	   had	   troublesome	   heartburn	  symptoms	  at	  the	  time	  of	  (normal)	  endoscopy.	  We	  would	  expect	  that	  25-­‐30%	  of	  our	  patients	  had	   functional	   heartburn45,	   300,	   301.	   It	   is	  possible	  that	   the	  difference	  of	   in	  
vitro	  mucosal	  behaviour	  between	  symptomatic	  subjects	  and	  controls	  is	  accounted	  for	   entirely	   by	   the	   GORD-­‐NERD	   subgroup,	   and	   the	   functional	   heartburn	   group	  responded	   in	   the	   same	   way	   as	   controls.	   This	   would	  mean	   that	   the	   differences	  observed	   between	   patients	   and	   controls	   could	   have	   even	   been	   slightly	  underestimated.	   An	   alternative	   interpretation	   could	   be	   that	   the	   mucosa	   in	  functional	   heartburn	   is	   not	   entirely	   normal.	   Although	   functional	   heartburn	  patients	  do	   not	   display	   DIS	  on	   electron	  microscopy167,	   changes	   in	   TER	  may	   still	  occur	   and	   contribute	   to	   these	   patients’	   symptoms.	   Patients	   with	   functional	  heartburn	  have	   been	  shown	   to	   be	  more	  sensitive	   to	   oesophageal	   acid	   perfusion	  than	  controls208.	   Whilst	   this	  may	   represent	   a	   central	   phenomenon,	   it	   is	   possible	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In vivo evaluation of acid-induced changes in 
oesophageal mucosal integrity and acid 
sensitivity in non-erosive reflux disease
CHAPTER 4: IN VIVO EVALUATION OF ACID-INDUCED CHANGES IN 
OESOPHAGEAL MUCOSA INTEGRITY AND SENSITIVITY IN NON-EROSIVE 
REFLUX DISEASE
4.1 Introduction and aims
Most	   studies	  of	  oesophageal	   integrity	  thus	   far	  have	  involved	  “static”	  measures	  of	  integrity	   in	   the	   form	   of	   morphological	   changes	   (DIS)	   and	   baseline	  measures	   of	  ionic	   permeability,	   often	   in	   animals.	   Human	   oesophageal	   mucosal	   integrity	   is	  unlikely	   to	   be	   a	   static	   phenomenon,	   but	   more	   likely	   is	   a	   dynamic	   phenomenon	  reClecting	  damage	  from	  gastro-­‐oesophageal	  reClux	  events,	  and	  the	  mucosal	  capacity	  to	  recover	  its	  integrity	  after	  this	  damage.	  Dynamic	   changes	  in	  human	  oesophageal	  mucosal	  integrity	  on	  exposure	  to	  reClux-­‐like	  solutions	  in	  vitro	  have	  been	  described	  in	  Chapter	  3.	   	  However,	  to	  better	  understand	  the	  pathophysiology	  of	  the	  mucosa	  in	  non-­‐erosive	   reClux	  disease,	   in	   vivo	   studies	  are	  desirable,	   and	  measurement	   of	  the	  recovery	  capacity	  of	  the	  mucosa	  would	  be	  of	  interest.Multichannel	   oesophageal	   intraluminal	   impedance	   is	   a	   technique	   that	   has	   been	  developed	   to	   complement	   pH	   measurements	   in	   reClux	   studies154.	   It	   allows	  detection	   of	   the	   movement	   of	   a	   bolus	   through	   the	   oesophagus.	   It	   does	   this	   by	  measuring	  the	  change	  of	  current	  Clow	  between	  a	  pair	  of	  electrodes.	  The	  current	  is	  not	   able	   to	   pass	   directly	   along	   the	   catheter,	   so	   it	   must	   pass	   through	  a	   material	  external	   to	   the	  catheter	   that	  bridges	   the	  gap	  between	  the	   electrode	  pair.	   Liquids	  (containing	   ions,	   such	   as	   gastro-­‐oesophageal	   reCluxate)	   are	   excellent	   electrical	  conductors	   and	   cause	   a	   fall	   in	   impedance	   as	   it	   bridges	   the	   electrode	   pair.	   In	  contrast,	  air	  is	  a	  very	  poor	  conductor	  and	  so	  when	  it	  bridges	  the	  electrode	  pair	  (as	  
Chapter 4
133
happens	   during	   a	   belch)	   there	   is	   a	   very	   sharp	   rise	   in	   impedance.	   Most	  modern	  impedance	   catheters	   have	   several	   (usually	   six)	   pairs	   of	   impedance	   electrodes	  spanning	  the	  oesophagus.	  This	  allows	  assessment	  of	  the	  direction	  of	  bolus	   Clow	  in	  the	   oesophagus	   (Cigure	   20).	   Most	   catheters	   incorporate	   pH	   sensors	   allowing	  assessment	   of	   the	   acidity	   of	   this	   bolus	  movement.	   Combined	  pH-­‐impedance	   is	   a	  very	   sensitive	   tool	   for	   reClux	   measurement298,	   and	   unlike	   conventional	   pH-­‐monitoring	   it	   allows	   detection	   of	   non-­‐acidic	   reClux,	   and	   is	   able	   to	   distinguish	  reCluxed	  from	  swallowed	  acid	   (e.g.	   as	   found	   in	   some	  drinks	  such	  as	  orange	  juice	  and	  cola).	  
Figure	  20:	   Illustration	  of	   impedance	  during	   liquid	  and	  air	   passage	   in	   the	   oesophagus.	   In	   the	   left	  panel	  there	  is	  a	  liquid	  swallow	  causing	  anterograde	  passage	  of	  low	  impedance	  liquid	  from	  proximal	  to	   distal	  catheter.	  The	  middle	  panel	  shows	  a	  liquid	  reIlux	  event,	  where	  passage	  of	   low	  impedance	  liquid	  occurs	   in	  anterograde	  direction.	   In	  the	  right	  panel	  there	  is	  an	  air	   swallow	  characterised	  by	  anterograde	  passage	  of	  high	  impedance	  air	  from	  proximal	  to	  distal	  catheter
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The	   empty	   oesophagus,	   as	   found	   in	   between	   swallows	   and	   reClux	   events,	   is	  collapsed.	   In	  the	  empty	  oesophagus	   it	   is	   the	  oesophageal	  mucosa	  that	  bridges	  the	  space	  between	  impedance	  electrode	  pairs,	  and	  thus	  it	  is	  the	  mucosa	  that	  offers	  the	  resistance	  to	  direct	  current	  Clow.	  It	  would	  follow	  that	  a	  more	  electrically	  tight	  (less	  permeable	   to	   ionic	   Clow)	   mucosa	   should	   offer	   higher	   impedance	   than	   a	   reClux-­‐damaged	  mucosa	  with	  disruption	  of	  epithelial	  tight	  junctions.	   Indeed,	  oesophageal	  impedance	   (when	  measured	  at	  baseline,	   Cigure	  21)	  has	  recently	  been	  highlighted	  as	   a	   potential	   surrogate	   tool	   for	   in	   vivo	   assessment	   of	   oesophageal	   mucosal	  integrity.	  
Figure	  21:	  The	  baseline	  impedance	  can	  be	  calculated	  by	   taking	  a	  mean	  impedance	  measurement	  from	   an	   impedance	   segment	   (usually	   the	  most	   distal)	   over	   a	   period	  of	   time	   (e.g.	   10	  minutes	   –	  shaded	  area).	  When	  measured	  for	  such	  a	  period	  with	  a	  high	  sample	  frequency	  (e.g.	  50	  Hz)	  the	  mean	  impedance	  is	  a	  good	  representation	  of	  the	  correct	  baseline
It	   has	   previously	   been	   shown	   that	   patients	   with	   overtly	   damaged	   mucosa	  (Barrett’s	   oesophagitis	   and	   erosive	   oesophagitis)	   have	   signiCicantly	   lower	   distal	  oesophageal	  mucosal	  impedance	  than	  patients	  with	  non-­‐erosive	  reClux	  disease155.	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It	  has	  also	  been	  shown	  that,	  within	  patients	  with	  non-­‐erosive	  reClux	  disease,	   those	  with	   higher	   oesophageal	   acid	   exposure	   have	   lower	   baseline	   distal	   oesophageal	  impedance	  values	  (correlation	  between	  baseline	  oesophageal	   impedance	  and	  24-­‐hour	  oesophageal	  acid	  exposure	  (%):	  r=-­‐0.7,	  p<0.001,	  Cigure	  22).	  Furthermore	  this	  impedance	  increases	  after	  treatment	  with	  proton	  pump	  inhibitors156.
Figure	   22:	   Correlation	  between	  baseline	   oesophageal	   impedance	   and	   24-­‐hour	   oesophageal	   acid	  exposure	  time.	  From	  Kessing	  et	  al.	  Am	  J	  Gastroenterol	  2011
Further	  support	   for	  a	  relationship	  between	   impedance	  and	  oesophageal	  mucosal	  integrity	  came	  from	  a	  study	  in	  2011	  by	  Farré	  et	  al.157.	   This	  study	   included	  animal	  and	  human	  data,	  and	  showed	  that	  there	  was	  a	  positive	  correlation	  between	  in	  vivo	  baseline	   impedance	   and	   in	   vitro	   TER	   measurements	   (r=0.72,	   p=0.002).	  Furthermore,	   it	   demonstrated	   that	  when	   the	  oesophagus	   is	   infused	  with	   acid	   in	  healthy	   human	   subjects	   a	   drop	   in	   impedance	   was	   observed	   followed	   by	   an	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incomplete	  recovery	  to	  baseline.	  In	  this	  study	  the	  mean	  impedance	  baseline	  before	  acid	  infusion	  was	  3256	  ±	  1165	  Ω,	  and	  after	  completion	  of	  the	  acid	  perfusion	  (pH	  1	  solution	  at	  2	  ml	  per	  minute	  for	  30	  minutes)	  this	  had	  fallen	  to	  1378	  ±	  291	  Ω.	  There	  was	  incomplete	  impedance	  recovery	  to	  baseline	  even	  at	  2	  hours	  post-­‐perfusion	  (to	  a	  mean	  of	  1550	  Ω).It	   is	   possible	   that	   the	   speed	   of	   this	   recovery	   of	   the	   impedance	   back	   towards	  baseline	  may	  reClect	  the	  health	  of	  the	  oesophageal	  mucosa.	  In	  addition,	  it	  may	  be	  of	  pathophysiological	   signiCicance.	   The	   barrier	   hypothesis	   of	   non-­‐erosive	   reClux	  disease	  suggests	  that	  an	  impaired	  barrier	  function	  will	  leave	  the	  subject	  vulnerable	  to	   symptomatic	   perception	   of	   a	   reClux	   event.	   If,	   after	   an	   acid	   reClux	   event,	   the	  mucosal	  barrier	  integrity	  is	  impaired	  (as	  suggested	  in	  chapter	  3),	  and	  then	  remains	  impaired	  for	  a	  period	  of	  time,	   the	  subject	  may	  remain	  vulnerable	  to	   symptomatic	  reClux	   events	  until	   integrity	   is	   restored.	   Perhaps	   a	   clinical	  correlate	   of	  this	   is	   the	  Cinding	   that	   a	   prior	   recent	   acid	   reClux	   burden	   is	   associated	   with	   an	   increased	  likelihood	  of	  symptomatic	  reClux	  perception210,	  213.Thus	  far,	  the	  in	  vivo	  dynamic	  properties	  of	  mucosal	  integrity	  in	  patients	  with	  reClux	  symptoms	  have	  not	  been	  studied.	  Oesophageal	  mucosal	  integrity,	  as	  expressed	  by	  baseline	   impedance,	   is	   probably	   a	   dynamic	   process	   reClecting	   1)	   the	   damaging	  effect	   of	   repeated	   acid	   reClux	   events	   and	   2)	   the	   mucosal	   capacity	   to	   recover	  integrity.	  Historically	   the	  acid	  perfusion	  test	  has	  been	  used	   in	  assessment	  and	  diagnosis	  of	  gastro-­‐oesophageal	  reClux	  disease.	  It	  was	  Cirst	  introduced	  in	  1958	  by	  Bernstein	  and	  Baker	   as	   an	   objective	  method	   to	   identify	   chemosensitivity	   to	   acid302.	   It	   uses	   a	  nasogastric	   tube	   to	   deliver	   Cirst	   a	   control	   solution	   of	  0.9%	  sodium	   chloride	   and	  then	   pH	   1	   hydrochloric	   acid	   into	   the	   mid-­‐oesophagus.	   The	   test	   was	   used	   to	  establish	   if	   acid	   infusion	   reproduces	   the	   patient’s	   symptoms	   (and	   originally	   to	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distinguish	  between	  chest	  pain	  of	  cardiac	  and	  oesophageal	  origin).	  It	  is	  still	  used	  in	  clinical	   practice	  by	  some	   centres,	   and	   continues	   to	  be	  used	   as	   a	   research	   tool	   to	  assess	   oesophageal	   chemosensitivity	   to	   acid.	   It	   also	   serves	   as	   a	   potential	   tool	   to	  deliver	  a	  standardised	  acid	  provocation	  challenge	  to	  the	  oesophagus.
The	  hypothesis	  of	  the	  study	  presented	  in	  this	  chapter	  is	  that	  there	  is	  a	  relationship	  between	   slow	   recovery	   of	   mucosal	   integrity	   after	   acid	   exposure,	   mucosal	  vulnerability	   (low	   baseline	   impedance)	   and	   increased	   perception	   of	   reClux	  episodes.	  
The	  aim	  of	  the	  study	  is	  to	  evaluate,	   in	  vivo,	  the	  integrity	  of	  oesophageal	  mucosa	  in	  basal	   conditions	   and	   during	   exposure	   to	   acid	   using	   oesophageal	   baseline	  impedance	   monitoring.	   Furthermore,	   it	   aims	   to	   compare	   the	   aforementioned	  oesophageal	   mucosa	   functional	   behaviour	   in	   vivo	   between	   patients	   with	   non-­‐erosive	  reClux	  disease	  and	  patients	  with	  functional	  heartburn.
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4.2 Material and methods
4.2.1	  Patients50	  patients	  (25	  male	  and	  25	  female,	  mean	  age	  44,	  range	  20	  to	  68)	  were	  studied	  at	  the	   upper	   gastrointestinal	   physiology	   unit	   at	   the	   Royal	   London	   Hospital.	   All	  patients	  had	  undergone	  prior	  upper	  gastrointestinal	  endoscopy	  either	  at	  the	  Royal	  London	  or	   at	   their	  local	   hospital,	   and	  all	   patients	  had	  oesophageal	  manometry	  at	  the	  unit	  prior	  to	  reClux	  testing.Patients	  were	   selected	   consecutively	   on	   fulCilling	   the	   entry	   criterion,	   which	  was	  that	  the	  predominant	  complaint	   for	   investigation	  was	  of	   typical	   reClux	  symptoms	  (i.e.	  heartburn	  and/or	  regurgitation).Exclusion	   criteria	   were	   1)	   The	   presence	   of	   erosive	   oesophagitis	   or	   Barrett’s	  oesophagus	   on	   endoscopy.	   2)	   The	   presence	   of	   major	   oesophageal	   motility	  abnormality	  (achalasia,	  absent	  peristalsis)	  on	  oesophageal	  manometry.Oesophageal	  reClux	  monitoring	  and	  acid	  sensitivity	  testing	  was	  done	  as	  part	  of	  the	  patients’	  clinical	  assessment	   for	  reClux	  disease.	  All	  patients	  gave	  written	  informed	  consent.	  PPIs	  were	  stopped	  for	  a	  minimum	  5	  days	  prior	  to	  testing.
4.2.2	  QuestionnairesBefore	   the	   study	   each	   subject	   completed	   an	   reClux	  disease	  questionnaire	   (RDQ).	  This	  is	  a	  self-­‐reported	  questionnaire	  assessing	  heartburn,	  regurgitation	  and	  upper	  abdominal	   pain.	   This	   is	  achieved	  by	   scoring	   twelve	   items	   on	  a	  six-­‐point	  modiCied	  Likert	  scale.	  The	  presence	  of	  an	  RDQ	  score	  above	  Cifteen	  is	   associated	  with	  GORD	  in	  over	  75%	  of	  subjects	  (Cigure	  23)13.
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 Figure	  23:	  The	  accuracy	  of	   the	  RDQ	  score	  in	  identifying	  patients	  with	  reIlux	  disease.	  It	  can	  be	  seen	  that	   a	   score	   above	   15	  is	   associated	  with	   a	   >75%	   detection	  of	   true	   GORD.	  This	   is	   similar	   to	   the	  subjective	  clinical	  opinion	  of	  a	  gastroenterologist.	  From	  Dent	  et	  al.	  Gut	  2010
Subjects	   were	   also	   asked	   to	   indicate	   on	   a	   visual	   analogue	   scale	   their	   overall	  perception	  of	  historical	   heartburn	  severity	   (scored	   from	  0	  to	   100,	   where	  0	  is	  no	  symptoms,	  100	  is	  the	  maximum	  severity	  imaginable).
4.2.3	  Impedance	  measurementsAn	   intraluminal	   combined	  pH-­‐impedance	   catheter	   (Sandhill	   ScientiCic,	   Highlands	  Ranch,	  CO,	  USA)	  was	  used	  for	  performing	  oesophageal	  mucosal	  impedance	  (Cigure	  24).	   This	   catheter	   incorporates	   a	   single	   water-­‐perfused	   manometry	   channel	  (sphincter	  locator	  port)	  that	  can	  also	  be	  used	  for	  perfusion.	  This	  enables	  perfusion	  of	   the	  mid-­‐oesophagus	  whilst	  measuring	   oesophageal	   impedance	  with	  the	  use	  of	  only	  one	  catheter.
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Figure	  24:	  The	  combined	  pH-­‐impedance	  catheter	  with	  integrated	  sphincter	  location	  port	  (used	  as	  a	  perfusion	  channel).	  LES	  =	  lower	  (o)esophageal	  sphincter
The	   lower	   oesophageal	   sphincter	   position	  was	   located	   using	   high	   resolution	   or	  water	   perfused	   manometry.	   After	   oesophageal	   manometry	   the	   pH-­‐impedance	  catheter	  was	  lubricated	  and	  passed	  transnasally	  into	  the	  oesophagus	  such	  that	  the	  pH	  sensor	  was	  placed	  5	  cm	  above	  the	  manometrically-­‐deCined	  lower	  oesophageal	  sphincter.	   This	   placed	  the	   perfusion	  port	   at	   11	  cm	   above	   the	   lower	  oesophageal	  sphincter.	  Throughout	  the	  study	  impedance	  was	  measured	  at	  a	  frequency	  of	  50	  Hz	  in	   the	  distal	   impedance	   segment	  at	  3	  cm	  above	   the	  lower	   oesophageal	   sphincter	  (i.e	   8	  cm	  below	   the	  perfusion	  port).	   The	   data	  was	   recorded	  on	  a	  portable	  digital	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data	   logger	   (Sandhill	   ScientiCic),	   and	   analysed	   on	   proprietary	   pH-­‐impedance	  analysis	  software	  (Bioview	  Analysis,	  Sandhill	  ScientiCic).	  	  
The	  experimental	  protocol	  was	  as	  follows	  (and	  shown	  in	  Cigure	  25).
Figure	   25:	   Schematic	   representation	   of	   the	   experimental	   protocol.	   The	   upper	   panel	   represents	  distal	  oesophageal	  impedance.	  The	  lower	  panel	  represents	  distal	  oesophageal	  pH	  
After	   placement	   of	   the	   pH-­‐impedance	   catheter	   a	   baseline	   distal	   oesophageal	  impedance	  measurement	  was	  made	  with	  the	  subject	  in	  an	  upright	  sitting	  position	  for	   15	   minutes.	   Following	   this	   the	   subject	   was	   told	   they	   were	   to	   receive	   two	  perfusions,	   one	   neutral	   and	   one	   acid.	   They	   were	   not	   told	   in	   which	   order	   the	  perfusions	  were	  performed.	  First,	  a	  0.9%	  sodium	  chloride	  solution	  (buffered	  to	  pH	  6.7	  with	  phosphate	  buffer)	  was	  perfused	  through	  the	  catheter	  perfusion	  port	  via	  a	  peristaltic	   pump	   at	   a	   rate	   of	   10	  ml	   per	   minute	   for	   10	   minutes	   (the	   rate	   was	  calibrated	  before	  beginning	  the	  experiment).	  This	   neutral	   perfusion	   was	   followed	   by	   a	   10	   minute	   rest	   period	   where	   no	  perfusion	  was	  performed.	  The	  second	  infusion	  (of	  hydrochloric	  acid	  at	  pH	  1.0)	  was	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then	  performed,	  also	  at	  10	  ml	  per	  minute	  for	  10	  minutes.	  The	  subject	  was	   asked	  to	   report	  whether	  or	  not	  heartburn	  was	   perceived	  during	  each	  perfusion.	   If	  heartburn	  was	  perceived,	   they	  were	  asked	  to	  rate	  the	  maximal	  symptoms	   severity	  on	  a	  scale	   of	  0	  −	  10	   (where	   0	   is	   no	   pain,	   10	   is	  the	  maximum	  imaginable	  pain).After	  the	  perfusion	  period	  subjects	  were	  free	  to	  ambulate,	  but	  were	  asked	  not	  to	  eat	  or	  drink,	  and	  to	  remain	  upright	  during	  the	  next	  120	  minutes.	  Patients	  subsequently	  completed	  their	  clinical	  24-­‐hour	  pH-­‐impedance	  reClux	  study.
4.2.4	  Data	  analysis
4.3.4.1	  Baseline	  impedanceThe	  baseline	  impedance	  was	   calculated	  as	  the	  average	  impedance	  between	  5	  and	  15	  minutes	  after	  catheter	  placement.	   The	  Cirst	  5	  minutes	  were	  excluded	  from	  the	  calculation	   to	   allow	   for	   acclimatisation	   to	   the	   catheter.	   ReClux	   episodes	   but	   not	  swallows	  were	  excluded	  from	  this	   calculation,	  or	   from	  subsequent	  measurements	  of	  mean	  impedance.	  
4.2.4.2	  Perfusion	  and	  recovery	  periodsMean	   impedance	   was	   calculated	   during	   the	   perfusion	   periods,	   and	   in	   the	   10	  minute	   rest	   period	   post-­‐neutral	   perfusion.	   The	   acid	   clearance	   time	   (time	   to	  oesophageal	  pH	  >	  4	  after	   the	  acid	  perfusion)	  was	  calculated	  (in	  seconds)	  for	  each	  subject.During	   the	   120	  minute	   recovery	   period	  mean	   impedance	   was	   measured	   at	   10-­‐minute	  intervals	  by	  measuring	  the	  mean	  impedance	  during	  the	  5	  minutes	  leading	  up	   to	   the	   time	   point	   (e.g.	   mean	   impedance	   at	   50	  minutes	   was	   measured	   as	   the	  mean	   impedance	   between	   45	   and	   50	   minutes).	   At	   the	   same	   intervals	   mean	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oesophageal	  pH	  was	  also	  measured.	   The	  impedance	  recovery	  after	  perfusion	  was	  calculated	  as	   the	  rate	   (Ω/minute)	  of	   impedance	   increase	  between	  minutes	  5	  and	  90	  after	  cessation	  of	  the	  acid	  perfusion.	  Minutes	   zero	   to	   Cive	  were	  not	   considered	  in	  order	  to	   allow	   for	  acid	  bolus	   clearance	  from	  the	  distal	  oesophagus.	   The	  rate	  of	  impedance	   recovery	   between	   5	   and	   90	   minutes	   was	   chosen	   because	   non-­‐experimental	   retrospective	  analysis	  of	  impedance	  data	   from	  acid	  sensitivity	  tests	  suggested	  that	   this	   is	   the	  most	   linear	   part	   of	  the	   recovery	   process.	   	   The	  rate	  of	  impedance	   recovery	   as	   a	  percentage	   of	  baseline	   impedance	   increase	   per	  minute	  was	  also	  calculated.
4.2.4.3	  ReMlux	  studyThe	  24-­‐hour	  reClux	  study	  was	  analysed	  according	  to	  our	  standard	  reClux	  protocol,	  with	   the	   exception	   that	   the	   Cirst	   3	   hours	   of	   recording	   (corresponding	   to	   the	  perfusion	  and	  recovery	  phase	  of	  the	  study	  protocol)	  were	  excluded	  from	  analysis.	  Patients	  were	  requested	  to	  press	  buttons	  on	  the	  data	  logger	  to	  indicate	  mealtimes,	  movement	   to	   the	   recumbent	  or	  upright	  position,	   and	  the	   presence	  of	   symptoms.	  Meal	   periods	  were	  excluded	  from	  reClux	  analysis	   according	  to	   standard	  protocol.	  Oesophageal	  acid	  exposure	  was	  deCined	  as	  the	  percentage	  time	  of	  oesophageal	  pH	  <4	  during	   the	  analysed	  study.	   Pathological	   acid	  exposure	  was	   considered	  as	  over	  4.2%48.	   ReClux-­‐symptom	   correlation	   was	   determined	   using	   the	   symptom	   index	  (SI)170	   and	  symptom	  associated	  probability	  (SAP)303.	   An	  SI	  >50%	  and	  SAP	  >95%	  were	   considered	   a	   positive	   test	   result.	   In	   this	   study	   a	   positive	   reClux-­‐symptom	  correlation	  was	   deCined	  as	  when	  symptom	   index	  was	  >50%	  and	   SAP	  was	  >95%.	  The	   patient	   was	   considered	   to	   have	   non-­‐erosive	   reClux	   disease	   if	   there	   was	  pathological	   oesophageal	   acid	   exposure	   and/or	   positive	   reClux-­‐symptom	  association.	   If	   there	   was	   neither	   pathological	   oesophageal	   acid	   exposure	   nor	  
Chapter 4
144
positive	  symptom-­‐reClux	  association	  the	  patient	  was	  considered	  to	  have	  functional	  heartburn.




4.3.1	  SubjectsThe	  median	  RDQ	  score	  for	  all	  subjects	  was	  27	  (interquartile	  range	  17	  to	   36).	   The	  median	  VAS	  score	  for	  heartburn	  was	  70	  (interquartile	  range	  40	  −	  85).14	  patients	  were	   current	  smokers.	  All	   patients	  had	  taken	  proton	  pump	  inhibitor	  therapy	  for	  their	  reClux	  symptoms,	  however	  15	  patients	  had	  ceased	  therapy	  due	  to	  perceived	   poor	   response.	   All	   other	   patients	   were	   on	   at	   least	   once	   daily	   proton	  pump	   inhibitor	   therapy	   (lansoprazole,	   pantoprazole,	   omeprazole	   or	  esomeprazole)	  which	  had	  been	  stopped	  only	  in	  order	  to	  have	  reClux	  investigation.	  All	  patients	  had	  undergone	  prior	  upper	  gastrointestinal	  endoscopy	  and	  none	  had	  evidence	  of	  erosions	   or	  Barrett’s	   oesophagus.	   None	  of	   the	   research	  participants	  needed	   to	   be	   excluded	   due	   to	   the	   presence	   of	   severe	   motility	   disorder	   on	  oesophageal	  manometry.	   11	  patients	   were	   found	   to	   have	  a	  hiatus	  hernia	   on	  this	  manometric	  investigation.
4.3.2	  24-­‐hour	  clinical	  reMlux	  monitoringThe	  median	  24-­‐hour	  oesophageal	   acid	  exposure	  was	   2.25%	  (interquartile	   range	  1.05	  −	  6.25%).	  According	  our	  stated	  criteria,	  20	  patients	  were	  classiCied	  by	  reClux	  testing	  as	  having	  non-­‐erosive	  reClux	  disease,	  30	  as	  functional	  heartburn.	  Within	  the	  non-­‐erosive	   reClux	   group,	   15	  were	   deCined	  on	   criteria	   of	   excessive	   oesophageal	  acid	   exposure	   (with	   or	   without	   positive	   reClux-­‐symptoms	   association),	   5	   were	  deCined	  on	  a	  positive	  reClux-­‐symptom	  association	  alone.	  Eight	  of	  the	  patients	  with	  non-­‐erosive	   reClux	   disease	   were	   female,	   and	   17	   of	   the	   patients	   with	   functional	  heartburn	  were	  female.	   Five	  of	   the	  subjects	   with	  hiatus	   hernia	  were	   in	   the	  non-­‐
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erosive	   reClux	   group.	   The	   median	   age	   in	   the	   non-­‐erosive	   reClux	   group	   was	   48	  (range	  41	   -­‐	  59).	  The	  median	  age	  in	  the	  functional	   heartburn	  group	  was	   44	  (35	  −	  66).
4.3.3	  Acid	  sensitivityNo	  subjects	  perceived	  heartburn	  during	  the	  neutral	  perfusion.	  Thirty-­‐one	  of	  the	  50	  (62%)	   patients	   experienced	   heartburn	   during	   the	   acid	   perfusion.	   The	   mean	  maximum	  symptom	  intensity	  perception	  in	  subjects	  perceiving	  heartburn	  was	  7.3	  out	  of	  10	  (range	  2	  −	  10).	  All	  patients	  completed	  10	  minutes	  of	  acid	  perfusion.
4.3.4	  Baseline	  oesophageal	  mucosal	  impedanceIn	   all	   study	   subjects	   the	   mean	   baseline	   impedance	   at	   3	   cm	   above	   the	   gastro-­‐oesophageal	  junction	  was	  2098	  Ω	  (range	  466	  −	  5388	  Ω).There	  was	  a	  weak	  but	  signiCicant	  negative	  correlation	  between	  baseline	  impedance	  and	  24-­‐hour	  oesophageal	  acid	  exposure	  (r=-­‐0.38,	  p=0.01,	  Cigure	  26).The	  median	  post-­‐perfusion	  acid	  clearance	  time	  was	  8	  minutes	  (interquartile	  range	  5.5	  −	  13.5	  minutes).	  The	  median	  number	  of	  pharyngeal	  swallows	  taken	  to	  achieve	  oesophageal	  pH	  of	  greater	  than	  4	  was	  4	  (interquartile	  range	  3	  −	  7).There	  was	   no	   correlation	  between	  post-­‐perfusion	  acid	  clearance	  time	  or	  number	  of	   swallows	   to	   pH4	   and	   baseline	   impedance	   (r=0.04,	   p=0.8;	   r=0.2,	   p=0.11	  respectively).Baseline	   impedance	   was	   lower	   in	   patients	   who	   perceived	   the	   acid	   perfusion	   as	  heartburn	  than	   in	   those	  who	   did	  not	   (1736	   ±	  784	  Ω	   vs.	   2741	  ±	  1256	  Ω,	   p<0.01,	  Cigure	  27).
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Figure	  26:	  Correlation	  between	  distal	  oesophageal	   baseline	   impedance	  and	  24-­‐hour	   oesophageal	  acid	  exposure	  time	  (%)
Figure	  27:	  Baseline	  impedance	  according	   to	   whether	   the	  subject	   perceived	  the	  acid	  perfusion	  as	  heartburn	  (acid	  sensitivity	  test	  +)	  or	  did	  not	  (acid	  sensitivity	  test	  -­‐)
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Even	   when	   only	   patients	   with	   functional	   heartburn	   were	   considered,	   baseline	  impedance	  was	  lower	  in	  those	  who	  perceived	  heartburn	  on	  acid	  perfusion	  (1927	  ±	  814	  Ω	  vs.	  3018	  ±	  1241	  Ω,	  p=0.01).
4.3.5	  Perfusion	  with	  neutral	  solutionPerfusion	  with	  neutral	  solution	  provoked	  a	  fall	  in	  impedance	  to	  675	  ±	  375	  Ω	  in	  all	  patients,	  occurring	  as	  the	  conductive	  saline	  surrounded	  the	  impedance	  electrodes.	  After	   cessation	   of	   the	   neutral	   perfusion	   there	   was	   a	   very	   fast	   recovery	   of	  impedance	   to	   baseline	   (within	  10	  minutes	   impedance	  was	  98	  ±	  28%	  of	  baseline,	  mean	  increase	  rate	  203.7	  ±	  83	  Ω/min).	  
4.3.6	  Perfusion	  with	  acidic	  solutionDuring	  the	  perfusion	  with	  acidic	   solution	  there	  was	  a	  fall	   in	   impedance	   to	   349	  ±	  141	  Ω	  in	  all	  patients	  as	  the	  conductive	  solution	  passed	  the	  impedance	  electrodes.After	  acid	  perfusion	  there	  was	  a	  much	  slower	  recovery	  of	  impedance	  compared	  to	  the	   recovery	   post-­‐neutral	   perfusion.	   The	   median	   impedance	   recovery	   rate	  measured	   between	   5	   and	   90	   minutes	   post-­‐acid	   perfusion	   was	   6.5	   Ω/min	  (25th-­‐75th	   percentile	   =	   3.3	   -­‐	   12.0	   Ω/min).	   The	   mean	   percentage	   of	   baseline	  increase	   rate	   was	   0.4%/min.	   Baseline	   impedance	   correlated	   well	   with	   post-­‐perfusion	  impedance	  recovery	  rate	  (r=0.7,	  p<0.01,	  Cigure	  28).
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Figure	  28:	  Correlation	  between	  baseline	  oesophageal	  impedance	  and	  impedance	  recovery	  rate	  after	  cessation	  of	  acid	  perfusion
Impedance	   recovery	   expressed	   as	   absolute	   values	   (Ω/min)	   and	   as	   percentage	  baseline	   increase	   (%	   baseline/min)	   showed	   a	   signiCicant	   positive	   correlation	  (r=0.73,	   p<0.01).	   At	  90	  minutes	  after	   perfusion	   the	  median	   impedance	  was	  73%	  (IQR	  67-­‐92%)	  of	  baseline.	  There	  was	  no	  correlation	  between	  impedance	  recovery	  rate	  and	  post-­‐perfusion	  acid	  clearance	  time	  to	  pH4	  (r=-­‐0.02,	  p=0.85).The	  post-­‐acid	  perfusion	  impedance	  recovery	  rate	  demonstrates	  a	  signiCicant	  inter-­‐individual	  variability.	   If	  one	   takes	   subjects	  with	  a	  recovery	   rate	   greater	   than	  the	  75th	  percentile	  (12	  Ω/min)	  and	  lower	  than	  the	  25th	  percentile	  (3.3	  Ω/min),	  then	  we	  may	   consider	   two	   groups:	   one	  with	   fast,	   and	  one	  with	   slow	   post-­‐acid	   perfusion	  impedance	  recovery	  (Cigure	  29).
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Figure	  29:	  Inter-­‐individual	  variability	  of	  post-­‐acid	  impedance	  recovery	  rate.	  Those	  subjects	  within	  the	  light	   grey	   circle	  may	   be	  considered	  to	   have	  a	  “slow”	  recovery	  rate,	   and	  those	  within	  the	  dark	  grey	  circle	  a	  “fast”	  recovery	  rate	  
In	  considering	  these	  two	  groups,	  patients	  with	  slower	  impedance	  recovery	  (n=12)	  had	  lower	  baseline	  impedance	  than	  those	  with	  fast	  recovery	  (n=11)	  (1273	  Ω	  ±	  720	  vs.	  3220	  Ω	  ±	  954,	  p<0.01,	  Cigure	  30).	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Figure	  30:	  Baseline	  impedance	  according	  to	  “slow”	  and	  “fast”	  post-­‐acid	  impedance	  recovery	  rate
Patients	   with	   slow	   impedance	   recovery	   also	   demonstrated	   a	   higher	   24-­‐hour	  oesophageal	   acid	   exposure	   than	   those	  with	   fast	   recovery	   (4.3	   ±	   4.0%	   vs.	   1.7	   ±	  1.3%,	  p=0.04,	  Cigure	  31).	  
Figure	  31:	  24-­‐hour	  oesophageal	  acid	  exposure	  according	  to	   “slow”	  and	  “fast”	  post-­‐acid	  impedance	  recovery	  rate
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Furthermore,	   patients	   with	   slow	   impedance	   recovery	   more	   often	   perceived	   the	  acid	   perfusion	  as	  heartburn	   than	  those	  with	  fast	   impedance	  recovery	   (10/12	   vs.	  4/12,	  p=0.03,	  Cigure	  32).
Figure	  32:	  Perception	  of	  the	  acid	  perfusion	   test	   as	   heartburn	  according	  to	   “slow”	  and	  “fast”	  post-­‐acid	  impedance	  recovery	  rate.	  Acid	  sensitivity	   test	   –ve	  means	  heartburn	  was	  not	   felt	   during	  acid	  perfusion.	  Acid	  sensitivity	  test	  +ve	  means	  heartburn	  was	  felt
4.3.7	   Comparison	   of	   patients	   with	   non-­‐erosive	   reMlux	   disease	   and	   functional	  




Functional	  heartburn Non-­‐erosive	  reGlux	  
disease 	  
Oesophageal	  acid	  exposure	  (%) 1.3	  (0.5	  -­‐	  2.4) 6.9	  (4.2	  -­‐	  9.4) p<0.001
Total	  number	  of	  reGlux	  events 22	  (8	  -­‐	  37) 27	  (20	  -­‐	  46) NS
%	  acid	  reGlux	  events 54	  (26	  -­‐	  71) 75	  (63	  -­‐	  81) p<0.01
Acid	  clearance	  time	  (s) 55	  (37	  -­‐	  92) 129	  (88	  -­‐	  196) p<0.05
Table	  4:	  ReIlux	  characteristics	  of	  functional	  heartburn	  and	  non-­‐erosive	  reIlux	  disease	  patients
In	  patients	   with	   non-­‐erosive	  reClux	   disease	   baseline	   impedance	  was	   signiCicantly	  lower	   than	   those	  with	   functional	   heartburn	   (1669	   ±	  814	  Ω	   vs.	   2384	   ±	  1156	  Ω,	  p=0.02,	  Cigure	  33).	  	  
Figure	  33:	  Baseline	  impedance	  according	  to	  patient	  disease	  phenotype
Patients	  with	  non-­‐erosive	  reClux	  disease	  had	  a	  slower	  rate	  of	  impedance	  recovery	  compared	   to	   patients	   with	   functional	   heartburn	   (6.0	   ±	   4.2	   Ω	   vs.	   10.7	   ±	   8.6	   Ω,	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p=0.03,	  Cigure	  34).	  
Figure	  34:	  Post-­‐acid	  perfusion	  impedance	  recovery	  rate	  according	  to	  patient	  disease	  phenotype




This	   study	   examined	   the	   relationship	  between	  baseline	  oesophageal	   impedance,	  and	   its	   dynamic	   response	   to	   an	   oesophageal	   acid	   challenge	   in	   patients	   with	  heartburn	  symptoms.	  It	  tested	  the	  hypothesis	   that	  there	  is	  a	  relationship	  between	  slow	  recovery	  of	  mucosal	  integrity	  after	  acid	  exposure,	  mucosal	  vulnerability	  (low	  baseline	   impedance)	  and	   increased	  perception	   of	  intra-­‐oesophageal	   acid.	   It	   used	  impedance	  as	  a	  surrogate	  marker	  of	  mucosal	  integrity	  at	  baseline,	  and	  as	  a	  marker	  of	  progression	  of	  restitution	  of	  the	  integrity	  after	  an	  acid	  insult.The	  study	  results	  show:	  1) Patients	  with	   low	   baseline	   impedance	   are	  more	   sensitive	   to	   perception	   of	   an	  acid	  perfusion	  as	  heartburn.2) A	   mid-­‐oesophageal	   perfusion	   of	   a	   neutral	   solution	   causes	   a	   drop	   in	   distal	  oesophageal	  impedance	  (due	   to	   the	  conductance	  of	  the	   liquid)	  that	   restores	   to	  normal	  almost	  immediately	  on	  cessation	  of	  the	  perfusion.3) A	   mid-­‐oesophageal	   perfusion	   of	   an	   acidic	   solution	   in	   patients	   with	   reClux	  symptoms	  causes	  an	  abrupt	  fall	  in	  impedance	  that	  recovers	  slowly,	  displaying	  a	  signiCicant	  inter-­‐individual	  variability	  in	  recovery	  rate.	  4) There	   is	   a	   relationship	   between	   rate	   of	   impedance	   recovery	   and	   baseline	  impedance	  i.e.	  the	  slower	  the	  recovery,	  the	  lower	  baseline	  impedance.	  5) A	   group	  of	  subjects	   can	  be	  identiCied	  who	   display	  slow	   recovery	  of	  impedance	  after	   acid	  perfusion,	   low	  baseline	   impedance,	   high	  24-­‐hour	  acid	  exposure,	   and	  high	  acid	  sensitivity.	  6) Compared	   to	   patients	   with	   functional	   heartburn,	   patients	   with	   non-­‐erosive	  reClux	   disease	  have	   slower	   recovery	   of	  mucosal	   integrity	   after	   acid	  perfusion,	  lower	  baseline	  impedance,	  and	  increased	  acid	  sensitivity.	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In	   contrast	   to	   the	   rest	   of	   the	   gastrointestinal	   tract,	   the	   oesophageal	   mucosa	   is	  characterised	  by	   tightly	   apposed	  non-­‐keratinised	  stratiCied	  squamous	  epithelium.	  Under	   physiological	   conditions	   the	   oesophageal	   epithelium	   forms	   an	   effective	  barrier	  against	  the	  passage	  of	  noxious	  substance	  such	  as	  acid	  from	  the	  oesophageal	  lumen	   into	   the	   deep	   epithelium304.	   In	   vivo	   and	   in	   vitro	   experimental	   mucosal	  exposure	  to	  acid	  impairs	   the	  barrier	  properties	  as	  assessed	  by	  morphological	  and	  permeability	  studies148,	  153,	   161,	  163.	  This	  failure	  of	  normal	  barrier	  function	  may	  allow	  the	  passage	   of	  acid	  or	   other	   noxious	   components	   of	  the	   reCluxate	   (e.g.	   pepsin	  or	  bile	   acid)	   such	   that	   they	   can	   stimulate	   submucosal	   nociceptors	   and	   provoke	  symptoms	  in	  the	  absence	  of	  macroscopic	  erosions162.	  Studies	  thus	  far	  have	  been	  in	  terms	  of	  static	  phenomena	  (such	  as	  the	  baseline	  impedance	  in	  relation	  to	  24-­‐hour	  acid	   exposure156),	   but	   the	   dynamic	   in	   vivo	   response	   of	   the	  oesophageal	  mucosal	  integrity	   to	   acid	   exposure	   has	   not	   been	   characterised	   in	   patients	   with	   reClux	  symptoms.	   Mucosal	   integrity	   is	   determined	   by	   dynamic	   circumstances,	   with	  repeated	  reClux	  events	  over	  the	  course	  of	  a	  day	  interacting	  with	  the	  mucosa,	  which	  in	   turn	   responds	   to	   and	   recovers	   from	   the	   damage	   caused	  by	   the	  exposures.	   As	  such,	  baseline	  impedance	  is	  likely	  to	  be	  a	  function	  of	  mucosal	  restoration	  capacity	  after	  repeated	  acid	  exposure.	  In	   vivo	  mucosal	   impedance	  measurement	  may	  allow	  an	  assessment	   of	  oesophageal	  mucosal	   integrity	  in	  these	  dynamic	  circumstances,	  and	   thus	   enables	   us	   to	   evaluate	   properties	   of	   oesophageal	   mucosal	   integrity	   in	  patients	  during	  and	  after	  a	  standardised	  acid	  challenge.As	   always	   with	   a	   new	   technique,	   it	   is	   important	   to	   recognise	   the	   potential	  limitations,	  and	  these	  should	  be	  remembered	  when	  making	  interpretations.	  During	  the	   introduction	   to	   this	   chapter	   supporting	   evidence	   (the	   lower	   baseline	  impedance	   in	  higher	   acid	  exposure	  patient	   groups	  and	   the	  good	  correlation	  with	  TER	   in	   animal	   studies)	   was	   given	   for	   the	   use	   of	   oesophageal	   impedance	   as	   a	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measure	   of	   mucosal	   integrity.	   This	   suggests	   that	   the	   technique	   is	   a	   valid	  representation	  of	   integrity,	   but	   this	   has	   not	   been	   deCinitively	   demonstrated.	   For	  example,	   it	   is	  possible	  that	  a	  low	  impedance	  occurs	  on	  acid	  exposure,	   not	  because	  of	  mucosal	  changes,	  but	  instead	  due	  to	  an	  increased	  liquid/mucous	  layer	  lining	  the	  mucosa.	   This	  could	  be	  due	  to	   increased	  salivary	  production,	   or	  due	  to	  submucous	  gland	  secretion.	  As	  yet,	  this	  possibility	  is	  untested.In	  addition,	  although	  impedance	  in	  vivo	  correlates	  with	  TER	  in	  vitro,	   this	  has	  been	  demonstrated	   in	   animals,	   and	   as	   such	   cannot	   be	   translated	   to	   humans	   with	  complete	   conCidence.	   Studies	   comparing	   this	   in	   humans	   are	   not	   performed,	  although	   a	   recent	   study	   using	   a	   similar	   technique	   (electrical	   tissue	   impedance	  spectroscopy	   )	   has	   demonstrated	   a	   correlation	   (r=-­‐0.65)	   between	   impedance	  measurements	  and	  TER	   in	  biopsies	   in	  humans305.	  This	  perhaps	   offers	  some	  more	  support	  for	  the	  application	  of	  impedance	  techniques	  in	  mucosal	  measurement,	  but	  cannot	  be	  interpreted	  as	  direct	  evidence	  for	  the	  technique	  used	  in	  our	  studies.The	  fall	   in	   impedance	   that	  occurs	  during	   acid	  perfusion	   is	   predominantly	  due	   to	  the	   conductance	   of	   the	   acid	   solution	   itself	   lying	   in	   contact	   with	   the	   impedance	  segment.	   However,	   this	   study	   demonstrates	   that	   a	   relatively	   low	   impedance	  persists	  for	  a	  long	  time	  after	  the	  clearance	  of	  the	  acid	  from	  the	  oesophageal	  lumen.	  The	  mucosal	   behaviour	   on	   acid	   exposure	   in	   vivo	   is	   in	   accordance	   with	   in	   vitro	  Cindings	  when	  human	  oesophageal	  mucosal	  biopsies	  are	  exposed	  to	  acid,	  as	  seen	  in	  Chapter	   3.	   The	   long	   lasting	   fall	   of	   the	   impedance	   implies	   that,	   not	   only	   is	   the	  barrier	  integrity	  of	  the	  mucosa	  disrupted	  when	  it	  is	  exposed	  to	  acid,	  but	  it	  remains	  impaired	  for	  some	  time	  after	  an	  acid	  exposure.	  The	  speed	  of	  recovery	  of	  the	  impedance	  after	  cessation	  of	  acid	  perfusion	  displays	  a	  signiCicant	   inter-­‐individual	   variability.	   This	   observation	   is	   of	   interest	   since	   it	  suggests	  that	  patients	  with	  acid-­‐induced	  mucosal	  damage	  do	  not	  reconstitute	  their	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mucosal	  integrity	  at	  the	  same	  rate.	  As	  such,	  one	  can	  hypothesise	  that	  patients	  with	  a	  slower	  recovery	  of	  integrity	  will	  be	  more	  likely	  to	  have	  long-­‐lasting	  vulnerability	  of	   their	  mucosa	   to	   exposure	   from	   subsequent	   gastro-­‐oesophageal	   reClux	   events.	  Indeed	   this	   study	   found	   a	   close	   association	  between	   slow	   recovery	   of	   integrity	  after	   acid	  challenge	  and	   a	   low	   baseline	   impedance	  value.	   It	   is	   therefore	   possible	  that	  low	  baseline	  impedance	  is	  partly	  a	  consequence	  of	  the	  impaired	  ability	  of	  the	  mucosa	   to	   rapidly	  reconstitute	   its	   barrier	   function	  after	   acid	  damage.	  We	   should	  also	  be	  aware	  that	  the	  excellent	  correlation	  between	  baseline	  impedance	  and	  rate	  of	  recovery	   could	  be	  interdependent	   in	   the	  other	  direction:	  that	  a	   lower	  baseline	  
results	  in	  a	  slower	  recovery.	   The	  complexities	  of	   this	   relationship	  have	  not	  been	  resolved	  in	  this	  study.A	   hypothesis	   formed	   in	   this	   thesis	   is	   that	   a	   patient	   whose	   oesophageal	  mucosa	  displays	  impaired	  integrity	  should	  be	  more	  sensitive	  to	  oesophageal	  acid	  exposure.	  This	   is	   supported	   in	   the	   current	   study	   by	   the	   Cinding	   that	   patients	   with	   low	  baseline	   impedance	   (more	   impaired	   integrity)	   have	   more	   sensitivity	   to	   acid	  perfusion	  than	  those	  with	  high	  baseline	   impedance.	   This	   is	   true	   even	  when	  only	  patients	   with	   functional	   heartburn	   are	   included	   in	   the	   calculation.	   This	   second	  point	   is	   of	   importance.	   It	   could	   be	   argued	   that	   patients	   with	   non-­‐erosive	   reClux	  disease	   have	   a	   lower	   impedance	   and	   more	   acid	   sensitivity	   than	   patients	   with	  functional	  heartburn,	  but	  that	  these	  two	  observations	  are	  unrelated.	  The	  Cinding	  of	  an	  association	  between	  lower	  baseline	  impedance	  and	  acid	  sensitivity	  within	  only	  functional	  heartburn	  patients	  makes	  a	  stronger	  argument	  for	  a	  pathophysiological	  relationship.	  This	   study	   could	   have	   used	   statistical	   analyses	   of	   reClux-­‐symptom	   correlation	  (such	  as	  SAP)	  from	  the	  24-­‐hour	  reClux	  study	  to	  assess	  acid	  sensitivity.	  This	  was	  not	  done,	  and	  instead	  perception	  of	  a	  standard	  acid	  challenge	  was	  used.	  Although	  the	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former	   method	   seems	   to	   be	   more	   physiological,	   most	   studies	   on	   oesophageal	  chemosensitivity	   rely	   on	   standard	   acid	   perfusion	   techniques	   due	   to	   large	   inter-­‐individual	   and	   day-­‐to-­‐day	   variability	   in	   symptom	   perception	   and	   patient	  behaviour	   during	   ambulatory	   reClux	   monitoring.	   As	   such	   it	   was	   felt	   that	   the	  administration	  of	  a	  Cixed	  concentration	  and	  volume	  acid	  challenge	  would	  result	   in	  more	  robust	  comparison	  of	  patients.
Patients	   with	   a	   slow	   impedance	   recovery	   had	   a	   lower	   baseline	   impedance	   and	  more	   acid	   sensitivity	   than	   patients	   with	   fast	   impedance	   recovery.	   The	   slower	  recovery	   group	   also	   had	  higher	  24-­‐hour	   acid	   exposure	   than	   the	   faster	   recovery	  group.	  This	   is	   important	   as	   one	  can	  consider	   the	  following	  paradigm:	   if	  a	  patient	  has	   a	  reClux	  episode,	   the	  oesophageal	  mucosal	   integrity	   is	   impaired.	  This	  mucosal	  integrity	   slowly	   recovers.	   During	   this	   time	   of	   low	   integrity,	   the	   patient	   is	   more	  vulnerable	   to	   symptoms	   from	   reClux	   episodes.	   As	  more	  reClux	   events	   (and	  more	  oesophageal	  acid	  exposure	  occurs),	  the	  integrity	  is	  further	  impaired,	  delays	  further	  the	  adequate	  reconstitution	  of	  barrier	   function,	  and	  renders	  the	  patient	  yet	  more	  vulnerable	  to	  reClux	  perception	  (a	  “multiple-­‐hit”	  hypothesis).	  A	  clinical	  correlate	  of	  this	  has	  previously	  been	  documented,	  whereby	  it	  was	  noted	  a	  reClux	  event	  is	  more	  likely	  to	  be	  perceived	  if	  there	  was	  a	  previous	  burden	  of	  acid	  exposure210,	  213.On	   comparison	   of	   patients	   with	   functional	   heartburn	   and	   non-­‐erosive	   reClux	  disease	   it	   can	  be	   seen	  that	  patients	  with	  non-­‐erosive	   reClux	  disease	  have	  a	   lower	  baseline	   impedance.	   This	   would	   be	   in	   keeping	   with	   previous	   observations	   of	  morphological	   changes	   (dilated	   intercellular	   spaces)	   in	   the	   distal	   oesophagus	   of	  patients	   with	   non-­‐erosive	   reClux	   disease,	   but	   not	   in	   patients	   with	   functional	  heartburn167.	   According	   to	   the	   paradigm	   presented	   in	   this	   Chapter,	   the	   lower	  baseline	  impedance	  in	  non-­‐erosive	  reClux	  disease	  would	  be	  more	  likely	  to	  occur	  if	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the	   recovery	   of	   impedance	   is	   slower	   than	   in	   functional	   heartburn	   patients,	   and	  indeed	  this	   is	  the	  case.	   Correspondingly,	   it	  was	  also	  demonstrated	  that	  perception	  of	   oesophageal	   acid	  challenge	   is	   more	   frequent	   in	  the	   non-­‐erosive	  reClux	  disease	  patient	  group.	  The	   mechanism	   of	   symptom	   perception	   in	   functional	   heartburn	   is	   unclear.	   By	  deCinition,	   true	   functional	  heartburn	  is	  not	  due	   to	   the	  contact	  of	  the	  oesophageal	  mucosa	  with	  gastro-­‐oesophageal	  reCluxate6.	   It	  is	  already	  known	  that	  patients	  with	  functional	  heartburn	  display	  a	  high	  “positive”	  rate	  when	  the	  acid	  sensitivity	  test	  is	  used	  as	   a	   diagnostic	   tool306.	   Within	   the	  functional	   heartburn	  group	  in	  this	  study,	  patients	  who	  perceived	  acid	  perfusion	  had	  lower	   baseline	   impedance	  than	  those	  who	   did	  not,	   suggesting	   that	  peripheral	   factors	  may	   still	   play	   a	   role	   in	   their	  acid	  perception.	   Indeed,	   one	  can	  identify	   a	  subgroup	  of	   functional	   heartburn	  patients	  who,	   despite	   having	   a	   normal	   reClux	   study,	   have	   a	   mucosal	   integrity	   behaviour	  phenotype	  that	   is	  very	  similar	  to	  non-­‐erosive	  reClux	  disease	  patients.	   This	  would	  be	  of	   interest	   to	   explore	   further.	   It	   is	   highly	   likely	   that	   a	   proportion	   of	   patients	  during	   their	   24-­‐hour	   study	   do	   not	   have	   a	   “typical”	  day	   (i.e.	   the	   presence	   of	   the	  catheter	   may	   alter	   behaviour	   in	   terms	   of	  meals	   and	   activities),	   and	   some	   may	  forget	  to	  press	  the	  event	  markers	  every	  time	  they	  perceive	  symptoms.	   Indeed	  it	  is	  known	  that	  a	  prolonged	  reClux	  study	  (48	  or	  72	  hours)	  can	  “convert”	  some	  patients	  previously	   determined	  as	   functional	   heartburn	   on	  a	  24-­‐hour	   study	   into	   patients	  with	  pathological	   gastro-­‐oesophageal	   reClux	  disease307.	   It	  would	  be	  interesting	  to	  investigate	   whether	   the	   mucosal	   characteristics	   of	   patients	   can	   aid	   in	   the	  phenotyping	  process.A	   limitation	   of	   this	   study	   is	   that	   impedance	   recovery	   was	   only	  measured	   for	   2	  hours	  post-­‐acid	  perfusion.	   	  Ideally	  this	  period	  would	  be	  longer	  since	  most	  subjects	  had	   not	   re-­‐attained	   baseline	   levels	   over	   2	   hours.	   	   Food	   and	   drink	   was	   not	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permitted	  during	  this	   recovery	  period	  as	  it	  creates	  signiCicant	  impedance	  artefact.	  As	   such	  the	  2-­‐hour	   timeframe	  was	   considered	  a	  satisfactory	  compromise	  since	  a	  recovery	   rate	   can	  be	  reasonably	   calculated	  in	  this	   time	   period,	   without	   the	  need	  for	  patients	  to	  undergo	  an	  even	  longer	  period	  of	  uncomfortable	  fasting.It	  is	  possible	  that	   the	  classiCication	  of	  non-­‐erosive	  reClux	  disease	  patients	  was	  not	  completely	  accurate.	   	  The	  reason	  for	  this	  is	  that	  patients	  had	  their	  reClux	  study	  as	  part	  of	  their	  clinical	  evaluation	  for	  refractory	  reClux	  symptoms.	  All	  had	  undergone	  prior	  endoscopy	  which	  demonstrated	  no	  erosive	  disease.	  However,	   some	  patients	  may	   previously	   have	   erosive	   oesophagitis	   that	   was	   “converted”	   to	   non-­‐erosive	  reClux	   disease	  by	   PPI	   therapy.	   However,	   all	   the	   patients	   had	   ongoing	   symptoms	  despite	   normal	   endoscopic	   mucosa,	   and	   we	   are	   interested	   in	   the	   physiological	  properties	  of	  this	  non-­‐eroded	  mucosa	  in	  persistent	  symptom	  generation.The	  perfusions	  were	  performed	  before	  knowing	  the	  patient	  phenotype	  (functional	  heartburn	  or	  non-­‐erosive	  reClux	  disease).	  For	  the	  objective	  of	  the	  study	  it	  was	  not	  necessary	  to	   know	  the	  phenotype	  before	   the	  test.	   Indeed,	   it	  ensured	  investigator	  blinding	  during	  the	  acid	  sensitivity	  test.It	   could	   have	   been	   very	   informative	   if	   the	   study	   could	   have	   incorporated	   a	  corresponding	   in	   vitro	  assessment	  of	  mucosal	   integrity	  by	   analysing	  oesophageal	  biopsies	  in	  Ussing	  Chambers	  (such	  as	  in	  Chapter	  3).	  To	  achieve	  this	  an	  experiment	  whereby	  serial	  endoscopic	  biopsy	  over	  a	  90	  minute	  period	  would	  be	  required,	  but	  would	  be	  unfeasible	  and	  distressing	  for	  the	  participant.	  However,	   it	  is	  known	  from	  previous	   animal	   studies	   that	   in	   vitro	   measures	   of	   mucosal	   permeability	   do	  correlate	   well	   with	   in	   vivo	   impedance	   measurements157,	   and	   as	   such	   the	  impedance	  Cindings	  are	  still	  of	  interest	  on	  their	  own	  strength.	  In	  summary	  this	  study	  indicates	  that	  impaired	  mucosal	  integrity	  can	  be	  induced	  by	  acid,	   and	   maintenance	   of	   this	   impaired	   status	   can	   be	   promoted	   by	   slow	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In vitro and in vivo assessment of mucosal 
integrity in the distal and proximal oesophagus
CHAPTER 5: IN VITRO AND IN VIVO ASSESSMENT OF MUCOSAL 
INTEGRITY IN THE DISTAL AND PROXIMAL OESOPHAGUS
5.1 Introduction and aimsHistorically	   the	   distal	   oesophagus	   has	   been	   the	   focus	   of	   investigation	   into	  pathogenesis	   of	   GORD.	   However,	   it	   has	   been	   increasingly	   documented	   that	   the	  proximal	  oesophagus	  may	  have	  a	  greater	  importance	  than	  was	  previously	  realised.	  The	  use	  of	  pH	  impedance	  techniques	  has	  allowed	  more	  spatial	  deCinition	  of	  reClux	  events.	  The	  most	  commonly	  used	  pH-­‐only	  probes	  have	  only	  one	  or	  two	  pH	  sensors	  and	  allow	   only	   detection	   of	   a	   pH	   drop	   in	   the	   distal	   oesophagus	   during	   a	   reClux	  event.	   This	   tells	   us	   little	   or	   nothing	   about	   the	   more	   proximal	   movement	   of	   the	  reCluxate.	   Multiple	   sensor	   pH	   probes	   or	   combined	   pH-­‐impedance	   catheters	  commonly	  have	  several	  measurement	  segments	   spanning	   from	  distal	  to	  proximal	  oesophagus.	   Studies	   with	   such	   techniques	   have	   enabled	   characterisation	   of	   not	  only	   the	   pH,	   but	   also	   the	   proximal	   movement	   of	   reClux	   events.	   Using	   such	  techniques	   it	  has	   been	  shown	  that,	   in	  patients	  with	  GORD,	   reClux	  events	   reaching	  the	   proximal	   oesophagus	   (deCined	   as	   15	   cm	   above	   the	   lower	   oesophageal	  sphincter)	   are	   more	   likely	   to	   be	   perceived	   than	   those	   reaching	   only	   the	   distal	  oesophagus209,	   210.	   As	   has	  been	  regularly	  emphasised	  in	  this	   thesis,	   there	  exists	  a	  signiCicant	  minority	  of	  patients	  with	  gastro-­‐oesophageal	  reClux	  disease	  who	  remain	  refractory	  to	  proton-­‐pump	  inhibitor	  therapy3.	  The	  majority	  of	  gastro-­‐oesophageal	  reClux	  events	   in	  this	   group	  of	  patients	   are	  weakly	   acidic	  (pH	  4	  to	  6)	  in	  nature.	   In	  patients	   taking	   PPI	   therapy,	   impedance-­‐pH	   studies	   have	   indicated	   that	   a	   high	  proximal	   extent	   of	   reClux	   events	   is	   the	   most	   important	   factor	   in	   determining	  whether	  a	  reClux	  episode	  will	  be	  perceived	  by	  the	  patient212,	  213.
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Whilst	   distal	   reClux	   events	   can	   be	   symptomatic	   (and	   can	   result	   in	   signiCicant	  complications	  ranging	  from	  erosions	  to	  adenocarcinoma),	  the	  distal	  reClux	  event	  is	  not	  immediately	  threatening	  to	  the	  individual.	   In	  contrast,	  a	  reClux	  event	  reaching	  the	  proximal	  oesophagus	  is	  in	  danger	  of	  reaching	  the	  pharynx	  and	  being	  aspirated	  into	   the	   airways.	   It	   is	   therefore	   likely	   that	   a	  heightened	  perception	  is	   needed	  to	  initiate	  subconscious	  (secondary	  peristalsis)	  and	  conscious	  (swallowing)	  clearance	  mechanisms,	  and	  to	  initiate	  fast	  oesophago-­‐sphincteric	  reClexes	  (which	  result	  in	  an	  abrupt	   increase	   in	   upper	   oesophageal	   sphincter	   pressure	   during	   an	   increase	   in	  intra-­‐oesophageal	  pressure)308,	  309.	  The	  physiological	  mechanism	  behind	  this	  increased	  perception	  to	  proximal	  reClux	  events	   remains	   unclear.	   There	   are	   indications	   that	   the	   proximal	   oesophagus	  appears	   more	   sensitive	   to	   acid	   during	   experimental	   perfusion	   than	   the	   distal	  oesophagus.	   Thus	   far	   a	   study	   by	   Thoua	   et	   al.	   is	   the	   only	   study	   to	   compare	  sensitivity	   to	   intra-­‐oesophageal	   acid	   perfusions	   of	   the	   distal	   and	   proximal	  oesophagus208.	   This	   was	   done	   in	   patients	   with	   GORD	   and	   controls	   by	   catheter	  perfusions	   of	   saline	   and	   pH	   1	   solutions	   at	   5	   cm	   and	   15	   cm	   above	   the	   lower	  oesophageal	  sphincter,	   and	  it	  was	   found	  that	   all	   subjects	   (particularly	  those	  with	  non-­‐erosive	   reClux	  disease	   and	  functional	   heartburn)	  perceived	  more	  discomfort	  during	   the	   proximal	   acid	   perfusion.	   Such	   an	   experimental	   design	   should	   be	  interpreted	   with	   caution,	   however,	   since	   the	   proximal	   acid	   perfusion	   will	   also	  simultaneously	   perfuse	   the	   distal	   oesophagus	   and	   so	   there	   may	   be	   cumulative	  sensitivity	  effect	   from	  proximal	  and	  distal	  oesophagus.	  We	  could	  only	   truly	  make	  interpretation	  of	  relative	  chemosensitivity	  from	  such	  a	  study	  if	  the	  segments	  of	  the	  oesophagus	  were	  isolated.	   It	  is	  possible	  that	  the	  mechanism	  of	  increased	  proximal	  oesophageal	  sensitivity	  is	  not	  due	  to	  a	  chemosensitivity	  effect,	  but	  perhaps	  another	  mechanism	  such	  as	  distension	  caused	  by	  the	  reCluxate	  in	  the	  proximal	  oesophagus	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(or	  a	  combination).	  For	  example,	  experimental	   studies	  have	  demonstrated	  that,	   in	  control	   subjects	   and	   in	   patients	   with	   Barrett’s	   oesophagus,	   the	   proximal	  oesophagus	  is	  more	  sensitive	  to	  balloon	  distension	  than	  the	  distal	  oesophagus207.	  
The	  mechanism	   of	  increased	  sensitivity	   of	  the	  proximal	   oesophagus	   is	  unknown,	  but	  may	  originate	  via	  a	  mucosal	  abnormality.	   In	  patients	  with	  non-­‐erosive	  reClux	  disease	  mucosal	  dilated	  intercellular	  spaces	  (DIS)	  are	  present	  in	  not	  only	  the	  distal	  oesophagus,	  but	  also	  in	  the	  proximal	  oesophagus164.	  Furthermore,	  there	  is	  also	  the	  interesting	  suggestion	  that	  proximal	  oesophageal	  acid	  exposure	  is	  not	  required	  for	  impairment	   of	   mucosal	   integrity	   in	   the	   proximal	   oesophagus.	   It	   is	   possible	   to	  induce	  DIS	  both	  in	  the	  distal	  (exposed)	  and	  proximal	  (non-­‐exposed)	  oesophagus	  in	  healthy	   subjects	   by	   way	   of	   experimental	   distal	   oesophageal	   acid	   perfusion161.	  Dilated	  intercellular	  spaces	  may	  allow	  easier	  access	  of	  noxious	  components	  of	  the	  gastro-­‐oesophageal	   reCluxate	   into	   the	   epithelium	   where	   they	   can	   stimulate	  nociceptors.	  How	  this	  spread	  of	  DIS	  (all	  over	  the	  length	  of	  the	  oesophagus)	  occurs	  is	  yet	  to	  be	  elucidated,	  but	  it	  does	  raise	  the	  possibility	  that	  distal	  acid	  exposure	  can	  sensitise	   the	  mucosa	   of	   the	  proximal	   oesophagus.	   This	   thesis	   has	   demonstrated	  that	   mucosal	   integrity	   can	   be	   assessed	   not	   only	   by	   morphological,	   but	   also	   by	  functional	   means.	   As	   yet	   the	   mucosa	   of	   the	   proximal	   oesophagus	   has	   not	   been	  investigated	  in	  these	  terms.It	   is	   also	   possible	   that	   the	   enhanced	   sensitivity	   of	   the	   proximal	   oesophagus	   is	  related	   to	   a	   distinct	   sensory	   neural	   innervation.	   Data	   on	   human	   oesophageal	  mucosal	   regional	   innervation	   is	   lacking,	   but	   there	  are	   animal	   data	  supporting	   an	  unequal	   innervation	  of	  the	  oesophagus.	  In	  the	  rat,	   density	  of	  nerve	   Cibres	   is	  most	  prominent	   in	   the	   upper	   cervical	   region	  of	   the	   oesophagus,	   and	  decreases	   in	   the	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lower	   cervical	   and	   thoracic	   oesophagus	   before	   slightly	   increasing	   again	   in	   the	  abdominal	  portion310-­‐312.A	   differential	   distribution	   of	   sensory	   afferent	   Cibres	   in	   the	   human	   oesophageal	  mucosa	  may	  contribute	  to	  proximal	  oesophageal	  hypersensitivity.	  The	  study	  presented	  in	  this	  chapter	  examines	  the	  status	  of	  mucosal	  integrity	  in	  the	  proximal	   oesophagus	   in	   patients	   with	   heartburn.	   It	   also	   investigates	   the	  distribution	  of	  sensory	  afferent	  mucosal	  nerves	  in	  the	  oesophagus.	  	  
We	   hypothesise	   that	   the	   proximal	   oesophageal	   mucosal	   integrity	   is	   more	  vulnerable	   to	   acid	  injury	   than	   the	   distal	   oesophagus,	   and	   that	   this	  may	   underlie	  proximal	  oesophageal	  chemosensitivity.	   It	   is	  also	   hypothesised	  that	  there	  may	  be	  an	   increased	   density	   of	   mucosal	   sensory	   afferent	   nerve	   Cibres	   in	   the	   proximal	  oesophagus	  compared	  to	  the	  distal.
The	  aims	  of	  the	  current	  study	  are:To	  investigate	  in	  patients	  with	  heartburn	  without	  oesophagitis:	  




5.2.1	  SubjectsOverall	   66	  patients	   were	   recruited	   for	   this	   study.	   The	   50	   patients	   described	   in	  Chapter	  4	  were	   also	   studied	   for	   in	   vivo	   impedance	   investigation	   of	   the	   proximal	  oesophagus.	   They	   had	   presented	   to	   the	   Royal	   London	   Hospital	   upper	  gastrointestinal	   physiology	   unit	   with	   typical	   symptoms	   of	   gastro-­‐oesophageal	  reClux	  disease.	  Exclusion	  criteria	  for	  this	  aspect	  of	  the	  study	  were	  1)	  The	  presence	  of	  erosive	  oesophagitis	  or	  Barrett’s	  oesophagus	  on	  endoscopy.	   2)	  The	  presence	  of	  major	   oesophageal	   motility	   abnormality	   (achalasia,	   absent	   peristalsis)	   on	  oesophageal	  manometry.	   3)	  Proximal	  oesophageal	   impedance	   fall	   of	  >5%	  during	  the	  neutral	  perfusion	  section	  of	   the	  protocol	   (which	  was	   taken	  as	  being	  possible	  proximal	   oesophageal	   contamination	   during	   perfusion,	   and	   as	   such	   further	  interpretation	   of	   “spread”	   of	   impairment	   of	   mucosal	   integrity	   to	   the	   distal	  oesophagus	  could	  not	  be	  considered	  reliable).	  10	  healthy	  subjects	  were	  also	   investigated	  with	  proximal	   oesophageal	   impedance	  measurements.A	   further	   16	   patients	   were	   recruited	   from	   the	   gastrointestinal	   endoscopy	  department	  of	  the	   Royal	   London	  Hospital	   for	   participation	   in	   the	   in	   vitro	   study.	  Entry	  criteria	  were	  the	  presence	  of	  daily,	  troublesome	  reClux	  symptoms	  (heartburn	  and/or	  regurgitation).	  Subjects	  were	  excluded	  if	  there	  was	  subsequent	  evidence	  of	  oesophagitis	   or	   Barrett’s	   oesophagus	   on	   endoscopy.	   In	   9	   of	   these	   patients	   one	  further	  distal	  and	  proximal	  biopsy	  was	  placed	  immediately	  into	  paraformaldehyde	  4%	  in	  0.1M	  PBS	  for	  subsequent	  histological	  evaluation.
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5.2.2	  In	  vivo	  impedance	  study	  of	  proximal	  mucosal	  integrity
5.2.2.1	  Impedance	  measurementsAs	   in	   chapter	   4,	   an	   intraluminal	   combined	   pH-­‐impedance	   catheter	   (Sandhill	  ScientiCic,	  Highlands	  Ranch,	  CO,	  USA)	  with	  integrated	  water-­‐perfused	  channel	  was	  used	   for	   performing	   oesophageal	   mucosal	   impedance	   and	   performing	   mid-­‐oesophageal	   perfusions.	   The	   lower	   oesophageal	   sphincter	   position	   was	   located	  using	   high	   resolution	   or	   water	   perfused	   manometry.	   After	   oesophageal	  manometry	   the	   pH-­‐impedance	   catheter	  was	   lubricated	   and	  passed	   trans-­‐nasally	  into	   the	   oesophagus	   such	   that	   the	   pH	   sensor	   was	   placed	   5	   cm	   above,	   and	   the	  perfusion	   port	   11	   cm	   above	   the	   manometrically-­‐deCined	   lower	   oesophageal	  sphincter.	  Throughout	  the	  study	  impedance	  was	  measured	  at	  a	  frequency	  of	  50	  Hz	  in	   the	   proximal	   impedance	   segment	   at	   17	   cm	   above	   the	   lower	   oesophageal	  sphincter	  (i.e	  6	  cm	  above	  the	  perfusion	  port).	  The	  data	  was	  recorded	  on	  a	  portable	  digital	  data	  logger	  (Sandhill	   ScientiCic,	  CO,	  USA),	  and	  analysed	  on	  proprietary	  pH-­‐impedance	  analysis	  software	  (Bioview	  Analysis,	  Sandhill	  ScientiCic,	  CO,	  USA).	  	  
5.2.2.2	  Experimental	  protocolAfter	   placement	   of	   the	   pH-­‐impedance	   catheter	   a	   baseline	  proximal	   oesophageal	  impedance	  measurement	  was	  made	  with	  the	  subject	  in	  an	  upright	  sitting	  position	  for	   15	   minutes.	   Following	   this	   the	   subject	   was	   told	   they	   were	   to	   receive	   two	  perfusions,	   one	  neutral	   and	  one	  acid.	   They	  were	  advised	  that	   they	  would	  not	   be	  told	  which	  order	  the	  perfusions	  will	   be	  performed.	   First,	  a	  0.9%	  sodium	  chloride	  solution	  (buffered	  to	  pH	  6.5)	  was	  perfused	  through	  the	  catheter	  perfusion	  port	  via	  a	  peristaltic	  pump	  at	  a	  rate	  of	  10	  ml	  per	  minute	  for	  10	  minutes.	  An	  acidic	  perfusion	  (of	  hydrochloric	   acid	  at	  pH	   1.0)	  was	   then	  performed	  at	  10	  ml	   per	  minute	  for	  10	  minutes.	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The	  subject	  was	   asked	  to	   report	  whether	  or	  not	  heartburn	  was	   perceived	  during	  each	  perfusion.	   If	  heartburn	  was	  perceived,	   they	  were	  asked	  to	  rate	  the	  maximal	  symptoms	   severity	  on	  a	  scale	   of	  0	  −	  10	   (where	   0	   is	   no	   pain,	   10	   is	  the	  maximum	  imaginable	  pain).Patients	  subsequently	  completed	  their	  clinical	  24-­‐hour	  pH-­‐impedance	  reClux	  study,	  allowing	   accurate	   phenotype	   as	   having	   either	   non-­‐erosive	   reClux	   disease	   or	  functional	  heartburn.Healthy	  volunteers	  had	  only	  baseline	  proximal	  impedance	  recorded,	  and	  change	  in	  proximal	  impedance	  during	  distal	  acid	  perfusion	  measured.	  The	  catheter	  was	  then	  removed	  after	  acid	  perfusion.
5.2.2.3	  Data	  analysis
Baseline	  impedanceThe	   baseline	   proximal	   oesophageal	   impedance	   was	   calculated	   as	   the	   average	  impedance	  between	  5	  and	  15	  minutes	  after	  catheter	  placement.	  Swallows	  were	  not	  excluded	  from	  this	  analysis	   since	   they	  are	  short	  lasting	  and	  make	  little	  difference	  to	   mean	  baseline	   over	   10	  minutes.	   ReClux	  episodes	   (if	   any)	  were	   excluded	   from	  baseline	  analysis.
Proximal	  impedance	  measurements	  during	  perfusionsThe	  impedance	  in	  the	  proximal	   impedance	  segment	  was	  Cirst	  measured	  during	  the	  neutral	   perfusion.	   The	  mean	  impedance	  during	  the	  second	  5	  minutes	   of	  the	   10-­‐minute	  perfusion	  was	  measured,	  and	  the	  percentage	  change	  (if	  any)	  compared	  to	  the	  baseline	   impedance.	   If	  there	  was	  a	  more	  than	   5%	  drop	   in	   impedance	   in	   the	  proximal	   impedance	   channel	   during	   the	   neutral	   perfusion	   the	   subject	   was	  excluded	  from	  further	  study.	  This	  is	  because	  in	  vivo	  and	  in	  vitro	  neutral	  exposures	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of	   the	   oesophagus	   to	   neutral	   solutions	   do	   not	   induce	  morphological	   changes	   in	  integrity	   (DIS),	   and	  as	  such	  a	   fall	   in	  impedance	  during	  the	  neutral	   perfusion	  was	  taken	   to	   be	   due	   to	   proximal	   contamination	   of	   the	   oesophagus	   by	   the	   perfusion	  Cluid.In	  those	  subjects	  who	  did	  not	  have	  a	  fall	  in	  proximal	  impedance	  during	  the	  neutral	  perfusion,	  the	  mean	  impedance	  during	  the	  second	  5	  minutes	  of	  the	  10-­‐minute	  acid	  perfusion	  was	  measured,	   and	   the	   percentage	   change	   (if	   any)	   from	   baseline	  was	  calculated	  (Cigure	  35).
Figure	  35:	  Experimental	  protocol	  for	  in	  vivo	  study	  of	  proximal	  impedance
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ReMlux	  studyThe	  subsequent	  24-­‐hour	  reClux	  study	  was	  analysed	  as	  described	  in	  Chapter	  4,	  with	  subsequent	  classiCication	  of	  patients	   into	  non-­‐erosive	  reClux	  disease	  or	   functional	  heartburn.
5.2.3	  In	  vitro	  assessment	  of	  proximal	  oesophageal	  integrity
5.2.3.1	  EndoscopyEndoscopic	  procedures	  were	  performed	  either	  under	  midazolam	  sedation	  or	  with	  pharyngeal	   local	   anaesthetic	   spray.	   In	   each	   subject	   two	   oesophageal	   mucosal	  biopsies	  were	  taken	  (Radial	   Jaw	  3	  forceps,	  Boston	  ScientiCic,	  USA),	  one	  from	  3	  cm	  above	  the	  squamo-­‐columnar	  junction	  (distal	  oesophageal	  biopsy),	  and	  one	  from	  20	  cm	  above	  the	  squamo-­‐columnar	   junction	  (proximal	  oesophageal	  biopsy).	  Biopsies	  were	   immediately	   placed	   in	   a	   pre-­‐oxygenated	  Krebs-­‐Henseleit	  buffer	   solution	  at	  pH	  7.4	  and	  at	  4oC,	   and	  rapidly	  transported	  to	   the	  laboratory	  for	  Ussing	  Chamber	  study.
5.2.3.2	  Ussing	  chamber	  studiesBiopsies	   were	   orientated	   and	   mounted	   into	   the	   adapted	   Ussing	   Chambers	   as	  described	  in	  chapter	  3.	  Immediately	  on	  mounting	  the	  biopsies	  they	  were	  bathed	  on	  both	  luminal	  and	  basal	   sides	  with	  Krebs-­‐Henseleit	  buffer	  at	  pH	  7.4,	  370C,	   and	  the	  solution	  was	   continuously	  bubbled	  with	  carbogen	  gas.	   After	  making	  a	  correction	  for	   Cluid	   and	   circuit	   resistance,	   basal	   transepithelial	   resistance	   (TER)	   was	  calculated	  according	  to	  Ohm’s	  law	  from	  the	  voltage	  deClections	  induced	  by	  bipolar	  current	  pulses	  of	  50μA,	  duration	  200	  ms	  every	  6	  seconds	  applied	  through	  platinum	  wires.	  All	  experiments	  were	  conducted	  in	  open-­‐circuit	  conditions.	  The	  system	  was	  equilibrated	   at	   370C	   until	   a	   stable	   TER	   baseline	   was	   established	   (typically	   20	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minutes).	   Biopsies	   that	   did	   not	   adequately	   cover	   the	   chamber	   aperture	   on	  visualisation	   under	   stereo-­‐microscopy,	   or	   with	   a	   baseline	   TER	   of	   less	   than	   50	  Ω.cm2	   were	   excluded	   from	   further	   analysis	   since	   these	   were	   deemed	   to	   be	  unsatisfactory.	   After	  a	  stable	  baseline	  was	   achieved	   the	  solution	  in	  the	  "luminal"	  bath	  of	  the	  chambers	  was	  replaced	  with	  an	  acidic	   solution	  (Krebs-­‐Henseleit	  at	  pH	  2	  +	  1	  mg/ml	  porcine	  pepsin	  +	  1	  mM	  taurodeoxycholic	  acid).	  The	  exposure	  to	   the	  acidic	   solution	  was	   for	   30	  minutes,	   and	  TER	   was	   continuously	  measured	  during	  this	  time.	  The	   baseline	   TER	   was	   determined	   as	   the	   TER	   after	   equilibration,	   immediately	  before	  the	  “test	  solution”	  was	  placed	  in	  the	  luminal	  bath.	  The	   change	   in	   TER	   caused	   by	   the	   test	   solution	  was	   expressed	   as	   a	   percentage	  change	  at	  the	  end	  of	  30	  minutes	  exposure,	   relative	  to	  the	  TER	  at	  the	  beginning	  of	  exposure,	   immediately	   after	   placing	  the	   test	   solution	   in	  the	   “luminal	   bath	  of	   the	  chamber.
5.2.3.3	  Immunohistochemical	  studiesProximal	   and	   distal	   oesophageal	   biopsies	   were	   Cixed	   in	   4%	   paraformaldehyde	  overnight.	   This	   was	   followed	   by	   cryoprotection	   in	   30%	   sucrose	   in	   phosphate-­‐buffered	   saline	   (PBS)	   for	   24-­‐hours	   at	   40C,	   followed	   by	   30%	   sucrose	   PBS:OCT	  embedding	  compound	  (1:1)	  at	  40C.	   Sections	  were	  embedded	  in	  OCT	  at	  -­‐250C	  and	  10	  μm	   sections	  were	  cut	  on	   a	   cryostat	   and	  mounted	   on	  positively	   charged	  glass	  slides.	  Sections	  were	  then	  air-­‐dried	  for	  1	  hour.	  400	  µl	  per	  slide	  of	  10%	  horse	  serum	  in	   PBS	   (blocking	   agent)	   +	   0.3%	   Triton-­‐X100	   was	   applied	   and	   left	   at	   room	  temperature	  for	  1	  hour.	   	  Sections	  were	  then	  incubated	  with	  a	  primary	  antibody	  to	  calcitonin	   gene-­‐related	   peptide	   (CGRP)	   (1:500	   monoclonal	   mouse	   anti-­‐human,	  Pierce	   Antibodies	   ABS	   026-­‐05-­‐02)	   at	   40C	   overnight.	   The	   primary	   antibody	  was	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made	  up	   in	  10%	  horse	   serum	   in	  PBS	  and	  0.3%	  Triton-­‐X100.	   Sections	  were	  then	  washed	  three	  times	  for	  10	  minutes	  in	  PBS	  +	  Triton-­‐X100,	   followed	  by	   incubation	  with	  the	  secondary	  antibody	   (donkey	  anti-­‐mouse	  Invitrogen,	   labeled	  with	  green-­‐Cluorescent	  Alexa	  Fluor	  488	  dye)	  and	  incubated	  for	  4	  hours	  in	  darkness.	   Sections	  were	  then	  washed	  again	  three	  times	  for	  10	  minutes,	  and	  mounted	  with	  Vectashield	  HardSetTM.	   Negative	   controls	  were	  prepared	  with	   the	  primary	   antibody	  omitted,	  and	  showed	   no	   labelling.	   Some	   sections	  were	   incubated	   instead	   with	   a	  primary	  antibody	   to	   neuroCilament	   (Dako:	   monoclonal	   mouse	   anti-­‐human	   neuroCilament	  protein	  clone	  2F11,	  1	  :	  500)	  to	  conCirm	  that	  neural	  structures	  were	  being	  labelled.	  Fluorescence	  was	  visualised	  using	  an	  epiCluorescent	  microscope	  (Olympus	  BX61).	  All	   images	   were	   obtained	   with	   a	   40x	   oil	   immersion	   lens	   under	   the	   488nm	  excitation	   setting.	   Where	   CGRP-­‐immunoreactive	   (IR)	   Cibres	   were	   seen	   on	  microscopy,	   their	   position	   relative	   to	   the	   luminal	   surface	   of	   the	   section	   was	  analysed	   (as	   number	   of	   cells	   from	   most	   superCicial	   location	   of	   the	   Cibre	   to	   the	  luminal	   surface).	   An	   estimate	   of	   the	   relative	  quantity	   of	   Cibres	   in	   the	   distal	   and	  proximal	  oesophagus	  was	  made	  by	  calculating	  the	  number	  of	  positive	  (with	  CGRP-­‐IR	  Cibres)	  sections	  relative	  to	  the	  total	  number	  of	  sections	  analysed.
5.2.4	  Statistical	  analysisData	  are	  presented	  as	  mean	  ±	  standard	  deviation.	  Normality	  of	  distributions	  was	  assessed	   using	   a	   D’Agostino	   and	   Pearson	   omnibus	   normality	   test.	   Changes	   in	  proximal	  impedance	  from	  baseline,	  to	  during	  neutral	  perfusion	  and	  to	  during	  acid	  perfusion	   were	   tested	   using	   repeated	   measures	   ANOVA.	   Bonferroni’s	   multiple	  comparison	  test	  was	  used	  to	   test	   signiCicance	  of	  differences.	  Comparison	  of	  mean	  change	   in	   impedance	   during	   acid	   perfusion	   between	   patients	   with	   non-­‐erosive	  reClux	  disease	  and	  functional	  heartburn	  was	   tested	  by	  an	  unpaired	  t	  test.	  Baseline	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5.3.1	  In	  vivo	  impedance	  study	  of	  proximal	  mucosal	  integrity
5.3.1.1	  SubjectsThe	  details	  of	  the	  50	  subjects	  studied	  are	  found	  in	  Chapter	  4.	  Although	  50	  patients	  with	  heartburn	  were	  studied,	  of	  these	  only	  23	  subjects	  were	  included	  in	  analysis	  of	  change	   of	   impedance	   during	   acid	   perfusion	   since	   the	   other	   27	   had	   a	   fall	   in	  proximal	   impedance	   of	   more	   than	   5%	   during	   the	   neutral	   perfusion.	   In	   the	  remaining	  23	  subjects	  there	  was	   a	  mean	  age	  of	  48	  (range	  20-­‐75).	   pH-­‐impedance	  monitoring	  subsequently	  identiCied	  that	  12	  of	  these	  had	  non-­‐erosive	  reClux	  disease,	  11	  had	   functional	   heartburn.	   All	   10	  healthy	   volunteers	   had	  proximal	   impedance	  tracings	  that	  were	  able	  to	  be	  used	  in	  analysis.
5.3.1.2	  Mean	  baseline	  proximal	  impedance	  versus	  distal	  impedanceIn	  all	  subjects,	  baseline	  proximal	  impedance	  was	  signiCicantly	  higher	  than	  baseline	  distal	  impedance	  (2949	  ±	  1103	  Ω.	  vs.	  1945	  ±	  1661	  Ω;	  p<	  0.001,	  Cigure	  36).
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Figure	  36:	  Baseline	   impedance	   in	   the	  distal	   and	   proximal	  oesophagus.	  The	   lines	   connect	   paired	  impedance	  measurements	  from	  the	  same	  patient.	  Horizontal	  lines	  represent	  the	  mean.
5.3.1.3	   Mean	   baseline	   proximal	   impedance	   in	   non-­‐erosive	   reMlux	   disease,	   functional	  
heartburn	  and	  healthy	  volunteersThere	   was	   no	   signiCicant	   difference	   in	   mean	   proximal	   oesophageal	   baseline	  impedance	  between	  subjects	  with	  non-­‐erosive	  reClux	  disease,	  functional	  heartburn	  or	  in	  healthy	  volunteers	  (2867	  ±	  935	  Ω	  vs.	  3039	  ±	  844	  Ω	  vs.	  2950	  ±	  765	  Ω,	  p>0.05	  for	  all	  comparisons,	  Cigure	  37).
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Figure	   37:	   Mean	   baseline	   proximal	   oesophageal	   impedance	   in	   subjects	   with	  non-­‐erosive	   reIlux	  disease	  (NERD),	  functional	  heartburn	  (FH),	  and	  healthy	  volunteers
5.3.1.4	   Change	   in	   proximal	   oesophageal	   impedance	   during	   distal	  oesophageal	   acid	  
perfusion
All	  subjectsDistal	   oesophageal	   perfusion	  with	   the	   neutral	   solution	   caused	   a	  mean	   proximal	  impedance	  change	  from	  baseline	  of	  182	  Ω	  (p>0.05).	  During	  distal	  oesophageal	  acid	  perfusion	  there	  was	  a	  mean	  change	   in	  proximal	   impedance	  from	  baseline	  of	  -­‐633	  Ω,	  a	  22%	  fall	  (p<0.001,	  Cigure	  38).	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Figure	  38:	  Mean	  proximal	  oesophageal	  impedance	  at	  baseline,	  during	  distal	  neutral	  perfusion,	  and	  during	   distal	   acid	  perfusion.	   The	   lines	   connect	   serial	   impedance	  measurements	   from	   the	   same	  patient.	  ns	  =	  not	  signiIicant
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Comparison	  between	  functional	  heartburn	  and	  non-­‐erosive	  reMlux	  diseaseThere	   was	   no	   difference	   in	   change	   of	   proximal	   impedance	   during	   distal	   acid	  perfusion	   between	   subjects	   with	   NERD,	   functional	   heartburn,	   or	   healthy	  volunteers	   (-­‐397	   ±	   750	   Ω	   vs.	   -­‐663	   ±	   920	   Ω	   vs.	   -­‐591	   ±	   660	   Ω,	   p>0.05	   for	   all	  comparisons,	  Cigure	  39).
Figure	  39:	   Proximal	  oesophageal	   fall	   in	  impedance	   from	   baseline	   during	  distal	   oesophageal	  acid	  perfusion	  in	  patients	   with	   non-­‐erosive	   reIlux	   disease	   (NERD),	   functional	   heartburn	  (FH),	   and	   in	  healthy	  volunteers
Comparison	  according	  to	  acid	  sensitivity	  Those	  subjects	  who	  perceived	  the	  acid	  perfusion	  as	  heartburn	  (n=18)	  did	  not	  have	  a	  signiCicantly	  different	   baseline	  distal	  or	  proximal	  impedance	  compared	  to	  those	  who	   did	  not	   (n=5)	  (2867	  ±	  842	  Ω	   vs.	   2979	  ±	  1218	  Ω,	   p=0.8).	   In	  addition,	   those	  subjects	  who	  perceived	  the	  acid	  perfusion	  as	  heartburn	  did	  not	  have	  signiCicantly	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different	  nadir	  proximal	   impedance	  during	   the	  acid	  perfusion	  compared	  to	  those	  who	  did	  not	  (2580	  ±	  1086	  Ω	  vs.	  2409	  ±	  1427	  Ω,	  p=0.8).	  On	  further	  analysis	  of	  the	  24-­‐hour	  pH	  impedance	  study,	  there	  was	  no	  difference	  in	  baseline	   proximal	   impedance	   between	   patients	   with	   a	   positive	   symptom	  associated	  probability	   (SAP)	   for	   reClux	   and	  heartburn	  compared	  to	   those	  with	  a	  negative	  SAP	  (3040	  ±	  1020	  Ω	  vs.	  2935	  ±	  863	  Ω,	  p=0.8).	   In	  contrast,	  baseline	  distal	  oesophageal	  impedance	  was	  signiCicantly	  lower	  in	  SAP+ve	  patients	  than	  in	  SAP-­‐ve	  patients	  (1302	  ±	  699	  Ω	  vs.	  2282	  ±	  1197	  Ω,	  p=0.02).
5.3.2	  In	  vitro	  assessment	  of	  proximal	  oesophageal	  integrity
5.3.2.1	  SubjectsOf	   the	   16	   subjects	   recruited	   for	   the	   study,	   15	   had	   adequate	   paired	   biopsies	  allowing	   further	  analysis.	   The	  remaining	  subject	  was	  excluded	  due	   to	  one	  of	  the	  biopsies	  being	  too	  small	  to	  adequately	  cover	  the	  chamber	  aperture.
5.3.2.2	  Baseline	  TEROverall,	   the	  mean	  baseline	  TER	   in	  the	  distal	   oesophagus	  was	  148.6	  ±	  82.7	  Ω,	   and	  179.0	   ±	  70.6	   Ω	   in	  the	   proximal	   oesophagus.	   There	  was	   no	   signiCicant	  difference	  between	  distal	  and	  proximal	  oesophageal	  baseline	  TER	  on	  paired	  analysis	  (p=0.24,	  Cigure	  40).
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Figure	  40:	  Baseline	  TER	   of	   biopsies	   from	   the	  distal	   and	  proximal	  oesophagus.	   The	   lines	   connect	  paired	  biopsies	  from	  the	  same	  patient.
5.3.2.3	   Change	   in	  TER	  from	  baseline	  on	   exposure	   to	  acidic	  solution	   in	   biopsies	   from	  
the	  proximal	  oesophagusOverall,	   the	   percentage	   change	   in	  TER	   from	   baseline	   on	   exposure	   to	   the	   acidic	  solution	  in	  the	  distal	  oesophagus	  was	  −20.1	  ±	  17.0%.	   In	  the	  proximal	  oesophagus	  this	  value	  was	  −11.2	  ±	  13.7%.	  On	  paired	  analysis	  there	  was	  a	  non-­‐signiCicant	  trend	  towards	   a	   reduced	   susceptibility	   to	   TER	   change	   in	   the	   proximal	   oesophagus	   on	  acid	  exposure	  when	  compared	  to	  the	  distal	  oesophagus	  (p=0.19,	  Cigure	  41).
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Figure	  41:	  Change	  in	  TER	   from	   baseline	  on	  exposure	  to	  acidic	   solution.	   The	   lines	   connect	   paired	  biopsies	  from	  the	  same	  patient.
5.3.3	  Histological	  studies:	  assessment	  of	  oesophageal	  mucosal	  nerve	  MibresOverall,	   8	  proximal	   and	  6	  distal	   biopsies	  were	   suitable	   for	   immunohistochemical	  evaluation.	   These	   comprised	   of	   paired	   biopsies	   from	   5	   patients,	   and	   proximal	  unpaired	  biopsies	   from	   a	   further	  3	  patients,	   and	  unpaired	  distal	   biopsies	   from	  1	  further	  patient	   (total	  9	  patients	   used).	  Unpaired	   samples	  were	   used	  because	   the	  corresponding	  paired	  biopsy	  was	   inadequate	  for	  accurate	  orientation	  analysis.	   A	  total	   of	   215	  proximal,	   and	   153	   distal,	   10	   µm	   sections	   were	   examined.	   CGRP-­‐IR	  Cibres	  were	  identiCiable	  in	  at	  least	  one	  section	  of	  all	  proximal	  biopsies,	  and	  in	  5	  of	  6	  distal	  biopsies.	  Fibres	  were	  identiCiable	  in	  55	  of	  215	  proximal	  sections,	  and	  in	  19	  of	  153	   distal	   sections	   (p=0.002	   for	   comparison,	   Fig	  42A).	   Sections	   were	   otherwise	  similar	  in	  size	  and	  morphology.	  Mucosal	   nerve	   Cibres	   were	   seen	   to	   be	   strikingly	   more	   superCicial	   in	   proximal	  oesophageal	  biopsies	  than	  in	  distal	  biopsies.	  Their	  morphology	  was	  also	  different:	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proximal	   Cibres	   were	   interspersed	   between	   Clattened	   squamous	   epithelial	   cells	  with	  a	  laminar	  appearance,	  whilst	  distal	  Cibres	  were	  interspersed	  between	  larger,	  rhomboid	  cells	  with	  a	  “pearl	  necklace”	  appearance	  (Fig	  42C).	   	  To	  ensure	  neuronal	  staining,	   in	   both	   cases	   similar	   structures	   were	   labelled	   with	   the	   pan-­‐neuronal	  neuroCilament	   protein.	   The	   mean	   number	   of	   cells	   between	   the	   Cibres	   and	   the	  luminal	  surface	  was	  5.7	  ±	  4.1	  in	  proximal	  biopsies	  and	  22.2	  ±	  11.3	  in	  distal	  biopsies	  (p<0.0001,	  Cigure	  42B).
Figure	  42:	  A:	  Proportion	  of	  sections	   in	  which	  CGRP-­‐IR	   Iibres	  were	  observed	  in	  proximal	  and	  distal	  oesophagus.	  B:	   Mean	   number	   of	   epithelial	   cells	   between	  CGRP-­‐IR	   nerve	   Iibres	   and	   the	   luminal	  surface	  in	  mucosal	  biopsies	   from	  the	  proximal	  and	  distal	  oesophagus.	  C:	  Representative	  examples	  of	   biopsies	   from	   the	  upper	   and	   lower	   oesophagus.	   The	   leftmost	   image	   (40x)	   is	   an	  example	   of	   a	  proximal	  oesophageal	  biopsy,	  with	  CGRP-­‐IR	   Iibres	  close	  to	   the	  luminal	  surface.	  The	  middle	  image	  (10x)	  is	   an	  example	  of	   the	  distal	  oesophagus,	  demonstrating	  a	  nerve	  Iibre	  in	  the	  basal	  epithelium,	  shown	  at	  higher	  power	  (40x)	  in	  the	  rightmost	  image.	  L	  =	  lumen.	  Scale	  bar	  represents	  50µm
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5.4 DiscussionThis	   chapter	   examined,	   in	   vitro	   and	   in	   vivo,	   the	   integrity	   of	   the	   proximal	  oesophageal	  mucosa,	  and	  its	  dynamic	  response	  to	  a	  direct	  or	  remote	  acid	  challenge	  in	   patients	   with	   heartburn	   symptoms.	   It	   also	   evaluated	   regional	   variability	   in	  mucosal	  sensory	  afferent	  nerves	  in	  the	  oesophagus.We	  know	  already	  that	  these	  patients	  are	  more	  sensitive	  to	  reClux	  events	  that	  reach	  the	  proximal	  oesophagus	  compared	  to	  those	  restricted	  to	  the	  distal	  part.	  
The	  main	  results	  of	  the	  study	  showed:	  	  1) A	  signiCicantly	  greater	  in	  vivo	  baseline	  impedance	  in	  the	  proximal	  oesophagus	  compared	  to	  the	  distal.	  	  2) A	   trend	   towards	   higher	   baseline	   oesophageal	   mucosal	   transepithelial	  electrical	  resistance	  (in	  vitro).	  3) Less	  vulnerability	  of	  the	  proximal	  oesophageal	  mucosa	  to	  in	  vitro	  exposure	  to	  acid	  and	  bile.	  	  4) In	  contrast	  with	  the	  relative	  robustness	  of	  the	  proximal	  oesophageal	  mucosal	  integrity,	   the	   density	   of	   mucosal	   peptidergic	   sensory	   nerve	   Cibres	   was	  greater,	  and	  the	  location	  of	  the	  Cibres	  was	  closer	  to	  the	  lumen	  in	  the	  proximal	  oesophagus	  when	  compared	  to	  the	  distal.	  5) In	  vivo	  exposure	  of	  the	  distal	  oesophagus	  to	  acid	  causes	  a	  fall	  in	  impedance	  in	  the	   proximal,	   unexposed	   oesophagus,	   suggesting	   a	   spread	   in	   mucosal	  integrity	  changes.
There	   has	   been	   increasing	   interest	   in	   the	   role	   of	   the	   proximal	   oesophagus	   in	  symptom	   perception	   in	   gastro-­‐oesophageal	   reClux	   disease.	   There	   is	   now	  substantial	   evidence	   from	   numerous	   studies	   indicating	   that	   the	   proximal	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oesophagus	   is	  more	   sensitive	  to	  pain	  from	  mechanical	   and	  chemical	   stimuli	   than	  the	  distal	   oesophagus,	   and	  that	  this	   appears	   important	  in	  symptom	  perception	   in	  GORD206-­‐208,	   213.	   Oesophageal	   sensation	   is	   highly	   likely	   to	   have	   a	   multifactorial	  basis.	  Afferent	  innervation	  from	  chemo-­‐	  and	  mechanosensitive	  Cibres,	  spino-­‐bulbar	  and	  cerebral	  processing	  of	  signals	  are	  all	  very	  important	  factors.	  Furthermore,	  the	  mucosal	   barrier	   function	   may	   have	   a	   signiCicant	   pathophysiological	   role.	   In	  Chapter	   3	   it	   was	   demonstrated	   that	   the	   distal	   oesophageal	   mucosa	   is	   more	  vulnerable	  to	  acid	  exposure	   in	  patients	  with	  NERD	  compared	  to	  control	   subjects.	  These	   patients	   not	   only	   have	   microscopic	   mucosal	   changes	   in	   the	   distal	  oesophagus,	   (DIS)	  but	   they	   also	   exhibit	   similar	  histological	   changes	   in	  the	  more	  proximal	   part164.	   It	   was	   originally	   hypothesised	   that	   an	   enhanced	   perception	   of	  reClux	   events	   reaching	   the	   proximal	   oesophagus	   in	   GORD	   patients	   may	   be	   a	  phenomenon	   related	   to	   altered	   baseline	   and/or	   dynamic	   proximal	   mucosal	  integrity.	   The	  Cindings	  of	  this	  study	  suggest	   that	  this	  is	  not	  the	  case.	  The	  baseline	  proximal	   impedance	   is	   not	   lower	   in	   patients	   with	   NERD	   compared	   to	   healthy	  controls.	  In	  basal	  conditions	  the	  integrity	  of	  the	  proximal	  mucosa	  appears	  stronger	  than	  the	  distal	   (with	  signiCicantly	  higher	  baseline	  impedance,	  and	  a	  trend	  towards	  a	  higher	  baseline	  TER).	  Additionally,	   the	  proximal	   oesophageal	  mucosal	   integrity,	  as	   measured	   by	   TER,	   does	   not	   appear	   more	   vulnerable	   to	   exposure	   to	   acidic	  solutions	  than	  the	  distal:	   indeed	  there	  is	  a	  trend	  towards	   less	   vulnerability	  in	  the	  proximal	  mucosa.	  If	   an	   increased	   mucosal	   vulnerability	   to	   acid	   were	   a	   cause	   of	   the	   increased	  proximal	  sensitivity,	  one	  would	  expect	  a	  greater	  fall	  in	  TER	  during	  acidic	  exposure.	  It	  appears	  that	  the	  enhanced	  sensitivity	  of	  the	  proximal	  oesophagus	  is	  because	  of	  a	  different	   mechanism.	   It	   was	   then	   hypothesised	   that	   the	   proximal	   oesophageal	  mucosa	   might	   have	   a	   distinct	   quantity	   or	   distribution	   of	   sensory	   nerves.	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Consequently	   biopsies	   from	   the	  distal	   and	   proximal	   oesophagus	  were	   examined	  for	  the	  presence	  of	  mucosal	   sensory	  afferent	   Cibres.	   It	  was	  found	  that	  there	  was	  a	  greater	   density	   of	   sensory	   Cibres	   in	   the	   proximal	   oesophageal	   mucosa.	  Furthermore,	   the	   location	   of	   these	   mucosal	   Cibres	   was	   much	   closer	   to	   the	  oesophageal	  lumen	  in	  the	  proximal	  oesophagus	  when	  compared	  to	   the	  distal.	   	  To	  my	   knowledge,	   this	   is	   the	   Cirst	   time	   that	   the	   distribution	   of	  human	  oesophageal	  mucosal	  sensory	  innervation	  has	  been	  investigated	  directly.	  The	  increased	  density	  and	  superCicial	  distribution	  of	  the	  proximal	  mucosal	  afferent	  Cibres	  may	  constitute	  the	   sensory	   component	   of	   a	   defensive	   mechanism	   against	   airway	   aspiration	  facilitated	  by	  proximal	  reClux	  events313.	  There	   are	   several	   features	   of	   the	   CGRP	   labelling	   that	   were	   seen	   which	   are	  important	   to	   note	   from	  a	   technical	   viewpoint.	   1)	  The	  same	  labelling	  is	   seen	  with	  neuroCilament	  and	  CGRP,	   conCirming	  neuronal	  origin.	  2)	  The	  superCicial	  pattern	  of	  proximal	  labelling	  shown	  in	  Cigure	  42C	  was	  not	  seen	  at	  all	   in	  distal	  oesophagus.	  3)	  With	  variable	  focus	  the	  Cibres	  could	  be	  followed	  back	  from	  the	  superCicial	  layers	  to	  the	  deeper	  layers,	   indicating	  they	  are	  not	  disconnected	  from	  the	  parent	  axon,	  and	  both	  types	  of	  ending	  (deep	  and	  superCicial)	  were	  seen	  in	  some	  sections	  of	  proximal	  oesophagus.	  4)	  Many	  desquamating	  cell	   regions	   in	  the	  proximal	  oesophagus	  were	  CGRP	  negative.	   5)	   The	   same	   CGRP	   antibody	   also	   labeled	  nerve	   Cibres	   in	  human	  colon	   sections	   and	   whole-­‐mounts	   (not	   shown).	   6)	   All	   control	   images	   were	  negative.	  In	   the	  presence	  of	   such	   a	  superCicial	   distribution	  of	   sensory	   innervation,	   why	   is	  pain	  not	  felt	  more	  often	  when	  drinking	  acidic	   fruit	  juices	  or	  carbonated	  drinks?	   It	  is	   possible	   that	   activation	   of	   these	  afferents	   is	   not	   painful	   in	  normal	   conditions.	  Indeed,	   there	  are	   other	   examples	  of	  afferent	   activation	  without	  pain.	   It	   has	  been	  shown	   that	   acid	  irritation	  of	  gastric	   mucosa	   leads	   to	   local	  homeostatic	   reactions	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and	  afferent	   nerves	   activation,	   but	   not	   neural	   activation	  in	   the	  spinal	   cord314.	   In	  contrast,	   in	  pathological	  situations,	   when	  these	  superCicial	  nerves	   are	  exposed	  to	  reCluxate	  there	  may	  be	  activation	  in	  the	  spinal	  cord	  and	  painful	  sensory	  perception.	  The	  in	  vivo	  provocative	  tests	   in	   this	  chapter	  may	  provide	  a	  potential	   reason	  as	  to	  why	  the	   Cibres	  become	  sensitised	  in	  GORD.	  As	   described	  in	  previous	  experiments	  in	  healthy	   subjects,	   distal	  oesophageal	  acid	  perfusion	  not	   only	  provokes	  mucosal	  changes	   (drop	   in	  impedance	  and	  DIS)	   in	  the	   perfused	   area	  but	   also	   in	   the	  more	  proximal	   non-­‐exposed	   oesophagus161.	   How	   these	   changes	   in	   proximal	   mucosal	  integrity	   contribute	   to	   proximal	   neural	   sensitisation	   is	   still	   unknown,	   but	   could	  include	   a	  more	   pronounced	   exposure	   of	   the	   superCicial	   Cibres	   and/or	   increased	  exposure	   and	   activation	   of	   Cibres	   located	   slightly	   deeper	   in	   the	   mucosa.	  Furthermore,	   distal	   oesophageal	   acidiCication	   might	   also	   promote	   mucosal	  inClammatory	  changes	  along	  the	  whole	  length	  of	  the	  oesophagus.	  Why	  are	  reClux	  events	   limited	  to	   the	  distal	   oesophagus	  less	  likely	  to	   be	  perceived	  as	   compared	   to	   those	   reaching	   the	   proximal	   oesophagus?	   	   Patients	   with	  NERD	  have	   impaired	  distal	   mucosal	   integrity.	   It	   has	   been	  hypothesised	   that	  distal	   DIS	  allows	   noxious	   components	   of	   the	   reCluxate	   to	   access	   afferent	   endings	   that	   are	  located	  in	  the	  deep	  epithelium.	  So	  far,	  this	  hypothesis	  has	  not	  been	  experimentally	  demonstrated.	   The	   results	   presented	   in	   this	   chapter	   suggest	   that	   the	   relatively	  lower	   distal	   oesophageal	   sensitivity	   can	   be	   due	   to	   the	   differences	   in	   afferent	  mucosal	  innervation,	  whereby	  there	  are	  fewer	  Cibres	  and	  deeper	  localisation	  in	  the	  distal	   oesophagus.	   It	   was	   interesting	   that	  neither	   the	  baseline	   impedance	  of	   the	  proximal	   oesophagus,	   nor	   the	   magnitude	   of	   change	   of	   proximal	   oesophageal	  impedance	   with	   distal	   acidiCication,	   was	   different	   between	   healthy	   controls,	  patients	  with	   functional	   heartburn,	   and	   patients	   with	  NERD.	   This	   is	   in	   contrast	  with	  the	  data	  from	  Chapter	  4	  showing	  that	  distal	  oesophageal	  impedance	  is	  normal	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in	   functional	  heartburn	  but	   low	   in	  patients	  with	  non-­‐erosive	  reClux	  disease.	   This	  suggests	   that	   oesophageal	   mucosal	   integrity	   may	   be	   of	   less	   relevance	   in	   the	  proximal	  compared	  to	  distal	  oesophagus.It	  can	  be	  proposed	  that	  the	  spread	  of	  mucosal	  changes	  from	  a	  distal	  exposed	  area	  to	   a	   proximal	   non-­‐exposed	   oesophagus	   may	   be	   important	   in	   modulating	   the	  perception	  of	  reClux	  episodes	  with	  high	  proximal	  extent.	  It	  has	  been	  observed	  that	  distal	  oesophageal	  exposure	  to	  weakly	  acidic	  solutions	  (containing	  pepsin	  and	  bile	  acids)	  can	  also	  produce	  spread	  of	  mucosal	  changes	  to	  the	  proximal	  oesophagus161.	  A	  similar	  type	  of	  distal	  oesophageal	   exposure	  occurs	   in	  patients	  “on”	  PPI	  therapy.	  It	   is	   possible,	   therefore,	   that	   the	  proximal	   spread	  of	  mucosal	   changes	   is	  part	  of	  a	  process	  that	  sensitises	  the	  proximal	  afferents	  to	  symptomatic	  perception	  of	  reClux:	  i.e.	   the	   painful	   perception	  of	  proximal	   reClux	   is	   dependent	  on	   distal	  oesophageal	  exposure	   to	   gastric	   contents	   (acid,	   or	   weakly	   acidic,	   depending	   on	  PPI	   therapy	  status).	   The	   mechanism	   underlying	   the	  mucosal	   spread	   of	   these	   changes	   is	   still	  unknown.	   A	   potential	   candidate	  mechanism	   can	   involve	   reClex	   connections	  with	  sympathetic	  pathways315.	   One	   can	  speculate	   that	   distal	   oesophageal	   acidiCication	  might	  trigger	  a	  sympathetic	  reClex	  that	  can,	  in	  turn,	  increase	  mucosal	  blood	  Clow	  to	  the	  proximal	  oesophagus.	   The	  increased	  blood	  Clow	  might	  modify	  mucosal	   ionic-­‐liquid	   composition	   with	   decreased	   transepithelial	   resistance	   and	   increased	  exposure	  of	  superCicial	  and	  deeper	  afferent	  nerve	  endings.	  
In	   summary,	   this	   study	   suggests	   that	   the	   relative	   increased	   sensitivity	   of	   the	  proximal	  oesophagus	  in	  GORD	  is	  not	  primarily	  due	  to	  a	  baseline	  impaired	  mucosal	  integrity,	  but	  is	  associated	  with	  an	  increased	  density	  and	  more	  superCicial	   location	  of	   proximal	   mucosal	   afferent	   nerves.	   It	   is	   thus	   far	   uncertain	   whether	   these	  anatomical	   differences	   are	  the	   sole	  mechanism	   for	  proximal	   sensitivity	  to	   reClux.	  
Chapter 5
190




Protection of human oesophageal mucosal 
integrity
CHAPTER 6: PROTECTION OF HUMAN OESOPHAGEAL MUCOSAL 
INTEGRITY 
6.1 IntroductionThe	  in	  vitro	  and	  in	  vivo	  studies	  presented	  in	  this	  thesis	  have	  suggested	  a	  role	  for	  an	  impaired	  oesophageal	  mucosal	   integrity	  in	  symptom	  pathogenesis	  of	  non-­‐erosive	  reClux	   disease.	   They	   have	   shown	   that,	   in	   basal	   conditions,	   distal	   oesophageal	  impedance	   is	   lower	   in	   patients	   with	   non-­‐erosive	   reClux	   disease	   than	   in	   control	  subjects	  or	  those	  with	  functional	  heartburn.	   Furthermore,	   the	  mucosa	  of	  patients	  with	  non-­‐erosive	   reClux	  disease	   is	  more	   vulnerable	   to	   changes	   in	   transepithelial	  electrical	  resistance	  on	  exposure	   to	   reCluxate-­‐like	  solutions	  than	  control	   subjects,	  and	  appears	  to	  have	  a	  slow	  post-­‐exposure	  recovery	  in	  vivo.	  Finally,	  those	  patients	  who	  have	  greater	  perception	  of	  an	  intra-­‐oesophageal	  acid	  challenge	  appear	  to	  have	  a	  lower	  baseline	  impedance	  in	  the	  distal	  oesophagus.	  Given	  that	  it	  is	  proposed	  that	  such	   functional	   parameters	   are	   representative	   of	   impaired	  mucosal	   integrity,	   it	  may	   be	   desirable	   to	   treat	   these	   patients	   with	   a	   drug	   that	   protects	   the	  mucosa	  against	  the	  damaging	  effects	  of	  the	  reCluxate,	  reducing	  its	  vulnerability	  and	  thereby	  decreasing	  perception	  of	  reClux	  events.	  For	  some	  time,	  the	  possibility	  of	  using	  a	  locally	  acting	  topical	  therapy	  in	  GORD	  has	  been	   considered	   desirable.	   	   This	   approach	  has	   obvious	   beneCits	   since	   it	   allows	  targeted	  therapy	  with	  a	  potential	  for	  limited	  systemic	   effects.	  There	  is	  a	  need	   for	  further	   treatments	   as	   a	   signiCicant	   number	   of	   patients	   remain	   refractory	   to	   PPI	  therapy.	  Furthermore	  there	  have	  been	  recent	  warnings	  about	  the	  long-­‐term	  safety	  of	  PPIs,	  particularly	  concerning	  an	  increased	  risk	  of	  intestinal	  infections.5	  A	  topical	  mucosal	   “protectant”,	   as	   a	   similar	  concept	   to	   sunscreen	   in	  dermatology,	   may	   be	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able	   to	   prevent	   the	  damaging	   effects	   of	   gastroesophageal	   reClux	   on	  oesophageal	  mucosal	  integrity.	  A	  number	  of	  attempts	  to	  develop	  topical	  therapies	  for	  GORD	  have	  been	  considered.	  Perhaps	  one	  of	  the	  most	  well-­‐known	  is	  sucralfate.	  Sucralfate	  is	  a	  salt	  of	  aluminium	  hydroxide	   and	   sucrose	   octasulphate.	   It	   is	   believed	   to	   have	   cytoprotective	  properties,	   and	   has	   been	   shown	   to	   have	   clinical	   therapeutic	   beneCit	   in	   reClux	  disease	   and	   in	  healing	  of	   gastric	   ulcers	   without	   causing	  a	  meaningful	   change	   in	  gastric	  pH.	   	  An	  early	  study	  examined	  the	  protective	  effect	  of	  sucralfate	  against	  the	  damaging	   effects	   of	   experimental	   acid	   exposure	   of	   the	   gastric	   mucosa	   in	  anaesthetised	  rats316.	  Subsequently	  sucralfate	  was	  shown	  to	  be	  able	  to	  protect	  the	  oesophageal	  mucosa	  of	  the	  rabbit	  and	  cat	   against	  acid	  injury317,	   318.	   Orlando	  et	  al.	  investigated	   its	   in	   vitro	   effect	   on	   rabbit	   oesophageal	   mucosa	  mounted	   in	  Ussing	  chambers319.	  Changes	  in	  electrical	  resistance	  on	  exposure	  to	  acidic	  solutions	  were	  measured.	   In	   untreated	   tissues,	   progressive	  fall	   in	   epithelial	   resistance	  was	   seen	  on	   acid	  exposure	   (as	   seen	   in	  the	   human	  tissue	   experiments	   of	   Chapter	   3	   in	  this	  thesis).	  Addition	  of	  sucralfate	  into	  the	  luminal	  bath	  reversed	  this	   fall	  in	  resistance	  (and	   increased	   luminal	  pH).	   A	   later	   experiment	   indicated	  that	   this	   property	  was	  due	  to	  a	  cytoprotective	  characteristic	  of	  the	  SO42-­‐	  ions	  contained	  in	  sucralfate	  (and	  sucrose	  octasulphate)320.	  In	  clinical	  application	  there	  is	   some	  evidence	  supporting	  the	  role	  of	  sucralfate	   in	  GORD.	   A	   single-­‐blind	   comparison	   with	   cimetidine	   in	   42	   patients	   with	   reClux	  oesophagitis	   demonstrated	   improvement	   in	   53%	   and	   complete	   macroscopic	  healing	  in	  31%	  of	  the	  sucralfate	  group	  (similar	  to	  the	  cimetidine	  group)263.	  Similar	  Cindings	  were	  seen	  in	  a	  comparison	  study	  against	  ranitidine264.	  Sucralfate	  has	  not	  been	   comprehensively	   tested	   in	   those	   patients	   with	   refractory	   disease.	   A	   pilot	  study	  of	  8	  patients	  with	  reClux	  oesophagitis	  and	  symptoms	  not	  responding	  to	  high-­‐
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dose	   histamine	   receptor	   antagonists	   and	   prokinetics	   found	   that	   the	   addition	   of	  sucralfate	   for	   8	   weeks	   improved	   symptoms	   and	   endoscopic	   appearances321.	   Of	  course,	   the	  low	  patient	  numbers,	   uncontrolled	  and	  unblinded	  nature	  to	  this	  study	  should	   be	   considered	   when	   interpreting	   it.	   A	   scintigraphic	   imaging	   study	  demonstrated	  a	  signiCicant	  limitation	  of	  sucralfate	  in	  offering	  oesophageal	  mucosal	  protection	   in	   the	   absence	   of	   erosion.	   This	   coating	   study	   revealed	   the	   failure	   of	  sucralfate	   to	   remain	   on	   the	   oesophageal	   wall	   after	   application	   in	   70%	   of	  subjects322.	  Sodium	   alginate	   solutions	   (usually	   in	   combination	  with	   antacid)	   are	   frequently	  used	  in	  treatment	  of	  gastro-­‐oesophageal	  reClux	  disease.	   	  In	  the	  presence	  of	  gastric	  acid,	   alginates	   precipitate,	   forming	   a	   gel	   that	   may	   confer	   beneCit	   via	   its	   physical	  rather	   than	   chemical	   properties.	   Alginates	   are	   natural	   polysaccharide	   polymers	  isolated	   from	   brown	   seaweed.	   Chemically	   they	   are	   copolymers	   of	   α-­‐L-­‐guluronic	  and	   β-­‐D-­‐mannuronic	   acid	   residues	   connected	   by	   1:4	   glycosidic	   linkages.	   In	   an	  acidic	   environment	   alginic	   salts	   and	   alginic	   acids	   precipitate	   within	  minutes	   to	  form	   a	   viscous	   gel,	   and	   may	   have	   advantageous	   mechanical	   and	   adhesive	  properties.	  The	  treatment	  of	  GORD	  with	  alginate-­‐antacid	  combinations	  has	  been	  investigated	  in	   a	   number	   of	   studies.	   A	   randomised	   double-­‐blind	   placebo	   trial	   of	   Gaviscon	  Advance	   (alginate,	   calcium	   carbonate	   and	   potassium	   bicarbonate)	   liquid	   in	   the	  treatment	   of	   patients	   with	   heartburn	   symptoms	   (with	   no	   endoscopic	   or	  physiological	   criteria)	   was	   published	   in	   1999266.	   Ninety-­‐eight	   patients	   were	  randomised	   to	   either	   4	   weeks	   of	   10	  ml	   Gaviscon	   Advance	   four	   times	   daily,	   or	  placebo.	  Physician	  and	  patient	  assessment	  found	  Gaviscon	  Advance	  to	  be	  superior	  to	   placebo	   in	   symptom	   control	   at	   2	   and	   4	   weeks.	   A	   further	   placebo-­‐controlled	  crossover	   trial	   of	   Gaviscon	   tablets	   in	   60	   patients	   with	  meal-­‐induced	   heartburn	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found	   Gaviscon	   to	   be	   superior	   to	   placebo	   in	   symptom	   control	   (80%	   relief	   vs.	  47%)267.	   There	   are	   theoretically	   advantageous	   properties	   of	   alginate-­‐containing	  preparations	   over	   pure	   antacid.	   	   Despite	   these	   theoretical	   advantages,	   studies	  comparing	  alginate-­‐antacid	  with	  pure	  antacids	  have	  been	  conClicting	  in	  describing	  differences	   between	   the	   two.	   Whilst	   some	   studies	   have	   suggested	   symptomatic	  beneCit	   of	   alginate-­‐antacids	   over	   antacid	   alone323-­‐325,	   others	   have	   found	   no	  differences	  between	  the	  two259,	  326.	  What	  may	   be	   the	  mechanisms	   of	   the	   potential	   beneCits	   of	   alginate	   solutions	   in	  patients	  with	  GORD?	   The	  gel	   that	   is	   formed	  when	  alginates	   encounter	   low	  pH	   or	  calcium	   is	   able	   to	   form	   a	   physical	   raft	   on	   top	   of	   the	   gastric	   juice.	   This	   Cloating	  capability	   is	  often	  enhanced	  by	   the	  inclusion	  of	  bicarbonate,	   which	  facilitates	   the	  production	  of	  CO2	   in	  the	  acid	  stomach	  environment,	  which	  is	  proposed	  to	   turn	  the	  raft	   into	  a	  foam	  that	   aids	  buoyancy265.	   This	   alginate	   gastric	  raft	   is	  able	   to	   reduce	  the	  number	  of	  acid	  reClux	  episodes	   in	  healthy	  volunteers327,	   328,	  with	  this	  property	  being	   considered	   as	   due	   to	   the	   viscous	   barrier	   surface	   tension	   reducing	   reClux	  through	  the	  gastro-­‐oesophageal	  junction.	  A	   second	  important	  physical	  property	  of	  alginate	  rafts	  appears	  to	  be	  its	  ability	  to	  abolish	  or	  displace	  the	  post-­‐prandial	  “acid	  pocket”	  in	  patients	  with	  symptomatic	  GORD329.	  It	   is	  possible	  that,	   in	  addition	  to	   the	  antacid	  and	  gastric	  mechanical	   properties	  of	  alginate-­‐antacids,	   there	  may	   also	  be	  an	  oesophageal	   mucosal	   protective	   effect	   in	  gastro-­‐oesophageal	   reClux	   disease.	   This	   is	   because	   they	   are	   thought	   to	   have	  additional	  bioadhesive	  properties	  to	  the	  oesophageal	  mucosa.	  SpeciCic	  delivery	  and	  prolonged	   retention	   of	   a	   drug	   in	   the	   oesophagus	   is	   highly	   desirable	   in	   the	  treatment	  of	  GORD	  (and	  indeed	  other	  oesophageal	  disorders	  such	  as	  eosinophilic	  oesophagitis	  and	  hypersensitive	  oesophagus).	  The	  defensive	  properties	  of	  alginate	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solutions	  are	  of	  interest	  in	  the	  treatment	  of	  GORD,	  where	  acid,	  pepsin	  and	  bile	  acid	  are	  all	  believed	  to	  be	  important	  in	  symptom	  pathogenesis.	  The	  study	  presented	  in	  this	  chapter	   investigates	  the	  in	  vitro	  effects	  of	  an	  alginate-­‐antacid	   solution	   (Gaviscon	   Advance)	   on	   human	   oesophageal	   mucosa	   when	  exposed	  to	  solutions	  containing	  acid,	  pepsin	  and	  bile	  acid.	  




6.2.1	  PatientsPatients	  with	   typical	   symptoms	   of	   gastro-­‐oesophageal	   reClux	   disease	   (heartburn	  and/or	  regurgitation)	  were	  recruited	  from	  the	  endoscopy	  department	  of	  the	  Royal	  London	   Hospital.	   Subjects	   with	   oesophageal	   erosions	   or	   Barrett’s	   oesophagus	  were	  excluded	  from	  the	  study.	  18	   subjects	   were	   studied.	   Four	   were	   excluded	   due	   to	   having	   at	   least	   one	  inadequate	  biopsy	  according	  to	  the	  criteria	  described	  in	  Chapter	  3.	  The	  remaining	  14	  subjects	  each	  had	  3	  biopsies	  that	  could	  be	  compared	  by	  application	  of	  one	  each	  of	   the	   “protectant	   solutions”	   (i.e	   alginate	   solution,	   viscous	   control	   and	   liquid	  control).	  
6.2.2	  EndoscopyEndoscopic	   procedures	   were	   performed	   under	   midazolam	   sedation	   or	   with	  pharyngeal	   local	   anaesthetic	   spray.	   	   Three	   oesophageal	   mucosal	   biopsies	   were	  taken	  (Radial	  Jaw	  3	  forceps,	  Boston	  ScientiCic,	  USA)	  from	  3	  cm	  above	  the	  squamo-­‐columnar	   junction,	   and	   immediately	   placed	   in	   a	   pre-­‐oxygenated	   Krebs-­‐Henseleit	  buffer	  solution	  at	  pH	  7.4.	  The	  biopsies	  were	  rapidly	   transported	  to	  the	  laboratory	  for	  Ussing	  Chamber	  study.	  All	  biopsies	  for	  the	  following	  studies	  were	  taken	  by	  the	  same	  endoscopist	  (Dr	  Woodland),	  using	  the	  same	  technique.	  
6.2.3	  Materials3	  “mucosal	  protectant”	  solutions	  were	  used	  in	  this	  study,	  one	  test	  solution	  and	  two	  control	  solutions.
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1) Alginate	   solution	   (Gaviscon	   advance,	   Reckitt	   Benckiser	   (UK)	   Ltd).	   Active	  ingredients	   sodium	  alginate	  100	  mg/ml,	  potassium	  bicarbonate	  20	  mg/ml,	  calcium	  carbonate	  20	  mg/ml.	  Viscosity	  2470	  cPs.	  Conductance	  12.8	  mS.2) Viscous	  control.	  Hydrogenated	  glucose	  syrup,	  xanthan	  gum.	  Viscosity	  3049	  cPs.	  Conductance	  1.9	  mS.3) Liquid	   control.	   Krebs-­‐Henseleit	   solution	   at	   pH	   7.4.	   	   No	   viscosity.	  Conductance	  7.1	  mS.
Viscosity	  of	  these	  solutions	  was	  determined	  by	  the	  mean	  of	  3	  measurements	  with	  a	  BrookCield	  LVDV-­‐II+	  viscometer.	  Conductance	  was	  measured	  using	  a	  Hanna	  EC215	  Conductivity	  Meter.
6.2.4	  Ussing	  chamber	  studyBiopsies	  were	  orientated	  and	  mounted	  in	  adapted	  Ussing	  chambers	  as	  described	  in	  Chapter	   3.	   Biopsies	   were	   mounted	   in	   the	   Ussing	   chamber	   and	   equilibrated	   in	  Krebs-­‐Henseleit	   buffer	   pH	   7.4.	   After	   making	   a	   correction	   for	   Cluid	   and	   circuit	  resistance,	   transmucosal	   potential	   difference	   was	   continuously	   monitored	   with	  Ag/AgCl	   electrodes.	   The	   basal	   transepithelial	   resistance	   (TER)	   was	   calculated	  according	   to	   Ohm’s	   law	   from	   the	   voltage	   deClections	   induced	  by	   bipolar	   current	  pulses	  of	  50μA,	  duration	  200	  ms	  every	  6	  seconds	  applied	  through	  platinum	  wires.	  All	   experiments	   were	   conducted	   in	   open-­‐circuit	   conditions.	   The	   system	   was	  equilibrated	   at	   370C	   until	   a	   stable	   TER	   baseline	   was	   established	   (typically	   20	  minutes).	  After	  reaching	  a	  stable	  TER	  baseline,	  recording	  was	  paused	  and	  the	  chambers	  were	  removed	   from	   the	   apparatus	   and	   the	   two	   halves	   separated.	   This	  was	  done	   such	  that	   the	   “luminal”	   aspect	   of	   the	   biopsy	   was	   exposed.	   200	   μl	   of	   a	   “protectant	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solution”	  was	  then	  applied	  to	   the	  exposed	  luminal	  aspect	  of	  the	  biopsy	  and	  left	  on	  the	  biopsy	  surface	  for	  5	  minutes	  (Cigure	  43).
Figure	   43:	  Technique	   for	   application	   of	   the	   mucosal	   protectant	   solution	   to	   human	   oesophageal	  biopsies	  in	  an	  Ussing	  chamber	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For	  each	  patient,	  3	  biopsies	  were	  studied:	  i.e.	  each	  biopsy	  was	  exposed	  to	  either	  1)	  Alginate	   solution;	   2)	   Viscous	   control;	   3)	   Liquid	   control.	   After	   5	   minutes	   the	  “protectant	   solution”	  was	   washed	   off	  with	  5	  ml	   Krebs-­‐Henseleit	   pH	   7.4	  solution,	  and	  the	  chambers	  rejoined	  and	  Cilled	  with	  Krebs-­‐Henseleit	  at	  pH	  7.4.	  The	  biopsies	  were	  then	  allowed	  to	  re-­‐equilibrate	  and	  wash	  in	  neutral	  solution	  for	  a	  further	  15	  minutes.	   For	  each	  biopsy	  the	   solution	   in	  the	   luminal	  chamber	  was	   then	  replaced	  with	  an	  acidic	  solution	  (Krebs-­‐Henseleit	  at	  pH	  2	  +	  1	  mg/ml	  porcine	  pepsin	  +	  1	  mM	  taurodeoxycholic	   acid).	   This	   acidic	   exposure	   continued	   for	   30	   minutes,	   during	  which	  time	  TER	  was	  continuously	  measured	  (Cigure	  44).	  Percentage	  change	  in	  TER	  from	  baseline	  at	  30	  minutes	  was	  calculated	  as	  described	  in	  Chapter	  3.
Figure	  44:	  Study	  scheme	  for	  mucosal	  protectant	  experiment
6.2.5	  Effect	  of	  antacid	  component	  of	  alginate	  solutionThe	   viscous	   placebo	   solution	   does	   not	   contain	   antacid.	   It	   is	   possible	   that	   any	  protectant	  effect	  of	  the	  alginate	  solution	  is	  not	  due	  to	   the	  alginate,	  but	  rather	  due	  to	   the	   antacid	   component.	   To	   consider	   this	   possibility	   the	   experiment	   was	  repeated	   in	   biopsies	   from	   a	   further	   6	   subjects	   whereby	   the	   viscous	   control	  “protectant	   solution”	   was	   applied,	   this	   time	   containing	   2.0	   mmol	   calcium	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carbonate	   (the	   same	  antacid	   at	   the	  same	   concentration	   as	   found	   in	   the	  alginate	  solution),	   and	  vigorously	   shaken	   before	   application.	   The	   protection	  experiments	  with	  this	  solution	  were	  conducted	  in	  the	  same	  way	  as	  detailed	  above.




6.3.1	  Ussing	  chamber	  experimentsBiopsies	  pretreated	  with	  liquid	   control	   solution	  did	  not	  appear	  to	  beneCit	   from	  a	  protection	  effect,	   since	   there	  was	  mean	  change	   in	  TER	   of	   −21.1	  ±	  16.6%.	   This	   is	  very	   similar	   to	   the	  fall	   seen	  without	   topical	   treatment	  seen	  in	   the	  “unprotected”	  biopsies	   from	  patients	  when	  exposed	  to	   the	  acidic	   solution	   in	  Chapter	  3	  (-­‐22.8	  ±	  11.9%).When	   biopsies	   were	   pre-­‐treated	   with	   the	   viscous	   control	   solution,	   the	   acid-­‐induced	  change	   in	  resistance	  was	  of	  −15.26	  ±	  13.8%,	  which	  was	   not	   signiCicantly	  different	  to	  the	  liquid	  control	  results.	  When	  biopsies	  were	  pre-­‐treated	  with	  the	  alginate	  solution,	  acid	  failed	  to	  provoke	  a	  signiCicant	   drop	   in	   resistance,	   with	   a	  mean	   change	   in	  TER	   of	   −2.7	   ±	   6.9%	  from	  baseline.	  This	  change	  was	  signiCicantly	   smaller	  than	  was	   seen	  in	  both	  the	  viscous	  and	  liquid	  control	  biopsies	  (table	  5	  and	  Cigure	  45).
Comparison Mean 
difference
P value 95% CI
Alginate vs. Viscous Control 12.51 P < 0.05 2.170 to 22.85
Alginate vs. Liquid Control 18.35 P < 0.001 8.005 to 28.69
Viscous Control vs. Liquid 
Control
5.83 P > 0.05 -4.507 to 16.18
	  Table	  5:	  Bonferroni’s	  multiple	  comparison	  test	  of	  repeated	  measures	  ANOVA
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Figure	  45:	  Comparison	  of	  change	  percentage	  change	  in	  TER	   compared	  to	  baseline	  on	  exposure	  of	  biopsy	   to	   pH2	   solution	   containing	   pepsin	   and	   taurodeoxycholic	   acid	   after	   topical	  pre-­‐treatment	  with	  alginate	  solution,	  viscous	  control	  and	  liquid	  control.	  NS	  =	  not	  signiIicant
6.3.2	  Assessment	  of	  contribution	  of	  antacidThe	  effect	   of	  addition	  of	   calcium	  carbonate	  2.0	  mmol	   to	   the	  viscous	   control	   was	  compared	   in	  6	   subjects.	   The	  mean	  change	   in	  TER	   from	   baseline	   in	  biopsies	   pre-­‐treated	  with	   viscous	   control	   +	   antacid	   was	   −23.1	   ±	   9.1%,	   which	  was	   a	   similar	  change	   from	  baseline	  as	  seen	   in	  the	  standard	  viscous	   control	   (in	  fact	  numerically	  slightly	  greater	  change,	  but	  statistically	  insigniCicant	  at	  p=0.22,	  Cigure	  46).
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If	  the	  mucosa	  of	  symptomatic	   patients	   is	  vulnerable	   to	   noxious	  effects	   of	  gastro-­‐oesophageal	   reCluxate,	   then	   a	   therapy	   that	   reduces	   the	   noxious	   exposure	   is	  desirable	   as	   it	   allows	   fast	   protection	   at	   the	   site	   of	   potential	   injury.	   	   This	   study	  investigated	   the	  potential	   of	  a	   topically	   applied	  alginate	   solution	   to	   reduce	  acid-­‐induced	  integrity	  change	  in	  human	  oesophageal	  biopsies.
The	  study	  results	  were	  the	  following:1) Topical	   pre-­‐treatment	   with	   an	   alginate	   solution	   was	   able	   to	   signiCicantly	  reduce	  in	  vitro	  change	  in	  TER	  caused	  by	  acid-­‐pepsin-­‐bile	  acid	  solutions.2) This	  property	  appears	  to	  be	  independent	  of	  the	  viscosity	  of	  the	  solution,	  and	  independent	  of	  the	  presence	  of	  antacid.
As	   such,	   these	  in	   vitro	  results	  suggest	  that	  an	  alginate-­‐containing	  solution	  may	  be	  able	  to	  reduce	  impact	  of	  reCluxate	  on	  mucosal	  integrity.	  The	  in	  vivo	  implications	  of	  this	  require	  further	  investigation.As	  previously	  described,	  attempts	  have	  previously	  been	  made	  to	  study	  the	  in	  vitro	  effects	   on	   mucosal	   electrical	   resistance	   of	   a	   topical	   treatment	   with	   sucralfate.	  Studies	  in	  cat,	  rabbit,	  and	  one	  study	  in	  human	  oesophageal	  mucosa	  (obtained	  from	  oesophagectomy	  specimens	  in	  patients	  with	  squamous	  cell	  carcinoma	  and	  exposed	  to	   prior	  radiotherapy)	  showed	  that	   sucralfate	  was	   able	   to	   attenuate	  the	  effect	  of	  acid	   exposure	   on	   mucosal	   electrical	   resistance319,	   320,	   330.	   This	   study	   is	   the	   Cirst	  using	   oesophageal	   biopsies	   from	   human	   subjects	   without	   cancer	   or	   previous	  chemotherapy/radiotherapy.	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In	  the	  study	   care	  was	   taken	   to	   control	   for	   the	  viscosity	  of	   the	  control	   solution	  as	  this	  could	  be	  a	  confounding	   factor	  if	  high	  viscosity	  was	  causing	  a	  physical	  barrier	  against	  the	  test	  solutions.	  To	  overcome	  this,	  a	  placebo	  solution	  of	  similar	  viscosity	  to	   the	   alginate	   solution	  (but	   lacking	   alginate	  or	   antacid)	  was	   used.	   The	  viscosity	  measured	   was	   actually	   very	   slightly	   higher	   in	   the	   viscous	   control	   than	   in	   the	  alginate	  solution	  (albeit	  in	  relative	  terms	  the	  results	  are	  very	  similar).	  This	  rejects	  the	  possibility	  that	   it	  is	  viscosity	  alone	  that	  protects	  the	  mucosa	  against	  access	  by	  the	   acid	   solution.	   Furthermore,	   in	   this	   study	   care	  was	   taken	   to	   be	   thorough	   in	  washing	  off	  “pre-­‐treatment	  ”	  solutions	  after	  applying	  them,	  both	  with	  a	  fast	  5	  ml	  pipette	  wash,	   then	  with	  a	  15	  minute	  period	  in	  neutral	  solution	  within	  the	  Ussing	  chamber	   before	   exposure	   to	   the	   acidic	   solution.	   If	   the	   alginate	   solution	  was	   an	  electrical	  insulator	  then	  application	  could	  have	  resulted	  in	  an	  artifactual	  high	  TER.	  However,	   the	   alginate	   solution	   was	   an	   excellent	   electrical	   conductor,	   with	  conductance	  that	  was	  in	  fact	  greater	  than	  seen	  in	  the	  control	  solutions.	  It	   was	   possible	   that	   the	   protective	   effect	   of	   the	   alginate	   solution	  was	   due	   to	   its	  antacid	   component	   rather	   than	   the	   alginate	   itself.	   The	   addition	   of	   calcium	  carbonate	  antacid	  to	   the	  viscous	   control	   did	  not	   lead	  to	   an	  additional	   protective	  beneCit	   over	   the	   standard	   viscous	   control.	   As	   such,	   it	   appears	   likely	   that	   the	  protective	  effect	  of	  the	  alginate	  solution	  is	  due	  to	  the	  alginate	  itself.It	  is	  of	  interest	  to	  consider	  the	  mechanism	  by	  which	  alginate	  solutions	  may	  protect	  the	   oesophageal	   mucosa.	   Along	   with	   their	   mechanical	   properties	   at	   the	   gastro-­‐oesophageal	   junction	   and	   on	   the	   acid-­‐pocket,	   alginates	   have	   been	   found	   to	  demonstrate	  bioadhesive	  potential,	   a	   property	  determined	   primarily	  by	  polymer	  chain	  length	  and	  the	  presence	  of	  ionisable	  groups	  rather	  than	  e.g.	   the	  viscosity	  of	  the	   gel	   used331.	   Furthermore	   they	   appear	   to	   become	   adhesive	   on	   hydration	   (as	  occurs	   in	   the	   gastrointestinal	   tract).	   An	   in	   vitro	   porcine	   model	   of	   oesophageal	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mucosal	   retention	  investigated	  the	  adhesiveness	  of	  Cluorescein-­‐labelled	  alginates.	  Alginates	   were	   applied	   to	   porcine	   oesophageal	   mucosa	   or	   cellular	   acetate,	   and	  washed	   continuously	   at	   1	   ml	   per	   minute	   with	   a	   series	   of	   solutions	   (including	  artiCicial	   and	  human	   saliva).	  With	   all	   of	  the	   alginates	   applied	   to	   the	   oesophagus	  there	   was	   approximately	   20%	   mucosal	   retention	   after	   30	   minutes	   washing,	  suggesting	   a	   potential	   for	   bioadhesion.	   This	   appeared	   to	   be	   due	   to	   an	  alginate-­‐mucosal	   interaction	  since	  there	  was	  no	  retention	  on	  a	  cellular	  acetate	  model332.	  A	  further	  study	   using	   a	  porcine	   in	   vitro	  model	  determined	   that	   the	  high	  molecular	  weight	   polymers	   exhibited	   better	   bioadhesion	   than	   low	   molecular	   weight	  polymers	  (with	  approximately	  40%	  versus	  20%	  retention	  at	  20	  minutes)333.	  It	  has	  also	   been	  shown	   that	  the	   nature	  of	  the	   vehicle	  used	   for	   the	  alginate	  preparation	  can	   inCluence	   bioadhesive	   properties.	   Suspensions	   containing	   a	   vehicle	   that	  required	   a	   low	   level	   of	   dilution	   to	   initiate	   swelling	   (such	  as	   glycerol)	   are	  more	  mucoretentive	  in	  in	   vivo	  studies334.	  When	  adhered	  to	   the	  oesophageal	  epithelium,	  the	   alginate	   solution	   may	   enable	   protection	   against	   reCluxate	   damage.	   In	   vitro	  diffusion	   studies	   (using	   a	   dialysis	   membrane)	   have	   shown	   that	   the	   presence	   of	  alginates	   signiCicantly	   reduces	   acid	   and	   pepsin	   diffusion	   across	   the	   membrane	  when	  compared	  to	  control335.	  The	  alginate-­‐based	  formulation	  of	  Gaviscon	  Advance	  (Reckitt	  Benckiser	  (UK)	  Ltd)	  has	  been	  found,	  in	  vitro,	  to	  inhibit	  pepsin	  activity	  and	  to	   reduce	   pepsin	   and	   bile	   acid	   (taurocholate,	   glycocholate	   and	   deoxycholate)	  diffusion	  across	   an	   artiCicial	  membrane336.	   Since	  we	   know	   that	  mucosal	   integrity	  appears	   to	   be	   impaired	  by	   the	  presence	  of	  acid,	   pepsin	  and	  bile	  acid	   it	  would	  be	  possible	  that	  the	  impact	  Gaviscon	  has	  on	  diffusion	  and	  activity	  of	  these	  substances	  plays	  a	  role	   in	  the	  protective	  effect	  seen	  in	  this	  study.	  The	  bioadhesive	  properties	  appear	  to	  have	  enabled	  protection	  to	  be	  present	  after	  active	  and	  passive	  washing	  phases	  totalling	  more	  than	  15	  minutes.
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Whilst	   these	  Cindings	  of	  our	  study	  are	  of	  interest,	  it	  is	  important	   to	  note	  that	  they	  are	   preliminary	   in	   nature.	   The	   in	   vitro	   testing	   environment	   of	   such	   a	   drug	   is	  obviously	  an	  artiCicial	   environment.	  The	  method	  of	  application	  for	  5	  minutes	  was	  not	  representative	  of	  normal	  conditions,	   as	  in	  vivo	   there	  is	  oesophageal	  peristalsis	  and	  saliva	  that	  will	  act	  to	  clear	  some	  of	  the	  drug.	  Although	  the	  solution	  was	  washed	  off	   before	   exposure	   to	   acid,	   during	   the	   application	   period	   no	   such	   washing	  occurred.	   There	   is	   also	   no	   indication	   of	   how	   these	   in	   vitro	   changes	   directly	  translate	   into	   the	   in	   vivo	   situation.	   However,	   these	   preliminary	   data	   serve	   as	   a	  platform	  to	  further	  study	  properties	  of	  topical	  protectant	  solutions	  (alginate-­‐based	  or	   otherwise).	   It	   will	   be	   interesting	   to	   examine	   the	   in	   vitro	   effects	   of	   topical	  solutions	  in	  greater	  detail.	  For	  example,	  it	  is	  highly	  likely	  that	  acid	  exposure	  of	  the	  oesophageal	   epithelium	   causes	   activation	   of	   epithelial	   acid-­‐sensitive	   receptors	  (such	  as	  TRPV1),	  with	  the	  release	  of	  inClammatory	  mediators337,	   338.	   It	   is	  possible	  that	  release	  of	  such	  mediators	  can	  be	  evaluated	  (by	  sampling	  the	  “basal”	  chamber),	  and	  the	  effect	  of	  a	  topical	  protectant	  could	  be	  assessed.	   It	  may	  even	  be	  possible	  to	  “clamp”	  mucosal	  afferents	  and	  assess	  activation	  in	  response	  to	  acidiCication,	  which	  again	  could	  be	  assessed	  after	  topical	  protection.	  Furthermore,	   candidate	  acid/bile	  acid	   sensitive	   receptors	   could	   also	   be	   targeted	  with	   drugs	   added	   to	   the	   topical	  solution,	   and	  effect	  on	   integrity	   change	  or	   neurotransmitter	  released	  assessed	  in	  
vitro	  before	  translation	  to	  the	  in	  vivo	  situation.We	   know	   that	   PPIs	   are	   very	   effective	   therapies	   for	   GORD,	   and	   it	   would	   not	   be	  expected	  that	  a	  topical	  therapy	  could	  replace	  PPI	  as	  a	  treatment.	  However,	  as	  has	  previously	   been	  described,	   a	  signiCicant	   number	   of	  patients	   remain	   refractory	   to	  PPI	  therapy,	  and	  as	  such	  there	  is	  an	  unmet	  need	  for	  improved	  therapy.	  The	  role	  of	  topical	   treatments	   would	   be	   expected	   to	   be	   either	   as	   an	   on-­‐demand	   therapy	   in	  patients	  with	  mild	  disease,	   or	   as	   an	  add-­‐on	  therapy	   in	   those	  with	  an	  incomplete	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response	  to	  PPI	  or	  surgery.	  It	   is	  a	  particularly	  attractive	  strategy	  in	  PPI-­‐refractory	  GORD	   since	   it	   could	   offer	   potentially	   protection	   against	   components	   of	   the	  reCluxate	   other	   than	   strong	   acid	   (e.g.	   weak	   acid,	   bile)	   that	   are	   the	   cause	   of	  refractory	  reClux	  in	  some	  cases70,	   339.	  Topical	  therapy	  could	  also	  serve	  as	  a	  potential	  therapy	  for	  those	  patients	  with	  acid-­‐hypersensitive	  oesophagus,	  whereby	  they	  are	  sensitive	  to	  very	  short-­‐lasting	  acid	  exposures	  (which	  can	  continue	  to	  occur	  on	  PPI	  therapy).





CHAPTER 7: GENERAL DISCUSSION
The	  prevalence	  of	  gastro-­‐oesophageal	  reClux	  disease	  (GORD),	  Barrett’s	  oesophagus	  and	  oesophageal	  adenocarcinoma	  is	   increasing	   rapidly.	   There	   is	   a	  clear	   link	  with	  obesity,	  which	  is	  also	  becoming	  an	  increasing	  public	  health	  problem.	  As	  such	  GORD	  is	  being	  increasingly	  encountered	  in	  primary	  and	  secondary	  healthcare.	  Refractory	  GORD	  remains	  a	  signiCicant	  problem,	  and	  most	  patients	  who	  reach	  secondary	  care	  clinics	   have	   failed	   over	   the	   counter	   medications	   and	   then	   anti-­‐secretory	  medications	   given	   in	   primary	   care.	   These	   patients	   present	   a	   challenge	   to	   the	  gastroenterologist	  assessing	  them.	  This	  means	  there	  is	  a	  need	  to	  better	  understand	  the	  pathophysiology	  of	  GORD	  and	  progress	  towards	  new	  treatment	  strategies.Non-­‐erosive	  disease	  perhaps	  presents	  the	  greatest	  challenge	  to	   clinicians,	   since	  it	  has	  less	  objective	  end	  points	  than	  erosive	  disease	  (in	  which	  mucosal	  healing	  can	  be	  evaluated)	  and	  it	  may	  have	  a	  poorer	  response	  to	   PPI	  therapy.	   The	  mechanisms	  of	  symptom	   perception	   are	   also	   less	   intuitive	   in	   non-­‐erosive	   reClux	   disease,	   where	  there	   is	   an	  absence	   of	  obvious	  mucosal	  damage	   and	   inClammation.	   Nevertheless,	  recent	   years	   have	   highlighted	   the	   microscopic	   impairment	   of	   the	   oesophageal	  mucosa	   in	  non-­‐erosive	  reClux	  disease,	   and	   this	  has	  prompted	   the	  hypothesis	   that	  an	   impaired	   mucosal	   integrity	   may	   play	   a	   role	   in	   disease	   pathogenesis	   and	  symptom	   perception.	   It	   has	   been	   suggested	   that	   this	   impaired	   integrity	   can	   be	  assessed	  not	  only	  morphologically	  (in	  the	  form	  of	  dilated	  intercellular	  spaces),	  but	  also	   functionally	   (in	   terms	   of	   in	   vitro	   transepithelial	   electrical	   resistance	   and	   in	  
vivo	   oesophageal	   mucosal	   impedance).	   Dilated	   intercellular	   spaces	   are	   a	   static	  measure	   of	   integrity,	   and	   do	   not	   tell	   us	   about	   the	   response	   of	   the	   tissue	   to	   an	  aggressor	  challenge.	  Functional	  measures	  of	  integrity	  allow	  assessment	  of	  integrity	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over	   time,	   and	   therefore	   can	   be	   used	   to	   assess	   the	   dynamic	   responses	   of	   the	  mucosa.	  
Throughout	   the	   thesis,	   the	   concepts	   of	   hypersensitivity	   and	   sensitisation	   are	  commented	  on,	   and	  their	  relationship	  in	  the	  context	  of	  this	  thesis	  deserve	  further	  discussion.	   In	   the	   opinion	   of	   many,	   the	   concept	   of	   hypersensitivity	   is	   a	   purely	  neural	   concept	   representing	   an	   abnormal	   neural	   response	   to	   a	   stimulus.	   The	  complex	  nature	  of	  the	  mucosal	  interface	  with	  the	  gastro-­‐oesophageal	  reCluxate	  has	  led	  the	  concept	  of	  hypersensitivity	  to	  be	  discussed	  in	  a	  broader	  sense	  through	  this	  thesis.	  Whilst	  the	  sensitivity	  to	  a	  stimulus	  can	  indeed	  be	  exaggerated	  by	  a	  purely	  abnormal	  neural	  response	  (at	  the	  peripheral	  afferent	  level,	  or	  at	  the	  central	  spinal	  or	   cerebral	   level),	   other	   variables	   in	   the	   locality	   of	   the	   mucosa	   will	   affect	   the	  strength	  of	  the	  neural	   response	  to	  a	  given	  stimulus,	  and	  thus	  are	  also	  described	  in	  terms	  of	  hypersensitivity.	  This	  means	   that,	   in	  this	  context,	   there	  are	   times	  when	  the	   oesophageal	   mucosa	   is	   hypersensitive	   to	   reClux	   due	   to	   an	  abnormal	   barrier	  function,	   not	   a	   neural	   abnormality.	   In	   such	   a	   case	   there	   may	   be	   increased	  activation	   of	   normal	   neurones	   due	   to	   increased	   access	   of	   noxious	   stimuli	   to	   it	  (because	  of	  an	  impaired	  mucosal	  integrity).In	   contrast,	   chapter	   5	   describes	   the	   concept	   of	   an	   “increased	   sensitivity”	   of	   the	  proximal	   oesophagus	  compared	  to	   the	  distal	   oesophagus.	   In	   this	  context	   it	   is	  not	  intended	   to	   reClect	   an	   abnormal	   process,	   but	   rather	   a	  differential	   distribution	  of	  “normal”	   afferent	   nerves	   that	   may	   result	   in	   the	   proximal	   oesophageal	   mucosa	  being	  more	  sensitive	  to	  a	  given	  stimulus	  than	  the	  distal	  mucosa.	  There	  is	  also	  the	  possibility	  that,	   in	  reality,	  the	  story	  is	  even	  more	  complex.	  As	  yet	  we	  are	  unsure	  of	  the	  mechanisms	  that	  result	   in	  changes	  to	  the	  permeability	  of	  the	  mucosa.	   It	   may	   be	   that	   the	   same	   mechanisms	   that	   contribute	   to	   permeability	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changes	  can	  also	  cause	  neuronal	  sensitisation	  (such	  as	  may	  happen	  in	  the	  case	  of	  an	  inClammatory	  reaction	  to	   the	  stimulus)	  and	  thus	  cause	  hypersensitivity	  both	  by	  increasing	   access	   or	   noxious	   stimuli	   to	   the	   afferent	   nerve	   and	   by	   causing	   an	  abnormal	   response	  of	   the	  nerve	   itself.	   We	  do	   not	   know	   whether	   such	   processes	  may	   also	   be	   involved	   in	   the	  proximal	   oesophagus	   in	  NERD,	   but	   if	   so	   this	   could	  accentuate	   the	   already	   marked	   differences	   of	   the	   normal	   proximal	   mucosa	  compared	  to	  the	  distal.
At	   the	  end	  of	  Chapter	  1,	  remaining	  questions	  were	  identiCied,	  and	  these	  shall	  now	  be	  addressed	  in	  the	  light	  of	  the	  Cindings	  of	  the	  studies	  presented	  in	  this	  thesis.
How	   does	   human	   oesophageal	  mucosa	   compare	   with	   animal	   oesophageal	   mucosa	  
previously	  used	  in	  experimental	  work?Our	   in	   vitro	   and	   in	   vivo	   experiments	   have	   provided	   novel	   data	   that	   can	   be	  compared	  to	  animal	  studies.	  Except	   for	   a	   few	  studies	   addressing	  baseline	  human	  mucosal	   characteristics,	   previous	   in	   vitro	   studies	   of	   functional	   oesophageal	  integrity	  have	  been	  assessed	  in	  animals	  (predominantly	  rabbits	  and	  rats).An	  immediately	  noticeable	  Cinding	  is	  that	  the	  baseline	  TER	  in	  the	  human	  mucosa	  is	  much	  lower	   than	  that	  seen	  in	  other	  animals.	   In	  Ussing	  chamber	  studies	  of	  rabbit	  oesophageal	   mucosa,	   Farré	   et	   al.	   found	   baseline	   TER	   values	   in	   the	   range	   of	  approximately	  1500	   to	   2500	  Ω.cm2	   153.	   The	  group	  of	   Tobey	   et	   al.	   also	   measured	  baseline	  rabbit	  oesophageal	  mucosal	  TER	  to	  be	  approximately	  2000	  Ω.cm2	  340.	  The	  data	  from	  studies	  presented	  in	  this	  thesis	  demonstrate	  a	  much	  lower	  TER	  baseline,	  in	  the	  range	  of	  68	  to	  285	  Ω.cm2.	  A	  part	  of	  the	  reason	  for	  this	  discrepancy	  between	  rabbit	   and	   human	  baseline	  TER	   may	   be	   due	   to	   size	   of	  the	   tissue	   sample.	   In	   the	  aforementioned	   studies	   rabbit	   oesophagus	   was	   cut	   in	   sections	   and	  mounted	   in	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chambers	  with	  an	  aperture	  of	  0.3	  to	  1.2	  cm2.	   In	  the	  human	  studies	  an	  aperture	  of	  0.017	  cm2	  was	  used.	  There	   is	  considerably	  more	  “edge	  effect”	  at	  smaller	  aperture	  sizes:	  i.e.	  there	  is	  inevitably	  damage	  at	  the	  edge	  of	  the	  biopsy	  due	  to	  pressure	  from	  the	  apposing	  halves	  of	  the	  chamber,	  and	  for	  a	  smaller	  aperture	  the	  circumference	  where	   this	   damage	   occurs	   is	   a	   higher	   overall	   proportion	   of	   the	   tissue	   being	  studied.	   To	   investigate	   this	   further	  we	  have	  also	  mounted	  mucosal	   sections	   from	  human	   oesophagectomy	   specimens	   in	   chambers	   with	   a	   0.5	   cm2	   aperture,	   and	  found	  the	  baseline	  to	  be	  around	  300	  to	  400	  Ω.cm2.	   This	   suggests	   that	  edge	  effect	  can	  have	  a	  signiCicant	  impact,	  but	  nevertheless	  the	  basal	  TER	  is	  considerably	  lower	  than	  is	   seen	   in	   rabbits.	   Corroborating	  with	  our	  data	  are	   two	   studies	   from	  other	  groups	   who	   have	   examined	   basal,	   static,	   TER	   in	   human	   oesophageal	   mucosal	  biopsies.	   Jovov	  et.	  al.	   in	  the	  USA	  have	  published	  values	  between	  approximately	  70	  to	   300	   Ω.cm2	   133,	   and	  Weijenborg	   et	   al.	   in	   the	   Netherlands	   have	   found	   values	  between	   approximately	   70	   to	   125	   Ω.cm2	   294.	   Overall	   this	   suggests	   an	   inherent	  difference	   in	   the	   baseline	   integrity	   characteristics	   of	   rabbit	   and	   human	  oesophageal	  mucosa.	  When	  considering	   the	   effects	   of	   acidic	   solutions	   on	   dynamic	   changes	   of	   TER	   in	  animal	  and	  humans	  there	  is	  less	  data	  available	  to	  compare.	  The	  best	  comparator	  is	  the	   study	   by	   Farré	   et	   al.	   investigating	   the	   effect	   of	   acidic	   solutions	   containing	  pepsin	  and	  bile	  acid	  on	  TER	  of	  rabbit	  oesophageal	  mucosa	  in	  Ussing	  chambers153.	  In	  this	  study,	  the	  concentrations	  of	  bile	  acids	  used	  were	  mostly	  high	  (2	  to	  5	  mmol/l),	  but	  a	  concentration	  of	  0.5	  mmol/l	  was	  also	  used.	   It	  can	  be	  seen	  that,	  when	  the	  mucosa	   was	   exposed	   to	   pH	   2	   solution	   with	   pepsin	   and	   0.5	   mmol/l	  taurodeoxycholic	  acid,	  there	  was	  a	  mean	  change	  in	  TER	  of	  −17%.	  On	  exposure	  to	  a	  similar	  solution	  with	  a	  2	  mmol\l	  bile	  acid	  concentration	  there	  was	  a	  mean	  change	  of	   -­‐58%.	   The	   overall	   mean	   change	   in	   TER	   seen	   in	   our	   studies	   using	   1	   mmol/l	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taurodeoxycholic	   acid	  was	   −14.4%,	   i.e.	   slightly	   less	   than	   that	   seen	   in	   the	   rabbit	  mucosa	  when	  exposed	  to	   the	  lower	  concentration	  of	  bile	  acid.	   This	   suggests	   that,	  although	   ionically	   less	   “tight”	   at	   baseline,	   the	   human	   mucosa	   may	   be	   less	  vulnerable	  to	  integrity	  changes	  on	  exposure	  to	  reCluxate-­‐like	  solutions.	  At	  baseline,	  since	   the	  TER	   is	   formed	   almost	   entirely	   from	   characteristics	   of	  paracellular	   ion	  diffusion,	   it	  suggests	  that	  this	  pathway	  is	  more	  ionically	  permeable	  in	  humans	  than	  in	   rabbits.	   Differences	   in	   resistance	   in	   this	   pathway	   are	   likely	   to	   be	   due	   to	  differences	   in	   the	   tight	   junction-­‐apical	   membrane	   morphology	   and/or	   function	  between	  species,	  but	  this	  is	  as	  yet	  untested.	  Changes	   in	  TER	  on	  exposure	  to	  reClux	  is	   likely	   to	   involve	   more	   complicated,	   dynamic	   mechanisms,	   and	   these	   can	   be	  discussed	   when	   considering	   the	   in	   vitro	   and	   in	   vivo	   response	   of	   human	  oesophageal	  mucosa	  to	  acid.An	   important	   question	   is	   whether	   the	   previous	   studies	   in	   animal	   oesophageal	  mucosa	   can	  be	  used	  to	   understand	  human	  disease.	   There	  are	  several	  qualitative	  similarities	  with	  humans	  that	  suggest	  they	  can.	   For	  example,	   the	  formation	  of	  DIS	  in	  response	  to	  acid	  is	  similar,	  and	  the	  functional	  changes	  in	  impedance	  and	  TER	  are	  also	   similar.	   As	   such,	   mechanistically,	   they	   appear	   similar	   to	   humans.	   The	  main	  differences	  are	   in	  the	  quantitative	  results	  of	  baseline	  TER	  values	   and	  response	  to	  acid.	  Of	  course,	  perhaps	  the	  greatest	  beneCit	  of	  studying	  human	  tissue	  rather	  than	  animal	  is	  the	  possibility	  of	  clinicopathological	  correlation.
How	   does	   the	   normal	   human	   oesophageal	   mucosa	   respond	   when	   it	   is	   exposed	   to	  
reMlux	  (experimentally	  and	  in	  vivo)?It	  is	  known	  that	  patients	  with	  non-­‐erosive	  reClux	  disease,	  but	  not	  healthy	  controls,	  display	   dilated	   intercellular	   spaces	   (DIS)	   in	   the	   oesophageal	   mucosal	   basal	  epithelium,	  and	  that	  the	  healthy	   oesophagus	  develops	  DIS	  when	  exposed	   to	   acid.	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The	  development	  of	  DIS	  is	  an	  “all	   or	  nothing”	  phenomenon,	  and	   its	  measurement	  has	   inherent	   difCiculties	   (such	   as	   a	   difCiculty	   to	   perform	   truly	   “random”	  measurements,	   and	   large	   intra-­‐individual	   variability	   of	   spaces),	   meaning	   that	  interpretation	   of	   dynamic	   changes	   and	   objective	   comparison	   within	   closely	  matched	   groups	   (e.g.	   between	   patients	   with	   non-­‐erosive	   reClux	   disease)	   is	   not	  feasible.	  As	   such	   the	  studies	  presented	  in	  this	  thesis	  used	  measures	  of	  functional	  integrity	  to	  assess	  dynamic	  changes	  on	  exposure	  to	  acidic	  solutions.	  These	  in	  vitro	  and	   in	   vivo	   experiments	   reveal	   that,	   on	  exposure	   to	   acidic	   solutions,	   the	  human	  oesophageal	  mucosa	   responds	  with	  an	   impairment	  of	   integrity.	   In	   vitro,	   this	   was	  measured	  in	  terms	  of	  a	  reduction	  in	  TER	  from	  baseline	  during	  the	  exposure.	  This	  was	   tested	  on	   exposure	   to	   acidic	   and	  weakly	   acidic	   solutions	   (representative	  of	  reCluxate	  composition	  both	  in	  “off”	  and	  “on”	  PPI	  conditions).	  It	  can	  be	  seen	  that,	   in	  all	  subjects,	  the	  exposure	  to	  the	  acidic	  solution	  (pH	  2	  +	  pepsin	  +	  bile	  acid)	  results	  in	   an	   overall	   greater	   mean	   reduction	   in	   TER	   compared	   to	   the	   weakly	   acidic	  solution	  (pH	  5	  +	  pepsin	  +	  bile	   acid)	  (-­‐14.4	  ±	  15.3%	  vs.	   -­‐1.6	  ±	  11.0%),	   suggesting	  that	  this	  change	  in	  integrity	  is	  indeed	  pH	  dependent.	  The	  in	  vivo	  studies	  used	  intraluminal	  mucosal	   impedance	  as	  a	  surrogate	  marker	  of	  mucosal	  integrity.	  In	  the	  study	  presented	  in	  Chapter	  4,	  we	  can	  see	  that	  perfusion	  of	  a	  neutral	   (pH	   6.7)	  solution	  did	  not	   cause	   any	   reduction	   in	  impedance	  after	   a	  10	  minute	   exposure.	   This	   corroborates	   Cindings	   from	   Farré	   at	   al.	   during	   their	  morphological	  studies	  of	  the	  healthy	  human	  oesophagus,	  where	  they	  found	  that	  in	  
vivo	  neutral	  perfusion	  did	  not	  cause	  any	  change	  in	  intercellular	  space	  diameter161.	  In	  contrast,	  perfusion	  of	  acidic	  (pH	  1)	  solution	  causes	  a	  profound	  fall	  in	  impedance.	  For	  all	  subjects	   the	  mean	  change	  in	  distal	  oesophageal	   impedance	  from	  baseline	  5	  minutes	  after	  cessation	  of	  the	  acidic	  perfusion	  was	  -­‐1215	  Ω	  (a	  change	  of	  −51%).	   It	  was	   very	   apparent	   that	   this	   change	   in	   impedance	   was	   not	   a	   brief,	   transient	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phenomenon,	   but	   was	   long-­‐lasting.	   At	   90	  minutes	   post	   acid	   perfusion	   the	  mean	  baseline	  was	  still	  only	  73%	  of	  baseline.	  The	  reason	  for	   the	  acid-­‐induced	  changes	  in	  human	  oesophageal	  mucosal	  integrity	  are	  as	  yet	  unknown,	  but	  are	  of	  interest	  to	   future	  understanding	  and	  management	  of	   GORD.	   The	   most	   widely	   held	   belief	   is	   that	   the	   mechanism	   underlying	   such	  changes	   in	   integrity	   are	   related	   initially	   to	   acid-­‐induced	   epithelial	   junctional	  barrier	   damage.	   The	   theory	   proposed	   by	   Orlando	   et	   al.	   is	   that	   acid	   is	   able	   to	  directly	  damage	  this	  junction,	   leading	  initially	  to	  increased	  ionic	  permeability,	  then	  further	  disruption	   as	   water	   follows	   chloride	   ions	   into	   the	   epithelium	   and	  swells	  the	  intercellular	  spaces	  (and	  so	  increasing	  permeability	  further)291.	  This	  group	  has	  published	   a	   study	   indicating	   that	   there	   is	   cleavage	   of	   e-­‐cadherin	   (an	   important	  component	   of	   the	   epithelial	   adherens	   junction)	   in	   the	   mucosa	   of	   patients	   with	  GORD	  (including	  erosive	  disease)133.	  This	  was	  associated	  with	  a	  reduction	  in	  basal	  TER	   in	   corresponding	   biopsies	   studied	   in	   Ussing	   chambers.	   This	   model	   is	   an	  intuitive	   one,	   but	   the	  relationship	  is	  not	  necessarily	  causal.	   It	   is	   entirely	  possible	  that	   the	   disruption	   in	   integrity	   occurs	   via	   a	  more	   indirect	   pathway.	   It	   has	   been	  noted	  that	  the	  squamous	  epithelium	  of	  the	  oesophagus	  has	  numerous	  receptors	  in	  quite	  superCicial	  locations	  (such	  as	  the	  acid-­‐sensitive	  receptor	  TRPV1)337.	  Acid	  may	  be	  able	   to	   directly	   stimulate	   such	  receptors	   on	   the	   superCicial	   epithelium	   of	   the	  oesophagus,	   resulting	   in	   release	   of	   several	   inClammatory	   mediators	   such	   as	  platelet	   activating	   factor	   (PAF)338.	   These	   in	   turn	   could	   mediate	   inClammatory	  disruption	  of	   the	  epithelial	   integrity,	   such	  as	   is	   seen	  in	  eosinophilic	   oesophagitis	  (where	  DIS	  is	  also	  seen341).	  Such	  inClammatory	  disruption	  could	  lead	  to	  peripheral	  sensitisation	   by	   increasing	   permeability	   to	   noxious	   components	   of	   the	   reCluxate	  and	  by	   sensitising	  mucosal	   sensory	   afferent	   nerves.	   Our	   studies	   cannot	   support	  one	  or	  the	  other	  of	  these	  hypotheses,	  and	  this	  can	  be	  a	  focus	  of	  work	  in	  the	  future.
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The	  other	  phenomenon	  we	  have	  observed	  in	  our	  in	   vivo	   studies	  is	  the	  “spread”	  of	  integrity	   change	  from	  the	  distal	   to	   proximal	  oesophagus	   on	  distal	   acid	  perfusion	  (i.e.	  perfusion	  of	  the	  distal	  oesophagus	  was	  able	  to	  cause	  a	  change	  in	  impedance	  in	  not	   only	   the	   distal,	   perfused	   oesophagus,	   but	   also	   in	   the	   proximal,	   unexposed	  oesophagus).	   This	   phenomenon	  was	   seen	   previously,	   again	   using	  morphological	  means,	   by	   Farré	   et	   al.161.	   Acid	   perfusion	   of	   the	   distal	   oesophagus	   of	   healthy	  volunteers	   (without	   pre-­‐existing	  DIS)	  was	   able	   to	   provoke	  DIS	   formation	   in	   the	  proximal	   oesophagus.	   Correspondingly,	   patients	   with	  non-­‐erosive	   reClux	  disease	  have	  DIS	  in	  the	  distal	  and	  (less	  often	  acid	  exposed)	  proximal	  oesophageal	  mucosa.	  Perhaps	   these	   observations	   support	   the	   more	   “indirect”	   theory	   of	   integrity	  impairment.	   Mechanisms	   other	   than	   direct	   acid	   exposure	   are	   able	   to	   affect	  oesophageal	   mucosal	   integrity.	   Furthermore,	   it	   appears	   that	   mucosal	   integrity	  does	  not	  begin	  and	  end	  at	  DIS.	   The	   in	   vivo	   and	  in	   vitro	   studies	   in	  this	  thesis	  have	  been	  performed	  in	  patients,	  who	  in	  many	  cases,	  would	  be	  presumed	  to	   have	  pre-­‐existing	  DIS	   (i.e.	   those	  with	  refractory	  GORD	   in	  the	   in	   vitro	   study,	   and	  especially	  those	  with	  GORD	  not	  currently	  taking	  PPI	  in	  the	  in	  vivo	  study).	  Despite	  this	   likely	  pre-­‐existing	  DIS	   in	  both	  proximal	   and	  distal	  oesophagus,	   acid	  exposure	  is	   able	  to	  cause	  further	  disruption	  in	  integrity	  in	  both	  the	  distal	  and	  proximal	  oesophagus.	   It	  would	  suggest	   that	   cell	   barrier	   function	  is	   not	   at	   its	  most	   impaired	  when	  DIS	   is	  present	   and	   can	   be	   further	   damaged	   perhaps	   by	   further	   acid	   damage	   to	  intercellular	  junctions	  and/or	  activation	  of	  epithelial	  receptors	  (whose	  availability	  to	  reCluxate	  may	  be	  enhanced	  by	  the	  presence	  of	  DIS).	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Is	  the	  oesophageal	  mucosa	  different	  or	  more	  vulnerable	   to	  reMlux	   in	  different	  disease	  
phenotypes?A	   very	   interesting	   and	   potentially	   important	   Cinding	   of	   the	   in	   vitro	   and	   in	   vivo	  studies	   presented	   in	   this	   thesis	   has	   been	   the	   difference	   in	   response	   of	   the	  oesophageal	  mucosa	  between	  patients	  with	  different	  disease	  phenotypes.	   	  The	  in	  
vitro	  study	  in	  Chapter	  3	  compared	  mucosal	  biopsies	  from	  patients	  with	  refractory	  reClux	  symptoms	  and	  control	  patients	  with	  no	  upper	  gastrointestinal	  symptoms.	   It	  found	  that	  biopsies	   from	  symptomatic	  patients	  had	  a	  more	  dramatic	   reduction	  in	  TER	  than	  controls	  when	  exposed	  to	  the	  same	  reCluxate-­‐like	  solution.	  This	  was	  true	  for	   the	   acidic	   (pH	   2	   +	   pepsin	   +	   bile	   acid)	   solution,	   but	   perhaps	   even	   more	  interestingly	   it	   was	   also	   true	   for	   the	   weakly	   acidic	   (pH	   5	   +	   pepsin	   +	   bile	   acid)	  solution.	  This	  solution	  was	  representative	  of	  the	  “on”	  PPI	  condition.	  Biopsies	  from	  the	  control	  subjects	  did	  not	  respond	  to	  exposure	  to	  this	  solution	  with	  a	  fall	  in	  TER.	  In	   contrast,	   the	   symptomatic	   patients	   responded	  with	   a	   statistically	   signiCicant	  mean	   reduction	   in	   TER.	   It	   has	   been	   documented	   that	   some	   subjects	   who	   are	  refractory	   to	   PPI	   therapy	   are	   symptomatic	   to	   weakly	   acidic	   (i.e.	   pH	   >4)	   reClux	  episodes339.	  This	  study	  raises	  the	  intriguing	  possibility	  that	  a	  reason	  for	  refractory	  GORD	  in	  some	  cases	  may	  be	  a	  distinct	  vulnerability	  of	  the	  oesophageal	  mucosa	  to	  weakly	  acidic	  reClux	  events.	  The	   in	   vivo	   study	   in	   Chapter	   4	   compared	   mucosal	   integrity	   characteristics	   (as	  measured	  by	  impedance)	  of	  symptomatic	  patients	  with	  non-­‐erosive	  reClux	  disease	  and	  functional	   heartburn.	   It	   can	  be	   seen	   that,	   at	   baseline,	   the	   distal	  oesophageal	  impedance	  is	  signiCicantly	   lower	  in	  patients	  with	  non-­‐erosive	  reClux	  disease	  (with	  increased	  24-­‐hour	  acid	  exposure)	  than	  in	  patients	  with	  functional	  heartburn	  (with	  physiological	   acid	   exposure).	   This	   lower	   impedance	   does	   indeed	   appear	   to	   be	  related	   (at	   least	   in	   part)	   to	   chronic	   acid	  exposure	   since	   the	   baseline	   impedance	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correlates	   signiCicantly	   with	   the	  24-­‐hour	  acid	  exposure	   time.	   Whilst	   the	   baseline	  impedance	   characteristics	   and	   Cindings	   of	   the	   in	   vitro	   study	   in	   Chapter	   3	   offer	  insight	   into	   vulnerability	   to	   acid	   damage,	   the	   acid	   perfusion	   study	   in	   Chapter	   4	  investigates	  the	  recovery	  capacity	  of	  the	  mucosa	  after	  acid	  injury.	  Using	  impedance	  as	   a	   surrogate	   marker,	   it	   can	   be	   seen	   that	   not	   only	   is	   there	   a	   long-­‐lasting	  impairment	  of	  distal	  oesophageal	  mucosal	   integrity	  after	  acid	  perfusion,	  but	  there	  is	   an	   intra-­‐individual	   variability	   in	   the	   rate	   of	   recovery	   of	   the	   mucosa	   after	  exposure.	   The	   rate	   of	   impedance	   recovery	  after	   cessation	   of	  acid	   perfusion	  was	  signiCicantly	  slower	   in	   subjects	  with	  non-­‐erosive	   reClux	   disease	   than	  was	   seen	   in	  patients	  with	  functional	  heartburn.	  Bringing	  together	  the	  Cindings	  from	  Chapters	  3	  and	  4	  it	  could	  be	  suggested	  that	  there	  is	  a	  mucosal	  phenotype	  seen	  in	  patients	  with	  non-­‐erosive	  reClux	  disease	  of	  impaired	  baseline	  integrity	  (at	  least	  as	  measured	  by	  impedance),	   more	   dramatic	   impairment	   of	   integrity	   when	   exposed	   to	   reClux	  events,	  and	  a	  slower	  recovery	  of	  this	  integrity	  after	  the	  reClux	  event	  has	  passed.	   It	  could	  be	  hypothesised	  that	  the	  occurrence	  of	  regular	  reClux	  episodes	  with	  resulting	  damaged	   mucosal	   integrity	   and	   the	   slow	   recovery	   of	   the	   integrity	   is	   able	   to	  perpetuate	   the	   low	   baseline	   integrity	   seen	   in	   patients	   with	   non-­‐erosive	   reClux	  disease	  (which	  is	  likely	  to	  reClect	  a	  situation	  of	  vulnerability	  to	  reClux	  perception).	  On	   treatment	   with	   PPI,	   the	   extent	   of	   integrity	   change	   during	   reClux	   is	   likely	  reduced,	   and	   the	   baseline	   impedance	   is	   seen	   to	   increase	   in	   treated	   subjects156.	  However,	   there	  remain	  a	  subset	  of	  patients	  whose	  mucosa	  remains	  vulnerable	  to	  weakly	  acidic	  reClux,	  and	  these	  patients	  may	  remain	  refractory	  to	  PPI.
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What	   is	  the	   relationship	   between	  human	  oesophageal	   sensitivity	  to	  acid	   (heartburn	  
perception)	  and	  oesophageal	  mucosal	  integrity?An	   intuitive	   step	   from	   investigating	   the	  mucosal	   changes	   described	   above	   is	   to	  consider	   the	   relationship	   between	   oesophageal	   integrity	   and	   acid	   sensitivity.	  There	  is	  circumstantial	  evidence	  for	  a	  relationship	  between	  integrity	  and	  symptom	  perception.	   In	   morphological	   terms	   it	   has	   been	   shown	   that	   DIS	   is	   present	   in	  patients	   with	   GORD,	   but	   not	   in	   controls163.	   Furthermore,	   the	   DIS	   resolves	   on	  successful	   treatment	   of	   GORD166,	   except	   in	   the	   circumstance	   when	   symptoms	  persist	  on	  PPI	  treatment,	   in	  which	  case	  DIS	  can	  be	  seen	  to	  persist167.	   In	  functional	  terms,	   this	  thesis	  has	  shown	  that	  impedance	  is	  lower	  in	  patients	  with	  non-­‐erosive	  reClux	   disease	   than	   in	   those	   with	   functional	   heartburn,	   and	   others	   have	   shown	  impedance	   increases	  with	  successful	  PPI	  therapy156.	  Clinically,	   it	  has	  been	  shown	  that	  a	  reClux	  event	   is	  more	  likely	   to	  be	  perceived	  if	  it	  was	  recently	  preceded	  by	  a	  prior	  reClux	  event210,	   213,	  which	  in	  the	  context	  of	  our	  Cindings	  may	  be	  explained	  by	  the	  presence	  of	   a	   transiently	  more	   impaired	  mucosal	   integrity	  due	   to	   a	  previous	  “acid	   exposure	   burden”.	   The	   study	   in	   Chapter	   4	   also	   attempted	   to	   address	   this	  question	  more	  objectively.	  Not	  all	  subjects	  are	  able	  to	  perceive	  an	  oesophageal	  acid	  perfusion	  as	   heartburn,	   even	   those	  with	  GORD	  (an	   observation	  that	   has	   led	  to	   a	  reduction	   in	   the	   use	   of	   the	   acid	   sensitivity	   test	   in	   clinical	   practice).	   The	   study	  showed	   that	   subjects	   who	   perceived	   the	   acid	   perfusion	   as	   heartburn	   had	   a	  signiCicantly	  lower	  baseline	  distal	  oesophageal	  impedance	  than	  those	  who	  did	  not.	  It	  could	  be	  argued	  that	  this	  is	  because	  those	  with	  a	  lower	  baseline	  impedance	  were	  mostly	   represented	   by	   the	   non-­‐erosive	   reClux	   disease	   phenotype	   (rather	   than	  functional	   heartburn),	   and	   as	   such	   were	   more	   likely	   to	   have	   acid	   sensitivity.	  Countering	   this	   suggestion	   was	   the	   Cinding	   that	   even	   when	   only	   those	   with	  functional	  heartburn	  were	   included	  in	  the	  analysis,	   there	  was	   still	   a	   signiCicantly	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lower	  baseline	  impedance	  in	  acid	  perceivers.	  Supporting	  the	  hypothesis	  is	  a	  recent	  abstract	  (presented	  at	  UEGW	  2012)	  by	  a	  group	  from	  Amsterdam,	  who	  have	  found	  that	  in	  vivo	  sensitivity	  to	  acid	  perfusion	  was	  negatively	  correlated	  to	   in	  vitro	  basal	  integrity	  markers	  (transmucosal	  Cluorescein	  Clux)294.	  The	   Cindings	   discussed	   above	   suggest	   strongly	   that	   mucosal	   integrity	   plays	   an	  important	  role	   in	  pathogenesis	   and	  symptom	  perception	   in	  GORD.	   It	  may	  be	  that	  the	   variability	   in	   mucosal	   vulnerability	   between	   subjects	   may	   play	   a	   part	   in	  explaining	  why	   a	   similar	   acid	   reClux	   burden	   can	   result	   in	   a	   wide	   variability	   of	  symptom	   severity.	   Of	   course,	   however,	   mucosal	   integrity	   is	   only	   a	   part	   of	   the	  process	   leading	   to	   symptomatic	   reClux	  disease.	   As	  well	   as	   the	   integrity	   changes,	  there	  will	  also	  be	  factors	  such	  as	  activity	  of	  mucosal	  nociceptors	  and	  afferent	  nerve	  Cibres,	   contribution	   of	   other	   properties	   of	   the	   reCluxate	   (e.g.	   volume	   and	   gas	  causing	   oesophageal	   distension),	   and	   spinal	   and	   cerebral	   processing	   of	   sensory	  information	  that	  inCluence	  perception.	  The	  Cindings	  of	  the	  studies	  in	  Chapter	  5	  are	  a	  useful	  platform	  for	  further	  discussion	  of	  this	  point.
Is	   the	   regional	   difference	   in	   oesophageal	   sensitivity	   observed	   in	   humans	   due	   to	  
distinct	  oesophageal	  mucosal	  characteristics?It	   has	   been	   shown	   in	  multiple	   studies	   that	   reClux	   events	   reaching	   the	   proximal	  oesophagus	   are	  more	   likely	   to	   be	   perceived	   than	   those	  only	   reaching	   the	   distal	  oesophagus211-­‐214.	  It	  has	  also	  been	  suggested	  that	  the	  proximal	  oesophagus	  is	  more	  sensitive	   to	   acid	   perfusion	   than	   is	   the	   distal	   oesophagus.	   Given	   the	   Cindings	  summarised	  in	  the	  paragraphs	  above,	   it	  was	  hypothesised	  that	  part	  of	  the	  reason	  for	   this	   relative	   hypersensitivity	   may	   be	   related	   to	   a	   more	   vulnerable	   mucosal	  integrity	   in	  the	  proximal	  oesophagus	   compared	  to	  the	  distal.	   This	  may	  have	  been	  expressed	   as	   a	  more	   impaired	   integrity	   at	   baseline	   (as	  measured	  by	  baseline	   in	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vitro	  TER	  or	  in	  vivo	  impedance),	  or	  a	  more	  dramatic	  change	  in	  TER	  on	  exposure	  to	  reCluxate-­‐like	  solutions.	  The	  Cindings	  in	  Chapter	  5	  did	  not	  support	  this	  hypothesis.	  The	   baseline	   impedance	   was	   higher	   in	   the	   proximal	   compared	   to	   distal	  oesophagus,	  and	  there	  was	  also	  a	  trend	  towards	  a	  higher	  basal	  TER	  in	  the	  proximal	  mucosal	   biopsies.	   The	   change	   in	   TER	   of	   proximal	   biopsies	   was	   not	   greater	   on	  exposure	  to	  acidic	  solutions,	  and	  in	  fact	  trended	  towards	  a	  smaller	  effect	  compared	  to	   distal	   biopsies.	   These	   Cindings	   demonstrate	   the	   multifaceted	   nature	   of	  oesophageal	  nociception,	  involving	  several	  factors	  in	  addition	  to	  mucosal	  integrity.	  In	  fact,	   it	  appears	   logical	   that	  there	  may	  be	  different	   factors	   involved	  in	  proximal	  versus	  distal	  reClux	  nociception.	  The	  distal	  oesophagus,	  even	  in	  healthy	  individuals,	  is	  subject	  to	  dozens	  of	  acid	  reClux	  episodes	  every	  day.	  It	  is	  required	  to	  be	  relatively	  resistant	   to	   reClux	   perception.	   On	   the	   other	   hand,	   the	   proximal	   oesophagus	   is	  usually	   required	   to	   be	   very	   sensitive	   (at	   least	   at	   a	   subliminal	   level)	   since	   the	  presence	  of	  a	  reClux	  event	  at	  the	  proximal	  oesophagus	  threatens	  aspiration	  into	  the	  airways,	   and	   hence	   must	   trigger	   reClex	   activity	   (such	   as	   upper	   oesophageal	  sphincter	   closure	   and	   peristaltic	   bolus	   clearance)	   in	   defence308.	   The	   lack	   of	  difference	  in	  integrity	  between	  proximal	  and	  distal	   oesophageal	  mucosa	  led	  us	  to	  investigate	  other	  characteristics	  of	  the	  oesophageal	  mucosa,	  in	  the	  form	  of	  afferent	  mucosal	   innervation.	   Striking	   differences	   were	   found	   in	   the	   sensory	   afferent	  innervation	   of	   the	   distal	   and	   proximal	   oesophagus,	   with	   the	   nerve	   Cibres	   being	  more	   numerous	   and	   in	   a	   position	   much	   closer	   to	   the	   luminal	   surface	   in	   the	  proximal	  mucosa.	  This	  afferent	  neuronal	  distribution	  is	  ideally	  located	  to	  perform	  the	   fast,	   defensive	   actions	   required,	   usually	   in	   the	   absence	   of	   pain.	   The	   deeper	  epithelial	  location	  of	  the	  distal	  oesophageal	  afferent	  nerves	  perhaps	  reveal	   insight	  into	  why	  mucosal	   integrity	   is	  important	  in	  this	  region.	   An	  intact	  mucosal	   barrier	  may	  be	   able	   to	  mostly	   “shield”	  these	  afferent	  neurones	   (and	   their	  corresponding	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nociceptive	  receptors)	  from	  noxious	   components	  of	  the	  reCluxate.	   As	  the	  integrity	  of	  this	  barrier	   is	   impaired,	  access	   to	   these	  nociceptive	  neurones	  is	   increased,	  and	  as	  DIS	  develops	  perhaps	  the	  available	  surface	  area	  of	  these	  nociceptors	  increases,	  further	  sensitising	  the	  mucosa.In	   the	   proximal	   oesophagus,	   as	   mentioned,	   acidic	   solutions	   (such	   as	   those	   in	  drinks)	   do	   not	   usually	   cause	   heartburn	   symptoms.	   So	   what	   sensitises	   these	  superCicial	  neurones	  to	  cause	  more	  perception	  in	  reClux	  disease?	  Mucosal	  integrity,	  or	  at	  least	   the	  mechanisms	  underlying	   the	  changes	   in	  mucosal	  integrity	  may	  have	  an	   important	   role.	   In	   particular,	   the	   “spread”	   of	  mucosal	   changes	   from	   distal	   to	  proximal	   oesophagus	   may	   be	   important	   in	   modulating	   the	   perception	   of	   the	  proximal	   oesophagus.	   Whether	   this	   is	   via	   an	   inClammatory	   “Cield	   change”	   in	   the	  oesophagus,	  via	  changes	  in	  local	  blood	  supply,	  or	  via	  an	  alternative	  mechanism	  is	  unknown.	  The	  result	  may	  be	  a	  sensitisation	  of	  afferent	  neurones	  and	  a	  recruitment	  of	  more	  available	  nociceptors	  via	  disruption	  of	  the	  barrier	  integrity.	  This	  paradigm	  would	   suggest	   that,	   indeed,	   distal	   acidiCication	   via	   gastro-­‐oesophageal	   reClux	   is	  required	   to	   sensitise	  the	   proximal	   oesophagus	   to	   painful	   perception	   of	  proximal	  reClux.	  More	  studies	  are	  required	  to	  investigate	  this	  interesting	  possibility.	  
Can	  the	  human	  oesophageal	  mucosa	  integrity	  be	  protected	  with	  a	  topical	  agent?The	   thesis	   has	   indicated	   that	   mucosal	   integrity	   has	   an	   important	   role	   in	   the	  pathophysiology	   of	   GORD.	   Although	   PPIs	   are	   an	   excellent	   treatment	   for	   GORD,	  there	  is	  still	  a	  large	  unmet	  need	  of	  20-­‐30%	  of	  disease	  sufferers	  with	  PPI-­‐refractory	  symptoms.	  For	  these	  patients	  an	  alternative	  strategy	  that	  protects	  not	   just	  against	  strong	  acid,	  but	  other	  components	  of	  the	  reCluxate	  and	  lower	  acid	  concentrations	  is	  warranted.	   A	   topical	   therapy	   that	   can	   protect	   the	   mucosa	   against	   these	  components	  and	  that	  can	  reduce	  the	  damaging	  effects	  on	  mucosal	  integrity	  would	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CHAPTER 8: FUTURE DIRECTIONS
The	  in	  vitro	  effects	  of	  acid	  exposure	  on	  the	  integrity	  of	  human	  oesophageal	  mucosa	  are	   intriguing	   and	   are	   of	   clinical	   relevance.	   The	  molecular	  mechanisms	   of	   these	  changes	   are	   subject	   to	   discussion,	   but	   with	   little	   in	   the	   way	   of	   supporting	  experimental	  data.	  In	  an	  initial	  study	  of	  this	  we	  wish	  to	  evaluate	  the	  inClammatory	  response	  of	   the	  mucosa	  and	  its	   temporal	   relationship	  to	   changes	   in	   integrity	   (as	  measured	   by	   TER).	   We	  would	   aim	  to	   sample	   the	   “basal”	  bathing	   solution	  of	   the	  Ussing	  chamber	  at	  time	  intervals	  and	  perform	  ELISA	   for	   inClammatory	  mediators	  such	   as	   IL-­‐8.	  We	  propose	   to	   plot	   the	   release	  of	   inClammatory	  mediators	   against	  changes	   in	  TER,	  with	  an	  aim	   of	  establishing	  whether	  any	   inClammatory	   response	  precedes	   or	   follows	   integrity	   change	   in	   the	  mucosa.	   This	  may	   guide	   us	   closer	   to	  understanding	  the	  mechanism	  of	  integrity	  impairment	  in	  response	  to	  acid.The	  mucosal	  behaviour	  in	  response	  to	   in	  vivo	  acid	  perfusion	  is	  of	  interest	  to	  us.	  We	  see	   that	   the	   oesophageal	   mucosa	   of	   different	   individuals	   can	   handle	   acid	   in	  different	   ways.	   In	   general	   those	   with	   GORD	   appear	   to	   have	   a	   lower	   baseline	  impedance	  and	  slower	  post-­‐acid	  impedance	  recovery	  than	  those	  with	  normal	  acid	  exposure	   on	   24-­‐hour	   study,	   but	   there	   is	   some	   signiCicant	   overlap.	   Indeed,	   some	  patients	  with	  functional	  heartburn	  have	  mucosal	  behaviour	  that	   is	  very	  similar	  to	  what	   is	   seen	   in	   patients	   with	   non-­‐erosive	   reClux	   disease.	   The	   diagnosis	   of	  functional	   heartburn	   is	   very	   much	   dependent	   on	   results	   of	   reClux	   monitoring.	  There	   is	   some	   discussion	   as	   to	   whether	   a	   24-­‐hour	   reClux	   study	   is	   sufCicient	   for	  diagnosis	   of	   functional	   heartburn.	   Some	   subjects	   will	   inevitably	   react	   to	   the	  presence	  of	  a	  recording	  catheter	  by	  modifying	  their	  behaviour:	  perhaps	  eating	  less	  freely,	  exercising	  less,	  or	  sleeping	  less	  well.	  Prolonging	  the	  study	  may	  allow	  better	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acclimatisation,	   and	   it	   has	   been	   seen	   that	   a	   48,	   72	   or	   even	   96	   hour	   study	   can	  increase	  the	  pickup	  of	  true	  reClux	  disease.	  We	  propose	  that	  mucosal	  behaviour	  may	  help	   identify	   those	   subjects	   who	   initially	   are	   identiCied	   as	   having	   functional	  heartburn	  on	  a	  24-­‐hour	  study,	   but	  who	  would	  be	  revealed	  as	  having	  pathological	  gastro-­‐oesophageal	  reClux	  disease	  on	  a	  prolonged	  study.	  We	  intend	  to	  investigate	  this	   possibility	   with	   a	   study	   using	   in	   vivo	   acid	   challenge	   and	   prolonged	   pH	  monitoring	  in	  patients	  with	  heartburn.We	  have	  identiCied	  a	  difference	  in	  mucosal	  afferent	  innervation	  between	  the	  distal	  and	  proximal	  oesophagus.	  We	  intend,	  in	  collaboration	  with	  Professor	  Blackshaw	  at	  our	   institution,	   to	   investigate	   this	   further.	   First	   we	  wish	   to	   fully	   delineate	   these	  nerves	   into	   their	   spinal	   and	   vagal	   components.	   Second	  we	   wish	   to	   investigate	  (with	   a	   combination	   of	   immunohistochemistry	   and	   RNA	   analysis)	   the	   relative	  proximal	   and	   distal	   distribution	   of	   candidate	   nociceptive	   receptors	   including	  TRPV1,	  TRPV4,	  TRPA1,	  and	  ASIC3.We	   wish	   to	   objectively	   measure	   proximal	   and	   distal	   sensitivity	   to	   thermal	   and	  chemical	   stimuli	   in	   healthy	   volunteers	   and	   patients,	   and	   relate	   this	   to	   mucosal	  integrity,	   and	  nerve	  and	  receptor	  distribution	  as	   obtained	  from	  mucosal	  biopsies.	  With	  this	  we	  hope	  to	  build	  a	  more	  comprehensive	  picture	  of	  the	  factors	  involved	  in	  oesophageal	  nociception.	  Finally,	   we	   also	   wish	   to	   investigate	   further	   the	   potential	   of	   using	   a	   mucosal	  protectant	   in	   reClux	   disease.	   In	   the	   shorter	   term	  we	   intend	   to	   expand	  on	  our	   in	  
vitro	  studies,	  and	  perform	  in	  vivo	   studies	  of	   the	  effect	  on	  mucosal	   integrity	  using	  impedance.	   We	   would	   like	   to	   investigate	   the	   effect	   on	   pain	   sensitivity	   to	  oesophageal	  acid	  perfusion,	  and	  relate	  this	   to	  any	  effects	  on	  integrity.	  We	  are	  also	  very	  interested	  in	  the	  effect	  prior	  treatment	  with	  a	  topical	  agent	  may	  have	  on	  post-­‐acid	   exposure	   impedance	   recovery,	   and	   on	   proximal	   changes	   in	   integrity	   after	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distal	   acid	   perfusion.	   In	   the	   medium	   term	   future	   we	   would	   like	   to	   better	  understand	  the	   duration	  of	   the	  protective	  effect,	   and	   the	  effect	   on	  multiple	   acid	  exposures.	   In	  the	   longer	  term	  future	  we	  would	  like	  to	  use	  our	  in	  vitro	  and	  in	   vivo	  studies	  to	   investigate	   for	  better	  adhesive-­‐protective	  formulations,	   and	  to	   attempt	  to	   combine	   the	  topical	   solution	  with	  drugs,	   the	   targets	   being	  determined	  by	  our	  studies	  on	  nociceptor	  distribution	  in	  the	  oesophagus	  (for	  example,	  a	  topical	  TRPV1	  antagonist).	  
Overall,	   the	  research	  involved	  in	  this	  PhD	  thesis	  aimed	  to	  build	  on	  our	  knowledge	  of	   oesophageal	   mucosal	   integrity	   and	   nociception	   in	   gastro-­‐oesophageal	   reClux	  disease,	   and	   to	   increase	   our	   potential	   to	   develop	   new	   effective	   treatments	   for	  GORD.
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